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0.1. Declaration 
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0.2. Abstract 
0.2.1. Background and methods 
Tuberculosis (TB) remains the leading reported cause of mortality among HIV-positive individuals in low- and middle-
income countries (LMIC), but disease prevalence and cause-specific mortality data are based on estimates; reliable data 
are needed to track progress towards targets for reductions in TB and HIV-related deaths.  The aim of this work was to 
estimate disease prevalence and causes of death (CoD) among people dying after enrolment to three large studies of 
TB and HIV in South Africa. 
Literature was systematically reviewed for autopsy studies estimating disease prevalence in HIV-positive adults; studies 
validating verbal autopsy (VA) for HIV and TB deaths; and studies directly estimating CoD in HIV-positive adults in LMIC.  
Primary data were collected concerning HIV-positive decedents from three parent studies and HIV-negative controls.  
Minimally-invasive autopsy (MIA), involving tissue biopsy, fluid aspiration, and bronchoalveolar lavage was conducted 
in a subset of HIV-positive decedents.  CoD were assigned, through structured review of clinical and research data 
(“reference-standard”) and VA data, collected using the World Health Organization (WHO) 2012 instrument and 
interpreted using physician-certified (PCVA) and computer-coded VA (CCVA) methods (InterVA-4 and SmartVA-
Analyze).  VA-assigned and reference-standard CoD were compared; agreement was measured at individual- and 
population-level.   
0.2.2. Results 
MIA was conducted for 34 HIV-positive adults: 16 (47%) had evidence of TB at autopsy, 14/16 (88%) had evidence of 
extrapulmonary disease, and 6/16 (38%) had not been started on TB treatment; 23/34 (68%) had evidence of bacterial 
pneumonia and 20/34 (59%) had evidence of two or more concomitant infections.  Most (94%) individuals who 
underwent MIA were assigned HIV-associated reference-standard CoD; this was underestimated by all three VA 
methods (PCVA 74% [chance-corrected concordance {CCC} 0.71], InterVA-4 47% [CCC 0.42], and SmartVA-Analyze 41% 
[CCC 0.31]).   
Reference-standard CoD were assigned, without MIA data, to 259 HIV-positive adults: 183 (71%) were assigned HIV-
associated causes.  Only the PCVA estimate was similar, at 80% (CCC 0.78); InterVA-4 and SmartVA-Analyze 
underestimated the HIV-associated mortality fraction (estimates 48% and 29%; CCC 0.48 and 0.20, respectively).  
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Agreement between VA methods and the reference-standard was poor at individual level (overall CCC ≤0.22) and 
slightly better at population level (cause-specific mortality fraction [CSMF] accuracy 0.43–0.79).  Only PCVA could 
estimate the HIV-associated TB mortality fraction, underestimating it when compared with a reference standard that 
included autopsy data (reference 41% vs. PCVA 32%; CCC 0.23) and overestimating it when compared with a reference 
standard without autopsy data (reference 27% vs. PCVA 42%; CCC 0.42). 
Among 356 HIV-positive and 103 HIV-negative adults with confirmed HIV status, the VA instrument was sensitive 
(84.3%) and specific (94.2%) in assigning HIV status; VA methods showed high specificity (all methods >89%) in 
assigning HIV-associated CoD; and both CCVA methods underestimated the likely true HIV-associated mortality fraction 
among confirmed HIV-positive decedents (InterVA-4 44.7% and SmartVA-Analyze 22.5%).  
0.2.3. Conclusions 
TB remains a leading CoD among HIV-positive adults in LMIC.  Changes are needed to disease classification systems and 
automated VA methods to allow for better estimation of HIV-associated mortality overall and mortality due to HIV-
associated TB.  Structured guidelines for assigning CoD in HIV-positive people in clinical settings and the use of MIA at 
sentinel surveillance sites may be useful additions to current methods. 
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1.1. Background 
1.1.1. Tuberculosis, HIV, and death 
There were 10.4 million new cases of tuberculosis (TB) and 1.8 million TB deaths in 2016 [1].  Among human 
immunodeficiency virus (HIV)-positive individuals, in whom TB is the leading cause of death, there were 1.2 million new 
cases and an estimated 390,000 deaths.  Mycobacterium tuberculosis (MTB) is an ancient organism; there is evidence to 
suggest that it may have originated around 70,000 years ago [2] and signs of TB disease have been found in 9,000-year-
old human remains [3,4].  Effective chemotherapy against MTB first emerged in the 1940s, with additional agents and 
various combinations trialled in the subsequent decades [5,6].  TB-related mortality, which had been in steady decline 
for most of the 20th century, likely due to improvements in hygiene & living conditions, reduced more sharply between 
1950 and 1980 [7].  The emergence of the HIV epidemic in the mid-1980’s, however, created an enormous pool of 
individuals with greatly increased susceptibility to TB disease, which led to higher numbers of TB cases and a dramatic 
spike in TB-associated mortality [8–10].  The last 30 years have seen increasingly coordinated efforts by members of the 
global health community working on TB; the establishment of specific funding streams, including the Global Fund to 
Fight AIDS, Tuberculosis, and Malaria; and the establishment of national TB programmes in almost all high-burden 
countries [1].  In the same period, the incidence of TB has fallen by almost 20% and mortality by almost 50%, and an 
estimated 43 million deaths have been averted [11].  Regardless, in 2015, TB remained the world’s leading infectious 
cause of death [1]. 
Any discussion of TB mortality in the 21st century must pay equal attention to HIV and the synergistic relationship 
between the two diseases (see Chapter 1.2.2).  Throughout the 1990s and early 2000s, HIV and the acquired immune 
deficiency syndrome (AIDS) became increasingly prominent underlying causes of death in adults; in sub-Saharan Africa, 
HIV was responsible for the reversal of some of the positive trends established over the previous decades, with life-
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expectancy falling or remaining static from 1990 until the mid-2000s [12,13].  In 2001, the United Nations (UN) General 
Assembly declared the HIV epidemic a ‘global crisis’ [14]; by 2003, HIV/AIDS was the leading cause of death in 
individuals aged 15–49 years, worldwide [15].  In addition to the increased vulnerability to TB seen in HIV-positive 
individuals, the conditions that allowed the rapid spread of the virus in low- and middle-income countries (LMIC) also 
helped set the scene for a TB co-epidemic.  People in LMIC of lower socio-economic status, with less access to food, 
education, sanitation, and health services, are disproportionately affected by both diseases, TB in particular, and are at 
higher risk of death [16,17]. 
In the early stages of the HIV epidemic, the absence of effective therapy for HIV itself meant that the treatment of an 
opportunistic infection simply delayed the inevitable; patients invariably experienced a progressive decline in immune 
function and eventually died.  In LMIC, death was very often from TB [18,19].  The advent of antiretroviral therapy 
(ART), together with sustained international efforts to improve access to treatment, has led to a dramatic reduction in 
all-cause mortality among people living with HIV [20,21], although mortality remains high among those with advanced 
disease in LMIC, particularly pre- and early on ART [22–25].  Assuming adherence to treatment, an individual living in a 
high-income country who is today diagnosed as HIV-positive can expect a lifespan much the same as an HIV-negative 
individual in the same context [26,27].  The same cannot be said for people living with HIV in LMIC, and the reasons for 
the marked differences in outcomes are likely structural, rather than biological [28–31]; despite substantial progress in 
providing access to care, a number of economic, societal, and political factors mean that many of those who need care 
are unable to or do not access it, or do so when their disease is at an advanced stage, increasing their risk of morbidity 
and death [32–34]. 
1.1.2. Ending the epidemics 
The World Health Organization (WHO) has published a set of targets as part of the ‘End TB’ strategy, launched in 2015 
[35].  A central aim is to reduce TB-related mortality to 75% and 95% of 2015 levels by 2025 and 2035, respectively.  
Equally ambitious is the aim of the Joint United Nations Programme on HIV/AIDS (UNAIDS), to reduce the absolute 
numbers of AIDS-related deaths from 1.1 million in 2015 to under 0.5 million by 2020 [36,37].  Both programmes have 
aligned their targets with the UN Agenda for Sustainable Development, Goal 3.3 of which is to end the TB and AIDS 
epidemics by 2030 [38]. 
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Aside from the considerable logistical and financial implications of trying to achieve these goals, measuring progress 
towards them will be a critical part of the process, providing essential information on the success, or otherwise, of 
specific activities, and determining the character, focus, and intensity of any subsequent actions.  There is, therefore, a 
need to establish robust methods that will accurately and consistently monitor the impact of interventions to reduce TB 
and HIV deaths and track progress towards these ambitious targets [35,36]. 
This chapter will provide context for some of the issues discussed in this thesis, including a description of some of the 
challenges faced in measuring disease-specific outcomes; the interactions between HIV and TB; the difficulties of 
diagnosing TB disease in individuals with advanced HIV; the methods currently used to estimate global disease burden 
and cause-specific mortality patterns, with a particular focus on HIV- and TB-associated mortality in LMIC; the current 
situation with other methods that could be used to estimate cause-specific mortality; and the setting in which a 
mortality study, the results of which make up the bulk of this thesis, was conducted.  This last section will include a 
description of the status of the TB and HIV epidemics in South Africa, the organisation of the South African health 
system at the time of the study, and a brief overview of the parent studies within which the mortality-study was 
nested.  Finally, this chapter will list the overall aims and objectives of the thesis, outline how it intends to meet those 
objectives, and give a detailed account of my contributions to the work presented here. 
1.2. Context 
1.2.1. Measuring cause-specific mortality 
Most health outcomes are context-specific.  They may be dependent on the perspective of the health professional or 
patient involved, or specific to a single disease in a particular sub-group.  Even supposedly standardised metrics, such as 
disability-adjusted life-years (DALYs) and quality-adjusted life-years (QALYs), are complex, compound measures, 
constructed by health economists; context and understanding shape the ways in which they are presented and 
interpreted [39–41].  The occurrence of a death, in contrast, is easier to define and should be easy to quantify, hence 
the frequency with which it is used as the base unit of measurement to estimate the effectiveness of health 
interventions. 
As this thesis will explore, counting deaths may appear easy, but it is often an imprecise and challenging process.  
Similar difficulties are encountered when trying to estimate disease prevalence in a population, either among living 
An autopsy study exploring the spectrum of disease in individuals with advanced HIV 
 in primary care clinics in South Africa 
 Page 24 of 383 Chapter 1: Introduction 
individuals or at death.  Importantly, the limitations of methods currently used to estimate morbidity and mortality are 
often not well understood by many of those who depend on these estimates to make major health policy decisions 
[42,43]. 
The simplest way to measure mortality is to count the overall number of deaths, a metric referred to as all-cause 
mortality.  Estimates of all-cause mortality, often stratified by age, gender, ethnicity, and socio-economic status, can be 
extremely useful when used in a well-defined population, for example, within a clinical trial or epidemiological study, 
where rigorous inclusion and exclusion criteria have already been applied.  Outside of research settings, among diverse 
groups of individuals in unpredictable environments, all-cause mortality is often too non-specific a method with which 
to measure the effect of an intervention.  Estimates of cause-specific mortality, in general, provide a better means for 
impact evaluation: for better or worse, most interventions are disease-specific, as are the structures of many health 
systems and governing bodies [44], and funding practices in the last two decades have led to a predominance of 
vertical programmes [45].  Disease-specific estimates also play a central role in a number of decision-making processes, 
including allocating funding, structuring health systems, and determining research frameworks [11,38,46,47].  As such, 
reductions in cause-specific mortality are prominent on the agendas of governing bodies at global and national levels 
[35,36,48] and success in global health is often measured by the ‘numbers of lives saved’ [49]. 
While efforts to unify funding streams and create holistic interventions are much needed, these changes will take time 
to implement.  In the meantime, estimates of disease burden and cause-specific mortality remain essential in 
measuring the effect(s) of many targeted public health interventions aiming to reduce mortality. 
1.2.2. HIV-associated tuberculosis 
Immunosuppressed HIV-positive individuals are up to 20–30 times more susceptible to active TB disease compared with 
HIV-negative, immunocompetent individuals [50].  Vulnerability to TB, and other infections, increases as immune 
function decreases.  TB disease often presents atypically in individuals with advanced HIV disease, and can be difficult 
to differentiate from other HIV-associated infections or even from non-specific symptoms caused by severe 
immunosuppression [51–53].  Microbiological investigations used to diagnose TB disease in immunocompetent 
individuals are also less useful in those who are immunosuppressed: the sensitivity of sputum microscopy (‘smear’) is 
markedly reduced and Xpert MTB/RIF, which detects MTB deoxyribonucleic acid (DNA) and is more sensitive than 
smear, performs less well in HIV-positive individuals with low CD4 counts or smear-negative disease or both [54,55].  
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Liquid mycobacterial culture is the most sensitive and specific investigation in these patients, but MTB is a slow-growing 
organism and culture may take several weeks to yield a positive result or to provide a negative result to help rule out TB 
disease [56].  In individuals with advanced HIV disease, at very high risk of death, long delays in starting treatment 
(either anti-TB treatment or ART) can be life-threatening [23–25,57–59].  At present, there is not a cheap, sensitive, 
point-of-care test that can be used to diagnose active TB disease in individuals with advanced HIV attending primary 
care in resource-limited settings [60–62].  As a result, there is a paucity of data on the prevalence of TB disease in these 
individuals.  Studies investigating this have found missed opportunities for investigation [63]; a lack of adequate 
investigation for individuals who initially test negative, even in the presence of persistent symptoms [64]; and a high 
prevalence of undiagnosed TB disease, including among individuals who initially test negative for TB [65–67]. 
More reliable estimates of TB prevalence come from autopsy studies, though many of these involve only small numbers 
of individuals dying in hospitals [68,69].  The burden of TB at autopsy is typically higher than in studies of living 
individuals.  This difference is likely to be artificially inflated, at least in part due to the increased difficulty of 
ascertaining TB disease in the living, and because the higher risk of TB disease and mortality in those with advanced HIV 
disease and higher risk of mortality in those with TB [23,70] may lead to the over-representation of TB among those 
who die.  However, as discussed above, the relative inadequacy of TB diagnostics in living individuals, particularly in 
those who are HIV-positive, suggests that current methods do underestimate the prevalence of disease in living 
patients; a systematic review of autopsy studies describing the autopsy prevalence of TB in HIV-positive adults dying in 
LMIC found that almost half of the active TB prevalent at autopsy had not been diagnosed ante mortem [71]. 
As discussed further below, national and international estimates of TB prevalence are derived, in part, from numbers of 
reported cases; these numbers are also used to generate estimates of TB mortality, particularly in HIV-positive 
individuals.  The potential underestimation of the true burden of TB and, by proxy, mortality due to TB, has implications 
not just for individual patients in whom the diagnosis is missed, but for the at-risk populations in high-burden countries, 
the healthcare workers treating them, and the surveillance and governing bodies that generate statistics and determine 
resource allocation [72,73]. 
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1.2.3. Measuring mortality 
1.2.3.1 Causes of death and the ICD 
The processes that lead to the death of an individual are often multiple and complex, but their distillation to a single 
‘underlying’ cause has been central to the approach taken to cause of death monitoring since its inception [74].  
Considering that methods have been in development for over a century, it can be argued this reductive process has led 
to data, at a national and international level, that are of poorer quality than are desirable. 
Modern classification systems have their origins in the ‘International List of Causes of Death’, first collated in the late 
19th century [75]. There was a recognition, from its earliest days, that any such list was never going to be 
comprehensive.  The intention was for it to be functional, to allow for structured observation and quantification of 
natural phenomena; rather than a list of “terminal causes”, it was intended to describe “the morbid condition that 
initiated the train of events ultimately resulting in death” [75].  Regular revisions were built in to the process to 
incorporate new evidence and knowledge to improve the accuracy of the list.  Revisions were initially scheduled to 
occur every 10 years; after the 9th revision in 1975, however, it was decided that cycles were too short, and the 10th 
revision was delayed until 1989.  The 10th revision of the International Statistical Classification of Diseases and Related 
Health Problems (ICD-10) was endorsed by WHO in 1990 and has undergone several minor updates in the intervening 
period [76], but the next major revision, ICD-11, is not due for release until 2018, a gap of almost thirty years [77]. 
In the early stages of the HIV epidemic there were few data available on its aetiology and clinical presentation.  As more 
knowledge emerged, a working case-definition was developed that allowed epidemiologists to identify and count cases 
of HIV-associated illnesses at a time when confirmatory diagnostics were not necessarily available [78,79].  In 1993, the 
Center for Disease Control (CDC) definitions of AIDS were developed and have been used, broadly, ever since [80].  
Codes for HIV-associated diseases were incorporated into the ICD system in 1990 and have been changed only slightly 
since then [81]. 
At present, all HIV-associated causes of death are classified under five, three-character codes: HIV disease resulting in 
infectious and parasitic diseases (B20); resulting in malignant neoplasms (B21); resulting in other specified disease 
(B22); resulting in other conditions (B23); and unspecified HIV disease (B24) [76].  More specific causes are specified 
with a digit after a point, i.e., a five-character code.  For example, B20.4, “HIV disease resulting in candidiasis” and 
B21.1, “HIV disease resulting in Burkitt lymphoma”.  Of particular relevance to this thesis is the way TB is classified by 
An autopsy study exploring the spectrum of disease in individuals with advanced HIV 
 in primary care clinics in South Africa 
 Page 27 of 383 Chapter 1: Introduction 
ICD-10.  TB as an underlying cause of death is classified under ICD-10 codes A15, “respiratory TB, bacteriologically or 
histologically confirmed”; A16, “respiratory TB, not confirmed bacteriologically or histologically”; A17, “TB of nervous 
system”; A18, “TB of other organs”; and A19, “Miliary (or disseminated) TB”.  However, these definitions all specifically 
exclude “HIV disease resulting in tuberculosis”, which is included under HIV-associated conditions (ICD-10 code B20.0).  
As described in more detail below, this may seem a straightforward division, and if the full five-character ICD codes 
were used in all settings, it would be.  In practice, however, many bodies, particularly in LMIC, use only three-character 
codes (B20, B21, etc.) and deaths due to HIV-associated TB are indistinguishable from other infectious and parasitic 
HIV-associated deaths, all of which are also included under the ‘B20’ umbrella [76]. 
1.2.3.2 Estimating cause-specific mortality in LMIC 
Many countries rely on civil registration and vital statistics (CRVS) systems as their primary source of mortality data.  In 
many LMIC, however, these systems are weak or non-existent, and estimates of disease burden and mortality must be 
compiled through other means [82,83].  For TB deaths, for example, WHO use a variety of sources to generate mortality 
estimates, including case notification data, results from TB prevalence surveys, estimates of HIV prevalence, and 
estimates of country-specific case-fatality rates [84].  Figures produced by WHO also depend heavily on mathematical 
models, most importantly those included in the Spectrum software suite (http://www.avenirhealth.org/software-
spectrum.php), which is also used by UNAIDS and other groups [85]. 
Attempts to estimate mortality due to HIV-associated TB are doubly hampered, however, by the issues with ICD-10 
described above.  Even in countries with functional CRVS systems, such as South Africa, estimates of mortality must still 
be derived through modelling, as cause-specific mortality figures are reported to WHO only in three-character format 
(i.e., B20, rather than B20.0) [11,72].  As a result, there are few examples available of direct (non-modelled) estimations 
of mortality attributable to HIV-associated TB. 
1.2.4. Alternative methods to directly estimate disease burden and mortality 
1.2.4.1 Pathological autopsy 
Pathological autopsy remains the most accurate method for assessing disease prevalence at death and assigning causes 
of death [68].  The procedure is usually conducted by a pathologist and involves exposure and visualisation of all the 
organs, with samples sent, at a minimum, for histological examination.  Pathological autopsies provide high quality data 
and, as organs are directly visualised, can also provide accurate estimates of disease prevalence among the decedents 
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examined.  However, global autopsy rates, while always low, have been in decline for several years.  This is thought to 
be for a number of reasons, including improvements in diagnostic facilities (in high-income settings), increasing 
reluctance on the part of family members to provide consent, and reluctance on the part of clinicians to request the 
procedure or to go through the consent procedure with families [86].  Many of these reasons also apply to resource-
limited settings, although, arguably, autopsies are even more important in these settings, where vital registration data 
are sparse and diagnostic facilities often limited [87–89]. 
Some of the technical strengths of pathological autopsy also count against it.  A comprehensive and technically complex 
procedure may produce high quality data, but also requires highly trained personnel and specialist facilities, both of 
which increase the cost and limit the feasibility of the procedure to different contexts.  As discussed in more detail in 
Chapter 2.2, this, at least in part, may explain why the majority of autopsy studies in LMIC have been conducted among 
hospitalised individuals.  More recent studies have therefore used minimally-invasive techniques to circumvent some of 
the issues encountered with complete autopsy. 
1.2.4.2 Minimally-invasive techniques 
Minimally-invasive autopsy (MIA), which entails post-mortem sampling of body fluids or solid organs through aspiration 
or tissue core biopsy, respectively, has become increasingly popular in recent years [90].  In resource-limited settings, in 
particular, it compares favourably to complete autopsy, as it is cheaper and faster to conduct, more acceptable to 
families, does not require specialist training, and provides reasonable accuracy for estimating the prevalence of 
communicable diseases [91–95].  Groups in LMIC have developed standardised protocols for the use of this technique 
in resource-limited settings [96–99].  However, shortcomings and challenges exist, particularly in estimating the 
prevalence of non-communicable diseases, and in assigning causes of death from MIA data, where protocols and 
guidelines are not yet established. 
1.2.4.3 Verbal autopsy 
A verbal autopsy (VA), in its most basic form, is a conversation with the relatives or carers of a deceased individual 
regarding the events leading up to death.  VAs have been used since the 1970s, initially to investigate maternal and 
child mortality [100].  The first paper describing the use of VA to quantify mortality among a more representative 
sample was published in 1986, reporting on a study conducted in Senegal [101].  Since then, as the scope of VA has 
expanded, considerable efforts have been made to refine both the interview and the methods used to assign causes of 
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death based on VA data [102].  In 2007, WHO convened a panel of VA experts to establish the first international 
standardised VA instrument [103].  Separate instruments are now used for the death of a child aged up to four weeks, a 
child aged four weeks to 14 years, and an adult (aged 15 years and above).  Unless otherwise specified, any references 
to ‘VA instrument(s)’ in this thesis pertain only to the third, adult questionnaire. 
The standard instrument consists, broadly, of four parts: first, basic details about the respondent (i.e., the person being 
interviewed), including their relationship to the deceased and the extent of their interaction during the final illness; 
second, basic details about the decedent, including demographic information, site of death, and cause(s) of death 
recorded on the death certificate; third, an open narrative section, allowing the respondent to describe, in their own 
words, the events leading up to death; and, finally, a set of closed, mostly yes/no, questions around diagnoses made by 
health professionals, symptoms witnessed or reported (including duration thereof), and any treatment sought or 
administered.  The last section makes up the bulk of the questionnaire (~80% of questions in the WHO 2012 instrument 
[104]).  Within this last section are also contained several discrete modules on specific topics.  The applicability of a 
module to a particular decedent is often determined by a single ‘entry’ question; for example, section 6 of the 2012 
WHO instrument is to be used only if the first question (“Did the deceased suffer from any injury or accident that led to 
her/his death?”) is answered in the affirmative; section 7 only if the decedent was female; and section 8 only if a female 
decedent was pregnant, had delivered, or had miscarried in the six weeks prior to death [104].  Various groups have 
also added their own modules, based on particular interests or location-specific mortality patterns; the research group 
at Agincourt health and demographic surveillance system (HDSS) site, in Mpumalanga Province, South Africa, for 
example, added modules asking detailed questions about epilepsy, stroke, and a history of work underground [105]. 
1.2.4.3.1 Using VA data to assign causes of death 
WHO VA instruments were updated in 2012, 2014, and 2016, though most changes made were relatively minor 
[104,106,107].  More dramatic, however, have been the changes in interpretation methods made over the same 
period.  Physician-certified verbal autopsy (PCVA) has been the most widely used method and is still widely perceived 
to be the most reliable in assessing cause-specific mortality fractions (CSMFs), to the extent that it is sometimes used as 
a reference standard in validating newer, experimental methods [108,109].  The PCVA method is described in detail 
later in this thesis (see Chapters 2, 5, and 6).  Briefly, it involves the review of VA data by two or more physicians who 
independently assign causes of death per ICD guidelines; causes assigned by reviewing physicians are then compared 
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and, if there is disagreement, the case is either discussed by the reviewing physicians or sent to another, independent 
physician for review (Figure 1:1).  Agreement between any two physicians is considered the final cause of death; if all 
three physicians are unable to agree, the deceased individual is assigned an ‘unknown’ or ‘indeterminate’ cause of 
death. 
Although the internal validity of the process is relatively high, with some care taken to account for interactions between 
reviewers, the cost, logistical difficulties, and time required for the process make it an inefficient choice for use on a 
larger scale.  In addition, there are concerns that the pre-existing beliefs or knowledge of the physicians involved may 
bias the assignment of certain causes of death, making it difficult to compare causes assigned in different contexts. 
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Figure 1:1. Illustrative overview of the PCVA process, incorporating discussion stage, per Agincourt HDSS site 
(adapted from upgrading appendix) 
 
CoD: cause of death; HDSS: health and demographic surveillance system; ICD: International Statistical Classification of 
Diseases and Related Health Problems (10th edition); PCVA: physician-certified verbal autopsy; VA: verbal autopsy; 
WHO: World Health Organization 
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In response to the sub-optimal reliability of PCVA and to overcome some of the logistical barriers to large-scale 
implementation of VA, recent efforts have focused on the development of computer-coded VA (CCVA) methods to 
achieve the same objectives [110,111].  Automated methods are easier to standardise; less expensive to run, especially 
when dealing with very large numbers of deaths; and give quicker results, potentially allowing for data to be analysed 
by several different methods in the same time it would take for physician review.  CCVA methods are therefore viewed 
as more suitable than PCVA for integration into civil registration systems, which is a major objective of some research 
and implementation groups [112–115]. 
The most prominent and widely used CCVA method is InterVA (http://www.interva.net), a programme that 
corresponds to the WHO 2012 VA instrument and interprets categorical VA data using a Bayesian algorithm.  InterVA 
assigns each decedent up to three causes of death, each with an associated probability [116,117].  Like most CCVA 
methods, InterVA assigns causes of death using a truncated list of 34 causes, each of which is a collection of more 
specific ICD-10 codes [118].  InterVA was first tested in the mid-2000s and has undergone a number of revisions [119]; 
the most recent version, issued in January 2016 and used in this thesis, is InterVA-4.03. 
The next most prominent programme, more recently made available for general use, is SmartVA-Analyze 
(http://www.healthdata.org/verbal-autopsy/tools).  This was developed by the Institute of Health Metrics and 
Evaluation (IHME) and uses the Tariff 2.0 method [120] to assign causes of death according to a list developed by the 
Population Health Metrics Research Consortium [121]. 
InSilicoVA [122,123], a probabilistic method developed more recently, has only just been made available for public use 
and is therefore not evaluated in this thesis (https://cran.r-project.org/web/packages/InSilicoVA/index.html).  As 
explored in more detail in Chapter 2.3, various other automated and algorithm-driven methods have been tested over 
the last decade, though most have now been abandoned in favour of the methods described above. 
1.2.5. South Africa 
1.2.5.1 General overview 
South Africa has one of the most unequal societies in the world.  In 2010, 53.8% of the population was living in poverty 
and, in 2011, the richest 10% of the population held 51% of the income share, compared with less than 1% held by the 
poorest 10% (Gini index 63.4) [124].  The political environment is also complex and volatile: the World Bank assigned 
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South Africa a ‘political stability’ score of −0.2 in 2015, placing it in the 38th percentile (90% confidence interval [CI] 
29.4–53.1) worldwide, compared with the most and least stable (Greenland,1.9, and Syria, −2.9, respectively [125]).  
With national unemployment at 26–36% (and consistently higher in those 15–34 years of age [126]), a minority tax base 
[127], and a seemingly constant threat of political and civil unrest, South Africa’s financial situation in recent years has 
been unsteady, as illustrated by the decline in the value of the Rand from 2012–2016 and the change in bond status to 
‘junk’ in early 2017 [128]. 
Many of South Africa’s current issues have their roots in the country’s tumultuous, and well documented, racial and 
political history, a detailed discussion of which is beyond the scope of this thesis.  It is sometimes easy to forget, in 
modern South Africa, that apartheid ended less than 25 years ago; the consequences of those policies continue to have 
a tangible impact on the daily lives of South Africans and exert considerable influence over the way national 
institutions, including health-related structures, are governed. 
1.2.5.2 The health system, HIV, and TB 
South Africa has the largest number of HIV-positive individuals of any country [129] and the second-highest number of 
new TB cases per year [1].  Health in the country has changed dramatically over the last twenty years, particularly in 
terms of HIV care: the dark days of AIDS denialism [130] are long past, in large part thanks to the tireless advocacy of 
civil society groups such as the Treatment Action Campaign [131] and investments made by the Zuma administration.  
The country now boasts the largest antiretroviral programme in the world, with an estimated 3.7 million individuals on 
treatment in 2016 [129]; has purchased almost as many Xpert MTB/RIF cartridges as the rest of the world combined 
(over 10.5 million from 2010–2016) [132]; and, in 2013, health expenditure per-capita was among the highest in the 
African region [12].  Great strides have been made in improving standardisation of care, monitoring and evaluation of 
critical outcomes [133], and in establishing a transparent process for translating evidence to policy [134]. 
Since the late 1990’s, there has been a steady move towards the decentralisation of healthcare in South Africa [135].  
Primary health clinics and community health centres are now a central pillar of the health system: among individuals 
aged five years or older, there were over 120 million visits to the 3,427 facilities operating in 2015/16 [136].  Health 
coverage of the population is varied, in part due to the wide variation in population density in different parts of the 
country (for example, Rustenburg municipality has a density of 160 persons/km2 and the City of Johannesburg 2,600 
persons/km2 [population 0.5 million and 4.4 million, respectively]) [137,138].  In 2013, WHO estimated that South 
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Africa had 5.9 health posts and 0.1 provincial hospitals per 100,000 population [12].  All public health facilities are 
served by a network of centrally coordinated laboratories (the National Health Laboratory Service [NHLS]) which allows 
for standardisation of protocols and testing nationwide [139].  The NHLS has also developed a national database, with 
online access available to practitioners and other healthcare professionals, allowing for greater accessibility of test 
results [140]. 
ART and TB treatment are available free of charge at all public facilities, a programme now majority financed by the 
South African government (79% of HIV spending and 91% of the national TB programme funding came from domestic 
sources in 2014 and 2016, respectively [1,129]).  Numbers of individuals on ART, in particular, have increased since the 
adoption of the nurse-initiated management of ART (NIMART) programme in 2007 [141], allowing for most individuals 
to receive their care in the community.  Efforts to improve adherence were given a boost by the introduction of a fixed-
dose combination ART formulation in 2013 [142], reducing the pill-burden for HIV-positive people.  Xpert MTB/RIF is 
now the first-line diagnostic test for TB and is used at over 200 laboratories across the country [139]. 
1.2.5.3 Current CRVS infrastructure 
South Africa is one of only three countries in the WHO African region with >70% coverage of deaths through civil 
registration [12].  Death certificates are completed by medical practitioners (or by tribal leaders in areas without 
medical practitioners) and causes of death are broadly classified as ‘natural’ or ‘unnatural’ [143].  Autopsies are 
generally conducted only for deaths due to unnatural causes, which include trauma, suicide, and deaths related to 
medical procedures.  Death certificates are collected by the Department of Home Affairs and collated by the Statistics 
South Africa, which produces, every year, a report on cause-specific mortality [144].  To do this, Statistics South Africa 
codes all causes of death listed on death certificates per ICD-10 and then uses two automated methods (the Medical 
Mortality Data System [MMDS] [145] and Iris [146]) to generate a single, underlying cause of death, per ICD rules.  
Death notification data are also collected by the South African Medical Research Council, who use the South African ID 
(a unique identifier assigned to each citizen) to keep records of the date and location of each death and produce 
periodic ‘Rapid Mortality Surveillance’ reports [147]. 
1.2.6. Lesedi Kamoso: “Light for the future” 
The results of the Lesedi Kamoso (“Light for the future”) study, a mortality sub-study nested within three large studies 
of TB and HIV in South Africa (described below), make up the bulk of this thesis.  The study aimed to determine the 
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autopsy prevalence of TB and other important infections among patients who died in the TB Fast Track, XPHACTOR, and 
XTEND studies; to perform verbal autopsies among the same target population; and to compare causes of death 
assigned by the two methods.  Detailed methods and findings from this study are presented throughout the thesis and 
are therefore not listed here.  This section describes briefly the three parent studies within which Lesedi Kamoso was 
nested. 
1.2.6.1 Parent study 1: TB Fast Track 
1.2.6.1.1 TB Fast Track: Background 
TB Fast Track was a pragmatic, open-label, cluster-randomised controlled trial conducted in South Africa from late 2012 
to mid-2015 [148] (Table 1:1; Appendix 2 [Chapter 8.2.1]).  The premise behind the study was straightforward: 
mortality among people with advanced HIV disease in LMIC is high, particularly pre- and early on ART; TB is thought to 
be a leading cause of death in these individuals, but is also more difficult to diagnose, with patients often not started on 
treatment due to delays in diagnosis, as described above.  The hypothesis was that identifying individuals at the highest 
risk of TB disease and starting them on TB treatment without waiting for microbiological confirmation (therefore 
circumventing the delays associated with routine diagnostic algorithms), followed by ART as soon as possible, would 
reduce all-cause mortality at six months.  The trial set out to evaluate whether a novel algorithm that incorporated 
point-of-care measurements would fulfil this purpose when implemented in a pragmatic way in a primary care setting. 
1.2.6.1.2 TB Fast Track: Setting and population 
The study was conducted at 24 primary health clinics in three provinces of South Africa: Gauteng, North West, and 
Limpopo (Figure 1:2).  Clinics were situated in diverse parts of the country, from Ekurhuleni Metropolitan municipality 
(Gauteng), the fourth most populous municipality in South Africa and one of the most densely populated, at 1,609 
persons/km2, to Moretele municipality in North West province (population density 136 persons/km2) and Greater 
Tubatse, in Limpopo (73 persons/km2) [149–151].  HIV prevalence among individuals aged 15–49 years, in 2012, was 
20.3% (95% CI 17.5–23.4) in North West province, 17.8% (95% CI 14.6–21.6) in Gauteng, and 13.9% (95% CI 10.2–18.7) 
in Limpopo [152].  All study sites were primary health clinics with no access to on-site Xpert MTB/RIF. 
Individuals were eligible for inclusion in the study if, at the time of enrolment, they were ≥18 years of age; HIV-positive 
with a CD4 count of ≤150 cells/µL; not receiving ART or TB treatment and had not received them in the preceding six or 
three months, respectively; and were well enough not to require referral to a secondary care facility.  To evaluate this 
An autopsy study exploring the spectrum of disease in individuals with advanced HIV 
 in primary care clinics in South Africa 
 Page 36 of 383 Chapter 1: Introduction 
final criterion, all potential participants underwent a brief examination to decide if they were well enough for inclusion.  
Individuals were excluded, per WHO recommendations [153], if they had a heart rate of more than 120 beats per 
minute, respiratory rate of more than 30 breaths per minute, systolic blood pressure of less than 90 mmHg, evidence of 
respiratory distress or jaundice, or were otherwise judged (by a health professional) as needing referral to a secondary 
facility.  Other exclusion criteria included a diagnosis of chronic hepatitis, a history of high alcohol intake (>112 or >84 
units of alcohol per month for men and women, respectively), a previous reaction to efavirenz, and pregnancy, 
although the last criterion was later removed due to changes in South African guidelines [154]. 
Figure 1:2. Map of South African provinces in which the TB Fast Track study was conducted 
 
1.2.6.1.3 TB Fast Track: Study procedures 
Each primary health clinic was treated as a cluster; 12 each in the intervention and control arms.  At intervention sites, 
the body mass index (BMI) of each participant was calculated; their haemoglobin measured, using a point-of-care assay; 
and their urine tested, using a dipstick lateral-flow assay, for lipoarabinomannan (LAM), a marker of mycobacterial 
disease.  A participant with any of BMI <18.5 kg/m2, haemoglobin <10 g/dL, or positive (1+ or higher) urine LAM, 
irrespective of symptoms, was considered to have a ‘high probability’ of active TB and was started on TB treatment as 
soon as possible, followed by ART two weeks later (Figure 1:3).  Participants who did not meet any of the above criteria 
and had no TB symptoms were considered to have a ‘low probability’ of active TB and were initiated on ART as soon as 
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possible.  Those who did not meet high probability criteria but did have symptoms suggestive of TB were considered 
‘medium probability’ and were investigated further and reassessed after a week. 
Figure 1:3. The TB Fast Track study algorithm, reproduced with the kind permission of Prof Alison Grant 
 
ART: antiretroviral therapy; BMI: body mass index; Hb: haemoglobin; LAM: lipoarabinomannan; TB: tuberculosis 
1.2.6.1.4 TB Fast Track: Implementation  
TB Fast Track completed enrolment in December 2014 and follow-up in June 2015.  A total 3,053 participants were 
recruited, 31 (1.0%) of whom were subsequently excluded, leaving 3,022 in the final analysis.  Some 364 individuals 
died after enrolment to the study, 285 (78.3%) within six months.  The results of the study were presented at the 2016 
Conference on Retroviruses and Opportunistic Infections (CROI) in Boston, USA [155]. 
1.2.6.2 Parent study 2: XPHACTOR 
The XPHACTOR study ran from mid-2012 to mid-2014 in four out-patient clinics in the Johannesburg area and evaluated 
a risk-based algorithm that prioritised investigation for TB (using Xpert MTB/RIF) among HIV-positive adults attending 
for routine care (Table 1:1).  The study enrolled individuals established on ART as well as those with low CD4 counts 
who had not yet initiated ART.  All participants were followed up for at least three months after enrolment; a small 
subset of individuals with continuing symptoms suggestive of TB but without a diagnosis of TB at three months were 
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further investigated and followed up for an additional three months.  The study enrolled 3,722 HIV-positive adults at 
the four sites, 125 (3.4%) of whom died.  Only data from a subset of the overall cohort have been published so far 
[156], though other results were presented in 2015 [157]. 
1.2.6.3 Parent study 3: XTEND 
In 2012, South Africa planned to roll-out Xpert MTB/RIF to replace sputum smear at clinical sites across the country.  
Embedded within this roll-out was the XTEND study [158], a pragmatic, cluster-randomised trial to assess the effect on 
mortality of the implementation of Xpert MTB/RIF in primary care facilities in South Africa (Table 1:1).  The study was 
conducted at 20 laboratories and 40 primary health clinics, with each cluster defined as one laboratory and two clinics.  
Adults (≥18 years) were enrolled, irrespective of TB symptoms or HIV status, who were being investigated for TB by 
clinic staff, i.e., had sputum sent to a laboratory for testing.  Depending on cluster, sputum samples underwent either 
immediate testing with Xpert MTB/RIF or examination by smear microscopy.  Laboratories using smear microscopy 
during the study period implemented Xpert MTB/RIF around six months after the end of enrolment.  The primary 
outcome was all-cause mortality at six months after enrolment. 
Between June and November 2012, the study enrolled 4,656 adults, of whom 2,206 (47.4%) self-reported as HIV-
positive.  Some 231 individuals died after enrolment, at least 97 (42.0%) of whom were HIV-positive.  Results of the 
study were published in 2015 [159]. 
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Table 1:1. Summary of basic characteristics of three parent studies, including study populations and inclusion/exclusion criteria 
 TB Fast Track XPHACTOR XTEND 
Enrolment period December 2012 to December 2014 September 2012 to March 2014 June to November, 2012 
Minimum follow-up Six months Three months Six months 
Location 24 primary health clinics in Gauteng; North 
West; and Limpopo provinces. 
Four out-patient clinics in Gauteng province (all 
in the Johannesburg area). 
40 primary health clinics in Eastern Cape, Free 
State, Gauteng, and Mpumalanga provinces. 
Population HIV-positive adults (≥18 years) attending 
primary health clinics. 
HIV-positive adults (≥18 years) attending out-
patient clinics for HIV care. 
Adults (≥18 years) attending primary health 
clinics  
Inclusion criteria • CD4 count ≤150 cells/µL • Already receiving ART or pre-ART • Being investigated for TB by clinic staff 
Exclusion criteria • Receiving or had received ART in the 
preceding 6 months 
• Receiving or had received TB treatment in 
the preceding 3 months 
• Any contraindication to efavirenz (until Aug 
2013) 
• Pregnant (until Aug 2013) 
• Unwell at enrolment (HR >120, RR ≥30, SBP 
<90 mmHg, respiratory distress, jaundice, 
or haemoptysis) 
• High alcohol intake 
• Diagnosis of chronic hepatitis 
• Receiving or had received TB treatment in 
the preceding 3 months 
• Receiving TB treatment 
• Not resident in the catchment area 
• Planning to relocate within subsequent 8 
months 
Enrolled, n 3,022 3,722 4,656* 
Female, n (%) 1,668 (55.2) 2,625 (70.5) 2,891 (62.1) 
Age (years), median (IQR) 37 (32–44) 39 (33–46) 36 (28–47) 
Total deaths, n (%) 364 (12.0) (until the end of the study period; 
285 occurred within 6 months of enrolment) 
125 (3.4) 231 (5.0) 
*2,206 (47.4%) self-reported HIV-positive at enrolment 
ART: antiretroviral therapy; HR: heart rate; IQR: interquartile range; RR: respiratory rate; SBP: systolic blood pressure TB: tuberculosis 
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1.3. Aims and objectives 
1.3.1. Aims 
This thesis aims to describe the burden of disease, particularly TB, in HIV-positive adults dying in resource-constrained 
settings; causes of death in HIV-positive adults using clinical data, with and without pathological autopsy; and causes of 
death in HIV-positive adults using verbal autopsies interpreted by different methods, with a particular focus on the 
measurement of mortality attributable to HIV-associated TB. 
1.3.2. Objectives 
The objectives of this thesis are to:  
1. Synthesize the literature describing, in HIV-positive adults dying in LMIC, 
a) the use of pathological autopsy to estimate the burden of TB and other diseases,  
b) the use of VA to estimate HIV- and TB-related mortality, and 
c) direct estimations of causes of death using clinical and/or autopsy data; 
2. Estimate the prevalence of TB and other infections, based on pathological autopsy, in adults with advanced 
HIV dying after enrolment to a pragmatic trial of empirical TB treatment in South Africa; 
3. Evaluate, among HIV-positive adults, the performance of different VA interpretation methods compared 
with a clinical reference standard derived from research and autopsy data, in 
a) assigning HIV-related causes of death at individual and population levels, and 
b) differentiating HIV-associated TB from other HIV-associated causes of death; and 
4. Evaluate, among adults with confirmed HIV status,  
a) the sensitivity and specificity of the ‘HIV diagnosis’ question included in the WHO 2012 VA instrument 
in assigning HIV status, and 
b) the specificity of different VA interpretation methods in assigning HIV-associated causes of death. 
 
1.4. Thesis structure 
This thesis follows a ‘research paper’-style format.  A review of the literature is presented in two parts in Chapter 2, 
pertaining to (1) tissue autopsy estimates of disease burden in HIV-positive adults in LMIC and (2) the validation of VA 
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methods in estimating HIV- and TB-associated causes of death.  The first research paper makes up Chapter 3, a 
systematic review of the literature around the direct estimation of causes of death in HIV-positive adults in LMIC.  
Chapters 4, 5, and 6 report methods and results of fieldwork conducted in South Africa, presented as three further 
research papers.  Chapter 4 aims to address objective 2, describing the prevalence of TB and other infections at 
autopsy, and chapters 5 and 6 address objectives 3 and 4, respectively, describing the performance of VA in estimating 
TB and HIV-associated mortality, as well as the sensitivity and specificity of individual VA questions in detecting HIV 
status and/or ART use.  Finally, Chapter 7 summarises and discusses the various elements raised in the thesis, their 
relation to one another and to wider policy and practice, and offers a list of recommendations and conclusions. 
1.5. Contribution to the work presented in this thesis 
1.5.1. Conception, study design, protocol development, and regulatory approvals 
I was not involved in the conception of the idea for this study, which came from discussions between Prof Alison Grant 
and colleagues at the Aurum Institute (including Dr Salome Charalambous and Dr Kerrigan McCarthy) and Johns 
Hopkins University (Dr Chris Hoffmann).  The managers of the three parent studies were also involved at an early stage 
(Dr McCarthy [XTEND], Dr Yasmeen Hanifa [XPHACTOR, LSHTM], and Dr Mpho Tlali [TB Fast Track, the Aurum 
Institute]).  My first involvement was in helping develop the Lesedi Kamoso study protocol and applying for funding.  
Once funding had been secured, I was closely involved in study design, including applications to regulatory bodies.  I 
developed standard operating procedures (SOPs), hired and trained staff, and established the study among the various 
stakeholders (primarily mortuary owners, clinic staff, and hospital management).  A particularly large undertaking was 
the training of TB Fast Track study staff in obtaining written informed consent for MIA, something that was done at the 
point of enrolment in TB Fast Track.  I devised the training, led workshops, monitored progress, and worked closely with 
individual researchers to improve consent rates. 
Various minor aspects of the protocol were modified as the study was implemented, the majority of which were at my 
direction, as the individual most familiar with study progress.  The largest and most notable change to the study 
protocol, to conduct VAs among HIV-negative individuals to assess the specificity of VA in assigning HIV-associated 
causes of death, was suggested by Prof Daniel Chandramohan, who was not a study investigator, but is a member of my 
PhD advisory panel, and whose advice was sought part-way through the study. 
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1.5.2. Study management and data collection 
1.5.2.1 Parent studies 
The primary responsibilities for the management of the three parent studies were with the three trial managers.  I was 
closely involved, however, in the day-to-day running of TB Fast Track, including in the design and piloting of case 
reports forms, data management, monitoring of study sites, and staff training.  I was not involved in any study activities 
for XPHACTOR or XTEND. 
1.5.2.2 Lesedi Kamoso sub-study 
I oversaw all study activities and line-managed the five individuals in the study team.  I wrote SOPs for MIAs, VAs, data 
collection from hospital files, and selection of HIV-negative deceased individuals from hospital mortuaries.  I conducted 
the majority of MIAs and oversaw VA data collection (the VA interviews themselves were conducted by research 
assistants) and coordinated data collection from clinics, hospitals, and the National Health Laboratory Service (NHLS) 
online database.  In these last two tasks, I received some assistance from Dr Natalie Wood, a student from LSHTM who 
volunteered to work with our team for a few months, and certain members of the TB Fast Track team.  I also reviewed 
registers at five hospital mortuaries and traced hospital files and lab results for several hundred deceased adults to find 
HIV-negative individuals for whom a VA could be conducted. 
The collection of VA data for decedents from the XTEND study was coordinated by a project manager at the Aurum 
Institute, Ms Noriah Maraba, who also led the initial analysis and write-up of those data; this was published in 2016 
[160].  I was closely involved in the analysis and writing process and am listed as the second author on the paper.  
Although VA data from these individuals are included in this thesis (research paper 4 [Chapter 6]), I conducted all 
analyses presented here.  This thesis also presents interpretation of these VA data by SmartVA-Analyze, something not 
done in the previous analysis. 
1.5.3. Data management & analysis 
VA data were entered directly into an online database by the interviewers; I conducted quality assurance of all VA data, 
including review of open narratives.  Results of tests conducted on pathological autopsy samples were recorded 
centrally by the private laboratory at which the majority of tests were conducted.  I wrote CRFs and built separate 
databases for remaining pathological autopsy data, hospitalisation data, secondary data from clinics, and data from the 
NHLS database.  Data entry and management for the parent studies were coordinated by the data management 
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department at the Aurum Institute; I was involved in data management for TB Fast Track only in an advisory capacity 
and had no involvement in data management for XPHACTOR or XTEND. 
I designed and managed the all physician review of verbal autopsies and clinical data.  To allow for easier review of 
clinical cases, I collated information from several sources (clinic files, hospital files, research databases, and the NHLS 
database) and produced a chronological summary for each decedent (see Appendix 4 [Chapters 8.4.2 and 8.4.3] for 
examples).  I also designed digital entry forms to allow for remote review and managed all secondary data created by 
reviewers. 
I conducted all analyses presented in this thesis.  This included the development of two large Stata do-files: the first for 
converting VA data from WHO 2012 format into a format suitable for SmartVA-Analyze, for which I received assistance 
from Prof Chandramohan, Dr Nicholas Maire, and Mr Vinit Mishra, who provided me with ‘R’ code that could be 
adapted for Stata (Appendix 5 [Chapter 8.5.4]); and the second for changing the causes of death assigned by physicians 
reviewing VA or clinical data into a suitable format for the Mortality Medical Data System (MMDS) to convert into a 
single ‘underlying’ cause (Appendix 5 [Chapter 8.5.5]). 
1.5.4. Multi-authored papers 
1.5.4.1 Research paper 1: Directly estimated causes of death among HIV-positive adults in low- and 
middle-income countries.  A systematic review and meta-analysis (Chapter 3) 
This manuscript has not yet been submitted for publication and has not yet been reviewed by all co-authors.  Prof 
Katherine Fielding and Prof Chandramohan both provided advice regarding the systematic review protocol and Prof 
Grant has critically reviewed the protocol and manuscript. 
1.5.4.2 Research paper 2: Autopsy prevalence of tuberculosis and other potentially treatable infections 
among adults with advanced HIV enrolled in out-patient care in South Africa (Chapter 4) 
I carried out all analyses, wrote all drafts, and maintained overall control of the content of this paper.  Dr Nicole Wolter 
managed and collated the results of tests carried out at the National Institute for Communicable Diseases (NICD).  Prof 
Fielding and Drs Anne von Gottberg, McCarthy, Tanvier Omar, Wolter, and Emily Wong made important suggestions 
regarding the presentation of results and Drs von Gottberg, Neil Martinson, McCarthy, and Wong suggested changes to 
the structure and content of the discussion.  All authors reviewed and approved the final manuscript prior to 
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submission.  The peer reviewer at PLoS One had several comments; the letter written in response to her/his remarks, 
which also details the resultant changes made to the manuscript, is included in Appendix 6 (Chapter 8.6.1). 
1.5.4.3 Research paper 3: Measuring mortality due to HIV-associated tuberculosis among adults in South 
Africa: Comparing verbal autopsy, minimally-invasive autopsy, and research data (Chapter 5) 
I conducted all analyses, wrote all drafts, created all the figures, and maintained overall control of the content of this 
paper.  Prof Chandramohan facilitated the development of code for converting WHO VA data into a format suitable for 
SmartVA-Analyze; Prof Fielding offered guidance around statistical methods and presentation of results; and Profs 
Chandramohan and Kathleen Kahn provided advice around the overall direction and tone of the manuscript.  All 
authors reviewed and approved the final manuscript prior to submission.  Peer reviewers at PLoS One had only a few 
comments, requesting minor changes to the discussion; the letter written in response, which also details resultant 
changes made to the manuscript, is included in Appendix 6 (Chapter 8.6.2). 
1.5.4.4 Research paper 4: Performance of verbal autopsy methods in estimating HIV-associated mortality 
among adults in South Africa (Chapter 6) 
I conducted all analyses, wrote all drafts, created all the figures, and maintained overall control of the content of this 
paper.  Prof Fielding made suggestions around presentation of results and table structure and Profs Chandramohan and 
Kahn provided advice around the overall direction and tone of the manuscript as well as around the structure and 
content of the discussion.  All authors reviewed and approved the final manuscript prior to submission.  This 
manuscript was rejected from PLoS Medicine (prior to peer review) and is currently being prepared for resubmission to 
another journal. 
1.5.5. Other individuals who provided guidance and/or input 
My upgrading committee, made up of Dr Corinne Merle and Profs Robin Bailey and Ron Behrens, provided advice and 
suggestions around methods for comparing causes of death assigned by different methods and, importantly, around 
structuring the review process to minimise physician learning.  Prof Sebastian Lucas provided helpful advice around 
some of the practicalities of the MIA procedure and Prof Stephen Lawn and Dr Stephen Morris-Jones gave input on 
testing pathological autopsy samples for TB and other bacteria. 
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Dr Ed Fottrell, at the very early stages of the study, provided input around some of the logistics involved in collecting 
data for verbal autopsies.  Dr Abraham Flaxman was very helpful in gaining access to the most recent version of 
SmartVA-Analyze, which, at the time, was not available from the Institute of Health Metrics and Evaluation. 
Several individuals offered useful perspectives and advice at various points during the study, all of which may have had 
an impact on study implementation, data analysis, or ideas expressed in this thesis, though their precise effects are not 
necessarily quantifiable.  They include Dr Kevin Cain, Dr Janneke Cox, Dr Haileyesus Getahun, Prof Judith Glynn, Dr 
Kobus Herbst, Dr Michael Kimerling, Dr Richard Lessells, Prof John Porter, Dr William Wells, and Prof Basia Zaba. 
Prof Grant was involved at every stage of the development of this thesis and critically reviewed and provided input on 
most or all of the material presented here.  
An autopsy study exploring the spectrum of disease in individuals with advanced HIV 
 in primary care clinics in South Africa 
 Page 46 of 383 Chapter 2: Literature review 
Chapter 2. Literature review 
Chapter contents 
2.1. Introduction ..................................................................................................................................................... 47 
2.2. Part 1: Pathological autopsy prevalence of TB and other infections among HIV-positive adults 
dying in low- and middle-income countries ............................................................................................................. 47 
2.2.1. Introduction .................................................................................................................................................... 47 
2.2.1.1 Aim ........................................................................................................................................................... 48 
2.2.2. Methods .......................................................................................................................................................... 48 
2.2.2.1 Search strategy ......................................................................................................................................... 48 
2.2.2.2 Screening and review ............................................................................................................................... 49 
2.2.2.3 Data extraction and management ............................................................................................................ 49 
2.2.3. Results ............................................................................................................................................................. 49 
2.2.3.1 Search results and screening .................................................................................................................... 49 
2.2.3.2 Overview of studies .................................................................................................................................. 51 
2.2.3.3 Prevalence of TB ....................................................................................................................................... 54 
2.2.3.4 Prevalence of other infections ................................................................................................................. 66 
2.2.4. Discussion ........................................................................................................................................................ 68 
2.2.4.1 Overview ................................................................................................................................................... 68 
2.2.4.2 Possible sources of bias ............................................................................................................................ 70 
2.2.4.3 Other limitations of this review ................................................................................................................ 71 
2.2.5. Summary ......................................................................................................................................................... 71 
2.3. Part 2: Studies that have used verbal autopsy to estimate HIV-associated mortality and 
compared findings to reference causes of death and/or HIV serostatus .................................................................. 72 
2.3.1. Introduction .................................................................................................................................................... 72 
2.3.1.1 Aims .......................................................................................................................................................... 73 
2.3.1.2 Objectives ................................................................................................................................................. 73 
2.3.2. Methods .......................................................................................................................................................... 73 
2.3.2.1 Search strategy ......................................................................................................................................... 73 
2.3.2.2 Inclusion and exclusion criteria ................................................................................................................ 74 
2.3.2.3 Data extraction and management ............................................................................................................ 75 
2.3.2.4 Analysis ..................................................................................................................................................... 75 
2.3.3. Results ............................................................................................................................................................. 77 
2.3.3.1 Search results, screening, and review ...................................................................................................... 77 
2.3.3.2 Description of studies included ................................................................................................................ 78 
2.3.3.3 Studies that compared VA-assigned causes of death to individually-assigned reference 
causes of death where most or all individuals assigned an HIV-associated cause were confirmed 
HIV-positive .......................................................................................................................................................... 80 
2.3.3.4 Studies that compared VA-assigned causes of death to individually-assigned reference 
causes of death in individuals without confirmed HIV status .............................................................................. 87 
An autopsy study exploring the spectrum of disease in individuals with advanced HIV 
 in primary care clinics in South Africa 
 Page 47 of 383 Chapter 2: Literature review 
2.3.3.5 Studies that compared VA-assigned causes of death to population estimates of HIV-
associated among individuals with confirmed HIV status .................................................................................... 92 
2.3.3.6 Studies conducted in adults with confirmed HIV status that assessed the specificity of VA 
methods in assigning HIV-associated causes of death and/or the performance of VA questions in 
assigning HIV status .............................................................................................................................................. 95 
2.3.4. Discussion ........................................................................................................................................................ 99 
2.3.4.1 Summary of findings ................................................................................................................................. 99 
2.3.4.2 Reference standards ............................................................................................................................... 100 
2.3.4.3 HIV-associated TB ................................................................................................................................... 100 
2.3.4.4 Previous reviews ..................................................................................................................................... 101 
2.3.4.5 Potential sources of bias ........................................................................................................................ 101 
2.3.4.6 Gaps in the literature and remaining questions ..................................................................................... 104 
2.3.5. Summary and conclusions ............................................................................................................................. 105 
 
2.1. Introduction 
This chapter includes two separate reviews of the literature.  The first review (Part 1) describes the findings of studies 
estimating the autopsy prevalence of TB and other infections in HIV-positive adults dying in LMIC.  This does not include 
discussion of causes of death assigned in autopsy studies, as this is discussed in detail in Chapter 3 (research paper 1).  
The second review (Part 2) will describe findings from VA validation studies conducted in areas of high HIV prevalence, 
with a particular focus on the types and quality of reference standards used for validation, and the accuracy of VA 
interpretation methods in assigning HIV- and TB-associated causes of death. 
2.2. Part 1: Pathological autopsy prevalence of TB and other infections 
among HIV-positive adults dying in low- and middle-income countries 
2.2.1. Introduction 
Pathological autopsy studies have been a source of information on disease processes, interactions, and epidemiology in 
many contexts for many decades [86].  Regarding HIV specifically, data from pathological autopsy studies conducted in 
the late 1980’s and early 1990’s were critical in the development and refinement of AIDS case definitions [78,79] and, 
through a better understanding of the spectrum of disease associated with HIV, allowed for more accurate estimation 
of the burden of HIV-associated disease in developing countries [161].  Autopsy studies have been particularly useful in 
better understanding the relationship between HIV and TB [68], the leading cause of death among PLHIV in LMIC.  Due 
to the difficulties involved in diagnosing TB in living individuals with advanced HIV (see Chapter 2), autopsies have been 
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relied upon to provide estimates of the burden of undiagnosed TB among HIV-positive individuals dying in these 
settings. 
As the global rollout of ART continues, pathological autopsy data remain important in allowing us to monitor progress 
and predict the evolution of the HIV epidemic.  As they have in the past, autopsy data remain key to the maintenance 
of up-to-date definitions that accurately reflect real-world phenomena and allow for reliable and meaningful estimates 
of disease, morbidity, and mortality.   
2.2.1.1 Aim 
To estimate the prevalence of TB and other infections among HIV-positive adults included in pathological autopsy 
studies conducted in LMIC. 
2.2.2. Methods 
2.2.2.1 Search strategy 
MEDLINE was searched (via PubMed) using variations of the following terms: HIV/AIDS, autopsy, and a list of LMIC 
(per the World Bank, 2015 [162] and the Cochrane Group, 2012 [163]; Table 2:1).  Conference abstracts and 
unpublished data were not searched.  The reference section of the recent systematic review of studies reporting the 
autopsy prevalence of TB in LMIC [71] was checked for additional articles. 
Table 2:1. Terms used to search the MEDLINE database (via PubMed) 
#1 (("hiv"[MeSH Terms])  
OR (acquired immune deficiency syndrome[MeSH Terms])  
OR (HIV) OR (human immunodef*)  
OR (AIDS) OR (acquired immune def*)  
OR (acquired immunodef*)) 
#2 (("autopsy"[MeSH Terms])  
OR (post mortem examination[MeSH Terms])  
OR (autops*)  
OR ((postmortem) OR (post-mortem) OR (post mortem))   
OR ((needle-autops*) OR (needle autops*))  
OR ((minimally invasive autops*) OR (MIA)) 
OR (necropsy)) 
#3 Filters for low- and middle-income countries as described by the Cochrane Group, 2012 [163], updated as per 
World Bank, 2016 [162] 
Final search 
#1 AND #2 AND #3 
MEDLINE: US National Library of Medicine® (NLM) bibliographic database; MeSH: Medical subject headings;  
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2.2.2.2 Screening and review 
I conducted all screening and review of articles.  Studies were excluded, based on titles and abstract, that included only 
children, only individuals without confirmed HIV status, only HIV-negative adults, or only HIV-positive adults in 
countries considered high-income at the time of data collection, or that assigned causes of death or measured only the 
prevalence of non-communicable diseases without describing the prevalence of infections.  The full text (where 
available) of the remaining articles was reviewed and the same exclusion criteria applied.  Where multiple articles 
described the findings from a single study or single group of individuals, the article was included that best described 
findings relevant to this review. 
2.2.2.3 Data extraction and management 
Using a standardised tool, data were extracted regarding study population, inclusion criteria, and autopsy and 
laboratory methods in all included studies.  The prevalence of TB and/or other infections found in each was recorded, 
as were the site of disease, autopsy method, completeness of reporting (single organ/system vs. full autopsy report), 
and ART status of decedents (where reported).  Data were entered into EpiData v3.1 (The EpiData Association, Odense, 
Denmark) and Microsoft Excel; all analyses were conducted using Stata v14 (StataCorp, College Station, TX, USA); and 
figures were formatted using Inkscape™ software (https://inkscape.org/). 
2.2.3. Results 
2.2.3.1 Search results and screening 
The search of Medline yielded 659 results, which included all but four of the studies included in the 2015 systematic 
review [71].  After screening of titles and abstracts, 574/663 (86.6%) articles were excluded and 89 full-text articles, 
where available, were reviewed.  Thirty six articles were excluded: 18 (50%) because they duplicated findings from a 
study already included (Table 2:2); six (17%) because they described only cause of death, not disease prevalence 
[95,164–168]; four (11%) because they reported findings for only one disease, other than TB [169–172]; four (11%) 
because they did not confirm the HIV status of decedents [97,173–175]; three (8%) because they did not report on the 
prevalence of infectious diseases [176–178]; and one (3%) because it was conducted in a high-income country [179]. A 
total 53 studies [19,87,93,94,180–228] were included in the review (Figure 2:1). 
Table 2:2. Pathological autopsy studies with more than one published article; articles that were included in and 
excluded from this review 
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Study 
location 
Data 
collected 
First/senior 
author(s) 
Included article(s) Excluded article(s) 
Cote d’Ivoire 1991 Lucas, SB AIDS, 1993 [19] BMJ, 1994 [229] 
Int J Cancer, 1994 [230] 
Tuber Lung Dis, 1994 [231] 
Cote d’Ivoire NS Domoua, K Revue de pneumologie 
clinique, 1993 [202] 
Medecine tropicale: revue du Corps de 
sante colonial, 1995 [232] 
India 1988–2007 Lanjewar, DN Path Res Int, 2011 [188] Clin Infect Dis, 1996 [233] 
Indian Heart J, 1998 [234] 
AIDS, 1998 [235] 
Indian J Pathol Microbiol, 1999 [236] 
HIV Med, 2001 [237] 
HIV Med, 2004 [238] 
Indian J Pathol Microbiol, 2016 [239] 
Kenya 1996–1997 Rana, FS JAIDS, 2000 [197] J Acquir Immune Def Syndr Hum 
Retrovirol, 1997 [240] 
Mexico 1984–1989 Mohar, A AIDS, 1992 [205] J Acquir Immune Def Syndr, 1990 [241] 
Mozambique 2002–2004 Menendez, C PLoS Med, 2008 [165] PLoS Med, 2009 [242] 
South Africa 2008–2009 Cohen, T PLoS Med, 2010 [185] Nat Med, 2016 [243] 
Tanzania 1997–1999 Ng’walali, P Forensic Sci Int, 2005 [228] Arch Pathol Lab Med, 1999 [244] 
Uganda 2009; 2013 Cox, JA PLoS One, 2012 [183] 
JAIDS, 2014 [94] 
J Clin Microbiol, 2015 [245] 
PLoS One, 2015 [246] 
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Figure 2:1. Flow diagram showing records found, screened, reviewed, and included in the analysis 
 
TB: tuberculosis 
2.2.3.2 Overview of studies 
Between 1984 and 2013, 53 pathological autopsy studies were conducted among HIV-positive adults in LMIC, including 
5,086 autopsies on HIV-positive adults (Table 2:3).  The majority were carried out in sub-Saharan Africa (23 [43.4%] 
studies; 2,040 [40.1%] autopsies) and Latin America and the Caribbean (19 [35.9%] studies; 2,249 [44.2%] autopsies).  
Brazil was the country with the highest number of individual studies (n = 15), followed by South Africa (n = 6) and India 
(n = 5).  Overall, low-income countries were under-represented, with most studies (32/53 [60.4%]) conducted in upper 
middle-income countries (2015 income threshold US$ 4,036–12,475 [162]).  Some of the most influential work in this 
area, conducted in Côte d’Ivoire and South Africa [19,211], was carried out in the 1990s, when ART was not available in 
most LMIC.  Though the subsequent decades have seen increasing numbers of autopsy studies in PLHIV, few have 
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included individuals who died after initiating ART (n = 9 studies: 2/21 [9.5%] published from 2000–2009; 7/15 [46.7%] 
published from 2010–2016).  Even in these nine studies, only half (531/1,120 [47.4%]) of the autopsies reported were 
conducted on individuals who had initiated ART. 
The majority of individuals undergoing autopsy were recruited and died in hospitals (40 [76%] and 36 [68%] studies and 
3,961 [78%) and 3,224 [63%] autopsies, respectively).  Even in studies which recruited individuals from the community 
as well as hospitals, most recruitment and death occurred within facilities.  Most studies used complete diagnostic 
autopsy, though three studies presented findings from only one system or organ [191,202,227].  Ten studies used 
partial autopsy or MIA, most (7/10) were conducted in sub-Saharan Africa.  Eight studies 
[19,87,93,184,185,195,197,212] used mycobacterial culture to estimate the prevalence of TB, and only three 
[87,184,186] attempted to culture other pathogens; more recent studies used Xpert MTB/RIF or other PCR methods 
on various samples to estimate TB prevalence, but most relied only on histology (38/53 [72%] used only histology and 
no other method). 
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Table 2:3. Inclusion criteria and methods used for pathological autopsy studies estimating disease prevalence in HIV-
positive adults in LMIC (including deaths from 1984–2013) and stratified by geographic area (n = 53 studies; n = 5,086 
autopsies) 
Category Studies, n (%) Autopsies, n (%) 
Region   
 Sub-Saharan Africa 23 (43.4) 2,040 (40.1) 
 Latin America & the Caribbean 19 (35.9) 2,249 (44.2) 
 South Asia 5 (9.4) 409 (8.0) 
 East Asia & the Pacific 5 (9.4) 359 (7.1) 
 Europe & Central Asia 1 (1.9) 29 (0.6) 
Country income category*   
 Low-income  7 (13.2) 549 (10.8) 
 Lower middle-income 14 (26.4) 1,312 (25.8) 
 Upper middle-income 32 (60.4) 3,225 (63.4) 
Recruited at   
 Hospital only 40 (75.5) 3,961 (77.9) 
 Hospital + community 4 (7.6) 199 (3.9) 
 Not specified 9 (17.0) 926 (18.2) 
Died at   
 Hospital only 36 (67.9) 3,224 (63.4) 
 Hospital and community 6 (11.3) 524 (10.3) 
 Not specified 11 (20.8) 1,338 (26.3) 
Basic inclusion criteria   
 Adults only 29 (54.7) 2,568 (50.5) 
 Adults + children 14 (26.4) 1,422 (28.0) 
 Males and females 51 (96.2) 5,005 (98.4) 
 TB diagnosis required  5 (9.4) 341 (6.7) 
 Other diagnosis required 4 (7.6) 497 (9.8) 
 Included any individuals on ART 9 (17.0) 1,120 (22.0)† 
Autopsy & laboratory methods   
 Complete autopsy‡ 39 (73.6) 3,996 (78.6) 
 Partial autopsy/MIA 10 (18.9) 717 (14.1) 
 Histology 46 (86.8) 4,150 (81.6) 
 Mycobacterial culture 8 (15.1) 937 (18.4) 
 Xpert MTB/RIF or other TB PCR 2 (3.8) 140 (2.8) 
 Other bacterial/fungal cultures/PCR 3 (5.7) 172 (3.4) 
* At time of study [247] 
†Total number of individuals included in these nine studies, not all initiated ART 
‡With or without examination of brain & spinal cord; some studies conducted complete autopsies but presented 
limited findings 
ART: antiretroviral therapy; LMIC: low- and middle-income countries; MIA: minimally invasive autopsy; PCR: 
polymerase-chain reaction; TB: tuberculosis  
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2.2.3.3 Prevalence of TB 
2.2.3.3.1 Studies that attempted to recruit a representative sample and obtained pathological specimens from only 
the lungs, or from the lungs and other anatomical sites  
Thirty studies, conducted between 1984 and 2013, made attempts to recruit consecutive samples of HIV-positive adults 
dying in LMIC (Table 2:4).  Most (24/30 [80%]) studies were included in a systematic review by Gupta et al., published in 
2015 [71], which included post-mortem studies of HIV-positive adult and/or child deaths in LMIC published before 
December 2013 and used a random-effects model to generate pooled estimates of TB prevalence for each geographical 
region.  The review excluded studies that included less than 10 individuals; that recruited individuals with a specific 
diagnosis (e.g., TB) or from a specific sub-group (e.g., miners); or that did not sample the lungs.  Thirty-six studies were 
included overall, 26 (72%) involving adults; each study was assessed for quality using a pre-determined checklist (scored 
out of 10), which included evaluation of participant selection and autopsy methods used.  Of the 26 studies, which 
described 2,397 autopsies, 22 (85%) had the full manuscript included and four (15%) only the abstract; 12 (46%) were 
from sub-Saharan Africa, seven (27%) from the Americas, four (15%) from South Asia, and three (12%) from South-East 
Asia; and 18 (69%) involved full autopsy (with or without brain and spinal cord), four (15%) limited autopsy, and four 
(15%) did not have autopsy methods specified.  The median quality score for the 26 studies was 5.0 (interquartile range 
[IQR] 3.5–6.9).  (Two studies included in the Gupta review were excluded from this review: one that was conducted in 
Taiwan, a high-income country [179,247] and another whose findings were replicated in a separate publication, which 
was included instead [241].) 
Based on random effects meta-analysis, the overall pooled prevalence of TB in adults included in the Gupta et al. 
systematic review was 39.7% (95% CI 32.4–47.0), with 45.8% (95% CI 32.6–59.1) of those with TB at autopsy not 
identified prior to death.  In sub-Saharan Africa, the pooled prevalence of TB was 43.2%, (95% CI 38.0–48.3; n = 9 
studies of adults) compared with 27.1% (95% CI 16.0–38.1; n = 5 studies) in the Americas and 63.2% (95% CI 57.7–68.7; 
n = 2 studies)) in South Asia.  Meta-regression analyses showed an increase in prevalence of ~5% every 10 years from 
1992–2002.  Twelve studies included information on dissemination: of decedents with TB, 87.9% (95% CI 82.2–93.7) 
had disseminated disease, with the lungs, liver, and spleen involved in 75–85% of cases (when sampled); central 
nervous system (CNS) involvement was seen only in ~20% of TB cases. 
Two large studies of the pathological autopsy prevalence of TB among HIV-positive adults in LMIC have been published 
since the 2015 systematic review was conducted (Table 2:4).  The first [94], conducted in a tertiary hospital in Kampala, 
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Uganda, recruited HIV-positive adults dying in hospital of non-maternal and non-traumatic causes in early-to-mid-2013.  
Complete autopsy and MIA were conducted for those who consented, with only histological examination used to assess 
for the presence of TB.  Among the 96 adults included (57% female; median age 35 years; median CD4 count 47 
cells/µL; 61% exposed to ART), complete autopsy found TB in 42 (44%), with the lungs (35/42 [83%]), liver (30/42 
[71%]), and spleen (29/42 [69%]) most often involved.  The authors did not report the proportion with disseminated 
disease, but at least 70% of individuals had extrapulmonary disease, suggesting high levels of dissemination; TB 
prevalence stratified by ART status was also not reported. 
The second major study [180] was conducted in a teaching hospital in Lusaka, Zambia, and recruited HIV-positive and 
HIV-negative individuals; aged >16 years; with next of kin; who were admitted for any reason; and who died in one of 
the general medical wards from 2012–2013.  Complete autopsy was conducted for those included, with histological 
examination and Xpert MTB/RIF used to assess for the presence of TB.  A total 125 individuals were included (36% 
female; median age 35 years; 65 [63%] receiving TB treatment), of whom 101 (81%) were HIV-positive (47 [48%] 
exposed to ART; other demographics not stratified by HIV status).  TB was found in 66/101 (65%) HIV-positive adults; all 
66 individuals had pulmonary TB and tested positive on Xpert MTB/RIF and 33/66 (50%) had disseminated disease.  
Data are not shown for TB prevalence stratified by TB treatment or ART status, but the authors reported no correlation 
between exposure to or duration of ART and the presence of TB at autopsy. 
A further four studies, conducted in China [187], Cote d’Ivoire [202], Mexico [205], and Brazil [206], recruited HIV-
positive individuals dying in hospitals and presented either all findings from complete autopsy or findings only from the 
lungs (Table 2:4).  The Chinese and Brazilian studies were both small (n = 7 and n = 15; TB prevalence 29% and 13%, 
respectively).  In the two larger studies, both of which were conducted in the pre-ART era, TB was found in 31/70 (44%; 
Cote d’Ivoire; respiratory findings only) and 45/177 (25%; Mexico) individuals.   
In the 30 studies, described in Table 2:4, that attempted to recruit representative samples of HIV-positive adults and 
obtained pathological specimens from at least the lungs, the prevalence of TB at autopsy ranged from 5.8% to 65.3%.  
Among the 2,999 individuals included, 1,111 had evidence of TB at autopsy, giving an overall crude prevalence of 
37.0%. 
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Table 2:4. Pathological autopsy studies that attempted to recruit a representative sample and obtained pathological specimens from only the lungs, or from the lungs and other 
anatomical sites (n = 30 studies; n = 2,999 autopsies) 
First author, 
year published 
Data 
collected 
Country Population Site of 
recruitment 
(death) 
Autopsy 
method 
TB lab 
method/s 
Among included HIV-positive adults Comments 
N (% 
female) 
On ART, 
n (%) 
Prevalence of 
TB, n 
(%) 
Crypto
, n (%) 
PCP, 
n (%) 
Bact. 
PNM, 
n (%) 
CMV
, n 
(%) 
T. 
gondii, 
n (%) 
Cox, 2014* [94] 2013 Uganda HIV+; died in 
medical ward 
(prospective)  
Hosp (Hosp) CDA + 
MIA 
Histo. 96 (57) 59 (62) 42 
(44) 
13 (14)  12 
(13) 
  Excluded deaths due to 
postpartum & trauma.  
Other bact. (6); KS (8); 
other fungi (4) 
Bates, 2015* 
[180] 
2012–
2013 
Zambia HIV+ or HIV-; 
died in hospital 
(prospective) 
Hosp (Hosp) CDA Histo.+ 
PCR 
101 (36) 48 (48) 66 
(65) 
 3 (3) 39 
(39) 
3 (3)  n = 35 on ART for 
median 6 (IQR 2–35) 
weeks; KS (6); 
meningitis (7) 
Siika, 2012 
[181] 
2012 Kenya Receiving ART Hosp (Hosp) CDA NS 223 (68) 223 
(100) 
80 
(36) 
  28 
(13) 
  Abstract only; ‘sepsis’ 
(19) 
Carrilho, 2012 
[182] 
2010 Mozambique Medical i/p 
deaths 
Hosp (Hosp) CDA NS 214 (NS) 0 64 
(30) 
  19 (9)   Abstract only; adults + 
children; bacterial 
meningitis (15); KS (15) 
Cox, 2012 [183] 2009 Uganda Consecutive 
deaths, ID/gastro 
ward 
Hosp (Hosp) CDA Histo. 35 (51) 10 (29) 16 
(46) 
8 (23) 1 (3) 5 (14) 1 (3)  KS (3); other bact. (4) 
Wong, 2012 
[184] 
2009 South Africa Consecutive i/p 
receiving/eligible 
for ART 
Hosp (Hosp) MIA Histo. + 
Culture + 
PCR 
39 (49) 25 (64) 25 
(64) 
4 (10) 1 (3) 6 (15) 1 (3)  Other bact. (9); NTM 
(2); other fungal (2) 
Cohen, 2010 
[185] 
2008–
2009 
South Africa Consecutive i/p 
deaths 
Hosp (Hosp) MIA Culture 226 (56) 39 (17) 106 
(47) 
     Samples pooled before 
testing for TB 
Garcia-Jardon, 
2010 [186] 
2000–
2008 
South Africa Medical i/p 
deaths 
Hosp (Hosp) CDA Histo. 86 (65) 0 33 
(38) 
6 (7) 7 (8) 17 
(20) 
 1 (1) Adults & children; KS 
(1); other bact. (12); 
other fungal (1) 
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First author, 
year published 
Data 
collected 
Country Population Site of 
recruitment 
(death) 
Autopsy 
method 
TB lab 
method/s 
Among included HIV-positive adults Comments 
N (% 
female) 
On ART, 
n (%) 
Prevalence of 
TB, n 
(%) 
Crypto
, n (%) 
PCP, 
n (%) 
Bact. 
PNM, 
n (%) 
CMV
, n 
(%) 
T. 
gondii, 
n (%) 
Li, 2009* [187] 2005–
2007 
China AIDS; died in 
hospital 
(retrospective) 
Hosp (Hosp) CDA Histo. 7 (0) 2 (29) 2 (29)  5 
(71) 
 2 
(29) 
1 (14) Other fungal (2); other 
bact. (1); n = 2 on ART 
for less than one week 
Lanjewar, 2011 
[188] 
1988–
2007 
India Medical i/p 
deaths 
Hosp (Hosp) CDA Histo. 236 (23) 0 152 
(64) 
18 (8) 11 
(5) 
48 
(20) 
35 
(15) 
 KS (2); other bact. (3) 
Eza, 2006 [189] 1999–
2004 
Peru I/p deaths; 
selected if 
unclear CoD 
Hosp (Hosp 
+ Comm) 
CDA Histo. 16 (38) 0 2 (13) 3 (19) 2 
(13) 
 7 
(44) 
 KS (1); other fungal (5) 
Souza, 2008 
[190] 
1996–
2003 
Brazil NS NS (NS) NS NS 129 (26) 0 36 
(28) 
7 (5) 11 
(9) 
22 
(17) 
 13 (10) Abstract only; adults & 
children; other bact. 
(6); histoplasmosis (17) 
Amarapurkar, 
2005 [191] 
1991–
2003 
India Hosp i/p Hosp (Hosp) CDA Histo. 60 (20) 0 35 
(58) 
1 (2)     Only liver findings 
reported; HCV (6); HBV 
(1) 
Viriyavejakul, 
2002 [192] 
NS Thailand Medical i/p 
deaths 
Hosp (Hosp) MIA Histo. 17 (NS) NS 1 (6) 2 (12) 1 (6) 2 (12) 2 
(12) 
 Adults & children; 
other bact. (2); other 
fungal (3) 
Deshmukh, 
2003 [193] 
1993–
2002 
 NS NS (NS) CDA NS 60 (NS) 0 22 
(37) 
     Adults & children 
Cury, 2003 
[194] 
1993–
2000 
Brazil Hosp i/p Hosp (Hosp) CDA Histo. 92 (25) 0 25 
(27) 
4 (4) 15 
(16) 
 16 
(17) 
8 (9) Other fungal (12) 
Soeiro, 2008 
[195] 
1990–
2000 
Brazil Deaths from 
acute resp. 
failure 
Hosp (Hosp) CDA Histo. + 
Culture 
250 (21) 0 36 
(14) 
9 (4) 68 
(27) 
91 
(36) 
33 
(13) 
18 (7) Adults & children; 
other bact. (10); 
‘sepsis’ (34); NTM (15) 
Satyanarayana, 
2003 [93] 
1998–
1999 
India NS NS (NS) MIA Histo. + 
Culture 
44 (NS) 0 18 
(41) 
12 (27)     Adults & children; 
other bact. (12) 
Ansari, 2002 
[196] 
1997–
1998 
Botswana Medical i/p 
deaths, inc. DOA 
Hosp (Hosp 
+ Comm) 
CDA Histo. 104 (46) 0 42 
(40) 
7 (7) 11 
(11) 
24 
(23) 
16 
(15) 
1 (1) KS (11); other bact. (7); 
NTM (2) 
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First author, 
year published 
Data 
collected 
Country Population Site of 
recruitment 
(death) 
Autopsy 
method 
TB lab 
method/s 
Among included HIV-positive adults Comments 
N (% 
female) 
On ART, 
n (%) 
Prevalence of 
TB, n 
(%) 
Crypto
, n (%) 
PCP, 
n (%) 
Bact. 
PNM, 
n (%) 
CMV
, n 
(%) 
T. 
gondii, 
n (%) 
Rana, 2000 
[197] 
1996–
1997 
Kenya Consecutive i/p 
deaths 
Hosp (Hosp) CDA Histo. + 
Culture 
75 (53) 0 38 
(51) 
4 (5) 3 (4) 22 
(29) 
3 (4) 2 (3) ≥17 with TB had non-TB 
'final diagnosis'; KS (2); 
other bact. (12) 
Liu, 1996 [198] 1996 China NS NS (NS) NS Histo. 151 (NS) 0 14 (9)      Abstract only; 25 cases 
of mycobacteriosis also 
had other infection or 
malignancy; NTM (20) 
Marques, 1996 
[199] 
1996 Brazil Medical i/p 
deaths 
Hosp (Hosp) NS Histo. 40 (NS) 0 21 
(53) 
      
Borges, 1997 
[200] 
1989–
1996 
Brazil Medical i/p 
deaths 
Hosp (Hosp) CDA + 
MIA 
Histo. 52 (NS) 0 9 (17)    16 
(31) 
  
Ayisi, 1997 
[201] 
1995 Ghana NS NS (NS) CDA NS 20 (NS) 0 7 (35)      Adults & children 
N'Dhatz, 1993* 
[202] 
NS Cote d'Ivoire HIV+; died in 
respiratory ward 
(prospective) 
Hosp (Hosp) CDA Histo. 70 (NS) 0 31 
(44) 
  21 
(30) 
  Present respiratory 
findings only. Only 
abstract available 
Lucas, 1993 
[19] 
1991 Cote d'Ivoire Consecutive i/p 
& community 
deaths 
Hosp (Hosp 
+ Comm) 
CDA Histo. + 
Culture 
247 (24) 0 94 
(38) 
8 (3) 7 (3) 74 
(30) 
45 
(18) 
 Other bact. (77); KS 
(22); other fungal (17); 
NTM (7) 
Nelson, 1993 
[203] 
1988–
1991 
Zaire Medical i/p 
deaths with AIDS 
+ unknown CoD 
Hosp (Hosp) CDA NS 64 (56) 0 26 
(41) 
19 (30) 2 (3)  13 
(20) 
11 (17) KS (16); other fungal 
(35) 
Abouya, 1992 
[204] 
1989 Cote d'Ivoire Consecutive 
deaths, 
pulmonary ward 
Hosp (Hosp) NS Histo. 53 (NS) 0 21 
(40) 
 5 (9) 18 
(34) 
  Extrapolated from CoD; 
KS (3) 
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First author, 
year published 
Data 
collected 
Country Population Site of 
recruitment 
(death) 
Autopsy 
method 
TB lab 
method/s 
Among included HIV-positive adults Comments 
N (% 
female) 
On ART, 
n (%) 
Prevalence of 
TB, n 
(%) 
Crypto
, n (%) 
PCP, 
n (%) 
Bact. 
PNM, 
n (%) 
CMV
, n 
(%) 
T. 
gondii, 
n (%) 
Mohar, 1992* 
†[205] 
1984–
1989 
Mexico AIDS; died in 
hospital 
(prospective) 
Hosp (Hosp) CDA Histo. 177 (7) 0 45 
(25) 
20 (11) 43 
(24) 
20 
(11) 
122 
(69) 
30 (17)  Adults & children 
(range 1–64 years; not 
stratified); other fungal 
(30); M. avium; KS (53) 
Michalany, 
1987* [206] 
NS Brazil Young males; 
AIDS; died in 
hospital 
(prospective) 
Hosp (Hosp) CDA Histo. 15 (0) 0 2 (13)   3 (20) 9 
(60) 
 Abstract only; TB not 
fully reported, but at 
least two cases; KS (2) 
*Not included in Gupta et al. 2015 systematic review [71] 
†Subset of these data included in Gupta et al. 2015 systematic review (Jessurun et al., 1990 [241]) 
AIDS: acquired immune deficiency syndrome; AM: ante mortem; ART: antiretroviral therapy; bact.: bacterial; CDA: complete diagnostic autopsy; CMV: cytomegalovirus; CoD: 
cause(s) of death; comm: community; crypto: cryptococcal disease; DOA: dead on arrival; i/p: in-patient; gastro.: gastroenterology; HBV: hepatitis B virus; HCV: hepatitis C virus; 
HIV-: HIV-negative; HIV+: HIV-positive; Hosp: hospital; Histo.: histology; ID: infectious diseases; IQR: interquartile range; MIA: minimally-invasive autopsy; KS: Kaposi sarcoma; M. 
avium: Mycobacterium avium; NS: not specified; NTM: non-tuberculous mycobacteria; PCP: Pneumocystis pneumonia; PCR: polymerase-chain reaction (including Xpert MTB/RIF); 
PM: post mortem; PNM: pneumonia; resp.: respiratory; T. gondii: Toxoplasma gondii; TB: tuberculosis 
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2.2.3.3.2 Studies that reported TB prevalence in non-consecutive samples, in only non-pulmonary specimens, or had 
other specific inclusion criteria 
Seven studies had eligibility criteria that included diagnoses other than HIV (Table 2:5).  Four of these, each of which 
required a prior diagnosis of TB, either ante or post mortem [87,207–209], were conducted in the Russian Federation, 
South Africa, Brazil, and Cote d’Ivoire and reported on individuals not exposed to ART.  TB was found in 29/29 (100%), 
37/47 (79%), 100/100 (100%), and 6/14 (43%) decedents, respectively.  A further two studies excluded individuals with 
prior diagnoses of TB or known causes of death, but still found high prevalence of TB at autopsy (12/38 [32%], lung and 
lymph node biopsies, Tanzania [210] and 7/20 [35%], lung and liver biopsies, South Africa [211]). 
Twelve studies reported only non-pulmonary findings (Table 2:6).  Four of these, all of which made attempts to include 
a representative sample of inpatient deaths, reported on entire organ systems: two CNS [213,217], one gastrointestinal 
(GI) tract (samples from several sites, from tongue to large bowel) [214], and one bone marrow (from three anatomical 
sites) [215].  Prevalence of TB was low in CNS samples (4/284 [1%] and 2/138 [1%]); prevalence was higher in the GI 
tract (9/92 [10%]; Brazil) and even higher in bone marrow (15/50 [36%]; Uganda).  Two studies conducted only liver 
biopsies and found TB in 19/117 (16%; Thailand [219]) and 34/100 (34%; Nigeria [218]; Table 2:6) samples; one sampled 
the kidneys (TB in 19/138 [14%]; Mexico [220]); and one the heart (TB in 3/32 [9%]; Puerto Rico [221]).  Four further 
studies [222–225], all from Brazil, included adults not exposed to ART (samples sizes 100–128), sampled only exo- or 
endocrine glands (salivary, adrenals, thyroid, or pancreas) and reported TB prevalence from 5% (adrenals) to 23% 
(thyroid).   
In the 12 studies that reported only non-pulmonary findings, 180 of 1,645 individuals had evidence of TB at autopsy, 
giving an overall crude prevalence of 10.9%.  If, however, the three studies that reported only CNS findings were 
excluded, the overall crude prevalence increased to 17.9% (174/971 with TB; n = 9 studies).   
Finally, two retrospective reviews of forensic autopsies, from Thailand [226] and Tanzania [228], and one of deaths 
among HIV-positive goldminers in South Africa [227] reported finding TB at autopsy in 19/67 (28%), 10/52 (19%), and 
14/66 (21%) decedents, respectively (Table 2:7).  Summary estimates of TB prevalence, stratified by geographic area, 
are presented in Table 2:8. 
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Table 2:5. Pathological autopsy studies that used specific diagnoses (other than HIV) as inclusion or exclusion criteria (n = 7 studies; n = 257 autopsies) 
First author, 
year 
published 
Data 
collec
tion 
Country Population 
(study design) 
Additional 
criteria 
Site of 
recruit-
ment 
(site of 
death) 
Autopsy 
method 
TB lab 
method
/s 
Among included HIV-positive adults Comments 
N (% 
female) 
On 
ART, n 
(%) 
Prevalence of 
TB, n 
(%) 
Crypto
, n (%) 
PCP, n 
(%) 
Bact. 
PNM., 
n (%) 
CMV, 
n (%) 
T. 
gondii, 
n (%) 
TB diagnosis                 
Balabanova, 
2011 [207] 
2008 Russian 
Federati
on 
HIV+; admitted 
through ED 
(retrospective)  
Included only if 
PM TB CoD 
H (H) CDA Histo. 29 (31) NS 29 
(100) 
   1 (3)  No CD4 data; no ART 
data; Diss. TB (16); 
TBM (5); Candida 
(7); Herpes (6) 
Martinson, 
2007 [87] 
2003–
2005 
South 
Africa 
HIV+ or HIV-; 
died in hospital 
(prospective) 
Included only if 
TB diagnosis 
H (H) CDA Histo. + 
Culture 
47 (55) 0 37 (79) 2 (4) 5 (11) 13 (28) 7 (15) 1 (2) KS (3); Salmonellosis 
(11) 
 
Gutierrez, 
2002 [208] 
1994–
1996 
Brazil HIV+ or HIV-; 
died in hospital 
(retrospective) 
Included only if 
AM or PM TB 
diagnosis 
H (H) CDA Histo. 100 (20) 0 100 
(100) 
4 (4) 14 (14) 10 (10) 4 (4)  KS (3); other fungal 
(4) 
Greenberg, 
1995 [209] 
1991–
1992 
Cote 
d'Ivoire 
HIV+; autopsy 
in hospital 
(retrospective) 
Included only if 
TB diagnosis 
H+C (H) CDA Histo. 14 (14) 0 6 (43)  1 (7)    All patients received 
TB treatment; other 
fungal (4); NTM (1); 
KS (2); Nocardia spp. 
(2) 
No TB diagnosis                
Kilale, 2013 
[210] 
NS Tanzania Died in hospital 
(prospective) 
Excluded if TB 
diagnosis/ CoD 
or non-
pulmonary 
diagnosis 
H (H+C) Lung & 
LN 
biopsies 
Histo. 38 (47) NS 12 (32)      Adults & children 
(range 15–44; not 
stratified) 
Karstaedt, 
1997 [211] 
NS South 
Africa 
AIDS; died in 
hospital 
(prospective) 
Included only if 
no CoD or no 
documented 
KS/lymphoma 
H (H) Lung & 
liver 
biopsies 
Histo. 20 (NS) 0 7 (35) 2 (10) 2 (10) 4 (20)   Liver>lung for TB (n 
= 7 vs. n = 2); 
Septicaemia (1) 
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First author, 
year 
published 
Data 
collec
tion 
Country Population 
(study design) 
Additional 
criteria 
Site of 
recruit-
ment 
(site of 
death) 
Autopsy 
method 
TB lab 
method
/s 
Among included HIV-positive adults Comments 
N (% 
female) 
On 
ART, n 
(%) 
Prevalence of 
TB, n 
(%) 
Crypto
, n (%) 
PCP, n 
(%) 
Bact. 
PNM., 
n (%) 
CMV, 
n (%) 
T. 
gondii, 
n (%) 
Other                 
Santosh, 
1995 [212] 
1989–
1994 
India HIV+; died in 
mental health/ 
neuroscience 
hospital 
(prospective) 
Included if 
psychiatric/ 
neurological 
presentation 
H (H) CDA/ 
CNS only 
Histo. + 
Culture 
9 (22) 0 1 (11) 5 (56) 1 (11)   2 (22)  n = 5 CDA; n = 4 CNS 
samples only.  Other 
bact. (2) 
AIDS: acquired immune deficiency syndrome; AM: ante mortem; ART: antiretroviral therapy; bact.: bacterial; C: community; CDA: complete diagnostic autopsy; CMV: 
cytomegalovirus; CNS: central nervous system; CoD: cause(s) of death; Crypto: cryptococcal disease; diss.: disseminated; ED: emergency department; i/p: in-patient; H: Hospital; 
HIV-: HIV-negative; HIV+: HIV-positive; Histo.: histology; ID: infectious diseases; KS: Kaposi sarcoma; LN: lymph node(s); NTM: non-tuberculous mycobacteria; PCP: Pneumocystis 
pneumonia; PM: post mortem; PNM: pneumonia; T. gondii: Toxoplasma gondii; TB: tuberculosis 
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Table 2:6. Pathological autopsy studies sampling or reporting findings from a single non-pulmonary organ or system only (n = 13 studies; n = 1,645 autopsies) 
First author, 
year 
published 
Data 
collected 
Country Population (study 
design) 
Site of 
recruit-
ment 
(site of 
death) 
Autopsy 
method 
Findings 
reported 
TB lab 
method/
s 
Among included HIV-positive adults Other results & 
comments N (% 
female) 
On 
ART, 
n (%) 
Prevalence of 
TB, n 
(%) 
Crypto
, n (%) 
P. 
jiroveci
i, n (%) 
Other 
bact. 
/fungi 
CMV, 
n (%) 
T. 
gondii, 
n (%) 
Systems                 
Silva, 2012 
[213] 
1989–
2008 
Brazil AIDS; autopsy at 
hospital 
(prospective) 
Hosp 
(NS) 
CDA CNS Histo. 284 
(28) 
75 
(26) 
4 (1) 45 (16) 1 (0.4) 11 (4) 7 (2) 85 (30)  
Guimaraes, 
2012 [214] 
1989–
1996 
Brazil Consecutive HIV+ 
autopsies at 
teaching hospital 
(retrospective) 
Hosp 
(Hosp) 
CDA GI tract Histo. 92 (17) 0 9 (10) 3 (3)  52 
(57) 
27 (29)  Protozoa (12); 
worms (8); KS (2); 
Three cases 
excluded due to 
poor samples 
Nabadda, 
2011 [215] 
2005–
2006 
Uganda HIV+; died in 
hospital from 
'natural causes' 
(prospective) 
Hosp 
(Hosp) 
Bone 
marrow 
Bone 
marrow 
Histo. 50 (48) NS 18 (36) 15 (30)  3 (6)    
Chimelli, 
1992 [216] 
NS Brazil HIV+ deaths 
(retrospective) 
NS (NS) CDA CNS Histo. 252 
(NS) 
0 NS 34 (13)   20 (8) 86 (34)  Abstract only; TB 
not reported; 
encephalitis (17) 
Wainstein, 
1992 [217] 
1985–
1990 
Brazil AIDS; autopsy in 
hospital 
(retrospective) 
NS 
(Hosp) 
CDA CNS Histo. 138 
(NS) 
0 2 (1) 17 (12)  2 (1)  29 (21) Abstract only 
(article in 
Portuguese) 
Solid organ(s)                 
Echejoh, 2006 
[218] 
2003–
2004 
Nigeria HIV+; died in 
hospital 
(prospective) 
Hosp 
(Hosp) 
Liver 
biopsies  
Liver Histo. 100 
(50) 
NS 34 (34)   17 
(17) 
  KS (5) 
Viriyavejakul, 
2000 [219] 
NS Thailand HIV+ (prospective) Hosp 
(Hosp) 
Liver 
biopsies 
Liver Histo. 117 
(23) 
NS 19 (16) 25 (21)  5 (4) 6 (5)  Adults & children 
(range 2–74 years; 
not stratified) 
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First author, 
year 
published 
Data 
collected 
Country Population (study 
design) 
Site of 
recruit-
ment 
(site of 
death) 
Autopsy 
method 
Findings 
reported 
TB lab 
method/
s 
Among included HIV-positive adults Other results & 
comments N (% 
female) 
On 
ART, 
n (%) 
Prevalence of 
TB, n 
(%) 
Crypto
, n (%) 
P. 
jiroveci
i, n (%) 
Other 
bact. 
/fungi 
CMV, 
n (%) 
T. 
gondii, 
n (%) 
Soriano-
Rosas, 1998 
[220] 
1986–
1991 
Mexico AIDS; autopsy in 
hospital 
(prospective) 
Hosp 
(NS) 
CDA Kidneys Histo. 138 
(14) 
0 19 (14) 10 (7)  4 (3) 8 (6)  Adults & children 
(not stratified)  
Altieri, 1992 
[221] 
NS Puerto 
Rico 
“Consecutive AIDS 
deaths" 
(prospective) 
NS (NS) CDA Heart Histo. 32 (16) 0 3 (9) 2 (6)  5 (16) 2 (6)  Abstract only; NTM 
(1) 
Endo- / exocrine                
Leon, 2009 
[222] 
1996–
1999 
Brazil AIDS; died in hospital 
(retrospective) 
Hosp 
(Hosp) 
CDA Salivary 
glands 
Histo. 105 
(31) 
NS 18 (17) 7 (7)   16 (15)  Adults & children 
Rodrigues, 
2002 [223] 
1989–
1998 
Brazil AIDS; autopsy in 
hospital 
(retrospective) 
Hosp 
(NS) 
CDA Adrenals Histo. 128 
(23) 
NS 7 (5) 7 (5)  8 (6) 62 (48)  HSV (2); protozoa 
(7) 
Basilio-de-
Oliveira, 2000 
[224]  
NS Brazil HIV+; pre-ART; 'died 
from AIDS 
complications' 
NS (NS) CDA Thyroid Histo. 100 
(NS) 
0 23 (23) 5 (5) 4 (4) 7 (7) 17 (17)  M. avium (5) 
Chehter, 2000 
[225] 
1995 Brazil AIDS and HIV−; i/p 
deaths; consecutive 
autopsies 
(prospective) 
Hosp 
(Hosp) 
CDA Pancreas Histo. 109 
(27) 
50 
(46) 
24 (22)  10 (9)   14 
(12.8) 
Immunohistochemis
try used for CMV, T. 
gondii, P. jirovecii, 
and mycobacteria 
AIDS: acquired immune deficiency syndrome; ART: antiretroviral therapy; bact.: bacterial; C: community; CDA: complete diagnostic autopsy; CMV: cytomegalovirus; CNS: central 
nervous system; CoD: cause(s) of death; Crypto: cryptococcal disease; GI: gastrointestinal; Hosp: Hospital; HIV−: HIV-negative; HIV+: HIV-positive; Histo.: histology; HSV: herpes 
simplex virus;  i/p: in-patient; ID: infectious diseases; KS: Kaposi sarcoma; LN: lymph node(s); NTM: non-tuberculous mycobacteria; neuro: neurological; NS: not specified; P. jirovecii: 
Pneumocystis jirovecii; PCP: Pneumocystis pneumonia; PM: post mortem; PNM: pneumonia; T. gondii: Toxoplasma gondii; TB: tuberculosis  
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Table 2:7. Pathological autopsy studies including only forensic cases or special populations (n = 3 studies; n = 185 autopsies) 
First 
author, 
year 
published 
Data 
collected 
Country Population (study 
design) 
Site of 
recruitment 
(site of 
death) 
Autopsy 
method 
TB lab 
method/
s 
Among included HIV-positive adults Comments 
N (% 
female) 
On 
ART, n 
(%) 
Prevalence of 
TB, n 
(%) 
Crypto, 
n (%) 
PCP, n 
(%) 
Bact. 
PNM., 
n (%) 
CMV, n 
(%) 
T. 
gondii, 
n (%) 
Peonim, 
2012 [226] 
2000–
2010 
Thailand Forensic autopsies 
(retrospective) 
H+C (H+C) CDA Histo. 67 (NS) NS 19 (28) 3 (4)  8 (12)   Salmonellosis (1); other 
bact. (6); meningitis (4) 
Murray, 
2007 [227] 
1990–
2002 
South 
Africa 
Miners, HIV+ and 
HIV− (retrospective) 
H+C (H) Cardio-
pulmona
ry 
Histo. 66 (0) 0 14 (21) 12 (18) 9 (14)    Only respiratory findings 
reported 
Ng'walali, 
2005 [228] 
1997–
1999 
Tanzania Forensic autopsies - 
'unusual' deaths; 
adults only 
(retrospective) 
H+C (H+C) CDA Histo. 52 (25) NS 10 (19) 3 (6)  7 (13)  1 (2)  
ART: antiretroviral therapy; bact.: bacterial; C: community; CDA: complete diagnostic autopsy; CMV: cytomegalovirus; Crypto: cryptococcal disease; H: Hospital; HIV−: HIV-negative; 
HIV+: HIV-positive; Histo.: histology; PCP: Pneumocystis pneumonia; PNM: pneumonia; T. gondii: Toxoplasma gondii; TB: tuberculosis 
Table 2:8. Crude summary estimates of the autopsy prevalence of TB in studies that sampled the lungs (n = 30) and studies that sampled only extrapulmonary sites, excluding 
the central nervous system (n = 9 studies), stratified by geographic area 
Type of study Crude prevalence, % (number of autopsies in which evidence of disease was sought) 
Overall Sub-Saharan Africa Latin America & the 
Caribbean 
South Asia East Asia & the 
Pacific 
Studies sampling the lungs (n = 30) 37.0 
(2,999) 
41.8 
(1,653) 
22.8 
(771) 
56.8 
(400) 
9.7 
(175) 
Studies sampling only extrapulmonary organs, excluding CNS (n 
= 9) 
17.9 
(971) 
34.7 
(150) 
14.6 
(704) 
- 
(0) 
16.2 
(117) 
CNS: central nervous system; TB: tuberculosis 
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2.2.3.4 Prevalence of other infections 
2.2.3.4.1 Cryptococcal disease 
Thirty-eight studies reported on the autopsy prevalence of cryptococcal disease in 3,789 autopsies: 17 (45%) were 
conducted in the Americas; 14 (37%) in sub-Saharan Africa; four (11%) in South Asia; and three (8%) in East Asia & the 
Pacific.  Prevalence ranged from 2% [191] to 30% [203] in studies of consecutive HIV deaths; the highest prevalence 
(56%) was seen in a study of nine individuals in India who presented with neurological symptoms [212].  Overall, 
evidence of disease was found in 346 individuals (crude prevalence 9.1%); disseminated disease was a common finding 
[184].  Crude estimates of the overall prevalence of TB and other infections are summarised in Figure 2:2.   
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Figure 2:2. Numbers of autopsies, number of individuals with evidence of disease, and overall crude autopsy prevalence of TB and other infections among pathological autopsy 
studies included in this review (n = 53 studies; n = 5,086 autopsies) 
 
*Excludes studies that selected for individuals with additional diagnoses (n = 7 [87,207–212]), forensic studies (n = 2 [226,228]), and studies in special groups (n = 1 [227]) 
†Excludes studies that sampled only the central nervous system (n = 3 [213,216,217]) 
Bact.: bacterial; Crypto.: cryptococcal disease; CMV: cytomegalovirus; EP: extrapulmonary; PCP: Pneumocystis pneumonia; PNM: pneumonia; NTM: non-tuberculous mycobacteria; 
TB: tuberculosis 
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2.2.3.4.2 Other infections 
Bacterial pneumonia was reported by fewer studies, but those that did found high proportions of decedents with 
evidence of disease.  Of 2,677 autopsies from 26 studies (majority [58%] in sub-Saharan Africa) evidence of bacterial 
pneumonia was found in 513 individuals, giving an overall crude prevalence of 19.2%.  Other bacterial infections, 
including non-specific sepsis and bacterial meningitis were reported in at least 324 individuals in 28 studies (3189 
autopsies; crude prevalence 10.2%).  Evidence of Nocardia spp. and Salmonella spp. were reported less often (n = 2 and 
n = 12 autopsies, respectively).   
The study that reported bacteriology most systematically was conducted by Wong et al. in Johannesburg, South Africa 
[184], where antigen testing and aerobic, anaerobic, and fungal cultures were performed for a range of specimens, with 
additional drug sensitivity testing as needed.  The authors also had pre-defined criteria that allowed them to separate 
‘pathologic’ organisms from probable contaminants.  Most decedents included in this study had several positive 
bacterial cultures; in 13/39 (33%), bacterial infections, most often due to Klebsiella spp. or multiple organisms, were 
considered severe enough to have been the main cause of death. 
Evidence of Pneumocystis pneumonia was found in 243 of 2,350 autopsied individuals (crude prevalence 10.3%; n = 27 
studies); non-tuberculous mycobacteria in 63 of 1,114 (5.7%; n = 9 studies); toxoplasmosis in 317 of 1,989 (15.9%; n = 
18 studies); cytomegalovirus in 501 of 2,951 (17.0%; n = 28 studies); and other fungal infections in 221 of 1,907 (11.6%; 
n = 22 studies; Figure 2:2). 
2.2.4. Discussion 
2.2.4.1 Overview 
Fifty-three pathological autopsy studies were included in this review, describing over 5,000 autopsies in HIV-positive 
adults.  There was variation in methods used to obtain samples and laboratory methods used to detect TB; almost all 
studies used histological examination, with only a few using mycobacterial culture and even fewer using Xpert 
MTB/RIF or other PCR.  In the 30 studies that presented finds from lung specimens (with or without other specimens), 
TB was found in 1,111 of 2,999 decedents, giving a crude overall prevalence of 37%.  Prevalence was also high in 
individual studies examining specific extrapulmonary organs, for example, bone marrow (36%) and liver (16% and 34%).  
Two studies that recruited only HIV-positive individuals without a diagnosis of TB still found a high autopsy prevalence 
of TB, at 32% and 35%.    
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2.2.4.1.1 Prevalence of TB 
The crude estimate of TB prevalence based on the 30 studies with lung samples corresponds with the pooled estimate 
of 39.7% generated by random-effects meta-analysis in the 2015 review by Gupta et al. [71], which included 25 of the 
studies included here.  The similar findings from more recent studies [94,180], including those involving individuals on 
ART, suggest that TB remains a major cause of morbidity, and likely mortality, in HIV-positive adults in LMIC.   
A striking finding of the Gupta systematic review was the high proportion of individuals with TB who had disseminated 
disease (88%).  However, the exclusion from the systematic review of studies that did not sample the lungs may have 
led to an overall underestimation of disease burden, as individuals may present with only extrapulmonary disease.  For 
example, in the study by Wong et al. [184] (South Africa, 2009), individuals with TB were more likely to have positive 
histology from liver (80%) and spleen (72%) than from lung (60%) samples.  This is supported by findings from the two 
subsequent large studies in Uganda and Zambia (70% [94] and 50% [180] extrapulmonary disease in those with TB) and 
from the studies assessing liver histology conducted in Uganda [218] (TB in 34% of liver samples) and South Africa (TB 
found in 7/20 [35%] of liver samples and not found in the lungs of 5/7 [71%] of these individuals).   
2.2.4.1.2 Co-prevalent disease 
The prevalence of multiple, concomitant infections was often not reported systematically in the studies included in this 
review, but in those studies where this was reported, it was a common finding.  For example, in the study by Cox et al. 
[94], 26/96 (27%) decedents had autopsy evidence more than one infection; this was seen in a similar proportion of 
decedents in the study by Soeiro et al. (67/250 [27%]) [195].  Few studies conducted culture for organisms other than 
TB, but in those that did, the proportions of decedents with multiple infections were higher (Wong et al. 17/39 [44%] 
decedents had more than one infection and in Martinson et al. 14/37 [38%] [87] decedents with TB also had another 
infection). 
2.2.4.1.3 Antiretroviral therapy 
Only nine studies included individuals who had initiated ART, who made up less than half of all decedents included in 
the studies.  Of these nine studies, only two presented their findings stratified by ART status.  Wong et al. (South Africa 
[184]) found evidence of TB in 87% of individuals with less than 90 days of ART (median 32 days) and 60% of individuals 
with more than 90 days ART (median 326 days).  Silva et al. (Brazil [213]) presented only neuropathological findings and 
found very low prevalence of TB overall.  However, the prevalence of all infections reduced slightly in individuals who 
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had received ART (no exposure to ART, 59.5% [n = 163]; <3 months of ART, 46.0% [n = 76]; and >3 months of ART, 
48.9% [n = 24]).  Neither study attempted to estimate adherence among decedents to ART; notably, none of the studies 
included in this review used data from VA or other sources (other than healthcare records), making it difficult to assess 
if adherence to treatment, or other behavioural or non-biomedical factors, had an impact on the prevalence of TB or 
other diseases in the individuals examined. 
2.2.4.2 Possible sources of bias 
2.2.4.2.1 Publication bias 
This review did not use formal systematic review methodologies and, as such, only one electronic database was 
searched, which may have led to the exclusion of relevant studies.  Studies were also included only if they were 
published in English or had a detailed abstract published in English, which may have led to studies published in other 
languages not being represented.  Finally, the grey literature was not searched, which will have biased the review 
towards articles published in peer-reviewed journals.  This review did, however, include some conference abstracts, 
sourced from the Gupta 2015 systematic review. 
2.2.4.2.2 Selection bias 
At least 78% and 63% of decedents were recruited and died in hospitals.  Hospitalised individuals are grossly over-
represented among these data, reducing their generalisability; many people in LMIC receive their care and may die out 
of hospital, so disease patterns described in these studies may not necessarily represent those in many countries most 
heavily affected by the HIV and TB epidemics.  This issue arises repeatedly among mortality studies in LMIC and is 
discussed in greater detail later in this chapter (Chapter 2.3.4.5.1).  
2.2.4.2.3 Autopsy and laboratory methods 
Although MIA has been shown to be very sensitive for many diseases, particularly infections [99], complete autopsy is 
still the most sensitive and remains the gold standard.  Studies that used MIA, therefore, may have not detected TB, or 
other diseases, that would have been detected by complete autopsy.  Estimates of disease prevalence at autopsy from 
studies that used MIA may therefore be lower than the true prevalence.   
Variations in laboratory methods, too, may account for differences in estimates.  The two studies that used PCR 
methods to estimate the prevalence of TB, conducted in South Africa [184] and Zambia [180], both reported very high 
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prevalence, at 64% and 65%, respectively.  Xpert MTB/RIF has been shown to be sensitive and specific when used 
with pulmonary and extrapulmonary post mortem samples [248].  However, the interpretation of a positive PCR result 
from an autopsy sample will vary based on the history and context of the individual decedent, particularly in the 
absence of confirmatory culture or histological findings.  The development of a standardised protocol for the use of 
PCR-based diagnostics on autopsy samples in resource-limited settings, including for the interpretation of results, 
would facilitate comparisons between studies and allow for more accurate monitoring of the disease burden over time.  
2.2.4.3 Other limitations of this review 
This review has a number of other limitations. Screening of titles and abstracts and review of full text articles, as well as 
data extraction from included articles were conducted only by me.  Although clear inclusion and exclusion criteria were 
defined prior to conducting the review, this may have led to systematic misapplication of these criteria, or 
misinterpretation of certain data.  Meta-analysis was not attempted as part of this exercise, meaning that the summary 
estimates of disease prevalence at autopsy do not take account of differences in sample size or population and should 
be interpreted with caution. 
2.2.5. Summary 
This review of pathological autopsy studies conducted among HIV-positive adults in LMIC, most of whom were 
recruited and died in hospitals, found that the prevalence of TB was consistently high, particularly in studies that 
included pulmonary samples.  A high proportion of individuals had bacterial infections, particularly pneumonia.  More 
data are needed on the autopsy prevalence of diseases in HIV-positive individuals who receive care and may die outside 
of hospitals and in individuals who die after long periods on ART.  There is also a need to standardise the methods used 
to estimate the autopsy prevalence of TB and other diseases; to obtain pathological samples; in the laboratory; and in 
the interpretation of results, to allow for comparison across different contexts and to adequately monitor progress 
towards international goals.  
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2.3. Part 2: Studies that have used verbal autopsy to estimate HIV-
associated mortality and compared findings to reference causes of death 
and/or HIV serostatus 
2.3.1. Introduction 
VA is the primary method used to estimate cause-specific mortality at HDSS sites [102,249,250].  VA data are also used 
to supplement mortality statistics, particularly in countries without robust CRVS systems [251].  Many of these 
countries have a high prevalence of HIV and TB, but VA has not been thoroughly validated for HIV- and TB-associated 
deaths.  At least in part, this is due to the absence of a consistent gold standard against which VA-assigned causes of 
death can be compared.   
Several validation studies have been conducted since the early 1990s, mostly in LMIC and often in areas of high HIV 
prevalence, but many have used, as reference standard, causes of death assigned by unstructured review of hospital 
files and/or death certificates.  The quality of record-keeping in health facilities is variable [252] and death certificates 
have consistently been shown to misclassify causes of death in LMIC [253–255].  Many studies have also assessed the 
accuracy of VA in assigning HIV-associated causes of death without necessarily confirming, as HIV-positive, all 
individuals assigned a reference HIV-associated cause.  Although it may be tempting simply to exclude these studies as 
being of insufficient rigour, they make up a sizeable proportion of validation attempts conducted to date, and many 
were designed with care, with efforts taken to ensure internal validity.  
Even in situations where HIV serostatus data were available, there have been few formal attempts to assess the 
accuracy of VA questions in detecting HIV status.  The sensitivity and specificity of individual questions are important in 
calibrating algorithms that may be used to assign causes of death from VA data, but some questions, particularly those 
regarding sensitive topics such as HIV, need to be tested in a variety of settings, to allow for differences in cultural 
norms.  Variability exists not only in the quality of data used to compile reference datasets, but also in the methods.  
For example, HIV-associated TB is likely responsible for a large proportion of mortality in the areas where many VA 
validation studies have been conducted, but few studies have made it a focus, often grouping together all HIV-
associated mortality, per ICD-10.    
The issues described above mean that there is uncertainty about the accuracy of VA methods in quantifying overall HIV-
associated mortality and, specifically, mortality due to HIV-associated TB.  The last decade has seen the development of 
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several automated VA interpretation methods, all of which require testing and validation using real-world data.  
Without consistency in the process and reference standards used, however, it is difficult to compare the performance 
of different methods. 
2.3.1.1 Aims 
To estimate the accuracy and precision of VA interpretation methods in estimating mortality due to HIV/AIDS, TB, or 
HIV-associated TB compared with clinical reference standards in settings of high HIV prevalence. 
2.3.1.2 Objectives 
Through review of the literature, to: 
5. Estimate the accuracy of various VA methods to estimate mortality due to HIV/AIDS, TB, or HIV-associated 
TB when compared with 
a) Individually assigned reference standard causes of death based on data from individuals with all or 
mostly confirmed HIV status, 
b) Individually assigned reference standard causes of death based on data from individuals without 
confirmed HIV status, and 
c) Population-level estimates of cause of death for individuals with confirmed HIV status; 
6. Estimate the specificity of various VA methods in estimating HIV-associated mortality in individuals with 
confirmed HIV status; and 
7. Estimate the sensitivity and specificity of the VA question, “Was there a diagnosis of HIV/AIDS?”, in 
individuals with confirmed HIV status.  
2.3.2. Methods 
2.3.2.1 Search strategy 
The MEDLINE database was searched using variations of the following terms in various combinations: ‘verbal 
autopsy’; ‘HIV’; and a list of LMIC, as defined by the World Bank and as published by the Cochrane Group [163] (Table 
2:9).  Additionally, reference sections of other VA articles, including a systematic review by Leitao et al., published in 
2014 [109], were searched for relevant titles. 
Table 2:9. Terms used to search the MEDLINE database (via PubMed) 
#1 (("hiv"[MeSH Terms])  
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OR (acquired immune deficiency syndrome[MeSH Terms])  
OR (HIV) OR (human immunodef*)  
OR (AIDS) OR (acquired immune def*)  
OR (acquired immunodef*)) 
#2 ((“Verbal autopsy”[MeSH Terms])  
OR (verbal autopsy)  
OR (VA)  
OR (PCVA)  
OR (physician-certified verbal autopsy)  
OR (InterVA)) 
#3 Filters for low- and middle-income countries as described by the Cochrane Group, 2012 [163], updated per The 
World Bank, 2016 [162] 
Final search 
#1 AND #2 AND #3 
AIDS: acquired immune deficiency syndrome; MeSH: Medical Subject Headings; PCVA: physician-certified verbal 
autopsy; VA: verbal autopsy 
2.3.2.2 Inclusion and exclusion criteria 
Studies of adults from LMIC, published before the end of 2016, were included that used VA data to assign causes of 
death and compared them with any of three types of reference standard: individually-assigned causes of death, all or 
mostly (≥66%) with confirmed HIV status; individually-assigned reference causes of death without confirmed HIV status; 
or causes of death assigned at population level based on confirmed HIV status for all included individuals.  Studies were 
also included that did not assign causes of death but used only HIV status to compare with VA findings, allowing for 
estimation of the specificity of various VA interpretation methods in assigning HIV-associated causes of death and the 
sensitivity and specificity of VA questions in assigning HIV status. 
Studies were excluded that reported only on child or maternal deaths; that required decedents to have a specific 
diagnosis (other than HIV); that reported only on deaths in high-income countries; that reported only VA findings, 
without any attempts at validation against a reference standard; or used, as a reference standard, causes of death 
assigned by another VA method (for example, comparing InterVA-assigned causes of death with PCVA-assigned causes 
of death as reference standard).  Studies were further excluded that used confirmed HIV status as reference but did not 
present their findings separately for HIV-positive and HIV-negative individuals, therefore not allowing for estimation of 
VA specificity.  
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2.3.2.3 Data extraction and management 
A standardised form was used to extract data on study setting; population size and characteristics; numbers of 
decedents confirmed HIV-positive; inclusion and exclusion criteria; data available to those assigning reference causes of 
death; methods used to assign reference causes of death; definitions of HIV/AIDS causes of death; HIV-associated 
mortality fraction; VA instrument used; time from death to VA; VA interpretation method(s) used; comparison methods 
used; and measures of agreement reported.  Data entry, screening, and organisation were conducted per methods 
described in Part 1 of this chapter (section 2.2.2.3). 
2.3.2.4 Analysis  
2.3.2.4.1 Rationale 
There are broadly two ways of estimating agreement between methods assigning causes of death: (1) at an individual 
level, i.e., comparing causes of death assigned to individuals by different methods; and (2) at a population level, i.e., 
comparing proportions of deaths in the entire population assigned to each cause (CSMFs) by different methods.  To 
measure individual agreement, older studies predominantly used Cohen’s kappa [256], a measure of chance-corrected 
agreement between two testing modalities across all causes of death (values range from 0 to 1, where 0 represents 
agreement no greater than chance and 1 represents perfect agreement).  Kappa, however, can vary depending on the 
CSMF composition of the reference dataset, which has led to questions regarding its suitability for use across different 
validation studies.  As a result, the Institute of Health Metrics and Evaluations (IHME) published recommendations on 
metrics for use in measuring the performance of different VA interpretation methods in validation studies [257].  For 
estimating individual-level agreement, they proposed that chance-corrected concordance (Equation 1) be used for each 
cause of death, and overall chance-corrected concordance (Equation 2) used for comparisons across several causes.  
These measures correct for the variability, based on CSMF distribution, seen in Cohen’s kappa. 
Equation 1: Cause-specific chance-corrected concordance 
𝐶𝐶𝐶𝑗 =
𝐶𝑗 − 1/𝐽
1 − 1/𝐽
 
Cj: cause-specific concordance for cause j; CCC: chance-corrected concordance; J: all possible causes 
Equation 2: Overall chance-corrected concordance 
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𝑂𝑣𝑒𝑟𝑎𝑙𝑙 𝐶𝐶𝐶 =  
1
𝐽
∑ 𝐶𝐶𝐶𝑗
𝑗
𝑗=1
 
CCCj: cause-specific concordance for cause j; CCC: chance-corrected concordance; J: all possible causes 
For estimating population-level agreement, older studies used Lin’s concordance correlation coefficient [258] or intra-
class correlation to quantify agreement, but the IHME team recommend CSMF accuracy (equation 3), more recently 
updated to chance-corrected CSMF accuracy (equation 4), which is now widely accepted as the standard method [259]. 
Equation 3: Cause-specific mortality fraction accuracy 
𝐶𝑆𝑀𝐹 𝑎𝑐𝑐𝑢𝑟𝑎𝑐𝑦 = 1 − 
∑ |𝐶𝑆𝑀𝐹𝑗
𝑡𝑟𝑢𝑒 − 𝐶𝑆𝑀𝐹𝑗
𝑝𝑟𝑒𝑑|𝐽𝑗=1
2(1 − 𝑚𝑖𝑛𝑗(𝐶𝑆𝑀𝐹𝑗
𝑡𝑟𝑢𝑒)
 
CSMF: cause-specific mortality fraction; J: all possible causes; pred: predicted 
Equation 4: Chance-corrected cause-specific mortality fraction accuracy 
𝐶𝐶𝐶𝑆𝑀𝐹 𝑎𝑐𝑐𝑢𝑟𝑎𝑐𝑦 =
(𝐶𝑆𝑀𝐹𝑎 − 0.632)
(1 − 0.632)
 
CCCSMF: chance-corrected CSMF; CSMFa: Cause-specific mortality fraction accuracy 
Basic measures of sensitivity and specificity are still useful if considering specific causes of death or the performance of 
specific questions in the VA instrument. 
2.3.2.4.2 Analysis activities 
Sensitivity, specificity, chance-corrected concordance, and chance-corrected CSMF accuracies were summarised for 
HIV/AIDS causes of death, where available; when possible, measures were derived from the data presented using the 
formulae listed above.  To estimate overall performance of each VA method against reference standards, crude 
summary measures (median and IQR) were calculated with exact binomial 95% CI using measures from each study or 
comparison, as applicable, and stratified by type of VA interpretation method (using the -diagt- Stata command).  
Summary measures were visualised using ‘box and whiskers’ plots.  All analyses were conducted using Microsoft Excel 
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and Stata v14 (Statacorp, College Station, TX, USA); figures were formatted using Inkscape™ software 
(https://inkscape.org). 
2.3.3. Results 
2.3.3.1 Search results, screening, and review 
The electronic search of the Medline database yielded 497 articles; nine further records, including two PhD theses, 
were obtained from other sources (Figure 2:3).  Of the 506 titles and/or abstracts screened, 453 (89.5%) were excluded 
based on the criteria described above.  Fifty-three full-text articles were obtained for review, of which 23 (43.4%) were 
excluded: seven did not compare VA to a reference standard [260–266]; seven did not include data on HIV status [267–
273]; five included HIV data, but did not show results stratified by HIV status [274–278]; two reported on sub-analyses 
[279,280] of data already included; and one, each, compared VA to a reference standard derived from VA data [281] or 
included only individuals who had received treatment for TB [282].  Several studies met more than one exclusion 
criterion; 30 articles were included in the analysis [120,123,283–309]. 
Figure 2:3. Flow diagram illustrating numbers of records found through electronic search and other sources, screened 
out by title or abstract, underwent full text review, and included in the analysis 
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*Some studies excluded for more than one reason 
CoD: cause(s) of death; TB: tuberculosis; VA: verbal autopsy 
2.3.3.2 Description of studies included 
The 30 studies included in this review involved analysis of 22 different reference datasets and describe a total 26,890 
adult deaths assessed by VA, at least 6,030 (22.4%) of which were in confirmed HIV-positive individuals (Table 2:10).  
Almost all datasets (20/22 [90.1%]) included adults from sub-Saharan Africa, where 61% of deaths occurred.  Reference 
standards used for comparison were broadly divided into four categories: individual causes of death assigned where 
most or all individuals assigned HIV/AIDS causes of death were confirmed HIV-positive (3/22 [13.6%] datasets; 8,825 
[32.8%] deaths; Table 2:11); individual causes of death assigned without confirmed HIV status (7/22 [31.8%] datasets; 
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7,248 [27.0%] deaths; Table 2:12); population-level estimates of causes of death in individuals with confirmed HIV 
status (3/22 [13.6%] datasets; 2,344 [8.7%] deaths; Table 2:13); and populations of individuals with confirmed HIV 
status, without attempts to estimate causes of death by means other than VA (9/22 [40.9%] datasets; 8,473 [31.5%] 
deaths; Table 2:14).  Several studies used different VA methods to compare VA and reference causes of death: a total 
41 comparisons were conducted in the 30 studies included; PCVA was used most often (15/41 [36.6%]) times), followed 
by InterVA software (10/41 [24.4%] times). 
Table 2:10. Description of studies included, datasets analysed, and adult deaths with VA, stratified by location, 
population, reference standard, and analysis methods (N = 30 studies; N = 22 reference datasets; N = 26,890 deaths) 
Characteristic Studies*,  
n (%) (N = 30) 
Reference standard 
datasets*,  
n (%) (N = 22) 
Adults included in 
analysis,  
n (%) (N = 26,890) 
Region    
 Sub-Saharan Africa 27 (90.0) 20 (90.9) 16,411 (61.0) 
 East Asia & The Pacific 11 (36.7) 3 (13.6) 5,918 (22.0) 
 South Asia 8 (26.7) 1 (4.5) 2,973 (11.1) 
 Latin America & The Caribbean 8 (26.7) 1 (4.5) 1,588 (5.9) 
Income category    
 Low  24 (80.) 17 (77.3) 13,828 (51.4) 
 Lower middle 11 (36.7) 3 (13.6) 4,610 (17.1) 
 Upper middle 14 (46.7) 6 (27.3) 8,452 (31.4) 
Recruited at    
 Hospital 16 (53.3) 7 (31.8) 13,927 (51.8) 
 HDSS site 6 (20.0) 7 (31.8) 8,026 (29.8) 
 Population-based cohort 7 (23.3) 7 (31.8) 3,025 (11.2) 
 Not specified 1 (3.3) 1 (4.5) 191 (0.7) 
Died at    
 Hospital only 17 (56.7) 8 (36.4) 13,968 (51.9) 
 Hospital and community 13 (43.3) 14 (63.6) 12,922 (48.1) 
Reference standard used    
 Individual CoD with confirmed HIV status 11 (36.7) 3 (13.6) 8,825 (32.8) 
 Individual CoD without confirmed HIV status 8 (26.7) 7 (31.8) 7,248 (27.0) 
 Population CoD with confirmed HIV status 3 (10.0) 3 (13.6) 2,344 (8.7) 
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Characteristic Studies*,  
n (%) (N = 30) 
Reference standard 
datasets*,  
n (%) (N = 22) 
Adults included in 
analysis,  
n (%) (N = 26,890) 
 HIV status only 8 (26.7) 9 (40.9) 8,473 (31.5) 
*Studies and datasets may have spanned more than one county and evaluated/been evaluated by more than one VA 
method.  Section row totals may therefore be higher than 30 or 22, respectively, and percentages may total more than 
100. 
CCVA: computer-coded VA; CoD: cause of death; HDSS: health and demographic surveillance system; PCVA: physician-
certified verbal autopsy; VA: verbal autopsy  
2.3.3.2.1 Definitions used 
All studies, except one [290], combined HIV-associated TB with other HIV-associated causes, per ICD guidelines.  The 
most systematic and structured reference dataset, with published criteria for each diagnostic category, is the 
Population Health Metrics Research Consortium (PHMRC) dataset (Table 2:11), discussed in more detail below: for an 
individual to be assigned a ‘Level 1’ diagnosis of ‘AIDS’, they were required to be confirmed HIV-positive and have a 
diagnosis of an AIDS-defining condition.  There was also potential for misclassification of causes of death in some 
studies.  For example, in the study by Tensou et al. [288] (Table 2:11), some decedents with absent HIV data were 
diagnosed with pulmonary or disseminated TB (ICD-10 codes A16 or A19) and counted as ‘AIDS’ deaths, whereas others 
were not; the authors do not specify the criteria used to classify individuals one way or the other and, as HIV status was 
not confirmed, data from these individuals were not included in this review.   
In the eight studies that assigned individual causes of death without HIV data (Table 2:12), there was considerable 
heterogeneity in the methods used to assign causes of death, from structured review by multiple physicians in at least 
two studies [293,296], to one that simply described the process as ‘expert review’ [294].  Three studies took a 
population approach to assigning causes of death (Table 2:13): Lopman et al., in two studies [298,300], counted as 
‘AIDS’ all deaths among HIV-positive individuals that were not from trauma or maternal causes; and Kanjala et al. [299] 
used HIV prevalence data from the entire HDSS site at which the study was conducted to calculate an HIV-associated 
mortality rate, which they then applied to the individuals who had died. 
2.3.3.3 Studies that compared VA-assigned causes of death to individually-assigned reference causes of 
death where most or all individuals assigned an HIV-associated cause were confirmed HIV-positive  
Eleven studies, evaluating three datasets, were included that assigned individual causes of death to adults with 
confirmed HIV status (Table 2:11).  The largest dataset, used in eight studies, which included 16 evaluations of VA 
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methods, is the PHMRC gold standard dataset, the compilation of which has been reported in detail [121].  In brief, VAs, 
using the PHMRC VA instrument, and clinical information were collected for over 12,000 hospital deaths at six sites in 
India, Mexico, the Philippines, and Tanzania.  Clinical data were reviewed by physicians and each individual assigned 
one of 53 mutually exclusive reference causes of death using pre-defined criteria.  Reference causes of death were also 
graded (as Level 1, 2A, 2B, or 3) based on the quality of the evidence available.  HIV and TB deaths were initially divided 
into three groups: ‘AIDS’, ‘AIDS with TB’, and ‘Pulmonary TB’.  For an individual to be assigned a Level 1 ‘AIDS’ cause of 
death, s/he was required to have a positive HIV test and an AIDS-defining illness (other than TB); for a Level 1 ‘AIDS with 
TB’ cause of death, a positive HIV test and a positive culture for MTB; and for a Level 1 ‘Pulmonary TB’ cause of death, a 
history consistent with pulmonary TB, a negative HIV test, and either a positive smear for acid-fast bacilli (AFB) or 
positive culture for MTB.  As discussed in Chapter 1.2.3.1, these categories are consistent with ICD-10, where codes for 
TB (A15–A19) specifically exclude ‘HIV disease resulting in tuberculosis’ [76].   
Of the 7,839 adults included, 353 (4.4%) were assigned an ‘AIDS’ cause of death (345/353 [97.7%] Level 1); 148 (1.9%) 
an ‘AIDS with TB’ cause of death (all Level 1); and 275 (3.5%) a ‘Pulmonary TB’ cause of death (196/275 [71.3%] Level 1).  
For all comparisons with VA, however, the authors combined some of the 53 cause of death categories to give a final 
list of 34 causes; among these were the ‘AIDS’ and ‘AIDS with TB’ categories, which, when combined, left 501 
individuals with a broad ‘AIDS’ cause of death (493/501 [98.4%] Level 1).  
The PHMRC dataset has been made publicly available [310], but comparisons with VA have been conducted mainly by 
IHME, the team partially responsible for compiling the dataset.  In 2011, the IHME group published a series of articles 
comparing causes of death assigned by various VA methods with the PHMRC dataset.  Established methods, such as 
PCVA [311] and InterVA [284], and more experimental methods, such as Tariff [120,285], Random Forests [287], and 
Simplified Symptom Pattern [286], were evaluated.  In 2014, the team published a further comparison between all 
methods, using updated versions of Tariff and InterVA software [283], and reported that all CCVA methods, apart from 
InterVA-4, performed better than PCVA across all causes and ages.  However, when narrowed to adult ‘AIDS’ and ‘TB’ 
deaths only, none of the CCVA methods performed better than PCVA in assigning individual or population an HIV/AIDS 
cause of death (PCVA chance-corrected concordance 67.5% and chance-corrected CSMF accuracy 96.6%) and only 
InterVA-4 performed better in assigning a TB cause of death (chance-corrected concordance 53.2% vs. 48.5% and 
chance-corrected CSMF accuracy 97.4% vs. 96.4% for InterVA-4 vs. PCVA).   
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Further evaluations of some of the CCVA methods, as well as more recent software that uses probabilistic methods 
(InSilicoVA), were conducted by McCormick et al. [123], who found that the simplified symptom pattern method was 
the most sensitive in assigning AIDS deaths (60.1%) and InSilicoVA most sensitive for TB (52.7%).  InSilicoVA, however, 
was very insensitive for AIDS deaths (16.7%).  The Murray 2014 and McCormick publications, both of which used the 
same reference dataset and very similar VA interpretation methods to assign causes of death, have some notable 
discrepancies in results: although most of the differences are minor, the estimates of specificity of InterVA-4 in 
assigning an HIV/AIDS cause of death vary quite dramatically; Murray et al. estimate specificity at 19.5% and 
McCormick et al. at 46.7% [123,283].    
Two other reference datasets included individually-assigned causes of death in adults with confirmed HIV status.  Data 
in the first [290], published in 1998, were collected in Ethiopia, Ghana, and Tanzania and involved 796 individuals, 72 
(9.0%) of whom were confirmed HIV-positive.  Deaths related to HIV and/or TB were categorised as ‘AIDS’, ‘AIDS with 
TB’, or ‘TB’, though specific criteria were not described for each category.  In the primary analysis, sensitivity and 
specificity of PCVA were 58% and 94% for ‘AIDS’ deaths (n = 55 deaths); 8% and 99% for ‘TB + AIDS’ deaths (n = 37 
deaths); and 59% and 96% for ‘TB’ deaths (n = 56 deaths).  When all TB and AIDS deaths were combined (n = 148 
deaths), the sensitivity and specificity of PCVA were 76% (95% CI 68–82) and 94% (95% CI 92–96), respectively.   
The third study in this category is also the smallest [288].  Conducted in Ethiopia in 2003, it involved 193 adults 
recruited in hospital, who died either in hospital or in the community; 101 (52.3%) were confirmed HIV positive and 108 
(64.7%) were assigned a reference ‘AIDS’ cause of death.  InterVA was 81% sensitive and 80% specific, with a chance-
corrected CSMF accuracy of 74.8% in assigning deaths due to ‘AIDS’ (estimate derived from data presented).  It should 
be noted that the procedures for assigning references causes of death in this study were not robust: reviewers used 
clinical data (available for only 38% of decedents) as well as the admission or discharge diagnosis to assign the cause of 
death.  A high proportion of individuals died outside of hospital and there is no indication as to the time between 
hospitalisation and death; it is therefore not clear how these diagnoses relate to the final cause of death.   
A total 8,825 adult deaths were included in the three datasets described in Table 2:11, at least 666 (7.5%) were 
confirmed HIV-positive, and 701 (7.9%) were thought to have died from HIV/AIDS.  All ‘AIDS’ definitions included HIV-
associated TB, per ICD-10.  Crude estimates of median sensitivity, specificity, chance-corrected concordance, and 
chance-corrected CSMF accuracy of all VA methods in assigning an HIV/AIDS cause of death compared with these data 
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were 57.1% (95% CI 47–67; n = 13 comparisons), 96.9% (95% CI 94–98; n = 13), 54.0% (95% CI 51–57; n = 6), and 92.6% 
(95% CI 86.2–94; n = 15), respectively (Figure 2:4).  PCVA performed best overall: median estimates of the above 
measures were 71.4% (95% CI 67–76; n = 2 comparisons), 95.7% (95% CI 94–97; n = 2), 67.5% (n = 1) and 96.6% (95% CI 
75–97; n = 3), respectively.  Median sensitivities of InterVA and Tariff in assigning an HIV/AIDS cause, when compared 
with these three datasets, were lower, at 46.7% (95% CI 20–81; n = 3) and 48.3% (95% CI 44–53; n = 2), respectively, 
though median chance-corrected CSMF accuracies were comparable, at 85.8% (95% CI 75–90; n = 3) and 92.3% (95% CI 
92–93; n = 2), respectively.   
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Table 2:11. Studies in adults in LMIC that compared VA-assigned causes of death with individually-assigned reference causes of death with data on HIV status for most/all 
individuals, listed by year of first death (n = 11 studies; n = 8,825 deaths; n = 666 confirmed HIV-positive) 
First 
author, 
year 
published 
Dates 
of 
death 
Country 
/ies 
Adults 
with VA, N 
(n, [%] 
confirmed 
HIV+) 
Reference standard VA 
interpret
ation 
method 
Verbal autopsy CoD 
Data 
source(s) 
AIDS, n (%) 
‘AIDS’ or HIV-associated TB 
Population 
Process TB, n (%) 
n (%) Sens., % 
(95% CI) 
Spec., % 
(95% CI) 
CCC, % 
(95% CI) 
CCCSMFa
* 
n (%) Sens. % 
(95% CI) 
Spec., % 
(95% CI) 
CCC, % 
(95% CI) 
CCCSMF
a* 
Mc-
Cormick, 
2016 [123] 
2007
–
2010 
India, 
Mexico, 
Philippines, 
Tanzania  
7,836 
(≥493 
[6.3]) 
Hospital files, 
lab results, 
death certs, 
autopsies 
501  
(6.4) 
IVA-4 NS 46.7 96.7   NS 35.3 97.6   
Tariff NS 44.1 98.8   NS 47.8 97.4   
In-hospital 
deaths 
(PHMRC 
dataset 
[121]) 
Graded; pre-
defined 
criteria 
275  
(3.5) 
SSP NS 60.1 96.3   NS 48.8 96.9   
ISVA NS 16.7 99.5   NS 52.7 95.8   
Serina, 
2015 [120] 
PHMRC dataset Tariff 2.0 NS   51.0 
(50.5–51.8) 
 NS   43.5 
(43.1–44.3) 
 
Murray, 
2014 [283] 
PHMRC dataset PCVA 418 
(5.3) 
66.7 97.3  96.9 169 
(1.5) 
48.7 97.7  96.2 
IVA-4 118 
(1.5) 
19.5 96.9  85.8 187 
(2.4) 
55.2 95.8  96.8 
Tariff 295 
(3.8) 
52.5 97.8  92.4 147 
(1.9) 
45.2 98.1  95.4 
SSP 300 
(4.8) 
57.1 98.5  92.6 148 
(1.9) 
48.4 98.1  95.4 
RF 302 
(3.9) 
55.3 97.9  97.3 143 
(1.8) 
46.9 98.2  95.3 
KL 268 
(3.4) 
   91.4 116 
(1.5) 
   94.3 
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First 
author, 
year 
published 
Dates 
of 
death 
Country 
/ies 
Adults 
with VA, N 
(n, [%] 
confirmed 
HIV+) 
Reference standard VA 
interpret
ation 
method 
Verbal autopsy CoD 
Data 
source(s) 
AIDS, n (%) 
‘AIDS’ or HIV-associated TB 
Population 
Process TB, n (%) 
n (%) Sens., % 
(95% CI) 
Spec., % 
(95% CI) 
CCC, % 
(95% CI) 
CCCSMFa
* 
n (%) Sens. % 
(95% CI) 
Spec., % 
(95% CI) 
CCC, % 
(95% CI) 
CCCSMF
a* 
Lozano, 
2011† 
[311] 
PHMRC dataset PCVA 410 
(5.2) 
  67.5 
(66.6–68.6) 
96.6 175 
(2.2) 
  48.5 
(47.5–49.8) 
96.4 
Lozano, 
2011† 
[284] 
PHMRC dataset IVA-3.2 243 
(3.1) 
  39.0 
(38.7–39.4) 
90.4 204 
(2.6) 
  53.2 
(52.8–53.5) 
97.4 
James, 
2011† 
[285] 
PHMRC dataset Tariff 305 
(3.9) 
  52.4 
(51.6–53.3) 
92.7 162 
(2.1) 
  46.4 
(44.9–47.4) 
95.9 
Murray, 
2011† 
[286] 
PHMRC dataset SSP 328 
(4.2) 
  55.6 
(54.9–56.4) 
93.6 163 
(2.1) 
  46.9 
(46.0–47.8) 
96.0 
Flaxman, 
2011† 
[287] 
PHMRC dataset RF 333 
(4.3) 
  56.5 
(55.7–57.1) 
93.7 159 
(2.0) 
  46.2 
(45.1–47.0) 
95.8 
Tensou, 
2010† 
[288] 
2003 Ethiopia 193 (101 
[52.3]) 
Hospital dx + 
patient card 
108‡ 
(64.7) 
IVA 103‡ 
(61.7) 
81§ 
(73–88) 
80§ 
(67–89) 
 74.8§ NS     
Recruited 
in hosp.; 
died in/out 
of hosp. 
AIDS vs. non-
AIDS vs. 
unknown 
NS 
Quigley, 
1999‖ 
[289]  
1993
–
1995 
Ethiopia, 
Ghana, 
Tanzania 
796 (72 
[9.0]) 
Hospital files, 
death 
certificates 
92 (11.6) Data 
algorithm 
78‖ 
(20.2) 
65 90  94.0 NS     
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First 
author, 
year 
published 
Dates 
of 
death 
Country 
/ies 
Adults 
with VA, N 
(n, [%] 
confirmed 
HIV+) 
Reference standard VA 
interpret
ation 
method 
Verbal autopsy CoD 
Data 
source(s) 
AIDS, n (%) 
‘AIDS’ or HIV-associated TB 
Population 
Process TB, n (%) 
n (%) Sens., % 
(95% CI) 
Spec., % 
(95% CI) 
CCC, % 
(95% CI) 
CCCSMFa
* 
n (%) Sens. % 
(95% CI) 
Spec., % 
(95% CI) 
CCC, % 
(95% CI) 
CCCSMF
a* 
In-hospital 
deaths 
Two 
physicians; 
pre-defined, 
graded 
criteria 
56 (7.0) 
Chandra-
mohan, 
1998¶ 
[290] 
Per Quigley et al., 1999 PCVA 88 
(11.1) 
76** 
(68–82) 
94** 
(92–96) 
 98.5 63 
(7.9) 
59 
(45–72) 
96 
(94–97) 
 97.4 
Expert 
algorithm 
115 
(14.4) 
68** 
(60–76) 
89** 
(86–91) 
 91.1 53 
(6.7) 
35 
(20–53) 
95 
(93–96) 
 98.9 
*When calculation possible, all chance-corrected CSMF accuracies derived for two causes of death (AIDS vs. not AIDS; TB vs not TB) using formulae described by Murray et al. [259] 
and Flaxman et al. [312] 
†Included in Leitao et al. 2014 systematic review [109]  
‡AIDS deaths as proportion of those confirmed ‘AIDS’ or ‘not AIDS’ (n = 167) 
§Sensitivity, specificity, and chance-corrected CSMF accuracy calculated across all 193 deaths 
‖All AIDS and TB deaths grouped together for analysis; measures of accuracy using only test dataset; n = 386 (71 [18.4%] with AIDS and/or TB) 
¶‘AIDS’ deaths include ‘AIDS + TB’ (reference 37/796 [4.6%]; PCVA 11/796 [1.4%], sensitivity 8% [95% CI 2–21], specificity 99% [95% CI 98–100]; algorithm 53/796 [6.7%], sensitivity 
35% [95% CI 20–53], specificity 95% [95% CI 93–96]) 
**As reported for any AIDS or TB cause of death 
AIDS: acquired immune deficiency syndrome; CCC: chance-corrected concordance; CCCSMFa: chance-corrected CSMF accuracy; certs: certificates; CI: confidence interval; CoD: 
cause of death; CSMF: cause-specific mortality fraction; dx: diagnosis; HIV: human immunodeficiency virus; HIV+: HIV-positive; ISVA: InSilicoVA; IVA: InterVA; KL: King-Lu; LMIC: low- 
and middle-income countries; N/A: not applicable; NS: not specified; PCVA: physician-certified verbal autopsy; RF: Random Forests; sens.: sensitivity; spec: specificity; SSP: 
Simplified Symptom Pattern; TB: tuberculosis; VA: verbal autopsy; WHO: World Health Organization
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Figure 2:4. Box plots illustrating crude summary measures of agreement between VA-assigned and reference 
HIV/AIDS causes of death from studies where most or all individuals assigned an HIV-associated cause of death were 
confirmed HIV-positive (n = 11 studies; n =666 confirmed HIV-positive) 
 
Measures of agreement for individual deaths (sensitivity, specificity, and chance-corrected concordance) and at a 
population-level (chance-corrected CSMF accuracy) for VA methods in assigning an HIV/AIDS cause of death (per 
individual study definition), stratified by type of VA interpretation method used.  Central horizontal line represents 
median; boxes represent interquartile range (IQR); and whiskers represent largest and smallest values within 1.5 IQR of 
the upper and lower quartiles, respectively 
AIDS: acquired immune deficiency syndrome CCC: chance-corrected concordance; CCCSMFa: chance-corrected cause-
specific mortality fraction accuracy; CoD: cause of death; CSMF: cause-specific mortality fraction; Ind: individual; PCVA: 
physician-certified verbal autopsy; Pop: population; VA: verbal autopsy 
2.3.3.4 Studies that compared VA-assigned causes of death to individually-assigned reference causes of 
death in individuals without confirmed HIV status 
Eight studies were included in this analysis, consisting of seven reference datasets and 7,248 deaths (Table 2:12).  Six 
(75%) studies were conducted in sub-Saharan Africa (n = 2,590 deaths) and the remaining two (25%) in South-East Asia 
(China and Thailand, respectively; n = 4,658 deaths).  All deaths occurred in hospitals.  The study conducted in China, by 
Yang et al. [294], reported only estimates of deaths due to TB, not HIV, so was not included in estimates of mortality 
due to HIV/AIDS, leaving 5,148 deaths for the primary analysis.  No study tried to differentiate between HIV and HIV-
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associated TB, classifying all HIV-associated TB deaths as ‘HIV/AIDS’.  All studies, except one, used PCVA to interpret VA 
data. 
Proportions of overall deaths attributed to HIV/AIDS varied widely, from 4.5% in South Africa (n = 102 [301]) to 33% in 
Tanzania (n = 1,912 [296]).  Of a total 5,148 adult deaths included, at least 931 (18.1%) were assigned an HIV/AIDS 
cause of death.  Crude summary estimates of VA sensitivity and specificity in assigning an HIV/AIDS cause of death were 
69% (95% CI 63–82; n = 8) and 84% (95% CI 79–91; n = 8), respectively (Figure 2:5 shows crude estimates from studies 
included in Tables 2:12 and 2:13).  Crude overall chance-corrected concordance was 36% (95% CI 33–39; n = 5) and 
chance-corrected CSMF accuracy 85% (95% CI 64–92; n = 7). 
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Table 2:12. Studies in adults in LMIC that compared VA-assigned causes of death with individually-assigned reference causes of death without confirmed HIV status; listed by 
year of first death (n = 8 studies; n = 7,248 deaths) 
First author, 
year 
published 
Dates of 
death 
Country/ies Adults with 
VA, N 
(confirmed 
HIV+, n [%]) 
Reference standard VA 
interpret
ation 
method 
Verbal autopsy CoD 
Basis of CoD 
assignment 
AIDS, n 
(%) 
AIDS or HIV-associated TB 
Data source/s 
Population TB, n (%) n (%) Sens., % 
(95% CI) 
Spec., % 
(95% CI) 
CCC, 
% 
CCCS
MFa* 
n (%) Sens., % 
(95% CI) 
Spec., % 
(95% CI) 
CCC, 
% 
CCCS
MFa* Process 
Bauni, 2011 
[291] 
2007–
2010 
Kenya 
145 
(NS) 
Individual 
33 (22.7) IVA 
38 
(26.2) 
70  
(5–84) 
87  
(79–92) 
39.3† 87.9 
18 
(12.4) 
83 
(36–100) 
91  
(85–95) 
66.7† 76.5 
Clinical & lab data 
HDSS; hosp. 
deaths 
6 (4.1) PCVA 
36 
(24.8)  
88  
(72–97) 
94  
(88–98) 
75.8† 92.7 
11 
(7.6)  
100 
(54–100) 
96  
(92–99) 
100† 90.2 Best judgement of 
physician 
Misganaw, 
2012 [292] 
2007–
2010 
Ethiopia 
335 
(NS) 
Individual 
69 (21)  
PCVA 
97 
(29) 
68  
(57–79) 
78  
(72–83) 
0.36† 71.4 
77 
(23) 
63 
(49–76) 
84  
(79–88) 
25.0† 72.5 
Hospital records 
Hosp. deaths 48 (14) Hospital clerks 
blinded to VA 
Polprasert, 
2010‡ [293] 
2005 
Thailand 
2,558 
(NS) 
Individual 
191 (7.5)  
PCVA 
123 
(4.8) 
60.7 
(53–68) 
99.7  
(99–99)† 
21.5† 92.2 
46 
(1.8) 
32.3  
(17–51) 
98.6 
(98–99)† 
−35.5
† 
98.4 
Medical & lab 
records 
Hosp. deaths 31 (1.2) Multiple 
reviewers; graded 
evidence [279] 
Yang, 2006‡ 
[294] 
2002   
China 
2,100  
(NS) 
Individual 
NS 
PCVA NS     
39 
(1.9) 
62.2  
(48–77) 
99.3 24.4† 99.2 Medical records 
Hosp. deaths 45 (2.1) 
‘Expert review’ 
Murray, 
2007 [295] 
Per Yang et al., 2006 SP NS     NS   88§  
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First author, 
year 
published 
Dates of 
death 
Country/ies Adults with 
VA, N 
(confirmed 
HIV+, n [%]) 
Reference standard VA 
interpret
ation 
method 
Verbal autopsy CoD 
Basis of CoD 
assignment 
AIDS, n 
(%) 
AIDS or HIV-associated TB 
Data source/s 
Population TB, n (%) n (%) Sens., % 
(95% CI) 
Spec., % 
(95% CI) 
CCC, 
% 
CCCS
MFa* 
n (%) Sens., % 
(95% CI) 
Spec., % 
(95% CI) 
CCC, 
% 
CCCS
MFa* Process 
Setel, 
2006‡‖ [296] 
2000–
2003 
Tanzania 
1,912  
(NS) 
Individual 634 
(33.2) 
PCVA 
563  
(29.4) 
60 
(55–65)  
86 
(84–88) 
 84.9 
188 
(9.8) 
51 
(43–58) 
94 
(93–95) 
 96.1  
Medical records & 
death certificates 
Facility or 
home deaths 
163 (8.5) Two physicians; 
graded based on 
evidence quality 
Hosegood, 
2004 [297] 
2000 
South Africa 
109  
(NS) 
Individual 
NS 
PCVA NS 80 82   NS     Hospital files 
Hosp. deaths NS 
NS 
Kahn, 2000 
[301] 
1992–
1995 
South Africa  
89  
(NS) 
Individual 
4 (4.5)§§ 
PCVA NS     NS 92 99   
Hospital records 
HDSS; 
hospital 
deaths 
NS One reviewer, 
blinded to VA 
*When calculation possible, chance-corrected CSMF accuracies derived for two causes of death (AIDS vs. not AIDS; TB vs not TB) using formulae described by Murray et al. [259] and 
Flaxman et al. [312] 
†Calculated from data provided; chance-corrected concordance derived using formula described by Murray et al. [259] 
‡Included in Leitao et al. 2014 systematic review [109] 
§Reports only ‘concordance’ of 88% for tuberculosis 
‖Includes all deaths in individuals >5 years of age; HIV-associated deaths include HIV-associated TB 
¶AIDS-specific mortality fractions shown for n = 102 deaths used as ‘test’ dataset 
**Number confirmed HIV-positive only reported for entire cohort (n = 1573), not specifically for those with VA (n = 1171) 
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††AIDS-specific mortality fractions shown for n = 555 deaths used as ‘test’ dataset 
‡‡Range, based on variations to the algorithm 
§§Reference CoD: ~23% ‘infectious/parasitic’ causes 
 
AIDS: acquired immune deficiency syndrome; CCC: chance-corrected concordance; CCCSMFa: chance-corrected CSMF accuracy; CI: confidence interval; CoD: cause of death; CSMF: 
cause-specific mortality fraction; CSMFa: CSMF accuracy; HDSS: health and demographic surveillance system; HIV: human immunodeficiency virus; HIV+: HIV-positive; IVA: InterVA; 
KL: King-Lu; LMIC: low- and middle-income countries; N/A: not applicable; NS: not specified; PCVA: physician-certified verbal autopsy; popn: population; RF: Random Forests; sens.: 
sensitivity; spec.: specificity; SSP: Simplified Symptom Pattern; TB: tuberculosis; VA: verbal autopsy; WHO: World Health Organization 
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2.3.3.5 Studies that compared VA-assigned causes of death to population estimates of HIV-associated 
among individuals with confirmed HIV status 
Three studies were included that used a reference standard derived from population estimates of HIV-associated 
mortality in individuals with known HIV status; these studies included three separate datasets reporting 2,065 deaths 
from Tanzania and Zimbabwe (Table 2:13).  All data were from longitudinal community studies conducted within HDSS 
sites; investigators had access to HIV test data for all decedents described, but did not attempt to assign individual 
cause of death.  In the two studies by Lopman et al., analysing deaths that occurred from 1998–2003 [300] and 1994–
2005 [298], all deaths among HIV-positive adults from causes that were not traumatic or maternal were considered 
‘AIDS’ deaths.  These studies, unsurprisingly, report relatively high proportions of ‘AIDS’ deaths (65–76%) in populations 
with high HIV prevalence.   
The third study, conducted in Tanzania [299], used HIV prevalence among individuals in the entire HDSS site (6% in 
1994–1995, 8.3% in 2000–2001, and 6% in 2011), the estimated age-specific mortality rate due to HIV in the studied 
population, and the overall mortality rate in the population to estimate the proportion of HIV-attributable deaths 
among those that died.  Among 1,573 (339 [21.6%] confirmed HIV-positive) deaths, 1,171 individuals also had VA data 
available.  The authors estimated that around 20% of deaths were HIV-associated, though the estimate generated by 
InterVA-4 was higher, at 30.8%.  The authors also attempted to assess mortality trends in relation to ART coverage; 
because of the absence of individual data, however, ART ‘availability’ was used as a proxy for ART use.  They report an 
overall reduction in HIV-associated mortality among males aged 15–44 from over 40% in the pre-ART periods to under 
40% after ART was widely available, but no similar changes among females.  In addition, proportions of mortality 
attributable to HIV among HIV-positive individuals did not undergo any substantial change after ART became widely 
available, staying at around 90%. 
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Table 2:13. Studies in adults in LMIC that compared VA-assigned causes of death to population estimates of HIV-associated mortality among individuals with confirmed HIV 
status (n = 3 studies; n = 2,344 deaths; ≥631 confirmed HIV-positive) 
First author, 
year 
published 
Dates of 
death 
 Adults with 
VA, N 
(confirmed 
HIV+, n [%]) 
Reference standard VA 
interpr
etation 
metho
d 
Verbal autopsy CoD 
Country/ies CoD basis AIDS, n (%) AIDS or HIV-associated TB 
Data source/s 
Population TB, n (%) n (%) Sens., % 
(95% CI) 
Spec., % 
(95% CI) 
CCC, 
% 
CCCS
MFa* 
n (%) Sens., % 
(95% CI) 
Spec., % 
(95% CI) 
CCC, 
% 
CCCS
MFa* Process 
Lopman, 
2006 [298] 
1998–
2003 
Zimbabwe 381 (292 [77]) Population 77 (75.5)† Algo-
rithm 
57 
(55.8)
† 
66 
(56–77) 
76 
(59–93) 
32.5 29.4 NS     
Serostatus 
Population 
study, 
confirmed 
HIV status 
NS 
All HIV+ assigned 
‘AIDS’ CoD unless 
trauma/maternal 
Kanjala, 
2014 [299] 
1994–
2010 
Tanzania 1,171  
(339 [21.6])‡ 
Population (20.3) IVA-4 361 
(30.8) 
   64.1 NS     
Serostatus 
Population-
based cohort 
NS 
Mortality 
estimated based 
on HIV prevalence 
Lopman, 
2010 [300] 
1994–
2005 
Tanzania, 
Zimbabwe 
792  
(NS) 
Population 363 (65.4)§  Algo-
rithm 
NS 54–83‖ 62–80‖   NS     
Serostatus 
Population 
study; 
confirmed 
HIV status 
NS 
All HIV+ assigned 
‘AIDS’ CoD unless 
trauma/maternal 
*When calculation possible, all chance-corrected CSMF accuracies derived for two causes of death (AIDS vs. not AIDS; TB vs not TB) using formulae described by Murray et al. [259] 
and Flaxman et al. [312] 
†AIDS-specific mortality fraction shown for n = 102 deaths used as ‘test’ dataset (n = 81 HIV-positive) 
‡Number confirmed HIV-positive only reported for entire cohort (n = 1573), not specifically for those with VA (n = 1171) 
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§AIDS-specific mortality fraction shown for n = 555 deaths used as ‘test’ dataset 
‖Range, based on variations to the algorithm, i.e., variations in weight given to answers of specific questions (weight loss, jaundice, etc.) and age groups   
AIDS: acquired immune deficiency syndrome; CCC: chance-corrected concordance; CCCSMFa: chance-corrected CSMF accuracy; CI: confidence interval; CoD: cause of death; CSMF: 
cause-specific mortality fraction; CSMFa: CSMF accuracy; HDSS: health and demographic surveillance system; HIV: human immunodeficiency virus; HIV+: HIV-positive; IVA: InterVA; 
KL: King-Lu; LMIC: low- and middle-income countries; N/A: not applicable; NS: not specified; PCVA: physician-certified verbal autopsy; popn: population; RF: Random Forests; sens.: 
sensitivity; spec.: specificity; SSP: Simplified Symptom Pattern; TB: tuberculosis; VA: verbal autopsy; WHO: World Health Organization 
 
An autopsy study exploring the spectrum of disease in individuals with advanced HIV 
 in primary care clinics in South Africa 
 Page 95 of 383 Chapter 2: Literature review 
Figure 2:5. Box plots illustrating crude summary measures of agreement between VA-assigned and reference 
HIV/AIDS causes of death in studies that used, as reference, individually-assigned causes of death without confirmed 
HIV status or population-assigned causes of death with confirmed HIV status (n = 10 studies; n = 9,592 deaths) 
 
Measures of agreement for individual deaths (sensitivity, specificity, and chance-corrected concordance) and at a 
population-level (chance-corrected CSMF accuracy) for VA methods in assigning HIV/AIDS CoD (per individual study 
definition), stratified by type of VA interpretation method used.  The central horizontal line represents the median 
value; boxes represent the interquartile range (IQR); and whiskers represent the largest and smallest values within 1.5 
IQR of the upper and lower quartiles, respectively. 
AIDS: acquired immune deficiency syndrome; CCC: chance-corrected concordance; CCCSMFa: chance-corrected cause-
specific mortality fraction accuracy; CoD: cause of death; CSMF: cause-specific mortality fraction; IQR: interquartile 
range; PCVA: physician-certified verbal autopsy; VA: verbal autopsy 
2.3.3.6 Studies conducted in adults with confirmed HIV status that assessed the specificity of VA methods 
in assigning HIV-associated causes of death and/or the performance of VA questions in assigning HIV 
status 
The final group of studies is those that compared VA findings to a reference standard composed only from confirmed 
HIV status and did not attempt to assign reference causes of death.  As HIV-positive individuals can die from a range of 
causes, including non-HIV-associated, these studies estimated only the specificity of VA methods in assigning an 
individual an HIV-associated cause of death and the sensitivity and specificity of individual questions in the VA 
instrument.  
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Eight studies were included in this group, including one PhD thesis [306]; 8,473 (4,819 [56.9%] confirmed HIV-positive) 
deaths from six countries, all in sub-Saharan Africa, were reported (Table 2:14).  Some 7,792 (92.0%) deaths were in 
individuals from HDSS sites, with the remainder (n = 681 [8.0%]) in individuals from population-based cohort studies 
conducted in Uganda [302,309], Guinea-Bassau [305], and Tanzania [307].  All studies, except one, evaluated the 
specificity of VA methods in assigning HIV-associated deaths; two studies [303,308] evaluated the sensitivity and 
specificity of the VA HIV question (written as “Was there any diagnosis of HIV/AIDS?” in the WHO 2012 instrument 
[104]) in assigning HIV status.  In the 10 comparisons conducted, PCVA was used five times to interpret VA data, InterVA 
four times, and a WHO checklist once.  In two studies [304,306], more than one VA method was used to analyse deaths 
from the same dataset, meaning the effective number of deaths used to evaluate the specificity of VA methods was 
8,307 (4,900 [59.0%] confirmed HIV-positive). 
The specificity of VA methods in assigning an HIV-associated cause of death varied widely, from 60.2% (95% CI 53–67 
[306]) to 100% (95% CI 83.2–100 [305]), depending on the VA interpretation method used.  One study, conducted in 
Malawi [304], used PCVA and InterVA-4 and found both methods to be highly specific (PCVA 99.4%; InterVA-4 90.7%; n 
= 417 deaths).  Reviewing physicians and InterVA software in this study, however, were not blinded to decedents’ HIV 
status.  These data (n = 417 deaths, evaluated twice) were therefore excluded from the summary estimates described 
below, leaving 7,473 (4390 [58.7%] confirmed HIV-positive) deaths.  A total 432/3,083 (14.0%) confirmed HIV-negative 
individuals were assigned an HIV/AIDS cause of death, giving an overall specificity of 86.0% (95% CI 84.7–87.2).  
Stratified by VA method, specificity was 90.4% (95% CI 87.3–92.9; n = 762 deaths) for PCVA and 85.1% (95% CI 83.6–
86.4; n = 6,533 deaths) for InterVA (Figure 2:6).  The WHO checklist used in one study [307] was 88.6% (95% CI 81–94) 
specific (n = 178 deaths).   
Two studies, examining 5,871 deaths occurring in five sub-Saharan countries between 1990 and 2014, assessed the 
sensitivity and specificity of the VA HIV question in assigning HIV status [303,308] (Table 2:14).  The VA HIV question 
was answered ‘Yes’ for 1,242/3,272 (38.0%) HIV-positive individuals and 144/2,599 (5.6%) HIV-negative individuals, 
giving an overall sensitivity of 38.0% (95% CI 36.3–39.6) and specificity of 94.5% (95% CI 93.5–95.3).  Only one study 
[303] assessed the sensitivity and specificity of a VA question asking about use of ART, reporting a sensitivity and 
specificity of 92.1% and 46.4%, respectively (n = 154 deaths). 
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Table 2:14. Studies that compared VA (VA-assigned cause of death or specific VA questions) to HIV serostatus data without estimation of reference causes of death; listed by 
year of first death (n = 8 studies; n = 8,473 decedents; n = 4,819 confirmed HIV-positive) 
First 
author, 
year 
published 
Dates of 
deaths 
 Adults with VA 
and confirmed 
HIV status, N 
(HIV+, n [%]) 
Verbal autopsy 
Country/ies Interpretatio
n method 
AIDS CoD assigned Specificity, % 
(95% CI)* 
VA HIV question 
Overall, n 
(%/all) 
In HIV-
negative, n 
(%/HIV-) 
Answered Yes Sens., % 
(95% CI)* 
Spec., % 
(95% CI)* 
Population All, n 
(%/all) 
In HIV+, n 
(%/HIV+) 
In HIV-, n 
(%/HIV-) 
Mayanja, 
2011† 
[302] 
2006–2008 Uganda 264 (59 [22.3]) PCVA 68 (25.8) 20 (9.8) 90.2 (85.3–93.9) NS     
Population-
based cohort 
McLean, 
2016 [303] 
2003–2014 Malawi 842 (279 [33.1]) N/A NS   246 (29.2) 232 
(83.2) 
14 
(2.5) 
82.3 (78.2–
87.4) 
97.5 (95.9–
98.6) 
HDSS site 
Glynn, 
2014‡ 
[304] 
2002–2012 Malawi 417 (255 [61.2]) PCVA 204 (48.9) 1 (0.6) 99.4 (96.6–100) NS     
HDSS site IVA-4 136 (32.6) 15 (9.3) 90.7 (85.2–94.7) NS     
Cooper, 
2010 [305] 
1999–2004 Guinea-Bassau 84 (64 [76.2])  PCVA 23 (27.3)§ 0 100 (83.2–100) NS     
Population-
based cohort 
Grollman, 
2014 [306] 
1994–2011 Tanzania 259 (105 [40.5])‖ PCVA 137 (52.9) 18 (11.7)¶ 88.3 (82.2–92.9) NS     
HDSS site 541 (250 [46.2])‖ IVA 203 (37.5) 56 (19.2)¶ 80.8 (75.7–85.1) NS     
1998–2011 Zimbabwe 963 (777 [80.7]) IVA 574 (74.5) 74 (29.8)¶ 60.2 (52.8–67.3) NS     
HDSS site 
Todd, 1997 
[307] 
1991–1993 Tanzania 178 (64 [36.0]) WHO / 
simplified 
checklist 
40 (22.5) 13 (11.4) 88.6 (81.3–93.8) NS     
Population-
based rural 
cohort 
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First 
author, 
year 
published 
Dates of 
deaths 
 Adults with VA 
and confirmed 
HIV status, N 
(HIV+, n [%]) 
Verbal autopsy 
Country/ies Interpretatio
n method 
AIDS CoD assigned Specificity, % 
(95% CI)* 
VA HIV question 
Overall, n 
(%/all) 
In HIV-
negative, n 
(%/HIV-) 
Answered Yes Sens., % 
(95% CI)* 
Spec., % 
(95% CI)* 
Population All, n 
(%/all) 
In HIV+, n 
(%/HIV+) 
In HIV-, n 
(%/HIV-) 
Byass, 
2013 [308]  
1990–2011 Malawi, South 
Africa, 
Tanzania, 
Uganda, & 
Zimbabwe 
5,029 (2,993 
[59.5]) 
IVA-4 1,436 (28.6) 245 (12.0)** 88.0 (86.5–
89.3)** 
1,140 
(22.7) 
1,010 
(33.7) 
130 (6.4) 33.7 (32.1–
35.5) 
93.6 (92.5–
94.6) 
HDSS sites 
Kamali, 
1996 [309] 
1990–1993 Uganda 155 (78 [50.3]) PCVA 73 (47.1) 6 (7.8) 92.2 (83.8–97.1) NS     
Population-
based cohort 
*Derived after excluding individuals with unknown HIV status 
†Study discusses ‘HIV status’, but this was actually HIV-associated cause of death  
‡VA cause of death estimates for ‘AIDS’ and ‘TB/AIDS’ combined; specificity derived based on 417 deaths with confirmed status; VA methods not blinded to HIV status 
§Study reported a high proportion (35/84 [41.7%]) of indeterminate causes of death; 25/35 (71.4%) of these individuals were HIV-positive 
‖Total n = 541 deaths at Tanzania site, but only n = 259 assessed by PCVA; all 541 assessed by InterVA-4 
¶Individuals considered HIV-negative if negative test ≤5 years prior to death 
**The study reports specificity of 90.1, but the authors did not include as HIV-negative the 130 individuals who tested HIV-negative but were reported HIV-positive by VA, 43% (n ≈ 
56) of whom were assigned an HIV/AIDS cause of death, bringing the total number of HIV-negative individuals assigned an HIV/AIDS cause of death to 245 
 
AIDS: acquired immune deficiency syndrome; CCC: chance-corrected concordance; CCCSMFa: chance-corrected CSMF accuracy; CI: confidence interval; CoD: cause of death; CSMF: 
cause-specific mortality fraction; CSMFa: CSMF accuracy; HDSS: health and demographic surveillance system; HIV: human immunodeficiency virus; HIV+: HIV-positive; IVA: InterVA; 
KL: King-Lu; LMIC: low- and middle-income countries; N/A: not applicable; NS: not specified; PCVA: physician-certified verbal autopsy; popn: population; RF: Random Forests; sens.: 
sensitivity; spec.: specificity; SSP: Simplified Symptom Pattern; TB: tuberculosis; VA: verbal autopsy; WHO: World Health Organization 
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Figure 2:6. Box plots illustrating crude summary measures of specificity of VA methods in assigning an HIV/AIDS 
cause of death (n = 7 studies; n = 7,631 deaths) 
 
The central horizontal line represents the median value; boxes represent the interquartile range (IQR); and whiskers 
represent largest and smallest values within 1.5 IQR of the upper and lower quartiles, respectively. 
AIDS: acquired immune deficiency syndrome; CoD: cause of death; PCVA: physician-certified verbal autopsy 
2.3.4. Discussion 
2.3.4.1 Summary of findings 
The literature describing the validation of VA for HIV-associated deaths is extensive and diverse.  Reference standards 
vary widely in the data and methods used in their development, with a general absence of standardisation between 
and within studies.  ICD-10 coding rules were widely used, but were sometimes applied incorrectly; for example, in the 
grouping together of all HIV-associated and TB deaths (regardless of HIV status).  PCVA has been evaluated more than 
other methods and was overall the most consistent and accurate.  Despite the number of validation studies, however, 
there does not as yet appear to be an automated method that is sensitive, specific, and consistent in assigning HIV-
associated causes of death.   
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2.3.4.2 Reference standards 
The number of automated methods developed and tested has greatly increased in recent years, though the newest 
methods, such as Naïve Bayes [313], open-source Random Forests, and open-source Tariff [108] have only been tested, 
so far, using PCVA-assigned causes of death as a reference standard.  There remains considerable heterogeneity 
between reference standards used for HIV and TB causes of death in these studies; this is a major obstacle to isolating 
the best method for use in high HIV prevalence settings.  In addition, very few individuals had data available from 
pathological autopsy, other than a few cases in the PHMRC [121] dataset and in the study by Polprasert et al. (Thailand) 
[293]. 
The development of the PHMRC gold standard dataset [121] was a major step in establishing global VA standards [314], 
but, in addition to the issues discussed above, it does have some important limitations when used to estimate HIV-
associated mortality.  Data were collected from four countries, only one (Tanzania) with relatively high HIV prevalence 
(4.2% [95% CI 4.2–5.3] in 2015) [129].  As a result, the HIV-associated mortality fraction among the overall population is 
low, at 6.4%.  The most recent global burden of disease study estimated that, in 2015, in countries with very high HIV 
prevalence, such as South Africa and Zimbabwe, 53.7% (95% CI 49–59) and 59.0% (95% CI 32–75), respectively, of 
mortality among individuals aged 15–49 years was due to HIV/AIDS [315].  Despite the precautions taken by various 
teams developing VA methods (i.e., repeated random sampling of the PHMRC dataset to generate CSMFs of varying 
distributions [283]), it is unlikely that test CSMFs generated will have reflected the extremely high HIV/AIDS-associated 
mortality fractions seen in populations such as these.  Therefore, despite the rigour with which the dataset was 
constructed, the low proportion of HIV-associated deaths included means that it is of limited use in evaluating a VA 
method’s accuracy in estimating HIV-associated mortality.  Estimates of HIV-associated mortality generated by VA 
interpretation methods that have, in the published literature, been compared only with reference causes of death from 
the PHMRC dataset (Tariff, Tariff 2.0, simplified symptom pattern, random forests, and InSilicoVA) should be 
interpreted with caution.   
2.3.4.3 HIV-associated TB 
Only one study, conducted in 1998, attempted to differentiate between HIV-associated TB and other HIV-associated 
causes [290].   Although the team that compiled the PHMRC dataset did initially include this distinction, the two 
categories have been combined for all comparisons to VA to date.  Several other studies, conducted in areas of high HIV 
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prevalence, combined all TB and HIV/AIDS deaths, which is not in accordance with ICD-10 and makes it difficult to 
assess VA specificity [270,271,304,316] 
2.3.4.4 Previous reviews 
Published in 2014, a review by Leitao et al. [109] compared causes of death assigned by CCVA methods to both clinical 
and PCVA reference standard causes of death.  The review included 19 studies, conducted between 1992 and 2012 and 
reported on over 116,000 adult and child deaths.  Due to the marked heterogeneity of the studies included, the authors 
did not attempt meta-analysis, describing instead mean sensitivities and specificities, with associated ranges, of 
different VA methods in assigning causes of death.  As such, the estimates of mean VA sensitivity and specificity for 
deaths due to HIV/AIDS are of limited use, at 59% (range 0–61) and 90% (range 0–96), respectively (n = 3 studies).  
Estimates for deaths due to TB are more precise (mean sensitivity 39% [range 18–62] and mean specificity 97% [range 
93–99]; n = 3 studies).  The authors report that no single method performed better overall; this is also true for deaths 
due to HIV/AIDS (median chance-corrected concordance 0.58–0.64 for all of PCVA, InterVA, Tariff, and SSP) and TB 
(median chance-corrected concordance 0.46–0.49 for the four methods). 
Of the 19 studies included in the Leitao 2014 systematic review, only 10 were included in this thesis: nine for 
comparison of causes of death [279,284–288,294,296,311], and one for comparison based on HIV status alone [302].  
Five studies were excluded because they used PCVA-assigned (n = 4 [271,317–319]) or InterVA-assigned (n = 1 [119]) 
causes of death as the reference standard, leading to circular comparisons, and two because they used only partially 
verified death certificates as reference standard [320,321].  A further two studies were excluded because they reported 
only on child deaths (n = 1 [322]) or described only overall CSMFs for the population studied, which did not allow for 
separation of mortality due to HIV/AIDS or TB (n = 1 [323]).    
2.3.4.5 Potential sources of bias 
2.3.4.5.1 Publication and selection bias 
This review did not use formal systematic review methodology; only one electronic database was searched, which may 
have led to potentially important publications being excluded.  However, attempts were made to mitigate this, through 
inspection of the reference sections of the 2014 systematic review discussed above [109] and other included 
publications, as well as the inclusion of known relevant articles.  The grey literature was also not searched, which will 
have biased selection towards data published in peer-reviewed journals.  Articles were included only if they were 
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written in English, or had a detailed abstract in English, which may have led to the exclusion of important data from 
non-English-speaking countries. 
Most individuals included in studies in this review died in hospitals, as seen in pathological autopsy studies (see Chapter 
2.2).  At least 53% of deaths were in hospitals, though the true figure is almost certainly much higher, as most studies 
conducted at HDSS sites did not specify the proportions of deaths occurring in hospitals vs. the community.  This 
proportion is unlikely to reflect overall mortality patterns in resource-limited settings, although this is not verifiable, as 
reliable CRVS data are not available for many LMIC, particularly in sub-Saharan Africa.   
Individuals who die out of hospitals are less likely to have access to facilities, are likely to fall into different socio-
economic categories, and may be exposed to different risk factors than those in urban areas or with access to 
healthcare.  Unfortunately, there are few reliable data on mortality patterns in rural populations, other than those 
collected through verbal autopsy.  In sub-Saharan Africa, only ~38% of the population live in urban areas, compared 
with 80% in the Americas and 71% in Europe.  Health services, too, are less accessible in these countries, with few 
clinics and fewer hospitals per 100,000 population [12].  South Africa, for example, has a population of 54.5 million; in 
2013, 64% of the population lived in urban areas and there were 0.53 district or rural hospitals per 100,000 population 
[12,324].  South Africa also has some of the best CRVS data of countries in sub-Saharan Africa; Statistics South Africa 
estimated that at least 22% of deaths in 2015 occurred at home, with 6% occurring outside of facilities, and a further 
22% in ‘unknown’ locations [144].  These proportions are likely to be much larger in countries with larger rural 
populations, poorer infrastructure, and reduced access to care; for example, Malawi (population of 17.2 million, only 
15% of whom lived in urban areas in 2013; 0.45 health posts per 100,000 population in 2013; and HIV prevalence was 
10.0% in 2014) and Zimbabwe (population of 15.6 million, 34% lived in urban areas in 2013; <0.01 health posts per 
100,000 population in 2013; and HIV prevalence was 16.7% in 2014) [12,324].  The assumption is, therefore, that a 
sizeable proportion of deaths occur in the community, but few data are available to corroborate this.  As VAs are used 
primarily in areas without adequate CRVS data, it follows that they should be tested in populations in whom they are 
going to be used; at present, the over-representation of individuals dying in hospitals may not allow for accurate 
estimations of CSMFs in the target populations.   
The majority of individuals included in this review had confirmed HIV status or were assigned individual causes of death 
with or without HIV status.  This may have led to the exclusion of groups with high proportions of HIV-associated deaths 
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but without HIV status data or sufficient data with which to estimate cause of death, which may have inflated or 
deflated the summary estimates of sensitivity or specificity.  Additionally, all individuals included in this review had VA 
data available, which itself may be a source of bias.  Individuals without families or carers, or whose family did not 
agree to be interviewed, may be at higher risk of certain causes of death and are not represented in these studies.  
Finally, a few studies selected specifically for HIV-positive individuals, which will have affected the constituent CSMFs 
and summary estimates of CSMF accuracy.  
2.3.4.5.2 Bias inherent in measures of agreement 
For individual-level agreement, the use of a purpose-developed metric, chance-corrected concordance, will have 
mitigated some of the issues with older measures such as Cohen’s kappa, which is known to vary based on the CSMF 
distribution of the evaluated dataset [259].  Similarly, for estimation of population-level agreement, the use of chance-
corrected CSMF accuracy, as opposed to CSMF accuracy or Lin’s concordance correlation coefficient, corrects for 
random guessing and allows for fairer comparisons between studies and populations [312].   
2.3.4.5.3 Bias inherent in verbal autopsy  
VA is, by definition, a ‘blunt instrument’, involving a second-hand account of events collected by a non-technical 
interviewer.  The way VAs are conducted, however, can bias the way data are collected and the causes of death 
assigned.  A concern frequently cited is that of recall bias on the part of the respondent, where it is thought that a 
longer interval between death and the interview will lead to changes in information reported, with respondents 
perhaps able to remember some symptoms better than others [325,326].  WHO recommends a maximum 12 months 
between death and interview [104]; most studies included in this review were comfortably within this, with a few 
exceptions.  Recent evidence, however, suggests that this may actually have little effect on the CSMFs assigned from 
data collected.  Two studies, one using the WHO 2012 VA instrument (n = 10,822) [327], and another using the PHMRC 
VA instrument (n = 1,394) [328], found only minor changes in CSMFs or CSMF accuracy between VAs conducted 0–5 
and 0–3 months, and 6–12 and 4–11 months after death, respectively. 
Further sources of heterogeneity and possible systematic bias within VA studies include the amount and nature of 
training and support provided to lay interviewers; the beliefs and attitudes of the interviewers and respondents, which 
will relate to societal beliefs and norms (e.g., stigma or perceived stigma that may reduce the likelihood of specific 
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diagnoses, such as HIV, being reported); and the questionnaires used for interview, which were not standardised prior 
to 2007. 
2.3.4.6 Gaps in the literature and remaining questions 
Fundamentally, there remains a need for better quality reference standards and greater standardisation among VA 
validation studies.  A major focus of this process should be in the development of large, shared, reference standard 
datasets that, ideally, use high quality diagnostic data and include findings from pathological autopsy.  The PHMRC 
dataset shows that the process can be conducted with a degree of rigour, although it is itself problematic with respect 
to HIV and TB-related deaths, as discussed above.  Shared reference datasets are therefore also needed that are more 
representative of mortality patterns in areas with high proportions of deaths due to HIV and TB, including 
representation of individuals who receive care and die in the community.  The development and use of guidelines for 
assigning causes of death, particularly in HIV-positive individuals, similar to the Coding Causes of Death in HIV (CoDe) 
project [329], would make the validation process easier and allow for clearer comparisons between different VA 
validation studies and between research and routine data. 
Another important aspect of standardisation is the way in which agreement, or VA performance, is measured.  The 
IHME recommendations for metrics are very useful [330] and have been adopted by more recent studies [108,109,313].  
In addition, the development of reporting guidelines for VA validation studies, such as those currently recommended 
for randomised controlled trials [331] and systematic reviews [332] would allow for greater reproducibility of results 
across studies. 
Finally, there is a need for studies conducted in areas of high HIV and TB prevalence to separate deaths due to HIV-
associated TB from deaths due to other HIV-associated causes.  Although this may be very difficult in practice, both in 
the development of reference datasets and in the interpretation of VA data, the potential benefits of having better data 
on mortality due to HIV-associated TB, as discussed in Chapter 1, outweigh the time and cost risks involved in the 
exercise.  More accurate estimates of mortality due to HIV-associated TB are essential if we are to adequately track 
progress towards the mortality reduction goals set by governing bodies [35,36].  Pathological autopsy, in research or 
routine practice, can only realistically be used for a small proportion of deaths.  Despite indications that VA may not be 
the ideal method with which to estimate this mortality fraction, it is, at present, and in the absence of robust and 
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validated CRVS data, the most feasible and cost-effective method available [333,334].  The use of VA to measure 
mortality due to HIV-associated TB should not be dismissed when its ability to do so has not really been evaluated.  
2.3.5. Summary and conclusions 
The literature around the validation of VA in areas of high HIV prevalence is diverse.  There is considerable 
heterogeneity in the quality of reference standards used for comparison, the methods used to interpret VA, and the 
metrics by which VA performance is measured.  At present, PCVA remains the most accurate and consistent method in 
assigning HIV-associated causes of death in areas of high HIV prevalence.  Very few attempts have been made to 
distinguish between HIV-associated TB and other HIV-associated causes of death; ICD-10 coding makes this difficult, 
although there is also variability in how ICD rules are interpreted.  There is a need for higher quality reference 
standards that, ideally, include data from pathological autopsy, and greater standardisation of VA procedures; this will 
be made easier through the development of shared reference standard datasets which are representative of mortality 
patterns in different settings.  Future studies should also attempt to differentiate between HIV-associated TB and other 
HIV-associated causes.  
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3.2.1. Abstract 
3.2.1.1 Background 
To track progress towards targets set by governing bodies for reductions in HIV- and tuberculosis (TB)-related mortality, 
it is important to know how many HIV-positive people die and from which causes.  In studies of HIV-positive adults 
dying in low- and middle-income countries (LMIC) in whom causes of death (CoD) were directly estimated (from 
autopsy or clinical records), this systematic review and meta-analysis aimed to estimate the proportions assigned HIV-
associated and TB CoD and to estimate these same proportions in individuals initiated on antiretroviral therapy (ART). 
3.2.1.2 Methods 
Three electronic databases were searched; studies were included that used autopsy or other clinical data to assign CoD 
in confirmed HIV-positive adults and excluded that required an additional diagnosis for participant inclusion, used non-
clinical data (without validation) to assign CoD, or were published in a language other than English without an English 
abstract.  The primary outcome was the proportion of decedents assigned HIV-associated CoD (defined as AIDS, other 
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infection, or ART toxicity).  Pooled proportions were generated using random-effects meta-analysis; relationships 
between CoD proportions and other variables were assessed using meta-regression.  
3.2.1.3 Results 
A total 3,818 unique records were identified from electronic databases and other sources; 3,701 were excluded based 
on titles and/or abstracts; 117 full text articles were reviewed, 56 (47.9%) of which were included in the meta-analysis, 
reporting on 10,291 deaths in HIV-positive adults, 4,009 of whom had initiated ART.  Heterogeneity between studies 
was very high (I2 >94%; p <0.01).  The pooled proportion of decedents assigned HIV-associated CoD was 79% (95% 
confidence interval [CI] 74–83) and, among studies reporting TB as a specific CoD, the pooled proportion assigned a TB 
CoD was 29% (95% CI 24–34; n = 47 studies).  TB accounted for 39% of all HIV-associated CoD.  Studies with higher 
proportions of decedents who initiated ART assigned fewer HIV-associated CoD (assigned to 86%, 76%, and 70% if 
<33%, 33%–65%, or ≥66% of decedents initiated, respectively; p = 0.01) but no changes were seen in proportions of TB 
CoD assigned (to 28%, 24%, and 26%, respectively; p = 0.52).  Among decedents who initiated ART, a pooled 72% (95% 
CI 66–79) were assigned an HIV-associated CoD and 26% (95% CI 18–34) a TB cause of death.  In general, studies that 
used autopsy data assigned higher proportions of HIV-associated and TB CoD than those that did not (all HIV-associated 
87% vs. 73%, p = 0.02; TB 37% vs. 24%, p = 0.04).   
3.2.1.4 Conclusions 
HIV-associated causes, specifically TB, accounted for a high proportion of deaths in studies in LMIC, including in adults 
who initiated ART.  More recent studies and those that included higher proportions of individuals on ART had fewer 
HIV-associated CoD assigned, but there was no reduction seen in proportions of TB CoD assigned.  To track progress 
towards global targets for reducing HIV and TB mortality, standardised methods are needed to assign CoD in HIV-
positive people who die in LMIC that are feasible for use at a programmatic level, allow for the quantification of all 
deaths in HIV-positive individuals, and correspond to the coding systems used to collate national, regional, and global 
estimates.  
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3.2.2. Introduction 
An estimated 1.2 million individuals died in 2015 due to HIV-associated causes [1], but accurate estimates of causes of 
death in HIV-positive individuals dying in low- and middle-income countries (LMIC) remain elusive, with cause-specific 
mortality estimates generated indirectly through mathematical modelling [2].  Often, this is because many countries 
with high HIV prevalence do not have functional civil registration and vital statistics (CRVS) systems and information on 
causes of death must be obtained from other sources: between 2009 and 2013 over 80% of countries in the African 
region had incomplete or no CRVS death data available [3–5]. 
Complete diagnostic (pathological) autopsy is the gold standard in assigning causes of death.  Even when pathological 
autopsy data are available, however, the process of cause of death assignment is often not precise [6,7].  Other than 
pathological autopsy studies, nearly all of which have been conducted among small numbers of individuals admitted to 
hospital, the next best direct estimates of cause-specific mortality in these populations are obtained from individual 
studies of in-hospital deaths, sub-studies of deaths after recruitment to a cohort study, or retrospective reviews of 
medical records with post hoc assignment of cause of death.  The types and quality of data available to these studies 
are extremely variable, as are the methods used to assign causes of death.  To remedy this, in 2004, the Coding Causes 
of Death in HIV (CoDe) project aimed to develop a standardised, validated method for assigning causes of death in HIV-
positive individuals [8,9].  In this aim the project was relatively successful, but two major obstacles to the wider uptake 
of the method have not yet been overcome: (1) the relative complexity and time requirements of the protocol mean 
that it is not feasible for use outside of research settings, making it difficult to compare estimates obtained through 
research and those obtained through routine data collection; and (2) the causes of death assigned do not readily 
translate into International Statistical Classification of Diseases and Related Health Problems (ICD) codes, which further 
increases the difficulties in relating results to routinely collected data.  In addition, the CoDe list of causes of death 
refers only to ‘AIDS’ or ‘Other infections’ and does not specifically mention tuberculosis (TB), the impact of which is 
already difficult to estimate. 
TB is the most important cause of death in HIV-positive individuals, causing an estimated 390,000 deaths in 2015 [10].  
In individuals with advanced HIV disease, however, TB disease is difficult to diagnose: a systematic review of 
pathological autopsy studies among HIV-positive adults in LMIC reported that almost half of those with evidence of 
active TB at autopsy had not been diagnosed before death [11].  The under-recognition of TB in people living with HIV 
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(PLHIV) suggests that we may underestimate the true burden of TB mortality in these populations.  This is compounded 
by the way ICD-10 classifies HIV deaths [12], where all HIV-associated deaths, whether due to TB or other cause, are 
counted together under five broad ‘HIV’ codes (B20–B24) [13,14].  This, in addition to the absence of a system that 
records the death of an HIV-positive individual from a non-HIV-associated cause, makes it difficult to differentiate 
between those dying from HIV and those dying with HIV, a distinction that is likely to become increasingly important to 
make. 
The global rollout of antiretroviral therapy (ART) has dramatically reduced the risk of mortality for many PLHIV [15,16], 
though those in lower-income settings are still at high risk of death early on treatment [17–19].  PLHIV on ART have 
greater life expectancies and reduced vulnerability to diseases associated with immunosuppression; changes in cause of 
death patterns among these individuals are inevitable [7,20] and the way that HIV-associated deaths are defined may 
need to change to mirror the evolving epidemic [21].  As seen in high-income countries, it is likely that causes of death 
in HIV-positive individuals will align more closely with those seen in the HIV-negative population, with non-
communicable diseases such as diabetes mellitus, hypertension, and cardiovascular disease becoming increasingly 
prominent [22–24].  Systems currently used to collate cause of death statistics, however, are designed to estimate only 
mortality due to HIV and do not provide estimates of all-cause mortality among HIV-positive individuals [21].  As we 
seek to track progress towards reductions in absolute numbers of HIV-associated deaths, as set out by the Joint United 
Nations Committee on HIV and AIDS (UNAIDS) [25], it will be critical to distinguish between individuals dying from HIV 
and with HIV.  To allow for estimation of trends and to measure the impact of interventions, however, it is important 
first to establish a baseline as regards the HIV-associated mortality fraction among HIV-positive individuals. 
The aims of this systematic review were to assess, among studies that directly estimated causes of death in HIV-positive 
adults in LMIC (through pathological autopsy, other post-mortem examination, or review of clinical data), (1) the 
proportions of deaths attributed to HIV-associated causes and, specifically, HIV-associated TB; and (2) to estimate these 
same proportions among individuals who died after initiating ART.  
3.2.3. Methods 
3.2.3.1 Search strategy 
MEDLINE, EMBASE, and Web of Science searched for variations of the following terms, combined by AND parameters: 
HIV, cause of death, and low- and middle-income countries (LMIC, as defined by the World Bank and the Cochrane 
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group [26,27]).  Articles published on or before 31 October 2016 were included.  Full details of the electronic search 
strategy are provided in Supplementary table 3:1.  Additional titles were obtained from the references of reviewed 
articles, including a 2015 systematic review of autopsy studies in sub-Saharan Africa [11] and three other recent 
reviews [23,28,29].   
3.2.3.2 Screening and exclusion criteria 
After removal of duplicates, titles and abstracts were screened independently by two reviewers (ASK and AD).  Studies 
were excluded that were conducted in high-income countries only; involved only pregnant women and/or children; 
included only individuals with a certain risk factor, such as mine-workers, or diagnosis, such as TB; or were written in a 
language other than English without an English abstract.  Full-text articles were reviewed, where available; studies were 
excluded if they had recruited only individuals with an HIV-associated or ‘AIDS’ cause of death, if they involved only 
estimates through indirect methods (such as verbal autopsy) without clinical correlation, or if they described only 
population-level causes of death. 
3.2.3.3 Data extraction 
Data were extracted from each manuscript using a standardised case report form; data collected included population 
size, study design, recruitment criteria, site of recruitment, site of death, numbers on ART and/or TB treatment, clinical 
data available, methods used to assign causes of death, and causes of death assigned.  Causes of death counted as ‘HIV-
associated’ were AIDS (per the 1993 revised Center for Disease Control [CDC] definition [30]), other infections thought 
to have caused death, and adverse effects of ART thought to have caused death.  This was implemented regardless of 
how individual studies had classified AIDS-associated or HIV-associated causes of death (for example, if studies 
classified deaths due to ART toxicity as ‘non-AIDS’, these were re-classified as ‘HIV-associated’ for the purposes of this 
review).  For other, more specific causes of death (e.g., TB), numbers of deaths were reported per the study 
publication. 
3.2.3.4 Assessment of quality, bias, and methods 
The quality of studies, including risk of bias, was assessed using the National Heart, Lung, and Blood Institute (NHLBI) 
quality assessment tool for observation cohort and cross-sectional studies (Supplementary table 3:2 [31]).  Based on 
the 14 variables included, each study was assigned a rating of ‘Good’, ‘Fair’, or ‘Poor’, in accordance with guidance 
provided.  In addition, a separate assessment of methodological rigour was carried out using a purpose-built scale 
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(Supplementary table 3:3).  Measures assessed were: the types of data available per participant per study; the 
numbers, roles, and independence of individuals assigning causes of death; the structure of the overall assignment 
process; the methods used to resolve discrepancies; and the standard of the case definitions used to assign each cause 
of death.  Each element was scored individually and the scores aggregated to give each study a total score between 
zero and six.  
3.2.3.5 Data management and statistical analyses 
Manuscripts were organised using Mendeley software; data were entered into an EpiData (The EpiData Association, 
Odense, Denmark) database and managed in a Microsoft Excel spreadsheet.  Pooled estimates of HIV-associated 
mortality and mortality due to HIV-associated TB with 95% confidence intervals (CI) were generated using a random-
effects model, incorporating the Freeman-Tukey double arcsine transformation of proportions, with the percentage of 
total variation due to heterogeneity (I2) measured between studies [32].  Estimates were further stratified by 
geographic region, economic group, calendar period (three periods, based on ART availability in LMIC: pre-2005 [very 
limited availability]; 2005–2010 [increasing availability]; and 2011–2015 [widespread availability]), proportions of 
decedents initiated on ART, and study quality, with heterogeneity measured between groups.  Forest plots were used 
to graphically represent mortality fractions in individual studies and pooled estimates.  Meta-regression was used to 
examine for relationships between mortality fractions and other key variables, including the year of data collection, the 
proportion of individuals in each study initiated on ART, the data & methods score assigned to each study, and the use 
of pathological autopsy data to assign causes of death.   
Further analysis was conducted to compare, where reported, causes of death assigned to individuals who had initiated 
ART with causes assigned with those who had not.  Pooled proportions of HIV-associated and TB causes of death 
assigned were generated using random-effects meta-analysis, as previously, although stratification and meta-
regression were conducted based only on geographic location, income group, and years of data collection, as quality 
and methods scores were assigned at study level.  All analyses were carried out using Stata v14 (StataCorp, College 
Station, TX, USA); figures were edited and formatted using Inkscape™ software (https://inkscape.org).    
3.2.3.6 Ethical considerations 
No participants or individual data were involved in this study; ethical approvals were not required. 
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3.2.4. Results 
3.2.4.1 Search results 
A total 3,818 unique records were identified from electronic databases and other sources; 3,701 were excluded after 
review of title and abstracts; 117 full text articles were reviewed, 56 (47.9%) of which were included in the meta-
analysis (Figure 3:1).  Details of individual studies are described in Table 3:1 and summarised in Table 3:2.  Of the 56 
studies included, 32 (57.1%) were conducted in sub-Saharan Africa, eight (14.3%) in South Asia, seven (12.5%) in Latin 
America and the Caribbean, and four (7.1%) in East Asia and the Pacific.  Studies were divided into three periods based 
on the last year of data collection: 15 (26.8%) studies completed data collection prior to 2005; 30 (53.6%) between 
2005 and 2010; and 11 (19.6%) between 2011 and 2015.  At least 34/56 (60.7%) studies reported causes of death in 
individuals who had initiated ART (11 studies did not specify): 1%– 66% of decedents initiated ART in 14/34 (41%) 
studies; 100% of decedents initiated ART in 17/34 (50%) studies.  Only one study completed before 2005 included 
adults who had initiated ART. 
Some 105,992 individuals were studied, 57,001 (53.8%) of them HIV-positive; 35,127 (61.6%) of these individuals had 
initiated ART.  There were 11,791 deaths among HIV-positive adults, 4,128 [35.0%] of whom had initiated ART; 
attempts were made to assign individual causes of death to 10,291 (87.3%) HIV-positive individuals, of whom 4,009 
(40.0%) had initiated ART.    
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Figure 3:1. PRISMA flow diagram showing records found, screened, reviewed, and included in analysis 
  
ART: antiretroviral therapy; CoD: cause of death; CRVS: civil registration and vital statistics; PRISMA: Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses; TB: tuberculosis; VA: verbal autopsy; WScience: Web of 
Science 
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Table 3:1. Studies that directly estimated causes of death in HIV-positive individuals in LMIC: population, selection criteria, study quality, overall methods score*, and 
proportion of decedents on ART for each study; listed by period of data collection and geographic area (n = 56 studies) 
Calendar period,  
region, period of 
data collection 
Country/ies 
Income 
group 
Study 
design 
Population and selection 
NHLBI 
grade 
Data available from Overall 
methods 
score 
Proportion 
on ART (%) Autopsy (%) Hospital (%) 
Pre-2005   
 
      
[33] LAm + Car 01  
(1993–2000)  
Brazil UM R Hospital in-patients 'submitted to autopsy' Good 100 73.9 2.7 NS 
[34] LAm + Car 02  
(1996–2003) 
Brazil UM R ‘AIDS’ patients undergoing autopsy Poor 100 0 1.0 NS 
[35] LAm + Car 03  
(1999–2004) 
Peru UM R In-patient deaths, HIV+ or CDC AIDS; unclear CoD preferred Good 100 100 2.0 0 
[36] SAsia 01  
(1991–2003) 
India LM R Hospital in-patients Poor 100 100 2.5 0 
[37] SAsia 02  
(2000–2003) 
India LM P Consecutive HIV+ admissions to hospital; report only on in-
patient deaths 
Poor 0 100 2.0 NS 
[38] SAsia 03  
(2002–2003) 
India LM R HIV+ admitted to medical wards of a large public hospital; 
report only on in-patient deaths 
Fair 0 100 2.0 NS 
[39] SSAfr 01  
(1986–1987) 
Rwanda L P Consecutive sample of HIV+ and HIV- women of childbearing 
age 
Good 0 NS 2.3 0 
[40] SSAfr 02  
(1988–1989) 
Cote d'Ivoire LM P Consecutive cadavers admitted to two mortuaries; deaths in 
hosp. or community (forensic deaths) 
Good 100 0 3.0 0 
[41] SSAfr 03  
(1989) 
Cote d'Ivoire LM P Consecutive deaths on pulmonary ward Poor 100 100 2.0 0 
[42] SSAfr 04  
(1991) 
Cote d'Ivoire LM P Consecutive in-patient & community deaths brought into 
hospital 
Good 100 88.8 3.9 0 
[43] SSAfr 05  
(1990–1996) 
Uganda L P Deaths after enrolment to population-based cohort Good 0 0 3.5 0 
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Calendar period,  
region, period of 
data collection 
Country/ies 
Income 
group 
Study 
design 
Population and selection 
NHLBI 
grade 
Data available from Overall 
methods 
score 
Proportion 
on ART (%) Autopsy (%) Hospital (%) 
[44] SSAfr 06  
(1996–1997) 
Kenya LM P Consecutive in-patient deaths on medical wards; excluded 
patients referred for specialist care  
Good 100 100 4.5 0 
[45] SSAfr 07  
(1997–1998) 
Botswana UM P Medical in-patient deaths, including DOA; favoured those 
without diagnosis/unexpected death, with pulmonary>gastro 
symptoms, or possible PCP; excluded forensic cases and DOA 
with trauma 
Good 100 100 4.0 0 
[46] SSAfr 08  
(2001) 
Congo, Rep. LM P Bodies of all individuals >14 years registered at morgue Poor 0 91.4 2.4 0 
[47] SSAfr 09  
(1998–2002) 
Senegal L P >15 years, ART-naïve, CD4 <350 cells/µL, VL >30,000 copies/ml, 
enrolled in observational cohort; consecutive starting ART in 
ISAARV 
Good 0 64.5 4.2 100 
2005–2010   
 
      
[48] EAsia + Pac 01  
(2003–2007) 
TAHOD† LM P Enrolled to observational cohort, started ART and had at least 
one f/up visit; community & hospital deaths 
Good 0 NS 4.3 100 
[49] EAsia + Pac 02  
(2007–2010) 
Vietnam LM P Deaths after enrolment to RCT to assess the effect of peer 
support on tx failure & drug resistance; ≥18 years, ART-naïve, 
willing to receive adherence support at home, eligible for ART 
Fair 0 76.7 0.8 100 
[50] Eur + CAsia 01  
(2003–2008) 
Russian 
Federation 
UM R HIV-positive adults who died in hospital in the Smolensk region Poor 100 0 1.0 NS 
[51] Eur + CAsia 02  
(1996–2009) 
Turkey UM R Unclear Poor 0 0 0.0 NS 
[52] LAm + Car 04  
(1997–2006) 
Brazil UM P ≥16 years, at least one f/up visit after enrolment to cohort 
study 
Good 0 100 5.0 67.7 
[53] LAm + Car 05  
(1986–2009) 
Brazil UM P ≥18 years, enrolled into IPEC cohort with minimum f/up of 60 
days 
Poor 0 NS 4.3 34.4 
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Calendar period,  
region, period of 
data collection 
Country/ies 
Income 
group 
Study 
design 
Population and selection 
NHLBI 
grade 
Data available from Overall 
methods 
score 
Proportion 
on ART (%) Autopsy (%) Hospital (%) 
[54] MEast + NAfr 
01 (1999–
2009) 
Morocco LM R Adults attending ID unit of hospital, started ART and died in 
the ID unit; excluded if on ART for <1 month 
Fair 0 100 2.5 100 
[55] SAsia 04  
(1992–2005) 
India LM R HIV+ deaths after admissions to hospital; report only on in-
patient deaths 
Poor 0 100 2.0 3.4 
[56] SAsia 05  
(1988–2007) 
India LM P Medical in-patient deaths among consecutive admissions to 
medical wards; excluded if admitted to neurology or 
neurosurgery wards 
Fair 100 100 2.0 0.8 
[57] SAsia 06  
(1996–2008) 
India LM P ≥18 years, ART-naïve prior to initiation; report only on in-
patient deaths 
Fair 0 100 3.0 100 
[58] SAsia 07  
(2000–2008) 
India LM P Adults initiating ART who died in hospital after enrolment to 
prospective cohort; report only on in-patient deaths 
Fair 0 100 1.5 100 
[59] SAsia 08  
(2009–2010) 
India LM R Deaths among consecutive ART-naïve patients, aged ≥15 years, 
initiating first-line ART at tertiary hospital; excluded pregnant 
women 
Poor 0 100 1.0 100 
[60] SSAfr 10  
(1996–2005) 
Togo L R In-patient deaths on neurology ward Fair 0 100 1.0 0 
[61] SSAfr 11  
(2002–2005) 
South Africa UM P Adults (≥18 years) dying after referral for ART; excluded if 
previously initiated ART at other clinic 
Good 8.8 100 2.6 54.4 
[62] SSAfr 12  
(2003–2005) 
Uganda & 
Zimbabwe 
L P Deaths among adults with CD4 <200 cells/µL and no previous 
ART enrolled to large pragmatic trial of ART monitoring (DART); 
excluded if death >12 months after enrolment 
Good 0 NS 2.3 100 
[63] SSAfr 13  
(2004–2005) 
Uganda L P Adults living within 20 km of Kampala dying after recruitment 
to a cohort study; included if eligible for ART and willing to 
f/up for two years 
Good 0 NS 1.3 100 
[64] SSAfr 14  
(2000–2007) 
Cameroon LM R In-patient deaths, HIV-positive and HIV-negative Fair 0 100 1.5 27.4 
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Calendar period,  
region, period of 
data collection 
Country/ies 
Income 
group 
Study 
design 
Population and selection 
NHLBI 
grade 
Data available from Overall 
methods 
score 
Proportion 
on ART (%) Autopsy (%) Hospital (%) 
[65] SSAfr 15 
(2005–2007) 
South Africa UM R Initiated on ART and died in hospital Good 0 74.2 4.2 100 
[66] SSAfr 16  
(2007) 
Ghana LM R Consecutive HIV-positive deaths within fevers unit in teaching 
hospital 
Fair 61.1 100 5.6 14.5 
[67] SSAfr 17 
(2000–2008) 
South Africa UM P + R Medical in-patient deaths among HIV-positive adults Poor 100 100 4.5 NS 
[68] SSAfr 18  
(2003–2008) 
Burkina Faso L R Death among adults ≥15 years who started ART for first time 
≥6 months before start of study; excluded if started ART at 
different facility or before January 2003 
Good 0 60.9 4.6 100 
[69] SSAfr 19 
(2004–2009) 
South Africa UM R Deaths (at home or in hospital) among adults (≥18 years) who 
initiated ART at hospital ART clinic 
Good 0 75.4 3.8 100 
[70] SSAfr 20 
(2006–2009) 
Nigeria LM R Died ≥6 months after enrolment in ART programme; died while 
on home-based or in-patient care 
Poor 0 49.5 2.0 100 
[71] SSAfr 21  
(2006–2009) 
Nigeria LM R Deaths among those aged >13 years, non-pregnant, and 
admitted to medical wards; included only those with ‘complete 
clinical details’ 
Good 0 100 4.0 83.3 
[72] SSAfr 22  
(2009) 
Uganda L P Consecutive deaths on ID/gastro ward; excluded if no next-of-
kin available 
Fair 100 100 5.5 28.6 
[73] SSAfr 23  
(2009) 
South Africa UM P Consecutive deaths on medical wards among adults 
receiving/eligible for ART; excluded if pregnant or had a history 
of defaulting/restarting ART 
Good 100 100 6.0 69.2 
[74] SSAfr 24  
(2004–2010) 
South Africa UM R ART-naïve adults (≥18 years) with CD4 ≤50 cells/µL attending a 
clinic for screening  
Fair 0 34.9 0.9 100 
[75] SSAfr 25  
(2010) 
Togo L P Adults and children dying after admission to 16 hospitals; 
excluded if died at home or in ambulatory care 
Poor 0 100 1.0 51.8 
[76] SSAfr 26  
(2010) 
Mozambique L R In-patient deaths among HIV-positive individuals undergoing 
autopsy 
Good 100 100 2.0 NS 
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Calendar period,  
region, period of 
data collection 
Country/ies 
Income 
group 
Study 
design 
Population and selection 
NHLBI 
grade 
Data available from Overall 
methods 
score 
Proportion 
on ART (%) Autopsy (%) Hospital (%) 
[77] SSAfr 27  
(2010) 
Cote d'Ivoire, 
Burkina Faso, 
Benin, Mali, & 
Senegal 
LM P Newly hospitalised HIV-positive adults; death after admission Fair 0 100 5.0 42.5 
2011–2016   
 
      
[78] EAsia + Pac 03  
(2009–2012) 
China UM P In-patient deaths among HIV-positive adults; deaths within 6 
months of admission 
Good 0 NS 0.3 34.3 
[79] EAsia + Pac 04  
(2007–2014) 
Vietnam LM P Adults in first year of ART attending HIV clinics in two large 
hospitals in Hanoi; excluded if never on ART or on ART for >1 
year 
Fair 0 0 1.5 100 
[80] Eur + CAsia 03  
(1989–2012) 
Georgia UM R HIV+ adults registered in Georgia HIV/AIDS database; died 
between 1989 and 2012 
Good 0 NS 4.3 NS 
[81] LAm + Car 06  
(2000–2011) 
Brazil UM P Adults (≥18 years) in longitudinal database receiving HIV care 
with a minimum 60 days follow up; excluded if heavy cocaine 
use, IVDU, unknown route of HIV acquisition, or no CD4 count 
during f/up 
Fair 0 NS 4.3 NS 
[82] LAm + Car 07  
(2010–2013) 
Mexico UM R Death in one of three hospitals; excluded if records not 
available 
Fair 0 100 3.5 18.8 
[83] MEast + NAfr 
02  
(2000–2014) 
Tunisia LM R Adults (≥15 years) followed up by hospital ID department Good 0 NS 2.3 68.5 
[84] SSAfr 28  
(2002–2011) 
Congo, Rep. LM R Adults (>15 years) dying during follow up at outpatient ART 
centre 
Poor 0 NS 0.3 100 
[85] SSAfr 29  
(2002–2012) 
Uganda L R Deaths among adults (≥18 years) receiving care at community 
HIV facility in Kampala; excluded those with unknown date of 
death 
Good 0 NS 3.9 38.4 
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Calendar period,  
region, period of 
data collection 
Country/ies 
Income 
group 
Study 
design 
Population and selection 
NHLBI 
grade 
Data available from Overall 
methods 
score 
Proportion 
on ART (%) Autopsy (%) Hospital (%) 
[86] SSAfr 30  
(2012) 
Kenya LM P Deaths among patients receiving ART at a hospital Poor 100 100 6.0 100 
[87] SSAfr 31  
(2013) 
Uganda L P Consecutive HIV+ adult deaths on medical wards + patients 
with autopsy requests from non-medical wards; excluded 
postpartum & traumatic deaths 
Fair 100 0 4.5 61.5 
[88] SSAfr 32  
(2013–2015) 
Mozambique L P In-patient deaths with autopsy requested by clinician; 
excluded traumatic and maternal deaths 
Good 100 100 6.0 NS 
*Based on assessment of data available to reviewers, reviewers and process of assigning causes of death, and criteria defined for each cause (Supplementary table 3:3) 
†TAHOD lower middle-income countries: Cambodia, India, Indonesia, Philippines, and Vietnam; TAHOD upper middle-income countries: China, Indonesia, Malaysia, and Thailand  
 
ART: antiretroviral therapy; CDC: Center for Disease Control; CoD: cause of death; DART: Development of Antiretroviral Therapy in Africa; DOA: dead on arrival; EAsia + Pac: East 
Asia & the Pacific; Eur + CAsia: Europe & Central Asia; f/up: follow-up; gastro: gastroenterology; HIV+: HIV-positive; ID: infectious diseases; IPEC: Evandro Chagas Institute of Clinical 
Research (Brazil); ISAARV: Senegalese ART drug access initiative; IVDU: intravenous drug user; km: kilometres; L: low; Lam + Car: Latin America & the Caribbean; LM: lower middle; 
MEast + NAfr: Middle East & North Africa; NHLBI: National Heart, Lung, and Blood Institute; NS: not specified; P: prospective; R: retrospective; RCT: randomised controlled trial; 
SAsia: South Asia; SSAfr: sub-Saharan Africa; TAHOD: TREAT Asia HIV Observational Database; tx: treatment; UM: upper middle 
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Table 3:2. Characteristics of studies included in analysis (n = 56 studies; n = 10,291 HIV-positive adult deaths; n = 
4,009 deaths after initiation of ART) 
Characteristic 
Studies, n (%) 
(N = 56) 
Included HIV-positive adults with CoD assigned 
Overall, n (%)  
(N = 10,291) 
Initiated ART,  
n (row %) 
Region*    
 Sub-Saharan Africa 32 (57.1) 6,572 (63.9) 3,045 (46.3) 
 South Asia 8 (14.3) 791 (7.7) 164 (20.7) 
 Latin America & the Caribbean 7 (12.5) 1,562 (15.2) 476 (30.5) 
 East Asia & the Pacific 4 (7.1) 374 (3.6) 232 (62.0) 
 Europe & Central Asia 3 (5.4) 847 (8.2) 0 
 Middle East & North Africa 2 (3.6) 145 (1.4) 128 (88.3) 
Income category*    
 Low  13 (23.2) 3,065 (29.8) 1,685 (55.0) 
 Lower middle 25 (44.6) 3,812 (37.0) 1,254 (32.9) 
 Upper middle 18 (32.1) 3,414 (33.2) 1,106 (32.4) 
Calendar period†    
 Pre-2005 15 (26.8) 2,118 (20.6) 93 (4.4) 
 2005–2010 30 (53.6) 5,249 (51.0) 2,916 (55.6) 
 2011–2015 11 (19.6) 2,924 (28.4) 1,036 (35.4) 
Site of recruitment    
 Hospital only 32 (57.1) 4,339 (42.2) 1,117 (25.7) 
 Community only 14 (25.0) 4,250 (41.3) 2,136 (50.3) 
 Hospital + community 9 (16.1) 1,666 (16.2) 756 (45.4) 
Site of death    
 Hospital only 27 (48.2) 3,080 (29.9) 927 (30.1) 
 Hospital + community 24 (42.9) 6,849 (66.6) 3,040 (44.4) 
NHLBI quality rating    
 Good 25 (44.6) 5,258 (51.1) 2,288 (43.5) 
 Fair  16 (28.6) 2,091 (20.3) 695 (33.2) 
 Poor 15 (26.8) 2,942 (28.6) 1026 (34.9) 
Data & methods    
 Data available    
  Pathological autopsy‡ 20 (35.7) 2,442 (23.7) 420 (17.2) 
  Hospital records‡ 49 (87.5) 9,627 (93.5) 3,994 (41.5) 
 Assignment process     
  At least two reviewers 36 (64.3) 7,519 (73.1) 3,399 (45.2) 
  Structured process 33 (58.9) 7,541 (73.3) 3,136 (41.6) 
  System for resolving disagreements 25 (44.6) 6,123 (59.5) 3,179 (51.9) 
  Criteria for individual CoD 34 (60.7) 7,601 (73.9) 2,894 (38.1) 
 Data & methods score§, median (IQR) 2.5 (1.7–4.3) 2.5 (1.7–4.3) 2.5 (2.0–4.0) 
*Per World Bank classification [27] 
†Based on last year of data collection 
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‡All participants from each study did not necessarily have these data available; numbers shown are maximum possible 
with data available 
§Based on data available and methods used to assign causes of death (Supplementary table 3) 
ART: antiretroviral therapy; CoD: cause of death; IQR: interquartile range; NHLBI: National Heart, Lung, and Blood 
Institute 
3.2.4.2 Proportions assigned HIV-associated causes of death  
The pooled proportion of HIV-positive adult decedents assigned any HIV-associated cause of death was 79% (95% CI 
74–83; Tables 3:3 and 3:4; Figure 3:2).  There was a high degree of heterogeneity between studies, (I2 96.8%, p <0.01), 
with proportions of decedents assigned HIV-associated causes ranging from 30% to 100%.  There were fewer 
differences between studies based on geographical regions (p = 0.79, based on meta-regression); income groups (p = 
0.85); and study quality, based on NHLBI grade (p = 0.25).  The 11 studies conducted from 2011–2015 assigned a slightly 
lower proportion of HIV-associated causes of death than those conducted in earlier periods (70% in 2011–2015 vs. 77% 
in 2005–2010 [n = 30 studies] vs. 87% pre-2005 [n = 15 studies]; p = 0.14; Figure 3:2).  Similarly, studies where larger 
proportions of decedents initiated ART assigned lower proportions of HIV-associated causes of death (85% if <33% on 
ART [n = 11 studies] vs. 76% if 33–65% on ART [n = 7 studies] vs. 71% if >66% initiated on ART [n = 21 studies]; p = 0.02; 
Figure 3:3).   
Meta-regression of the proportion of individuals on ART per study against middle year of data collection showed that 
proportions on ART were markedly higher in studies conducted more recently (p <0.001; Supplementary figure 3:1). 
The 20 studies that used autopsy data assigned more HIV-associated causes of death than the 36 studies that did not 
(87% vs 73%; p = 0.02; Figure 3:4).  Heterogeneity was high within groups (I2 >93%; p <0.01) but was variable between 
groups (p 0.53–1.0 between regions, income groups, and NHLBI grades; p = 0.06 and p = 0.01 between calendar periods 
and proportions on ART, respectively).   
3.2.4.3 Proportions assigned TB causes of death 
Of the 56 studies included, 47 (83.9%) reported the proportion of individuals assigned HIV-associated TB as a cause of 
death: 29/47 (61.7%) studies were conducted in sub-Saharan Africa, seven (14.9%) in South Asia, and four (8.5%) in 
Latin America; 12 (25.5%), 22 (46.8%), and 13 (27.7%) studies were conducted in low-, lower middle-, and upper 
middle-income countries, respectively; 21 (44.7%), 14 (30.0%), and 12 (25.5%) studies were assigned a grade of ‘good’, 
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‘fair’, and ‘poor’, respectively, using the NHLBI grading tool; 18 (38.3%) and 40 (85.1%) studies used autopsy data and 
hospital data, respectively to assign causes of death; and the overall median methods score was 2.5 (IQR 1.5–4.0). 
Among the 7,990 HIV-positive adult decedents included in studies where TB causes of death were reported, a pooled 
29% (95% CI 24–34; Table 3:4) were assigned a TB cause of death.  Heterogeneity between studies was high (I2 96.0%; p 
<0.01); proportions ranged from 0% to 76%.  Meta-regression revealed differences between groups based on 
geographical region (higher in South Asia [51%] than sub-Saharan Africa [25%] or Latin America [22%]; p = 0.01; Figure 
3:5) and income group (highest in lower-middle income countries [36%]; p <0.01).  In contrast to overall HIV-associated 
causes of death, no difference was seen in proportions of TB causes assigned based on calendar period of data 
collection (p = 0.37) or the proportions of decedents initiated on ART (p = 0.61; Figure 3:3).  In the 18 studies where 
autopsy data were used, a pooled 37% (95% CI 30–45) of decedents were assigned a TB cause of death, compared with 
a pooled 24% (95% CI 18–30) of decedents in the 29 studies without autopsy data (p = 0.04).  
When the analysis was restricted to studies conducted in sub-Saharan Africa (n = 29 studies, n = 5,722 deaths), 
differences were observed between income groups (15% low vs. 32% lower middle vs. 33% upper middle; p = 0.05; 
Table 3:4) and based on use of autopsy data (34% with autopsy data vs. 19% without; p = 0.07).  As in the overall 
analysis, the proportion of individuals initiated on ART in each study appeared to have no effect on the proportions of 
TB causes of death assigned, despite a decline in the proportions of overall HIV-associated causes of death assigned 
(meta-regression against proportion on ART: any HIV-associated cause, p = 0.02; TB cause of death in all decedents, p = 
0.85; Figure 3:3). 
3.2.4.3.1 TB as a proportion of HIV-associated causes of death 
Among decedents assigned an HIV-associated cause of death (n = 5,688 in the 47 studies where TB was reported), a 
pooled 39% (95% CI 33–46) were assigned a TB cause of death (heterogeneity 95.6%; p <0.01; Table 3:4).  This was 
much higher in studies conducted in South Asia (72%) compared with sub-Saharan Africa (34%), Latin America (24%), 
and other regions (38%; p <0.01).  Differences were also seen between income groups (lower middle 51% vs. upper 
middle 38% vs. low 21%; p <0.01) but not in relation to the proportion of decedents initiated on ART in each study (p = 
0.98). 
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Table 3:3. Summary of findings of studies that directly estimated causes of death in HIV-positive adults dying in low- and middle-income countries, listed by calendar period of 
data collection (n = 56 studies; n = 10,291 HIV-positive adult decedents) 
Reference,  
calendar period, 
region,  
study number, 
years data collected 
Country 
/ies 
Enrolled, 
N 
Fe-
male 
(%) 
Age, 
median 
(IQR), mean 
(SD), or 
range 
CD4 count 
(cells/µL), 
median 
(IQR), mean 
(SD), or 
range 
All HIV-positive adults (n = 10,291)* Adults who initiated ART (n = 4,009) 
All 
deaths, n 
(%/ 
enrolled) 
Assd. 
CoD† (%/ 
all 
deaths) 
Assd. 
HIV-
assoc. 
CoD (%/ 
assd. 
CoD) 
Assd. TB 
CoD (%/ 
assd. 
CoD) 
Deaths 
on ART, 
n (%/ 
enrolled) 
Time on 
ART 
(days), 
median 
(IQR) 
Assd. 
CoD† 
(%/ 
deaths 
on ART) 
Assd. 
HIV-
assoc. 
CoD (%/ 
assd. 
CoD) 
Assd. TB 
CoD (%/ 
assd. 
CoD) 
Pre-2005               
[33] LAm+Car 01  
(1993–2000)  
Brazil 1,478 25 Mean 34.8 
(range 19–
68) 
NS 92 (6.2) 92 (100) 86 (93.5) 22 (23.9) NS     
[34] LAm+Car 02  
(1996–2003) 
Brazil 129 25.6 32 (range 
13–64) 
NS 129 (100) 129 (100) 107 
(82.9) 
36 (27.9) NS     
[35] LAm+Car 03  
(1999–2004) 
Peru 281 37.5 32 (range 
19–62) 
NS 16 (5.7) 16 (100) 16 (100) 5 (31.3) 0 - - - - 
[36] SAsia 01  
(1991–2003) 
India 60 20 Mean 32.1 
(range 19–
55) 
NS 60 (100) 60 (100) 35 (58.3) 35 (58.3) 0 - - - - 
[37] SAsia 02  
(2000–2003) 
India 135 17 Mean 34 
(± 10) 
Mean 121 (± 
205) 
21 (15.6) 21 (100) 21 (100) 16 (76.2) NS     
[38] SAsia 03 
(2002–2003) 
India 655 25.3 Mean 35.2 
(± 9) 
66 (range 4–
446) 
172 
(26.3) 
172 (100) 112 
(65.1) 
91 (52.9) NS     
[39] SSAfr 01  
(1986–1987) 
Rwanda 3,702 100 Mean 28 NS 39 (1.1) 39 (100) 38 (97.4) 4 (10.3) 0 - - - - 
[40] SSAfr 02  
(1988–1989) 
C. d'Iv. 698 25.9 Range 15–? NS 266 
(38.1) 
266 (100) 130 
(48.9) 
32 (12.0) 0 - - - - 
[41] SSAfr 03 (1989) C. d'Iv. 473 NS NS NS NS  53 47 (88.7) 22 (41.5) 0 - - - - 
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Reference,  
calendar period, 
region,  
study number, 
years data collected 
Country 
/ies 
Enrolled, 
N 
Fe-
male 
(%) 
Age, 
median 
(IQR), mean 
(SD), or 
range 
CD4 count 
(cells/µL), 
median 
(IQR), mean 
(SD), or 
range 
All HIV-positive adults (n = 10,291)* Adults who initiated ART (n = 4,009) 
All 
deaths, n 
(%/ 
enrolled) 
Assd. 
CoD† (%/ 
all 
deaths) 
Assd. 
HIV-
assoc. 
CoD (%/ 
assd. 
CoD) 
Assd. TB 
CoD (%/ 
assd. 
CoD) 
Deaths 
on ART, 
n (%/ 
enrolled) 
Time on 
ART 
(days), 
median 
(IQR) 
Assd. 
CoD† 
(%/ 
deaths 
on ART) 
Assd. 
HIV-
assoc. 
CoD (%/ 
assd. 
CoD) 
Assd. TB 
CoD (%/ 
assd. 
CoD) 
[42] SSAfr 04 (1991) C. d'Iv. 6,752 24.1 34 80 (range 1–
166) 
1080 
(16.0) 
294 
(27.2) 
271 
(92.2) 
92 (31.3) 0 - - - - 
[43] SSAfr 05  
(1990–1996) 
Uganda 440 48.7 Range 22–
80 
NS 63 (14.3) 63 (100) 52 (82.5) 3 (4.8) 0 - - - - 
[44] SSAfr 06  
(1996–1997) 
Kenya 1,804 53.3 33 (29–42) 55 (10–230) 155 (8.6) 75 (48.4) 74 (98.7) 35 (46.7) 0 - - - - 
[45] SSAfr 07  
(1997–1998) 
Botswana 5,055 46.2 35 (range 
14–87) 
NS 565 
(11.2) 
104 
(18.4) 
86 (82.7) 38 (36.5) NS     
[46] SSAfr 08 (2001) Congo, 
Rep. 
1,309 48.7 NS NS 641 
(49.0) 
641 (100) 586 
(91.4) 
 0 - - - - 
[47] SSAfr 09  
(1998–2002) 
Senegal 404 54.7 37 (31–43) 128 (54–217) 93 (23.0) 93 (100) 77 (82.8) 17 (18.3) 93 (23.0) NS¶ 93 (100) 77 (82.8) 17 (18.3) 
2005–2010               
[48] EAsia+Pac 01  
(2003–2007) 
TAHOD‡ 1,557 21.4 39 (32–46) 66 (23–218) 56 (3.6) 56 (100) 22 (39.3)  56 (3.6) NS 56 (100) 22 (39.3)  
[49] EAsia+Pac 02  
(2007–2010) 
Vietnam 640 10 34.2 (29–
38) 
41 (17–104) 60 (9.4) 60 (100) 49 (81.7) 24 (40.0) 60 (9.4) 79 (29–
185) 
60 (100) 49 (81.7) 24 (40.0) 
[50] Eur+CAsia 01  
(2003–2008) 
Russian 
Fed. 
32 15.6 NS NS 32 (100) 32 (100) 32 (100) 24 (75.0) 32 (100) NS  NS   
[51] Eur+CAsia 02  
(1996–2009) 
Turkey 128 18 Mean 38.5 
(range 23–
67) 
Mean 454 
(range 10–
1480) 
36 (28.1) 36 (100) 25 (69.4) 7 (19.4) NS     
An autopsy study exploring the spectrum of disease in individuals with advanced HIV 
 in primary care clinics in South Africa 
 Page 127 of 383 Chapter 3: Research paper 1:  
Directly estimated causes of death among HIV-positive adults in low- and middle-income countries.  A systematic 
review and meta-analysis. 
Reference,  
calendar period, 
region,  
study number, 
years data collected 
Country 
/ies 
Enrolled, 
N 
Fe-
male 
(%) 
Age, 
median 
(IQR), mean 
(SD), or 
range 
CD4 count 
(cells/µL), 
median 
(IQR), mean 
(SD), or 
range 
All HIV-positive adults (n = 10,291)* Adults who initiated ART (n = 4,009) 
All 
deaths, n 
(%/ 
enrolled) 
Assd. 
CoD† (%/ 
all 
deaths) 
Assd. 
HIV-
assoc. 
CoD (%/ 
assd. 
CoD) 
Assd. TB 
CoD (%/ 
assd. 
CoD) 
Deaths 
on ART, 
n (%/ 
enrolled) 
Time on 
ART 
(days), 
median 
(IQR) 
Assd. 
CoD† 
(%/ 
deaths 
on ART) 
Assd. 
HIV-
assoc. 
CoD (%/ 
assd. 
CoD) 
Assd. TB 
CoD (%/ 
assd. 
CoD) 
[52] LAm+Car 04  
(1997–2006) 
Brazil 1,538 50.2 39 (24–53) 250 226 
(14.7) 
226 (100) 130 
(57.5) 
 153 (9.9) NS 153 
(100) 
75 (49.0)  
[53] LAm+Car 05  
(1986–2009) 
Brazil 3,530 26.4 35 265 (90–430) 868 
(24.6) 
868 (100) 639 
(73.6) 
 299 (8.5) NS 299 
(100) 
181 
(60.5) 
 
[54] MEast+NAfr 01 
(1999–2009) 
Morocco 1,243 49.5 Mean 36 
(range 24–
56) 
Mean 96 
(range 1–626) 
91 (7.3) 91 (100) 86 (94.5) 35 (38.5) 91 (7.3) 270 91 (100) 86 (94.5) 35 (38.5) 
[55] SAsia 04  
(1992–2005) 
India 2,050 24.1 43 (range 
16–69) 
NS 145 (7.1) 145 (100) 90 (62.1) 66 (45.5) 5 (0.2) NS 5 (100) NS NS 
[56] SAsia 05  
(1988–2007) 
India 236 22.9 Range 18–? NS 236 (100) 236 (100) 223 
(94.5) 
129 
(54.7) 
2 (0.8) NS 2 (100) NS NS 
[57] SAsia 06  
(1996–2008) 
India 4,848 24.6 34 (29–39) 58 (31–67) 155 (3.2) 69 (44.5) 56 (81.2) 20 (29.0) 155 (3.2) 150 69 (44.5) 56 (81.2) 20 (29.0) 
[58] SAsia 07  
(2000–2008) 
India 822 18.8 NS 80 56 (6.8) 32 (57.1) 23 (71.9)  56 (6.8) NSǁ 32 (57.1) 23 (71.9)  
[59] SAsia 08  
(2009–2010) 
India 1,182 23.2 35 (–) NS 56 (4.7) 56 (100) 45 (80.4) 27 (48.2) 56 (4.7) 73 56 (100) 45 (80.4) 27 (48.2) 
[60] SSAfr 10  
(1996–2005) 
Togo 5,347 46.9 Mean 38.9 
(± 13.4) 
NS 147 (2.7) 147 (100) 104 
(70.7) 
0 NS     
[61] SSAfr 11  
(2002–2005) 
S. Africa 712 74 33 (29–38) 94 68 (9.6) 68 (100) 53 (77.9) 10 (14.7) 37 (5.2) NS§ 37 (100) 28 (75.7) 5 (13.5) 
[62] SSAfr 12  
(2003–2005) 
Uganda & 
Zimbwe 
3,316 65 36 (31–42) 86 (31–139) 179 (5.4) 179 (100) 124 
(69.3) 
14 (7.8) 179 (5.4) NS§ 179 
(100) 
124 
(69.3) 
14 (7.8) 
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Reference,  
calendar period, 
region,  
study number, 
years data collected 
Country 
/ies 
Enrolled, 
N 
Fe-
male 
(%) 
Age, 
median 
(IQR), mean 
(SD), or 
range 
CD4 count 
(cells/µL), 
median 
(IQR), mean 
(SD), or 
range 
All HIV-positive adults (n = 10,291)* Adults who initiated ART (n = 4,009) 
All 
deaths, n 
(%/ 
enrolled) 
Assd. 
CoD† (%/ 
all 
deaths) 
Assd. 
HIV-
assoc. 
CoD (%/ 
assd. 
CoD) 
Assd. TB 
CoD (%/ 
assd. 
CoD) 
Deaths 
on ART, 
n (%/ 
enrolled) 
Time on 
ART 
(days), 
median 
(IQR) 
Assd. 
CoD† 
(%/ 
deaths 
on ART) 
Assd. 
HIV-
assoc. 
CoD (%/ 
assd. 
CoD) 
Assd. TB 
CoD (%/ 
assd. 
CoD) 
[63] SSAfr 13  
(2004–2005) 
Uganda 559 NS 38 (33–44) 98 (21–163) 99 (17.7) 99 (100) 83 (83.8) 13 (13.1) 99 (17.7) NS§ 99 (100) 83 (83.8) 13 (13.1) 
[64] SSAfr 14  
(2000–2007) 
Came-
roon 
362 51.9 Mean 40.2 
(± 11.6) 
NS 281 
(77.6) 
281 (100) 226 
(80.4) 
96 (34.2) 77 (21.3) 30 (13–
60) 
77 (100) NS NS 
[65] SSAfr 15  
(2005–2007) 
S. Africa 1,353 67 37 (31–45) 93 (37–148) 124 (9.2) 124 (100) 93 (75.0) 47 (37.9) 124 (9.2) 57 (28–
169) 
124 
(100) 
93 (75.0) 47 (37.9) 
[66] SSAfr 16 (2007) Ghana 716 52 39.7 (± 9) NS 221 
(30.9) 
221 (100) 215 
(97.3) 
69 (31.2) 32 (4.5) NS 32 (100) 32 (100)   
[67] SSAfr 17  
(2000–2008) 
South 
Africa 
86 NS Range 18–
70 
NS 86 (100) 86 (100) 80 (93.0)  NS     
[68] SSAfr 18  
(2003–2008) 
B. Faso 5,608 70 35 (30–41) NS 690 
(12.3) 
690 (100) 341 
(49.4) 
67 (9.7) 690 
(12.3) 
82 (30–
270) 
690 
(100) 
341 
(49.4) 
67 (9.7) 
[69] SSAfr 19  
(2004–2009) 
S. Africa 2,943 40.1 36 (range 
19–69) 
26 (range 1–
479) 
305 
(10.4) 
305 (100) 208 
(68.2) 
55 (18.) 305 
(10.4) 
NS§ 305 
(100) 
208 
(68.2) 
55 (18.0) 
[70] SSAfr 20  
(2006–2009) 
Nigeria 110 46.5 39.5 (range 
14–64) 
75 (range 6–
1003) 
110 (100) 101 
(91.8) 
64 (63.4) 64 (63.4) 110 (100) NS 101 
(91.8) 
64 (63.4) 64 (63.4) 
[71] SSAfr 21  
(2006–2009) 
Nigeria 3,464 47.3 36 (30–45) 136 (56–199) 66 (1.9) 66 (100) 58 (87.9) 27 (40.9) 19 (0.5) 91 (62–
1095) 
19 (100) 16 (84.2) 7 (36.8) 
[72] SSAfr 22 (2009) Uganda 290 51.4 Mean 38 Mean 50 (IQR 
14–87) 
 NS 35 32 (91.4) 13 (37.1) NS  10 10 (100) 5 (50.0) 
[73] SSAfr 23 (2009) S. Africa 39 48.7 36 (32–40) 50 (27–154) 39 (100) 39 (100) 38 (97.4) 26 (66.7) 27 (69.2) 32 (16–
50)** 
27 (100) 25 (92.6) 25 (92.6) 
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Reference,  
calendar period, 
region,  
study number, 
years data collected 
Country 
/ies 
Enrolled, 
N 
Fe-
male 
(%) 
Age, 
median 
(IQR), mean 
(SD), or 
range 
CD4 count 
(cells/µL), 
median 
(IQR), mean 
(SD), or 
range 
All HIV-positive adults (n = 10,291)* Adults who initiated ART (n = 4,009) 
All 
deaths, n 
(%/ 
enrolled) 
Assd. 
CoD† (%/ 
all 
deaths) 
Assd. 
HIV-
assoc. 
CoD (%/ 
assd. 
CoD) 
Assd. TB 
CoD (%/ 
assd. 
CoD) 
Deaths 
on ART, 
n (%/ 
enrolled) 
Time on 
ART 
(days), 
median 
(IQR) 
Assd. 
CoD† 
(%/ 
deaths 
on ART) 
Assd. 
HIV-
assoc. 
CoD (%/ 
assd. 
CoD) 
Assd. TB 
CoD (%/ 
assd. 
CoD) 
[74] SSAfr 24  
(2004–2010) 
S. Africa 395 66.1 34.4 (29–
40) 
22 (8–37) 63 (15.9) 63 (100) 43 (68.3) 23 (36.5) 63 (15.9) NS§ 63 (100) 43 (68.3) 23 (36.5) 
[75] SSAfr 25 (2010) Togo 24,054 55.7 Mean 32.2 Mean 181 309 (1.3) 309 (100) 113 
(36.6) 
12 (3.9) 160 (0.7) NS 160 
(100) 
55 (34.4) 6 (3.8) 
[76] SSAfr 26 (2010) Mozbque 742 NS NS NS 214 
(28.8) 
214 (100) 113 
(52.8) 
64 (29.9) NS     
[77] SSAfr 27 (2010) C. d'Iv., B. 
Faso, 
Benin, 
Mali, & 
Senegal 
823 58 40 (33–48) 75 (25–177) 315 
(38.3) 
315 (100) 280 
(88.9) 
113 
(35.9) 
134 
(16.3) 
NS 134 
(100) 
NS NS 
2011–2016               
[78] EAsia+Pac 03  
(2009–2012) 
China 1,112 20.2 Mean 43 
(± 11.7) 
31 (11–104) 216 
(19.4) 
216 (100) 154 
(71.3) 
 74 (6.7) NSǁ 74 (100) 51 (68.9)  
[79] EAsia+Pac 04  
(2007–2014) 
Vietnam 1,197 37.3 32 (18–73) 110 (range 1–
693) 
42 (3.5) 42 (100) 20 (47.6) 7 (16.7) 42 (3.5) 402 42 (100) 20 (47.6) 7 (16.7) 
[80] Eur+CAsia 03  
(1989–2012) 
Georgia 3,554 26.5 36 (30–42) 238 (106–408) 779 
(21.9) 
779 (100) 426 
(54.7) 
166 
(21.3) 
NS     
[81] LAm+Car 06  
(2000–2011) 
Brazil 2,224 36.7 35.6 (29–
43) 
189 (72–299) 103 (4.6) 103 (100) 64 (62.1)  NS     
[82] LAm+Car 07  
(2010–2013) 
Mexico 145 10.3 38 (range 
15–70) 
47 (range 2–
662) 
145 (100) 128 
(88.3) 
118 
(92.2) 
15 (11.7) 61 (42.1) NSǁ 24 (39.3) 24 (100) 0 
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Reference,  
calendar period, 
region,  
study number, 
years data collected 
Country 
/ies 
Enrolled, 
N 
Fe-
male 
(%) 
Age, 
median 
(IQR), mean 
(SD), or 
range 
CD4 count 
(cells/µL), 
median 
(IQR), mean 
(SD), or 
range 
All HIV-positive adults (n = 10,291)* Adults who initiated ART (n = 4,009) 
All 
deaths, n 
(%/ 
enrolled) 
Assd. 
CoD† (%/ 
all 
deaths) 
Assd. 
HIV-
assoc. 
CoD (%/ 
assd. 
CoD) 
Assd. TB 
CoD (%/ 
assd. 
CoD) 
Deaths 
on ART, 
n (%/ 
enrolled) 
Time on 
ART 
(days), 
median 
(IQR) 
Assd. 
CoD† 
(%/ 
deaths 
on ART) 
Assd. 
HIV-
assoc. 
CoD (%/ 
assd. 
CoD) 
Assd. TB 
CoD (%/ 
assd. 
CoD) 
[83] MEast+NAfr 02  
(2000–2014) 
Tunisia 260 35.2 Mean 44 
(± 11) 
NS 54 (20.8) 54 (100) 38 (70.4) 2 (3.7) 37 (14.2) NS 37 (100) NS NS 
[84] SSAfr 28  
(2002–2011) 
Congo, 
Rep. 
152 48.7 37 (16–71) 170 (1–772) 152 (100) 152 (100) 45 (29.6) 7 (4.6) 152 (100) NS 152 
(100) 
45 (29.6) 7 (4.6) 
[85] SSAfr 29  
(2002–2012) 
Uganda 4,784 58.1 36 (30–42) 90 (22–237) 1,249 
(26.1) 
1,028 
(82.3) 
848 
(82.5) 
347 
(33.8) 
395 (8.3) NS 395 
(100) 
312 
(79.0) 
103 
(26.1) 
[86] SSAfr 30 (2012) Kenya 253 60.1 40 (34–47) 87 (33–209) 253 (100) 253 (100) 160 
(63.2) 
80 (31.6) 253 (100) 330 (60–
930) 
253 
(100) 
160 
(63.2) 
80 (31.6) 
[87] SSAfr 31 (2013) Uganda 99 57.3 35 (29–40) 47 (17–165) 96 (97.0) 96 (100) 87 (90.6) 42 (43.8) NS     
[88] SSAfr 32  
(2013–2015) 
Mozbque 112 49.1 37 (range 
16–76) 
NS 73 (65.2) 73 (100) 67 (91.8)   NS     
*Includes the 4,009 individuals who initiated ART 
†Includes those assigned ‘unknown’ or ‘indeterminate’ cause of death 
‡TAHOD lower middle-income countries: Cambodia, India, Indonesia, Philippines, and Vietnam; TAHOD upper middle-income countries: China, Indonesia, Malaysia, and Thailand 
§At least 50% of deaths in those who initiated ART occurred within 3 months of initiation 
ǁAt least 50% of deaths in those who initiated ART occurred within 6 months of initiation (3-month mortality not reported) 
¶At least 50% of deaths in those who initiated ART occurred within 12 months of initiation  
**Median time listed for ‘Early-ART’ group, died <90 days post-initiation (n = 15); for ‘Late-ART’ group (>90 days post-initiation; n = 10), median time on ART 326 (IQR 148–531) days 
Assd.: assigned; assoc.: associated; ART: antiretroviral therapy; B. Faso: Burkina Faso; C. d’Iv.: Côte d’Ivoire; CoD: cause of death; EAsia + Pac: East Asia & the Pacific; Eur + CAsia: 
Europe & Central Asia; IQR: interquartile range; L: low; Lam + Car: Latin America & the Caribbean; LM: lower middle; MEast + NAfr: Middle East & North Africa; Mozbque: 
Mozambique; NS: not specified; Rep.: republic; Russian Fed.: Russian Federation; S. Africa: South Africa; SAsia: South Asia; SD: standard deviation; SSAfr: sub-Saharan Africa; 
TAHOD: TREAT Asia HIV Observational Database; TB: tuberculosis; UM: upper middle; Zimbwe: Zimbabwe  
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Table 3:4. Pooled prevalence of decedents assigned any HIV-associated and TB causes of death in studies of HIV-positive adults dying in low- and middle-income countries (n = 
56 studies) and restricted to studies conducted in sub-Saharan Africa (n = 32 studies) 
Group & sub-group All regions Sub-Saharan Africa only 
Proportion of decedents 
assigned any HIV-
associated CoD 
(N = 56 studies) 
Pooled proportion of decedents assigned TB CoD 
(N = 47 studies) 
Proportion of decedents 
assigned any HIV-
associated CoD (n = 32 
studies) 
Proportion of decedents assigned TB CoD 
(n = 29 studies) 
Among all HIV-positive 
adults 
(N = 10,290 deaths) 
Among all HIV-positive 
adults 
(n = 7,990 deaths) 
Among adults with 
HIV-associated CoD 
(n = 5,688 deaths) 
Among all HIV-positive 
adults 
(n = 6,572 deaths) 
Among all HIV-positive adults 
(n = 5,772 deaths) 
Among adults with 
HIV-associated CoD 
(n = 4,103 deaths) 
Studies, 
n (%) 
PP,  
% (95% CI) 
p* Studies, 
n (%) 
PP,  
% (95% CI) 
p* PP,  
% (95% CI) 
p* Studies, 
n (%) 
PP,  
% (95% CI) 
p* Studies, 
n (%) 
PP,  
% (95% CI) 
p* PP,  
% (95% CI) 
p* 
Overall 56 79 (74–83) - 47 29 (24–34) - 39 (33–46) - 32 79 (73–85) - 29 25 (19–31) - 34 (27–42) - 
Region 
                
 Sub-Saharan 
Africa 
32 79 (73–85) 
0.79 
29 25 (19–31) 
0.01 
34 (27–42) 
<0.01 
-  
 
-  
 
 
 
 South Asia 8 79 (65–90) 7 51 (43–58) 72 (56–85) -   -     
 Latin America & 
The Caribbean 
7 82 (71–90) 4 22 (13–32) 24 (14–37) -  
 
-  
 
 
 
 Other 9 73 (59–85) 7 28 (16–42) 38 (25–51) -   -     
Country income group               
 Low 13 77 (66–86) 
0.85 
12 15 (7–25) 
<0.01 
21 (11–32) 
<0.01 
13 77 (66–86) 
0.77 
12 15 (7–25) 
0.05 
21 (11–32) 
0.05  Lower middle 25 78 (70–85) 22 36 (29–44) 51 (41–61) 12 81 (68–90) 11 32 (23–42) 45 (33–57) 
 Upper middle 18 80 (74–86) 13 30 (23–38) 38 (29–47) 7 81 (72–89) 6 33 (21–47) 43 (29–57) 
Calendar period  
               
 Pre-2005 15 87 (78–93) 
0.14† 
14 32 (22–42) 
0.37† 
42 (28–56) 
0.46† 
9 87 (76–95) 
0.38 
8 24 (14–35) 
0.25 
28 (19–39) 
0.10  2005–2010 30 77 (70–83) 25 31 (23–39) 41 (31–51) 18 77 (67–85) 17 25 (17–35) 36 (24–48) 
 2011–2015 11 70 (59–81) 8 19 (12–28) 30 (21–40) 5 74 (53–90) 4 26 (13–43) 40 (29–50) 
Proportion on ART**                
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Group & sub-group All regions Sub-Saharan Africa only 
Proportion of decedents 
assigned any HIV-
associated CoD 
(N = 56 studies) 
Pooled proportion of decedents assigned TB CoD 
(N = 47 studies) 
Proportion of decedents 
assigned any HIV-
associated CoD (n = 32 
studies) 
Proportion of decedents assigned TB CoD 
(n = 29 studies) 
Among all HIV-positive 
adults 
(N = 10,290 deaths) 
Among all HIV-positive 
adults 
(n = 7,990 deaths) 
Among adults with 
HIV-associated CoD 
(n = 5,688 deaths) 
Among all HIV-positive 
adults 
(n = 6,572 deaths) 
Among all HIV-positive adults 
(n = 5,772 deaths) 
Among adults with 
HIV-associated CoD 
(n = 4,103 deaths) 
Studies, 
n (%) 
PP,  
% (95% CI) 
p* Studies, 
n (%) 
PP,  
% (95% CI) 
p* PP,  
% (95% CI) 
p* Studies, 
n (%) 
PP,  
% (95% CI) 
p* Studies, 
n (%) 
PP,  
% (95% CI) 
p* PP,  
% (95% CI) 
p* 
 <33% 18 86 (79–92) 
0.01‡ 
17 28 (19–39) 
0.52‡ 
37 (25–49) 
0.98‡ 
13 87 (79–94) 
0.02 
12 24 (15–35) 
0.85 
29 (18–40) 
0.47  33–65% 7 76 (63–86) 5 24 (10–42) 31 (20–44) 5 77 (56–93) 5 24 (10–42) 31 (20–44) 
 >66% 20 70 (62–77) 17 26 (18–35) 39 (26–51) 11 69 (59–78) 11 25 (15–36) 40 (24–57) 
Study quality 
                
 Good 25 78 (71–84) 
0.25 
21 22 (17–28) 
0.09 
29 (24–36) 
0.02 
18 81 (72–88) 
0.17 
17 24 (17–31) 
0.74 
31 (24–38) 
0.52  Fair 16 82 (75–88) 14 31 (21–42) 39 (27–52) 7 85 (76–93) 7 28 (14–44) 33 (18–50) 
 Poor 15 75 (64–85) 12 39 (23–55) 59 (38–78) 7 69 (45–88) 5 25 (6–50) 47 (13–83) 
Data availability 
                
 Autopsy data 20 87 (79–94) 
0.02 
18 37 (30–45) 
0.04 
47 (38–55) 
0.17 
14 86 (75–94) 
0.15 
12 34 (27–41) 
0.07 
42 (35–49) 
0.13 
 No autopsy data 36 73 (67–79) 29 24 (18–30) 34 (26–43) 18 74 (65–82) 17 19 (12–28) 29 (19–40) 
 Hospital data 49 79 (74–83) 
0.82 
40 29 (24–35) 
0.63 
40 (33–47) 
0.61 
29 80 (72–86) 
0.72 
26 26 (19–33) 
0.52 
35 (27–43) 
0.51 
 No hospital data 7 78 (60–92) 7 26 (13–42) 34 (20–50) 3 76 (44–97) 3 18 (3–41) 24 (6–49) 
Methods score                 
 <2.0 15 71 (60–81) 
0.13 
13 26 (13–40) 
0.51 
39 (20–59) 
0.95 
7 62 (44–79) 
<0.01 
7 17 (4–37) 
0.02 
32 (7–64) 
0.16  2.0–3.9 22 82 (75–88) 21 28 (21–35) 38 (28–48) 11 79 (69–87) 10 19 (13–27) 27 (18–36) 
 ≥4.0 19 80 (72–87) 13 34 (26–42) 41 (23–48) 14 87 (76–95) 12 35 (25–45) 42 (34–50) 
*Based on meta-regression  |  †Meta-regression conducted using last year of data collection  |  ‡Meta-regression conducted using proportion on ART (continuous) 
ART: antiretroviral therapy; CI: confidence interval; CoD: cause(s) of death; PP: pooled proportion; TB: tuberculosis  
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Figure 3:2. Forest plot showing the proportions of decedents assigned any HIV-associated cause of death in studies 
conducted in low- and middle-income countries, stratified by calendar period of data collection (n = 56 studies) 
 
Car: Caribbean; CI: confidence interval; EAsia: East Asia; ES: estimated proportion/prevalence; Lam: Latin America; 
MEast: Middle East; NAFr: North Africa; Pac: Pacific; SAsia: South Asia; SSAfr: Sub-Saharan Africa 
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Figure 3:3. Bubble plots showing relationships, based on meta-regression, between proportions of decedents initiated on ART per study (x axis) and proportions of decedents 
assigned any HIV-associated cause of death (y axis, top row) and proportions of decedents assigned a TB cause of death (y axis, bottom row) 
 
ART: antiretroviral therapy; CoD: cause of death; TB: tuberculosis
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Figure 3:4. Forest plot showing the proportions of decedents assigned any HIV-associated cause of death, stratified 
by use of autopsy data (n = 56 studies) 
 
Car: Caribbean; CI: confidence interval; EAsia: East Asia; ES: estimated proportion/prevalence; Lam: Latin America; 
MEast: Middle East; NAFr: North Africa; Pac: Pacific; SAsia: South Asia; SSAfr: Sub-Saharan Africa 
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Figure 3:5. Forest plot showing the proportions of decedents assigned a tuberculosis cause of death, stratified by 
geographic region (n = 47 studies) 
 
Car: Caribbean; CI: confidence interval; EAsia: East Asia; ES: estimated proportion/prevalence; Lam: Latin America; 
MEast: Middle East; NAFr: North Africa; Pac: Pacific; SAsia: South Asia; SSAfr: Sub-Saharan Africa 
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3.2.4.4 Sub-analysis: causes of death in individuals who initiated ART vs. individuals who did not 
In the 28 studies describing causes of death in those who had initiated ART (n = 3,695 deaths), 17 (60.7%) included only 
individuals on ART; proportions of decedents on ART in the remaining 11 studies ranged from 15% to 69%.  The 
majority of studies were conducted in sub-Saharan Africa (17/28 [60.7%]); 21 (75.0%) studies had completed data 
collection between 2005 and 2010; and 11 (39.2%) studies only recruited individuals after admission to hospital, 
compared with 11 (39.2%) that recruited from the community, and six (21.4%) that recruited from both sites.  Five 
(17.9%) studies used data from pathological autopsies to assign causes of death. 
The pooled proportions of decedents assigned HIV-associated and TB causes of death were 84% (95% CI 78–90) and 
22% (95% CI 13–33) in decedents who had not initiated ART (n = 23 studies, n = 3,968 deaths) and 72% (95% CI 66–79) 
and 26% (95% CI 18–34), respectively, in those who had (Table 3:5).  Heterogeneity between studies was high in both 
groups (I2 95.71 and 96.79, p <0.01).  There were very slight differences between proportions of causes of death 
assigned based on geographic or income group in either those who did not initiate ART or those who did (p 0.1–0.95 for 
HIV-associated and TB causes of death in both groups).  Fewer HIV-associated and TB causes were assigned to 
individuals who initiated ART in studies that completed data collection after 2010 (67% any HIV associated, 14% TB) 
compared with earlier periods (73–83% any HIV associated; 18–31% TB), but this may have been due to chance (p = 
0.94 and p = 0.41 for any HIV-associated and TB causes of death, respectively); this relationship was not seen in 
individuals who did not initiate ART. 
Similar patterns were seen when the analysis was restricted to only studies that included either 0% or 100% of 
decedents who initiated ART (n = 11 studies, n = 1,758 deaths if 0% initiated ART; n = 17 studies, n = 2,465 deaths if 
100% initiated ART).  Studies with 0% ART initiation assigned 85% (95% CI 74–94) of decedents an HIV-associated cause, 
compared with 69% (95% CI 68–83) assigned in studies where all decedents initiated ART (p = 0.05).  Almost no 
difference was seen, however, in the proportions of TB causes of death assigned (24% vs 26% in all decedents, 33% vs. 
39% in decedents with HIV-associated causes of death, 0% ART vs. 100% ART, respectively; p = 0.99 and p = 0.64). 
3.2.4.4.1 Duration of ART 
Only 12 studies reported the median time from ART initiation to death, which ranged from 30 days (n = 77; Cameroon 
[64]) to over one year (n = 42; Vietnam [79]).  The largest study that reported time on ART was a retrospective analysis 
of patient records across 13 districts of Burkina Faso [68], which included 690 decedents who initiated ART and died a 
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median 82 (IQR 30–270) days after initiation.  A number of studies did not report time on ART, but instead reported the 
numbers of individuals who died after specific intervals of time.  Seven studies [49,57,61–63,69,74], two of which also 
reported median time on ART, reported that at least 50% of the deaths among individuals who had initiated ART had 
occurred in the three months after initiation; a further three [58,78,82] reported that 54%–68% of deaths among those 
initiating ART had taken place in the six months after initiation (Table 3:3).  Only three studies [58,63,79], conducted in 
Uganda, India, and Vietnam, presented causes of death stratified by duration of ART (n = 99, n = 32, and n = 42 on ART, 
respectively).  Although all three studies found that overall mortality decreased with time on ART, the proportions of 
HIV-associated causes of death assigned were similar, regardless of duration of ART (Table 3:6). 
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Table 3:5. Pooled prevalence of deaths assigned any HIV-associated cause or TB cause in HIV-positive adult decedents who initiated ART (n = 28 studies) and in those who did 
not (n = 23 studies)  
Group &  
sub-group 
In HIV-positive adults who initiated ART (n = 28 studies), the proportion of 
decedents assigned 
In HIV-positive adults who did not initiate ART (n = 23 studies), the 
proportion of decedents assigned 
Any HIV-associated cause of death 
(n = 3,695 deaths) 
A TB cause of death (n = 3,049 deaths) Any HIV-associated cause of death 
(n = 3,968 deaths) 
A TB cause of death (n = 2,120 
deaths) 
Studies, 
n (%) 
PP, % (95% CI) p* Studies, 
n (%) 
PP, % (95% CI) p* Studies, 
n (%) 
PP, % (95% CI) p* Studies, 
n (%) 
PP, % (95% CI) p* 
Overall 28 72 (66–79) - 22 26 (18–34) - 23 84 (78–90) - 17 22 (13–33) - 
Region             
 Sub-Saharan Africa 17 72 (63–81) 
0.83 
16 25 (17–35) 
0.61 
16 85 (76–92) 
0.95 
14 20 (11–31) 
0.21 
 South Asia 3 79 (72–85) 2 37 (29–46) 2 89 (86–93) 2 16 (9–23) 
 Latin America & The 
Caribbean 
3 73 (50–91) 1 0 (0–14) 4 86 (77–93)  1 58 (46–70) 
 Other 5 69 (45–88) 3 32 (19–46) 1 73 (65–79) 0 - 
Country income group†             
 
 Low 7 72 (56–85) 
0.95 
7 14 (7–22) 
0.10 
6 79 (61–92) 
0.54 
6 11 (0–33) 
0.15  Lower middle 12 72 (58–84) 9 33 (20–48) 9 87 (76–95) 6 37 (23–53) 
 Upper middle 9 73 (64–81) 6 30 (13–51) 8 83 (78–88) 5 21 (10–34) 
Calendar period             
 
 Pre-2005 1 83 (74–89) 
0.94‡ 
1 18 (12–27) 
0.41‡ 
10 87 (75–95) 
0.87‡ 
9 28 (17–41) 
0.81‡  2005–2010 21 73 (66–81) 16 31 (21–42) 10 82 (70–92) 6 13 (1–31) 
 2011–2015 6 67 (48–84) 5 14 (5–27) 3 83 (74–91) 2 35 (31–38) 
*Based on meta-regression 
†Based on World Bank classification [27] 
‡Meta-regression conducted using middle year of data collection 
ART: antiretroviral therapy; CI: confidence interval; CoD: cause of death; PP: pooled proportion; TB: tuberculosis 
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Table 3:6. Causes of death assigned to individuals who initiated ART in studies that reported causes by duration on 
ART (n = 3 studies; n = 173 deaths) 
Reference, region, 
period of data 
collection 
Country Deaths 
after ART 
initiation, n 
Causes of death by time on ART 
[58] SAsia 07 
(2000-2008) 
India 32 15/18 (83%) deaths in the first 6 months were assigned HIV-associated 
CoD vs. 8/14 (57%) deaths >6 months post-initiation. 
[63] SSAfr 13 
(2004-2005) 
Uganda 99 72/80 (90%) deaths in the first 12 months were assigned HIV-
associated CoD, vs. 8/15 (53%) in months 13–24, and 3/4 (75%) in 
months 25–36. 
[79] EAsia+Pac 04 
(2007-2014) 
Vietnam 42 Report ‘no significant differences’ in survival time between the 19 
individuals who were assigned ‘AIDS-related’ CoD (median 1.05 years 
from ART initiation to death) and the 14 individuals assigned a ‘non-
AIDS’ CoD (median 1.61 years from ART initiation to death). 
AIDS: acquired immune deficiency syndrome; ART: antiretroviral therapy; CoD: cause(s) of death; EAsia+Pac: East Asia 
and the Pacific; SAsia: South Asia; SSAfr: sub-Saharan Africa 
3.2.5. Discussion 
Over 10,000 deaths among HIV-positive adults, occurring between 1986 and 2015, were included in this review: a 
pooled 79% of decedents were assigned an HIV-associated cause of death; almost 40% of these were thought to be due 
to HIV-associated TB (29% of all deaths).  Proportions of decedents assigned HIV-associated causes of death declined 
over the 30 years analysed, a reduction very likely driven by the higher numbers of individuals initiated on ART in more 
recent studies.  No differences were seen in the proportions of deaths attributed to TB, either by date of study or by 
the proportion of decedents in each study who initiated ART.  The same patterns were evident when the analysis was 
restricted only to ‘fair’ or ‘good’ studies (per the NHLBI scale) and only to studies conducted in sub-Saharan Africa.  
Causes of death were reported in 3,900 individuals who died before and over 4,000 who died after initiating ART; HIV-
associated causes of death were assigned to 84% and 71% and TB causes of death assigned to 22% and 25% of 
decedents in each group, respectively.   
A recent systematic review of ‘non-AIDS’ deaths in individuals on ART by Farahani et al. [23] estimated that 18.5% (95% 
CI 14–24) and 28.1% (95% CI 16–42) of deaths in sub-Saharan Africa and other LMIC, respectively, were due to non-
AIDS causes [23] (i.e., 76–86% and 58–84% of deaths, respectively, were due to AIDS).  However, this review counted 
deaths due to ART toxicity and deaths from non-AIDS infections as ‘non-AIDS’, suggesting that it may have 
underestimated overall HIV-associated mortality.  Additionally, the review included only studies in which all, or at least 
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66% of, participants were on ART, did not include any pathological autopsy studies, and included at least two studies 
that used only death certificates to report causes of death [89,90].   
Other reviews examining causes of death in PLHIV include a 2015 study of causes of hospital admission in PLHIV by Ford 
et al. [29], which reported that around 80% of in-hospital mortality was due to HIV-associated causes (57% [95% CI 46–
68] AIDS and 23% [95% CI 17–30] bacterial infections).  Although these estimates are similar to those generated by our 
analysis, they do include deaths in high-income countries; the proportions of decedents assigned HIV-associated causes 
of death would likely be higher if the analysis was restricted to LMIC only.  The Ford review also did not differentiate by 
the methods used to assign causes of death; the inclusion of mortality estimates generated by death certification 
and/or verbal autopsy will likely have led to reduced accuracy in the causes assigned.   
3.2.5.1 TB and the potential effects of ART 
ART has consistently been shown to reduce, substantially, all-cause mortality [16] and the incidence of TB in PLHIV 
[91,92]. The pattern observed in our review, of lower proportions of HIV-associated causes of death assigned in studies 
that included higher proportions of decedents initiating ART, is consistent with this, but the apparent absence of a 
similar reduction in TB deaths is surprising.  As the leading cause of death in PLHIV in LMIC, one would expect a 
reduction in overall mortality to also result in a reduction in TB mortality.  This may be partially explained by the under-
recognition, in older studies, of TB as a cause of death, due to limitations in diagnostics.  However, older studies were 
also more likely to use pathological autopsy data to assign causes of death and were therefore more likely to detect TB 
that was not diagnosed prior to death.  The two pathological autopsy studies that included individuals who had initiated 
ART both assigned a high proportion of decedents a TB cause of death (Wong et al. [South Africa [73]], 93% overall and 
100% of HIV-associated; Siika et al. [Kenya [86]], 32% overall and 50% of HIV-associated). 
A crude analysis of global estimates of mortality due to AIDS and HIV-associated TB shows a similar trend to that 
described above.  Based on estimates from UNAIDS, numbers of deaths due to all AIDS causes have dropped from ~2 
million in 2005 to ~1.2 million in 2015, an absolute reduction of 40% [93].  Per WHO figures, however, deaths 
attributable to HIV-associated TB have gone from ~480,000 in 2005 to ~320,000 in 2012 and ~390,000 in 2015 [10,94], 
a reduction of approximately 90,000 deaths per year over 10 years.  There are currently no estimates of all-cause 
mortality among HIV-positive individuals; we are therefore unable to compare these figures with the estimates of TB 
causes as a proportion of all causes of death generated by our analysis.  TB deaths as a proportion of all AIDS deaths, 
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however, appear to have increased steadily over the last few years, from 22.9% in 2012 to 35.5% in 2015 (Figure 3:6), 
which is to be expected, given the much steeper decline in overall AIDS deaths.  However, even the highest estimate 
from these data is below the overall pooled proportion generated by our analysis (39% overall; 38% if initiated ART) and 
much lower than the estimates from pathological autopsy studies (pooled 47%), including the two studies that used 
autopsy data to assign causes of death in individuals on ART.  The 2015 systematic review of pathological autopsy 
studies by Gupta et al. [11] also reported that a pooled 37.2% (95% CI 26–49) of ‘HIV/AIDS-related deaths’ were due to 
TB, based on findings from 10 studies.   
In summary, our findings suggest that although ART may be reducing overall mortality due to HIV-associated causes, it 
may be having less of an impact on mortality due to HIV-associated TB.  Our analysis also suggests, with the caveats 
mentioned above, that the numbers published by WHO and UNAIDS may be underestimates of the true mortality 
attributable to HIV-associated TB.  It should be noted that estimates from mortality studies, and autopsy studies in 
particular, are vulnerable to several possible sources of bias, and that the margins of error for global estimates are very 
large, because of well-documented issues with methods used to estimate and code causes of death [2,3,13].  Caution, 
therefore, should be exercised in interpreting any comparisons of global surveillance data to research findings. 
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Figure 3:6. Crude estimate of the proportions of AIDS deaths due to HIV-associated TB per year (line), based on 
estimates of absolute numbers (vertical bars) published by UNAIDS [93] and WHO, 2005–2015 [10,94] 
 
*Estimates of number of deaths due to HIV-associated TB not published for 2006 or 2008 
AIDS: acquired immune deficiency syndrome; TB: tuberculosis; UNAIDS: Joint United Nations Programme on HIV/AIDS; 
WHO: World Health Organization 
3.2.5.2 Methods for assigning causes of death 
There is wide variation in the methods and data used to assign causes of death, which makes it difficult to compare 
estimates across different studies.  This is illustrated by the high degree of heterogeneity seen in studies included in this 
review, despite the exclusion of studies that did not describe the methods used to assign causes of death or that used 
death certificates without validation (which have consistently been shown to correlate poorly with clinically-assigned 
causes of death [95,96]).   
As discussed above, previous attempts have been made at creating a standardised method for assigning causes of 
death in PLHIV [8]; for any such system to succeed, however, it must be simple enough for routine use in resource-
limited settings.  Although using such a system to certify all deaths is unlikely to be feasible, it may be possible to use it 
to validate a sample of death certificates in a structured manner, particularly in countries without robust CRVS systems.  
This would also allow for ready comparison between research findings and routinely collected data.  Crucially, any such 
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system would need to be compatible with the standard classification system for all deaths, in this case ICD-10, to allow 
for comparison with national, regional, and global estimates of disease and mortality. 
3.2.5.3 Distinguishing between deaths from HIV and deaths with HIV 
In addition to changes needed to ICD codes to better distinguish deaths from HIV-associated TB and other HIV-
associated causes, it would be ideal to be able to track all deaths in HIV-positive individuals, from any cause, to allow 
for the estimation of deaths with HIV and from HIV.  This could be done through the addition, to the standard death 
certification process, of a short list of yes/no questions regarding key comorbidities, including HIV, TB, and other non-
communicable and mental health conditions.  This may also allow for recording of non-biomedical factors, including 
socio-economic, education, and residential or migration status, all of which may improve the quality of cause-specific 
mortality data and could provide valuable insights into disease processes and risk profiles.  
3.2.5.4 Limitations and strengths 
This study had several limitations.  The high heterogeneity of sample sizes, methods used, and populations studied 
reduce the generalisability of our findings.  A few studies reported using the CoDe system, but some did not follow the 
full protocol and only used the cause classifications recommended by CoDe.  As previously discussed, the disconnect 
between the CoDe and ICD-10 classification systems does not facilitate easy comparison between studies.  Included 
studies were also predominantly conducted in sub-Saharan Africa, with North Africa, Central Asia, and East Asia poorly 
represented. 
Pathological autopsy studies provided the best estimates of causes of death but have only been conducted among a 
small number of individuals who had initiated ART.  There were also no reliable measures or real estimates of 
adherence to ART.  Individuals who were poorly adherent during the study period may have been more susceptible to 
diseases (and causes of death) associated with immunosuppression.  In addition, individuals whose adherence to ART 
during the study was good, but who had a history of poor adherence, will have been at increased risk of resistance to 
first-line therapy, which may not have been detected without viral load monitoring.  This shortcoming therefore 
allowed for analysis based only on individuals who had ‘initiated’ ART, rather than those ‘receiving’ ART.   
This study also had strengths.  It represents the first attempt to systematically review the literature around studies that 
have directly estimated causes of death in HIV-positive adults in LMIC, providing a baseline reference for future 
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mortality studies and estimates made through less direct means, such as verbal autopsy.  This study also provides 
additional evidence of the important contribution of TB to HIV-associated mortality, including in individuals who had 
initiated ART. 
3.2.6. Conclusions 
HIV-associated causes accounted for the majority of mortality among HIV-positive adults in LMIC, including in those 
who had initiated ART.  TB accounted for 30% of overall mortality and 40% of HIV-associated mortality; these 
proportions were similar in individuals who had initiated ART.  Studies that used pathological autopsy data assigned 
higher proportions of HIV-associated causes of death, suggesting that non-autopsy studies likely underestimate the true 
HIV-associated mortality fraction.  Heterogeneity between studies was very high; a standardised approach to the direct 
estimation of causes of death in clinical settings that aligns with global classification systems (i.e., ICD-10) would be 
useful in more closely monitoring HIV-associated mortality and for validating death certificates and instruments such as 
verbal autopsy.  A way for key diagnoses (including, but not limited to HIV and TB) to be recorded as part of an 
individual’s death notification, regardless of cause of death, would improve the quality of mortality surveillance data 
and allow for long-term, large-scale monitoring of the effects of multiple, concurrent epidemics on population health. 
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3.3. Supplementary material 
Supplementary table 3:1. Details of search strategies used and records found in three electronic databases 
PubMed Embase® Web of Science™ 
#1 HIV [MeSH] 
OR human immunodef* 
OR human immune def*  
OR HIV  
OR AIDS  
OR HIV/AIDS  
OR acquired immune def*  
OR acquired immunodef* 
#1 TITLE-ABS-KEY  
(("human immunodef*")  
OR ("human immune def*")  
OR ("HIV")  
OR ("AIDS")  
OR ("HIV/AIDS")) 
OR ("acquired immune def*")  
OR ("acquired immunodef*"))  
#1 TI (title) and TS (topic) fields searched for: 
((human immunodef*)  
OR (human immune def*) 
OR (HIV) 
OR (AIDS)  
OR (HIV/AIDS 
OR (acquired immune def*)  
OR (acquired immunodef*)) 
#2 Cause of death [Mesh] 
OR cause of death 
OR cause-specific mortality  
OR CSMF 
#2 TITLE-ABS-KEY  
(("cause* of death")  
OR ("cause-specific mortality") 
OR ("CSMF")) 
#2 TI (title) and TS (topic) fields searched for: 
((cause of death)  
OR (cause-specific mortality)  
OR (CSMF)) 
#3 Filters for low- and middle-income countries as 
described by the Cochrane Group, 2012 [26], 
updated as per the World Bank, 2016 [27] 
#3 Filters for low- and middle-income countries as described by 
the Cochrane Group 2012 [26], updated as per the World 
Bank, 2016 [27] 
#3 CU (country), TI (title) and TS (topic) fields searched for list 
of low- and middle-income countries as per the World 
Bank, 2016 [27] 
#4 (LIMIT-TO(DOCTYPE,"ar") 
OR LIMIT-TO(DOCTYPE,"re") 
OR LIMIT-TO(DOCTYPE,"cp" )) 
#4 CU (country), TI (title) and TS (topic) fields searched for:  
((low-income countr*)  
OR (middle-income countr*)  
OR (low- and middle-income countr*)  
OR (developing countr*)) #5 (LIMIT-TO(SUBJAREA,"MEDI") 
OR LIMIT-TO(SUBJAREA,"IMMU")  
OR LIMIT-TO(SUBJAREA,"MULT")) 
#6 (LIMIT-TO(SRCTYPE,"j")  
OR LIMIT-TO(SRCTYPE,"p")) 
Final search 
#1 AND #2 AND #3 
Final search 
#1 AND #2 AND #3 AND #4 AND #5 AND #6 
Final search 
#1 AND #2 AND (#3 OR #4) 
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= 1527 records = 1621 records = 2352 records 
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Supplementary table 3:2. National Heart, Lung, and Blood Institute Quality Assessment Tool for Observational 
Cohort and Cross-Sectional Studies 
Criteria Yes No 
Other 
(CD, NR, NA) 
1. Was the research question or objective in this paper clearly stated?    
2. Was the study population clearly specified and defined?    
3. Was the participation rate of eligible persons at least 50%?    
4. Were all the subjects selected or recruited from the same or similar populations 
(including the same time period)? Were inclusion and exclusion criteria for being in 
the study prespecified and applied uniformly to all participants? 
   
5. Was a sample size justification, power description, or variance and effect 
estimates provided? 
   
6. For the analyses in this paper, were the exposure(s) of interest measured prior to 
the outcome(s) being measured? 
   
7. Was the timeframe sufficient so that one could reasonably expect to see an 
association between exposure and outcome if it existed? 
   
8. For exposures that can vary in amount or level, did the study examine different 
levels of the exposure as related to the outcome (e.g., categories of exposure, or 
exposure measured as continuous variable)? 
   
9. Were the exposure measures (independent variables) clearly defined, valid, 
reliable, and implemented consistently across all study participants? 
   
10. Was the exposure(s) assessed more than once over time?    
11. Were the outcome measures (dependent variables) clearly defined, valid, 
reliable, and implemented consistently across all study participants? 
   
12. Were the outcome assessors blinded to the exposure status of participants?    
13. Was loss to follow-up after baseline 20% or less?    
14. Were key potential confounding variables measured and adjusted statistically for 
their impact on the relationship between exposure(s) and outcome(s)? 
   
Quality Rating (Good, Fair, or Poor; see guidance [31]) 
Rater #1 initials: 
Rater #2 initials: 
Additional Comments (If POOR, please state why): 
CD: cannot determine; NA: not applicable; NR: not reported 
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Supplementary table 3:3. Criteria used to grade study methods 
Category 
Score Proportion 
or category 
score 
(0–1) 
0 0.5 1.0 
Proportion of deaths 
with CoD assigned 
using autopsy data* 
    
Proportion of deaths 
with CoD assigned 
using hospital data* 
    
Reviewers (number, 
role)  
Only one, non-
pathologist reviewer 
OR  
Not specified 
At least two reviewers 
OR 
One pathologist 
reviewer 
At least two 
independent reviewers 
OR 
Multidisciplinary panel 
 
Description of CoD 
assignment process 
None 
Partial description, or 
allusion to methods 
Detailed description of 
standardised process 
OR  
Used CoDe protocol 
 
System for resolving 
disagreements 
None 
Attempt at 
independent review & 
validation, but not well 
implemented 
Structured review 
process 
OR  
Used CoDe protocol 
 
CoD criteria None 
Categories described, 
but criteria not well 
defined 
Described in detail with 
qualifying criteria for 
each 
OR  
Used CoDe CoD list 
 
Total score  
(0–6) 
 
*Proportion (range 0–1) used as proxy score for these two criteria 
CoD: cause of death; CoDe: Coding Causes of Death in HIV [8]; NS: not specified  
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Supplementary figure 3:1. Bubble plot showing results of meta-regression between the proportion of decedents per 
study who initiated ART and the middle year of data collection for that study (n = 45 studies) 
 
ART: antiretroviral therapy; CI: confidence interval 
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Table 4:2. Combined histopathological and microbiological findings; participants with evidence of each at autopsy; 
and demographics for select groups (n = 34) 
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4.2.4.4 Cryptococcal disease 
 
4.2.4.5 Other fungal and viral infections 
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Figure 4:1. Six examples of histological changes observed in MIA tissue samples (n = 4) 
 
 
 
 
 
 
 
 
 
4.2.4.6 Decedents with multiple pathogens identified 
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Figure 4:2. Venn diagram illustrating overlap between diagnoses made at autopsy: any active TB; extrapulmonary TB; 
any bacterial infection; bacterial pneumonia; disease due to non-tuberculous mycobacteria; cryptococcal disease; 
and Pneumocystis pneumonia (n = 31*) 
 
 
 
 
 
 
4.2.4.7 Additional findings 
 
 
4.2.5. Discussion 
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4.2.5.1 Disease prevalence and overlap 
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4.2.5.2 Interpretation of autopsy findings 
 
 
 
4.2.5.3 MIA in surveillance 
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4.4. Material provided as supplementary online appendices 
Supplementary table 4:1. Samples targeted, success rates, and yield from culture and molecular tests for each specimen (n=34) 
Site/sample 
ALL 
n (%) 
BAL 
n (%) 
Blood 
n (%) 
CSF 
n (%) 
Liver 
n (%) 
Lungs 
n (%) 
NP/OP 
n (%) 
Spleen 
n (%) 
Urine  
n (%) 
Decedents where attempts made - 31 13 32 34 34 13 34 12 
Successful attempts (based on histology for tissue) - 30 (97) 10 (77) 30 (94) 30 (88) 33 (97) 13 (100) 21 (62) 7 (58) 
M
Y
C
O
B
A
C
TE
R
IA
 
Mycobacterial culture 
Tested 164 30 - 28 33 32 - 34 7 
Positive (MTB) 26 (16) 7 (23)  5 (18) 4 (12) 5 (16)  5 (15) 0 
Positive (NTM) 11 (7) 1 (3)  1 (4) 3 (9) 2 (6)  3 (9) 1 (14) 
Negative 113 (69) 16 (53)  20 (71) 24 (73) 23 (72)  25 (74) 5 (71) 
Contaminated 14 (9) 6 (20)  2 (7) 2 (7) 2 (6)  1 (3) 1 (14) 
Xpert MTB/RIF 
Tested 29 29 - - - - - - - 
Positive 5 (17) 5 (17)        
B
A
C
TE
R
IA
 
Bacterial culture† 
Tested 131 29 7 14 16 33 - 32 - 
Positive 37 (28)   18 (62) 2 (29) 2 (14) 1 (6) 12 (36)  2 (6)  
Negative 45 (34) 2 (7) 2 (29) 12 (86) 9 (56) 11 (33)  9 (28)  
Contaminated 49 (37)  9 (31) 3 (43) 0 6 (38) 10 (30)  21 (66)  
Multiplex PCR (meningitis) 
Tested 23 - 10 13 - - - - - 
H. influenzae 1 (4)  1 (10) 0      
S. pneumoniae 3 (13)  1 (10) 2 (23)      
N. meningitidis 0  0 0      
Multiplex PCR (atypical 
pneumonias) 
Tested 24 11 - - - - 13 - - 
M. pneumoniae 0 0     0   
C. pneumoniae 0 0     0   
Legionella spp. 0 0     0   
Bordetella spp. 
Tested 24 11     13   
Positive 0 0     0   
Urinary antigen 
Tested 7 - - - - - - - 7 
S. pneumoniae 0        0 
L. pneumophila 0        0  
F U N G I Fungal culture Tested 131 29 7 14 16 33 - 32 - 
An autopsy study exploring the spectrum of disease in individuals with advanced HIV 
 in primary care clinics in South Africa 
 Page 176 of 383 Chapter 4: Research paper 2: 
Autopsy prevalence of tuberculosis and other potentially treatable infections among adults with advanced HIV enrolled 
in out-patient care in South Africa 
Site/sample 
ALL 
n (%) 
BAL 
n (%) 
Blood 
n (%) 
CSF 
n (%) 
Liver 
n (%) 
Lungs 
n (%) 
NP/OP 
n (%) 
Spleen 
n (%) 
Urine  
n (%) 
Positive 28 (21) 7 (24) 0 1 (7) 2 (13) 13 (40)  5 (16)  
Cryptococcal antigen 
Tested 33 - 7 26 - - - - - 
Positive 2 (6)  0 2 (8)      
Pneumocystis IFA 
Tested 26 26 - - - - - - - 
Positive 2 (8) 2 (8)        
V
IR
U
SE
S 
Multiplex PCR (respiratory) 
Tested 24 11 - - - - 13 - - 
Para-influenza viruses 1-3 0 0     0   
Adenovirus 0 0     0   
Enterovirus 0 0     0   
Human metapneumovirus 0 0     0   
Respiratory syncytial virus 1 (4) 0     1 (8)   
Rhinovirus 8 (33) 4 (36)     4 (31)   
Influenza A virus 1 (4) 0     1 (8)   
Influenza B virus 0 0     0   
Multiplex PCR (neurological) 
Tested 11 - - 11 - - - - - 
Cytomegalovirus 7 (64)   7 (64)      
Epstein-Barr virus 8 (73)   8 (73)      
Herpes simplex virus 1 & 2 0   0      
Human herpes virus 6 0   0      
Human herpes virus 7 1 (9)   1 (9)      
Parechoviruses 0   0      
Parvovirus B19 2 (18)   2 (18)      
Varicella zoster virus 1 (9)   1 (9)      
†A non-splenic sample growing only Enterococcus spp., and/or Enterobacter spp., and/or E. coli, and/or Proteus spp., and/or Bacillus spp., and/or coagulase negative staphylococci, 
and/or Viridans streptococci was considered contaminated, as was a splenic sample growing only one of the above, or growing only Gram-negative organisms in the absence of the 
growth of the same organism from another site. 
 
BAL: bronchoalveolar lavage; CSF: cerebrospinal fluid; IFA: indirect fluorescent antibody; MTB: M. tuberculosis; NP/OP: naso-/oro-pharyngeal swabs; NTM: non-tuberculous 
mycobacteria; PCR: polymerase-chain reaction  
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Supplementary table 4:2. Autopsy findings for each participant: histological, microbiological, DNA, and immunological evidence of tuberculosis, bacterial disease, and other 
diseases, listed by time from death to MIA (n=34) 
ID* 
Time in days Evidence of tuberculosis Evidence of NTM and/or other bacterial disease Other histological, microbiological, 
DNA, and immunological findings 
and site(s) 
Fr
o
m
 e
n
ro
lm
e
n
t 
to
 d
e
at
h
 
Fr
o
m
 d
e
at
h
 
to
 M
IA
 
O
n
 T
B
 T
x 
O
n
 A
R
T
 
Histological 
evidence 
and 
site(s) 
Positive 
culture 
and 
site(s) 
Xpert 
MTB/RIF 
positive 
(BAL only) 
If MTB 
found, 
INH/RIF 
sensitive? 
Histological 
evidence 
and site(s) 
Organism(s) grown 
or detected by PCR 
and site(s) 
07 48 1 48 - - 
CSF, LIV, 
SPL 
- ✓ - Klebsiella spp. (BAL) CrAg positive (CSF) 
30 1 2 - - - - - - LL, RL H. parainfluenzae (lungs) - 
06 21 2 - 15 - - - - RL Pseudomonas spp. (BAL, lungs) Histology: Extensive autolysis (LK, RK) 
15 34 2 - 30 - - - - - - 
Histology: Pneumonitis, ?viral + organising 
hyaline membrane disease (LL, RL) 
31 63 2 - 56 LIV, LL, RL, SPL - ✓ 
RIF resistant 
(BAL) 
- - 
Histology: Extramedullary haematopoiesis (RL; 
LL) 
PCR: EBV (CSF); PVB19 (CSF) 
08 28 3 - - LIV, LL, RL 
BAL, LIV, 
lungs 
✓ ✓ RL K. pneumoniae (BAL; lungs) 
Histology: Florid superadded CMV infection 
(LIV; LL; RL) 
24 33 3 33 13 LIV, SPL - - - LL, RL M. avium (LIV, SPL) PCR: CMV (CSF); EBV (CSF) 
09 38 3 - 29 LL, LK - - - - K. pneumoniae (BAL; lungs) 
Histology: Acute tubular necrosis with 
underlying acute suppurative pyelonephritis 
(RK; LK) 
10 41 3 48 32 RL - - - RL Klebsiella spp. (BAL) Histology: Acute tubular injury (RK; LK) 
18 49 3 - 50 LIV, LL, RL, SPL 
BAL, LIV, 
lungs, SPL 
✓ 
RIF resistant 
(BAL) 
- - - 
33 182 3 182 148 - BAL, CSF - ✓ - - 
Histology: Severe PCP (LL; RL) 
PCR: H. influenzae (BLD); Rhinovirus (BAL; 
NP/OP) 
12 9 4 9 - - - - - RL - - 
02 10 4 - 10 - BAL, CSF - ✓ - - 
Histology: Disseminated cryptococcosis (LIV; 
LL; RL)  
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ID* 
Time in days Evidence of tuberculosis Evidence of NTM and/or other bacterial disease Other histological, microbiological, 
DNA, and immunological findings 
and site(s) 
Fr
o
m
 e
n
ro
lm
e
n
t 
to
 d
e
at
h
 
Fr
o
m
 d
e
at
h
 
to
 M
IA
 
O
n
 T
B
 T
x 
O
n
 A
R
T
 
Histological 
evidence 
and 
site(s) 
Positive 
culture 
and 
site(s) 
Xpert 
MTB/RIF 
positive 
(BAL only) 
If MTB 
found, 
INH/RIF 
sensitive? 
Histological 
evidence 
and site(s) 
Organism(s) grown 
or detected by PCR 
and site(s) 
Culture: C. neoformans (lungs) 
CrAg positive (CSF) 
34 184 4 195 74 - - - -  K. pneumoniae (BAL, BLD, lungs) 
Histology: Disseminated CMV infection (LIV; 
LL; RL); Chronic active hepatitis B infection 
(LIV) 
29 359 4 40 88 LL, RL - - - LL, RL 
Nocardia sp. (lungs);  
K. pneumoniae (BAL; lungs) 
PCR: CMV (CSF); Rhinovirus (BAL; NP/OP) 
13 14 5 14 - - - - - RL 
P. aeruginosa (BAL);  
K pneumoniae (BAL) 
Histology: Interstitial pneumonitis, ?viral (LL) 
20 62 5 - 28 
LIV, LL, 
RL, SPL 
BAL, CSF, 
LIV, 
lungs, SPL 
✓ ✓ - 
S. pneumoniae 15A/F (CSF);  
Klebsiella spp. (BAL) 
PCR: Respiratory syncytial virus (NP/OP) 
32 100 5 - 100 - - - - Soft tissue 
Salmonella spp. (BAL, BLD, CSF, LIV, 
lungs, SPL) 
S. aureus (BAL, BLD)  
H. influenzae (BLD) 
Histology: Pneumonitis, ?viral (LL; RL) 
PCR: CMV (CSF); EBV (CSF); PVB19 (CSF) 
19 373 5 329 90 - - - - - 
S. aureus (BAL);  
K. pneumoniae (BAL) 
Histology: Disseminated cryptococcosis (LIV, 
LL, RL, SPL) 
Culture: C. neoformans (CSF, LIV) 
CrAg positive (CSF) 
PCR: Rhinovirus (BAL, NP/OP); CMV (CSF); EBV 
(CSF) 
16 4 6 4 - - - - - - - - 
26 8 6 7 - - - - - - S. pneumoniae 19F (BLD; CSF)  PCR: EBV (CSF) 
03 82 6 19 66 LIV, SPL SPL ✓ ✓ - - Histology: Significant steatosis (LIV) 
14 128 6 63 126 LIV, RL BAL, CSF - ✓ LL K. pneumoniae (BAL, lungs) - 
27 324 6 - 317 - - - - LIV M. intracellulare (LIV; lungs; SPL) Histology: Acute tubular necrosis (LK) 
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ID* 
Time in days Evidence of tuberculosis Evidence of NTM and/or other bacterial disease Other histological, microbiological, 
DNA, and immunological findings 
and site(s) 
Fr
o
m
 e
n
ro
lm
e
n
t 
to
 d
e
at
h
 
Fr
o
m
 d
e
at
h
 
to
 M
IA
 
O
n
 T
B
 T
x 
O
n
 A
R
T
 
Histological 
evidence 
and 
site(s) 
Positive 
culture 
and 
site(s) 
Xpert 
MTB/RIF 
positive 
(BAL only) 
If MTB 
found, 
INH/RIF 
sensitive? 
Histological 
evidence 
and site(s) 
Organism(s) grown 
or detected by PCR 
and site(s) 
K. pneumoniae (lungs) 
28 450 6 71 422 LIV, LL, RL, SPL Lungs - ✓ - - PCR: EBV (CSF) 
05 57 7 57 - - - - - - K. pneumoniae (lungs) 
Histology: Severe cryptococcal pneumonia (LL, 
RL) 
Culture: Aspergillus fumigatus (lungs) 
22 285 7 - 284 - - - - LL, RL 
S. aureus (BAL; CSF; lungs; SPL);  
S. pneumoniae 9A/V, 1 (CSF) 
PCR: Influenza A virus H32N (CSF, NP/OP); 
CMV (CSF) EBV (CSF); HHV-7 (CSF) 
17 14 8 - - - - - - - 
S. aureus (lungs); 
P. aeruginosa (BAL); 
Histology: Profound non-alcoholic steato-
hepatitis 
23 21 8 - 21 - - - - 
LIV, LL, RL, 
SPL 
M. avium  
(BAL; CSF; LIV; lungs; SPL; urine) 
PCR: CMV (CSF); VZV (CSF) 
04 122 8 120 108 
LIV, LL, pleura, 
RL 
BAL - ✓ - - - 
25† 122 8 126 46 - - - - - - Histology: mild autolytic changes (SPL) 
21 304 8 304 276 - - - - LL Klebsiella spp. (BAL, lungs) 
Histology: Chronic hepatitis 
PCR: Rhinovirus (BAL, NP/OP); CMV (CSF); EBV 
(CSF)  
01 175 9 173 153 - SPL - ✓ - Klebsiella spp. (BAL) Histology: Non-specific portal triaditis (LIV) 
11 84 11 82 67 - - - - - K. pneumoniae (BAL) 
Histology: Severe bilateral PCP 
PCP immunofluorescence positive (BAL) 
*ID denotes chronological order in which MIA was conducted (first October 2013, last June 2015)   
†Samples obtained as part of complete autopsy – heavily contaminated 
BAL: broncheo-alveolar lavage; BLD: blood; CMV: Cytomegalovirus; CSF: cerebrospinal fluid; EBV: Epstein-Barr virus; HHV: Human Herpes virus; INH: Isoniazid; LIV: liver; LK: left 
kidney; LL: left lung; MIA: minimally-invasive autopsy; MTB: M. tuberculosis; NP/OP: nasopharyngeal/oropharyngeal swab; NTM: non-tuberculous mycobacteria; PCP: Pneumocystis 
pneumonia; PCR: polymerase chain reaction; PVB19: Parvovirus B19; RIF: Rifampicin; RK: right kidney; RL: right lung; SPL: spleen; TB: tuberculosis; Tx: treatment; VZV: Varicella 
zoster virus
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Table 5:1 Demographics for all decedents for whom a VA was conducted, stratified by parent study (n = 259) 
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5.2.5.3 Performance of VA against L3 reference standard 
 
 
 
 
Table 5:2. Numbers and resultant CSMFs generated for grouped ICD-10 and study-defined CoD categories in those 
with autopsy data available, as assigned by the clinicopathological panel, PCVA, InterVA-4, and SmartVA-Analyze (n = 
34) 
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Figure 5:1. Alluvial* diagram showing CoD as assigned by the clinicopathological panel† (left) and PCVA (right); n = 34 
 
 
 
 
 
 
 
 
 
 
  
An autopsy study exploring the spectrum of disease in individuals with advanced HIV 
 in primary care clinics in South Africa 
 Page 191 of 383 Chapter 5: Research paper 3: 
Measuring mortality due to HIV-associated tuberculosis among adults in South Africa: Comparing verbal autopsy, 
minimally-invasive autopsy, and research data 
 
Figure 5:2. Alluvial* diagram showing CoD as assigned by clinicopathological panel† (centre), InterVA-4‡ (left), and 
SmartVA-Analyze (right); n = 34. 
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Table 5:3. Summary of measures of performance of PCVA, InterVA-4, and SmartVA-Analyze in assigning CoD in ICD-
10 or study-defined categories, compared to L3 (n = 34) and L2 (n = 259) reference standards. 
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Table 5:4. Numbers and resultant CSMFs generated for grouped ICD-10 and study-defined CoD categories, as 
assigned by L2 and L1 clinical panels, PCVA, InterVA-4, and SmartVA-Analyze (n = 259) 
 
 
 
 
 
Table 5:5. Sensitivity, specificity, and chance-corrected concordance of PCVA, InterVA-4, and SmartVA-Analyze in the 
detection of specific CoD compared to L3 (n = 34) and L2 (n = 259) clinical reference standards. 
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5.4. Material provided as supplementary online appendices 
Supplementary table 5:1. Grouped ICD-10 CoD categories and corresponding WHO 2014 CoD codes 
Grouped ICD-10 category* Corresponding WHO 2014 CoD codes [106] 
HIV/AIDS-related 01.03 HIV/AIDS-related death 
Pulmonary TB 01.09 Pulmonary tuberculosis 
Other infections 
01.01 Sepsis (non-obstetric) 
01.02 Acute resp. infection, incl. pneumonia 
01.04 Diarrhoeal illness 
01.05 Malaria 
01.06 Measles 
01.07 Meningitis and encephalitis 
01.08, 10.05 Tetanus 
01.10 Pertussis 
01.11 Haemorrhagic fever 
01.99 Other and unspecified infectious diseases 
Non-HIV malignancy 
02.01 Oral neoplasms 
02.02 Digestive neoplasms 
02.03 Respiratory neoplasms 
02.04 Breast neoplasms 
02.05, 02.06 Reproductive neoplasms M, F 
02.99 Other and unspecified neoplasms 
Other non-communicable 
diseases 
03.01 Severe anaemia 
03.02 Severe malnutrition 
03.03 Diabetes mellitus 
04.01 Acute cardiac disease 
04.02 Stroke 
04.03 Sickle cell with crisis 
04.99 Other and unspecified cardiac disease 
05.01 Chronic obstructive pulmonary disease 
05.02 Asthma 
06.01 Acute abdomen 
06.02 Liver cirrhosis 
07.01 Renal failure 
08.01 Epilepsy 
98 Other and unspecified NCD 
External / Traumatic / Pregnancy 09.01 Ectopic pregnancy 
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Grouped ICD-10 category* Corresponding WHO 2014 CoD codes [106] 
09.02 Abortion-related death 
09.03 Pregnancy-induced hypertension 
09.04 Obstetric haemorrhage 
09.05 Obstructed labour 
09.06 Pregnancy-related sepsis 
09.07 Anaemia of pregnancy 
09.08 Ruptured uterus 
09.99 Other and unspecified maternal CoD 
12.01 Road traffic accident 
12.02 Other transport accident 
12.03 Accidental fall 
12.04 Accidental drowning and submersion 
12.05 Accidental exposure to smoke, fire, & flame 
12.06 Contact with venomous plant/animal 
12.07 Accidental poisoning and noxious substances 
12.08 Intentional self-harm 
12.09 Assault 
12.10 Exposure to force of nature 
12.99 Other and unspecified external CoD 
Indeterminate Cause of death unknown 
*Categories used for analysis purposes 
 
AIDS: Acquired immune deficiency syndrome; CoD: cause of death; F: Female; HIV: Human immunodeficiency virus; 
ICD: International Classification of Diseases; M: Male; NCD: Non-communicable disease; TB: tuberculosis; WHO: World 
Health Organization 
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Supplementary table 5:2. Criteria used by clinical panels to assign study-defined CoD and associated certainty 
Study-defined 
category 
Certainty 
‘Definite’ ‘Probable’ ‘Possible’ 
Death due to TB in an 
HIV positive individual 
Documented evidence of positive HIV point-of-
care test or ELISA OR patient on ART 
Documented evidence of positive HIV point-of-care 
test or ELISA OR patient on ART 
History suggestive of HIV and active TB, but 
no clear evidence available 
AND AND 
History and clinicopathological features consistent 
with active TB disease 
History suggestive of active TB disease 
AND AND 
Microbiological evidence of TB  
(culture positive or Xpert MTB/RIF positive) 
Positive sputum smear, urine LAM or chest x-ray 
Death due to other 
HIV/AIDS-associated 
cause (excluding TB) 
Documented evidence of positive HIV point-of-
care test or ELISA OR patient on ART 
Documented evidence of positive HIV point-of-care 
test or ELISA OR patient on ART 
History suggestive of an AIDS-defining or HIV-
associated condition (other than TB) in a 
person thought to be HIV-positive or a 
condition thought to be due to ART 
AND AND 
History and clinicopathological findings consistent 
with an AIDS-defining or HIV-associated condition 
(other than TB), or a condition due to ART (only 
applicable if ART use documented) 
History consistent with an AIDS-defining or HIV-
associated condition (other than TB), or a condition 
likely due to ART (only applicable if ART use 
suggested) 
AND AND 
Microbiological/histological/cytological evidence 
for one of the above 
Documentation of one of the above conditions by a 
senior clinician 
Death due to cause 
unrelated to HIV in an 
HIV-positive adult 
Documented evidence of positive HIV point-of-
care test or ELISA OR patient on ART 
Documented evidence of positive HIV point-of-care 
test or ELISA OR patient on ART 
Documented evidence of positive HIV point-
of-care test or ELISA OR patient on ART 
AND AND AND 
History and clinicopathological findings consistent 
with a condition unrelated to HIV 
History consistent with a condition unlikely to be 
related to HIV 
History suggestive of a condition unlikely to 
be related to HIV 
Death due to TB in an 
HIV-negative adult 
Documented evidence of negative HIV point-of-
care test or ELISA in the 90 days prior to death 
Documented HIV-negative point-of-care test or ELISA 
over 90 days but less than 180 days prior to death) 
Patient self-reports HIV negative 
AND AND AND 
History consistent with active TB disease of a 
severity sufficient to cause death 
History suggestive of active TB disease of a severity 
sufficient to cause death 
No other evidence of HIV disease or an HIV 
test 
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Study-defined 
category 
Certainty 
‘Definite’ ‘Probable’ ‘Possible’ 
AND AND AND 
Microbiological evidence of TB (culture positive, 
Xpert MTB/RIF positive) 
Positive sputum smear or urine LAM or chest x-ray 
History suggestive of active TB disease (of a 
severity sufficient to cause death) 
Death due to cause 
other than TB in an 
HIV-negative adult 
Documented evidence of negative HIV point-of-
care test or ELISA in the 90 days prior to death 
Documented HIV-negative point-of-care test or ELISA 
over 90 days but less than 180 days prior to death) 
Patient self-reports HIV negative 
AND 
AND AND No other evidence of HIV disease or HIV test 
No evidence (history or investigations) of TB 
No evidence (history or investigations) of TB  
OR  
Possible evidence of TB disease (e.g.: suggestive 
symptoms) but clinical history not consistent 
AND 
No evidence (history or investigations) of TB  
OR  
Possible evidence of TB infection/previous 
exposure but clinical history not consistent 
Death due to 
indeterminate cause 
Cause of death unclear 
AIDS: Acquired immune deficiency syndrome; ART: antiretroviral therapy; CoD: cause of death; ELISA: Enzyme-linked immunosorbent assay; HIV: human immunodeficiency virus; 
LAM: lipoarabinomannan; TB: tuberculosis 
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Supplementary table 5:3. CoD for decedents with 'Autopsy' data: ICD-10 immediate and underlying CoD, as assigned by reviewers; grouped ICD-10 category; and study-specific 
categories as assigned by clinicopathological panel (L3), PCVA, InterVA-4, and SmartVA-Analyze (n=34) 
ID† Level three CoD  Physician-certified VA CoD InterVA-4 CoD SmartVA-
Analyze CoD 
‘Immediate’ ‘Underlying’ Grouped ICD-10  Study-defined ‘Immediate’ ‘Underlying’ Grouped ICD-10  Study-defined Grouped ICD-10 
1 HIV disease  HIV/AIDS-related Indeterminate PTB HIV disease HIV/AIDS-related TB in HIV-
positive 
HIV/AIDS-
related 
HIV/AIDS-
related 
2 Disseminated 
TB 
HIV disease HIV/AIDS-related TB in HIV-
positive 
PTB HIV disease HIV/AIDS-related TB in HIV-
positive 
Pulmonary TB HIV/AIDS-
related 
3 Disseminated 
TB 
HIV disease HIV/AIDS-related TB in HIV-
positive 
PTB HIV disease HIV/AIDS-related TB in HIV-
positive 
HIV/AIDS-
related 
Other NCD 
4 Cryptococcal 
disease 
HIV disease HIV/AIDS-related HIV/AIDS, excl. 
TB 
PTB HIV disease HIV/AIDS-related TB in HIV-
positive 
HIV/AIDS-
related 
HIV/AIDS-
related 
5 Gastroenteritis HIV disease Other infectious HIV/AIDS, excl. 
TB 
Stroke HIV disease HIV/AIDS-related HIV/AIDS, excl. 
TB 
Other NCD Other infectious 
6 Disseminated 
TB 
HIV disease HIV/AIDS-related TB in HIV-
positive 
Bacterial 
meningitis 
HIV disease HIV/AIDS-related HIV/AIDS, excl. 
TB 
Non-HIV 
malignancy 
HIV/AIDS-
related 
7 Disseminated 
TB 
HIV disease HIV/AIDS-related TB in HIV-
positive 
Bacterial 
infection 
HIV disease HIV/AIDS-related HIV/AIDS, excl. 
TB 
HIV/AIDS-
related 
Other NCD 
8 Disseminated 
TB 
HIV disease HIV/AIDS-related TB in HIV-
positive 
Disseminated 
TB 
HIV disease HIV/AIDS-related TB in HIV-
positive 
HIV/AIDS-
related 
HIV/AIDS-
related 
9 Bacterial 
pneumonia 
HIV disease HIV/AIDS-related TB in HIV-
positive 
PTB HIV disease HIV/AIDS-related TB in HIV-
positive 
Pulmonary TB HIV/AIDS-
related 
10 Salmonellosis HIV disease HIV/AIDS-related HIV/AIDS, excl. 
TB 
HIV disease  HIV/AIDS-related HIV/AIDS, excl. 
TB 
Other 
infectious 
Non-HIV 
malignancy 
11 PCP HIV disease HIV/AIDS-related HIV/AIDS, excl. 
TB 
Gastroenteritis HIV disease Other infectious HIV/AIDS, excl. 
TB 
HIV/AIDS-
related 
HIV/AIDS-
related 
12 CNS disorder HIV disease HIV/AIDS-related Indeterminate Stroke HIV disease HIV/AIDS-related Non-HIV in 
HIV-positive 
Other NCD Indeterminate 
13 Bacterial 
pneumonia 
HIV disease HIV/AIDS-related HIV/AIDS, excl. 
TB 
PTB HIV disease HIV/AIDS-related TB in HIV-
positive 
Pulmonary TB HIV/AIDS-
related 
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ID† Level three CoD  Physician-certified VA CoD InterVA-4 CoD SmartVA-
Analyze CoD 
‘Immediate’ ‘Underlying’ Grouped ICD-10  Study-defined ‘Immediate’ ‘Underlying’ Grouped ICD-10  Study-defined Grouped ICD-10 
14 Disseminated 
TB 
HIV disease HIV/AIDS-related TB in HIV-
positive 
Gastroenteritis HIV disease Other infectious HIV/AIDS, excl. 
TB 
Other 
infectious 
Other infectious 
15 LRTI HIV disease HIV/AIDS-related Indeterminate HIV disease  HIV/AIDS-related HIV/AIDS, excl. 
TB 
HIV/AIDS-
related 
Other NCD 
16 Disseminated 
TB 
HIV disease HIV/AIDS-related TB in HIV-
positive 
Peptic ulcer EPTB Other NCD TB in HIV-
positive 
Non-HIV 
malignancy 
Non-HIV 
malignancy 
17 Indeterminate HIV disease HIV/AIDS-related Indeterminate PTB HIV disease HIV/AIDS-related TB in HIV-
positive 
Other NCD HIV/AIDS-
related 
18 Disseminated 
TB 
HIV disease HIV/AIDS-related TB in HIV-
positive 
HIV disease  HIV/AIDS-related HIV/AIDS, excl. 
TB 
HIV/AIDS-
related 
HIV/AIDS-
related 
19 Cryptococcal 
disease 
HIV disease HIV/AIDS-related HIV/AIDS, excl. 
TB 
PE HIV disease HIV/AIDS-related Non-HIV in 
HIV-positive 
Non-HIV 
malignancy 
Indeterminate 
20 Disseminated 
TB 
HIV disease HIV/AIDS-related TB in HIV-
positive 
Liver disease HIV disease HIV/AIDS-related HIV/AIDS, excl. 
TB 
HIV/AIDS-
related 
Indeterminate 
21 Bacterial 
pneumonia 
HIV disease HIV/AIDS-related HIV/AIDS, excl. 
TB 
Pneumonia Type two 
diabetes 
Other infectious Non-TB in HIV-
negative 
Other 
infectious 
Other NCD 
22 Bacterial 
pneumonia 
HIV disease HIV/AIDS-related HIV/AIDS, excl. 
TB 
Gas gangrene HIV disease HIV/AIDS-related Non-HIV in 
HIV-positive 
Non-HIV 
malignancy 
Other NCD 
23 NTM disease HIV disease HIV/AIDS-related HIV/AIDS, excl. 
TB 
Chronic renal 
failure 
HIV disease HIV/AIDS-related HIV/AIDS, excl. 
TB 
HIV/AIDS-
related 
Other infectious 
24 NTM disease HIV disease HIV/AIDS-related HIV/AIDS, excl. 
TB 
PTB HIV disease HIV/AIDS-related TB in HIV-
positive 
Pulmonary TB Indeterminate 
25 Transport 
accident 
 External/trauma Non-HIV in HIV-
positive 
Injuries to 
spine and trunk 
Transport 
accident 
External/trauma Non-TB in HIV- 
negative 
Pulmonary TB HIV/AIDS-
related 
26 EPTB HIV disease HIV/AIDS-related TB in HIV-
positive 
GI obstruction  Other NCD Non-TB in HIV-
negative 
Other NCD Indeterminate 
27 NTM disease HIV disease HIV/AIDS-related HIV/AIDS, excl. 
TB 
HIV disease  HIV/AIDS-related HIV/AIDS, excl. 
TB 
HIV/AIDS-
related 
Other infectious 
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ID† Level three CoD  Physician-certified VA CoD InterVA-4 CoD SmartVA-
Analyze CoD 
‘Immediate’ ‘Underlying’ Grouped ICD-10  Study-defined ‘Immediate’ ‘Underlying’ Grouped ICD-10  Study-defined Grouped ICD-10 
28 Disseminated 
TB 
HIV disease HIV/AIDS-related TB in HIV-
positive 
HIV disease  HIV/AIDS-related HIV/AIDS, excl. 
TB 
HIV/AIDS-
related 
HIV/AIDS-
related 
29 Nocardiosis HIV disease HIV/AIDS-related HIV/AIDS, excl. 
TB 
HIV disease  HIV/AIDS-related HIV/AIDS, excl. 
TB 
HIV/AIDS-
related 
HIV/AIDS-
related 
30 Pneumonia HIV disease HIV/AIDS-related HIV/AIDS, excl. 
TB 
HIV disease  HIV/AIDS-related HIV/AIDS, excl. 
TB 
HIV/AIDS-
related 
4. 
Indeterminate 
31 Disseminated 
TB 
HIV disease HIV/AIDS-related TB in HIV-
positive 
Gastroenteritis HIV disease Other infectious HIV/AIDS, excl. 
TB 
HIV/AIDS-
related 
Other infectious 
32 Disseminated 
TB 
HIV disease HIV/AIDS-related TB in HIV-
positive 
Bacterial 
pneumonia 
HIV disease HIV/AIDS-related HIV/AIDS, excl. 
TB 
Pulmonary TB 4. 
Indeterminate 
33 CMV HIV disease HIV/AIDS-related HIV/AIDS, excl. 
TB 
Hepatic failure PTB Other NCD TB in HIV-
positive 
HIV/AIDS-
related 
HIV/AIDS-
related 
34 PCP HIV disease HIV/AIDS-related HIV/AIDS, excl. 
TB 
Hepatic failure PTB Other NCD HIV/AIDS, excl. 
TB 
Pulmonary TB PTB 
†ID denotes chronological order in which participants died 
 
AIDS: Acquired immune deficiency syndrome; CMV: cytomegalovirus; CNS: central nervous system; CoD: cause of death; excl.: excluding; EPTB: Extrapulmonary tuberculosis; GI: 
gastrointestinal; HIV: Human immunodeficiency virus; ICD: International Classification of Diseases; L3: level three reference cause of death (‘operational’, ‘research’, and ‘autopsy’ 
data); LRTI: lower respiratory tract infection; NCD: non-communicable disease; NTM: Non-tuberculous mycobacteria; PCP: Pneumocystis pneumonia; PCVA: physician-certified 
verbal autopsy; PE: pulmonary embolism; PTB: pulmonary tuberculosis; TB: tuberculosis; VA: verbal autopsy 
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Supplementary figure 5:1. Numbers of individuals enrolled to each of the parent studies, number of deaths, number of VAs conducted, data sources for clinical cause of death 
assignment, data availability by parent study, and which data contributed to different CoD levels 
 
CoD: cause of death; MIA: minimally-invasive autopsy; NHLS: National Health Laboratory Services; TB: tuberculosis; VA: verbal autopsy
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6.2.1. Abstract 
6.2.1.1 Background 
Causes of death (CoD) among HIV-positive adults are difficult to measure, and global estimates of HIV-associated 
mortality are partially derived through mathematical modelling.  Antiretroviral therapy (ART) is changing mortality 
patterns; verbal autopsy (VA) is to be integrated into civil registration systems, but has not undergone robust validation 
for HIV-associated CoD.  This study aimed to assess the sensitivity and specificity of VA questions in detecting HIV status 
and ART initiation, and to compare the HIV-associated mortality fractions assigned by the three leading VA 
interpretation methods. 
6.2.1.2 Methods and findings 
HIV-positive adults (≥18 years) in South Africa who died after enrolment to one of three studies of tuberculosis (TB) 
diagnosis and/or treatment, and HIV-negative adults who died in hospitals from non-traumatic and non-maternal 
causes were included.  The 2012 World Health Organization VA instrument was used with questions added around ART; 
CoD were assigned by physician-certified (PCVA) and computer-coded (CCVA) methods (InterVA-4 and SmartVA-
Analyze).   
Data from 356 HIV-positive and 103 HIV-negative adults were analysed: sensitivity and specificity of VA questions were 
84.3% (95% confidence interval [CI] 80–88) and 94.2% (95% CI 88–98) in assigning HIV status, and 91.0% (95% CI 86–95) 
and 53.2% (95% CI 43–64) in detecting ART initiation.  Of 356 HIV-positive individuals, 283 (79.5%) were assigned an 
HIV-associated CoD by PCVA, 166 (46.6%; cause-specific mortality fraction [CSMF] 44.7%) by InterVA-4, and 80 (22.5%) 
by SmartVA-Analyze.  Agreement between VA methods was poor at individual and population levels (Cohen’s kappa 
0.05 and 0.04 and CSMF accuracy 56% and 28% for PCVA vs. InterVA-4 and PCVA vs. SmartVA-Analyze, respectively).  All 
VA interpretation methods showed high specificity in assigning HIV-associated CoD, at 96.1%, 89.3%, and 95.1% for 
PCVA, InterVA-4, and SmartVA-Analyze, respectively.   
This study was limited by inability to estimate sensitivity of VA methods (because of the absence of a reference CoD); 
HIV-positive and HIV-negative groups were not age-matched, which may have led to overestimation of specificity; and 
narrative data were not provided to SmartVA-Analyze, which may have influenced its accuracy in assigning CoD. 
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6.2.1.3 Conclusions  
VA interpretation methods gave very different estimates of HIV-associated mortality, and CCVA methods 
underestimated the HIV-associated mortality fraction.  However, VA questions were sensitive and specific in detecting 
HIV status and sensitive in detecting ART initiation.  To track progress towards international targets to reduce HIV-
associated mortality, adjustments to automated VA methods and changes to classification systems are needed that 
allow for estimation of all CoD among HIV-positive individuals. 
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6.2.2. Introduction 
An estimated 1.2 million individuals died due to HIV-associated causes in 2015; 75% of these deaths occurred in low- 
and middle-income countries (LMIC) [1].  The Joint United Nations Programme on HIV/AIDS (UNAIDS) aims to bring 
down the number of AIDS-related deaths to under 0.5 million by the year 2020 [2].  Mortality data form the bedrock of 
health research and policy agendas [3,4] but, at present, there are few direct estimates of overall or cause-specific 
mortality among HIV-positive individuals in LMIC.  Figures from the Global Burden of Disease study are arrived at 
through complex mathematical models that use data from a variety of sources, including civil registration and vital 
statistics (CRVS) systems, seroprevalence surveys, and antenatal and antiretroviral therapy (ART) monitoring 
programmes [1,5–7].  Estimates published by UNAIDS are developed through similar methods [8].  The scarcity of 
reliable cause of death (CoD) data suggests it will be extremely difficult to track progress towards the ambitious goals 
set by UNAIDS. 
The direct estimation of HIV-associated mortality is challenging.  The disease remains associated with considerable 
stigma in many areas; this may lead to the diagnosis being omitted from death certificates, even when the certifying 
physician is aware of an individual’s HIV status and considers the CoD to be HIV-related [9–11].  A number of studies 
have shown poor agreement between CoD listed on death certificates and those estimated through clinical or autopsy 
methods [12–15].  Even when death certificates are correctly completed, many countries do not have robust CRVS 
systems; between 2009 and 2013, over 80% of countries in the African region had incomplete or no CRVS death data 
available [16–19].  In these situations, estimates of cause-specific mortality are generated through verbal autopsy (VA), 
a structured interview with a relative or carer of a deceased individual [7], conducted at health and demographic 
surveillance system (HDSS) sites.  VA data can be interpreted using several methods, all of which assign CoD per 
International Classification of Diseases (ICD) rules.  For demographic purposes, most countries use only a single 
‘underlying’ CoD for each decedent, thereby classifying all HIV-associated CoD under one of five ICD codes: B20, HIV 
disease resulting in infectious and parasitic diseases; B21, HIV disease resulting in malignant neoplasms; B22, HIV 
disease resulting in other specified diseases; B23, HIV disease resulting in other conditions; or B24, Unspecified HIV 
disease [20]. 
HIV-positive individuals who die from causes thought to be unrelated to HIV are likely to be increasingly important in 
monitoring the evolution of the epidemic.  The global rollout of ART has already had an impact on all-cause mortality in 
An autopsy study exploring the spectrum of disease in individuals with advanced HIV 
 in primary care clinics in South Africa 
 Page 216 of 383 Chapter 6: Research paper 4: 
Performance of verbal autopsy methods in estimating HIV-associated mortality among adults in South Africa 
areas of high HIV prevalence [21–23] and cause-specific patterns are certain to change as more individuals receive 
treatment [24,25].  Recent guidelines advocating ART for all people living with HIV will likely accelerate this process 
[26], but current national and global systems do not allow for the estimation of all-cause mortality among HIV-positive 
individuals, estimates which are needed to distinguish deaths due to HIV-related immunosuppression from other CoD 
among HIV-positive people.  The World Health Organization (WHO) standardised VA instrument does ask about HIV 
status but, until very recently, did not include questions about ART [27].  Although VA has been used extensively in 
areas of high HIV prevalence [28–30], it has not been validated against a robust gold standard for HIV- and tuberculosis 
(TB)-related deaths [31]. 
This article describes an analysis of data from a study partly nested within three large studies of HIV and TB in South 
Africa.  The aims were to estimate the sensitivity and specificity of existing WHO VA questions in detecting HIV status 
and of additional questions in detecting ART initiation, compared to a reference standard of confirmed HIV status from 
clinical and research data; the proportions of deaths among HIV-positive adults attributed by VA methods to HIV-
associated causes; and the specificity of VA interpretation methods in assigning HIV-associated CoD, compared to 
confirmed and VA-reported HIV status. 
6.2.3. Methods 
6.2.3.1 Parent studies 
This study was nested within three large studies conducted in South Africa between 2012 and 2015.  (1) ‘TB Fast Track’ 
was an open, cluster-randomised trial of empirical TB treatment in ambulatory adults with advanced HIV who were not 
on ART or TB treatment at the point of enrolment; it was conducted across 24 primary health care clinics (PHCs) in 
three provinces of South Africa and completed follow-up in June 2015 [32].  (2) ‘XPHACTOR’ was an interventional 
cohort study investigating the use of Xpert MTB/RIF in a systematic sample of HIV-positive adults attending out-
patient clinics for HIV care; participants were followed up for at least three months.  (3) ‘XTEND’ was an evaluation of 
the impact on mortality of Xpert MTB/RIF rollout; it enrolled adults, both HIV-positive and HIV-negative, from 40 
PHCs across South Africa having sputum sent for TB investigation and followed them up for six months [33].   
6.2.3.2 HIV-negative individuals 
To estimate the specificity of the VA question “Was there any diagnosis of HIV/AIDS?” in detecting HIV status, VAs were 
conducted among confirmed HIV-negative adults who died in one of five TB Fast Track referral hospitals.  Based on an 
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estimated sample of 329 VAs in HIV-positive individuals and a predicted VA specificity of 90% in assigning HIV-
associated deaths (based on figures from a large study in five African countries [29]), a target was set of 121 VAs in HIV-
negative adults (giving an HIV prevalence of 73%) to achieve 95% confidence intervals (CI) of width ±5% around a point 
estimate of specificity of 90%.  Registers of in-patient deaths were reviewed at hospital mortuaries; all adults who died 
between June 2014 and October 2015 with a hospital-assigned CoD that was not explicitly HIV-associated, traumatic, or 
maternal were included for further review.  Inclusion was initially restricted to individuals aged 18–55 years to be 
similar in age to HIV-positive decedents, but due to the low numbers of deaths among young individuals from non-HIV, 
non-traumatic, and non-maternal causes, this was expanded to 18–70 years.  The name, sex, date of birth, date of 
death, and hospital identifiers of each included adult were recorded; hospital files and the National Health Laboratory 
Service (NHLS) online database were then searched for HIV test results.  For those with a negative HIV test (rapid test or 
Enzyme Linked Immunosorbent Assay [ELISA]) in the one year prior to death and no evidence of a subsequent positive 
test, the date of negative HIV test and contact details of next-of-kin, where available, were recorded.  The relatives of 
these individuals were contacted and a VA conducted per standard procedures; all decedents were assigned a unique 
identifier to ensure anonymity. 
6.2.3.3 Data collection 
VAs were conducted for as many individuals as possible who died after enrolment to one of the parent studies; trained 
lay-interviewers conducted the VA at the home of the family/carers or at another location of their choosing, one to 
twelve months after the death of the individual, as recommended by WHO [27].  All interviews were conducted using 
the WHO 2012 VA instrument [34], with questions around ART initiation, treatment for TB, and adherence to treatment 
added by the study team (Supplementary table 6:1).  Questions around ART and TB treatment were asked only to 
respondents who had answered “Yes” to either the “Was there any diagnosis of HIV/AIDS?” or the “Was there any 
diagnosis of tuberculosis?” question, respectively.  For example, questions around ART initiation were not asked if a 
respondent reported that the decedent in question was HIV-negative.   
VA data were interpreted by both physician-certified verbal autopsy (PCVA) and computer-coded verbal autopsy 
(CCVA).  The PCVA method was based on WHO recommendations, modified in line with changes made at the Medical 
Research Council/Wits University Agincourt HDSS site, South Africa [35].  Two physicians, blinded to all other clinical 
information, including information on ART obtained through VA, independently reviewed standard VA data and 
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separately assigned CoD using ICD-10 codes.  Assigned CoD were compared and, where there were discrepancies, the 
cases were discussed by the two physicians, aiming for consensus.  If a consensus could not be reached, a third, 
independent physician reviewed the data; if the CoD assigned by physician 3 matched that assigned by physicians 1 or 
2, it was considered the final CoD.  If no consensus was reached after review by three physicians, the individual was 
assigned an ‘indeterminate’ CoD. 
6.2.3.4 Reference definitions 
Clinical data to confirm HIV status, ART initiation, TB diagnosis, and TB treatment were obtained from clinic and hospital 
files, parent study databases, and the NHLS online database.  Data were available for all decedents regarding HIV status 
and for all HIV-positive individuals regarding initiation of ART.  An individual was considered HIV-positive if a positive 
test result had been recorded at any point prior to death and HIV-negative if a negative test result had been recorded in 
the one year prior to death without a subsequent positive result.  An individual was considered to have initiated ART if 
this had been recorded in a clinic, hospital, or research file; estimation of adherence to treatment was not possible 
based on the data available.  Self-report was not considered sufficient evidence of HIV status (positive or negative) or 
ART initiation.  A death was considered HIV-associated if it was assigned an underlying CoD of one of ICD-10 codes B20–
B24 by PCVA, an ‘HIV/AIDS’ CoD by InterVA-4, or an ‘AIDS’ CoD by SmartVA-Analyze; a death from any other cause was 
considered non-HIV-associated. 
6.2.3.5 Data management and statistical analyses 
Quantitative VA data were entered directly into an online database (Mobenzi Technologies, Durban, South Africa) 
through a cell phone interface; narrative data were captured on paper.  Data collected from hospital files and the NHLS 
database were entered into an EpiData v3.1 database (The EpiData Association, Odense, Denmark) and data from the 
parent studies into SQL databases (Bytes Technology Group, Johannesburg, South Africa).  VA data were mapped to the 
WHO 2014 instrument and fed into InterVA-4.03 (http://www.interva.net/), with the prevalence of malaria set to ‘Low’ 
and HIV/AIDS to ‘High’.  InterVA-4 cause-specific mortality fractions (CSMFs) were generated by dividing the sum of the 
likelihoods of each cause category by the sum of likelihoods for all causes [36]; estimations of specificity and individual 
agreement used the ‘mostly likely’ assigned cause for comparison.  VA data were also mapped to the Population Health 
Metrics and Research Consortium (PHMRC) full instrument and fed into SmartVA-Analyze v1.1.1 
(http://www.healthdata.org/verbal-autopsy/tools), with ‘Malaria region’, ‘Health Care Experience’, and ‘Free text’ 
options deselected.  Narrative data were not provided to SmartVA-Analyze as they were captured on paper.  The 
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Mortality Medical Data System (MMDS) 2011 software package 
(ftp://ftp.cdc.gov/pub/Health_Statistics/NCHS/Software/mmds/2011) was used to generate a single ‘underlying’ CoD 
from ICD-10 codes assigned by PCVA.  All analyses were conducted using Stata v14 (StataCorp, College Station, TX, 
USA).   
Individuals with unknown HIV status were excluded from all analyses.  For estimation of sensitivity and specificity, 
answers to VA questions of ‘Do not know’ were re-coded as ‘No’, to match the methods used by both InterVA-4 and 
SmartVA-Analyze [36–39].  The sensitivity and specificity of VA questions regarding HIV status and ART initiation were 
calculated with exact binomial 95% CI.  The specificities of the three VA methods in assigning HIV-associated CoD were 
calculated compared to both confirmed HIV status, collected from clinical records, and VA-reported HIV status, to 
simulate situations in which clinical HIV data may not be available.  Reference CoD were not available for all decedents 
and, because HIV-positive individuals may die from a range of causes, including those unrelated to HIV, sensitivity of 
the VA methods in assigning CoD could not be estimated.  In line with previous recommendations [40,41], Cohen’s 
kappa (K) and chance-corrected concordance (CCC) were used to measure individual agreement between VA methods 
and Lin’s concordance correlation coefficient (ρC), CSMF accuracy, and chance-corrected CSMF (CCCSMF) accuracy used 
to measure population-level agreement based on two possible CoD: HIV-associated and non-HIV-associated (as defined 
above). 
6.2.3.6 Ethical considerations 
Separate approvals were obtained for this sub-study from the human research ethics committees of the London School 
of Hygiene & Tropical Medicine and the University of the Witwatersrand.  All decedents were assigned numeric 
identities to ensure anonymity during collection of clinical data and all VA respondents gave written informed consent 
for interview. 
6.2.4. Results 
6.2.4.1 Demographics 
VA data from 459 individuals were included, 356 (77.6%) HIV-positive and 103 (22.4%) HIV-negative (Figure 6:1; Table 
6:1).  Overall, 240 (52.3%) were female and the median age was 41.5 (interquartile range [IQR] 34–52) years.  Further 
demographics are described in Table 6:1; a comparison between HIV-positive and HIV-negative individuals showed 
important differences only in median age (39.6 vs. 52.1 years; p<0.001).  
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Figure 6:1. Flow diagram showing numbers enrolled into each of the parent studies*, subsequent deaths, numbers of verbal autopsies completed, and numbers of confirmed 
HIV-positive and HIV-negative individuals included in final analysis 
 
*TB Fast Track and XPHACTOR enrolled only HIV-positive adults; XTEND enrolled HIV-positive and HIV-negative adults being investigated for TB  
HIV: human immunodeficiency virus; TB: tuberculosis; VA: verbal autopsy 
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Table 6:1. Demographics for all decedents, stratified by confirmed HIV status (n=459) 
Characteristic All (n=459) n (%) or 
median (IQR) 
Confirmed HIV-
positive (n=356) n 
(%) or median 
(IQR) 
Confirmed HIV-
negative (n=103) n 
(%) or median 
(IQR) 
p‡ 
Female 240 (52.3) 195 (54.8) 45 (43.7) 0.05 
Age at death, years 41.5 (33.6–51.5) 39.6 (33.0–47.4) 52.2 (42.4–60.9) <0.001 
Black African 457 (99.6) 354 (99.4) 103 (100) 0.45 
South African national 433 (94.3) 336 (94.4) 97 (94.2) 0.94 
Enrolled or hospitalised in peri-
urban area* 
330 (71.9) 253 (71.1) 77 (74.8) 0.46 
Initiated ART after enrolment† 117 (25.5) 117 (32.9) NA - 
Time from     
 Enrolment† to death, days 80.5 (35–161) 
(n=356) 
80.5 (35–161) 
(n=356) 
NA - 
 HIV-negative test to death, days 14 (5–59) 
(n=103) 
NA 14 (5–59) - 
 Death to VA, days 218.5 (106–325) 235 (102–338) 174 (110–271) 0.04 
*Site of enrolment for individuals enrolled to one of the three parent studies; site of hospitalisation for HIV-negative 
individuals recruited from hospitals  
†Enrolment into parent study 
‡Kruskal-Wallis or Chi-squared test, as appropriate 
ART: antiretroviral therapy; HIV: human immunodeficiency virus; IQR: interquartile range; VA: verbal autopsy 
6.2.4.2 Sensitivity and specificity of VA questions 
The VA question, “Was there any diagnosis of HIV/AIDS?” correctly identified 300/356 (sensitivity 84.3% [95% CI 80.1–
87.9]) HIV-positive individuals and incorrectly identified 6/103 (specificity 94.2% [95% CI 87.8–97.8]) HIV-negative 
individuals as HIV-positive (K 0.68; CCC 0.69; Table 6:2).  The question “Did the deceased ever take ART?”, added to the 
WHO VA instrument, was asked to the 306 individuals who answered ‘Yes’ to the HIV diagnosis question: 193/212 
(sensitivity 91.0% [95% CI 86.4–94.5]) individuals who had initiated ART were correctly reported as having done so, but 
the question was also answered ‘Yes’ for 44/94 (specificity 53.2% [95% CI 42.6–63.6]) individuals who had not initiated 
ART (K 0.48; CCC 0.82). 
An autopsy study exploring the spectrum of disease in individuals with advanced HIV 
 in primary care clinics in South Africa 
 Page 222 of 383 Chapter 6: Research paper 4: 
Performance of verbal autopsy methods in estimating HIV-associated mortality among adults in South Africa 
6.2.4.3 ART initiation dates 
Dates of ART initiation were available from both VA interviews and clinical records for 125 individuals.  The median 
difference between the dates obtained from the two sources was 29 (IQR 11–111) days; 90/125 (72.0%) and 108/125 
(86.4%) ART initiation dates obtained from VA interviews were within 90 days and one year, respectively, of the dates 
in clinical records.  Of the 237 individuals who were reported, at VA, to have been taking ART, 36 (15.1%) were reported 
not to have been taking it at death and 62 (26.2%) not to have been taking it every day. 
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Table 6:2. Sensitivity, specificity, and measures of agreement of VA questions regarding HIV status and ART initiation (n=459) 
VA question Answers Sensitivity†, % (95% 
CI) 
Specificity†, % 
(95% CI) 
Overall 
agreement†‡, % 
Cohen’s kappa† 
(95% CI) 
CCC† 
Yes No DNK 
Was there any diagnosis of 
HIV/AIDS? (n=459) 
306 (66.7) 111 (24.2) 42 (9.2) 84.3 (80.1–87.9) 94.2 (87.8–97.8) 86.5 0.68 (0.60–0.74) 0.69 
Did s/he ever take ART? 
(n=306)* 
237 (77.5) 50 (16.3) 19 (6.2) 91.0 (86.4–94.5) 53.2 (42.6–63.6) 81.4 0.48 (0.37–0.59) 0.82 
*VA respondents were only asked about ART initiation if they answered ‘Yes’ to HIV question, therefore confirmed HIV-positive individuals who were not reported as such by the 
respondent were not included in this analysis.  Of the 306 individuals reported as HIV-positive at VA, 212 (69.3%) had initiated ART and 94 (30.7%) had not. 
†’No’ and ‘Do not know’ answers combined for analysis. 
‡Overall agreement is the proportion considered ‘positive’ or ‘negative’ by both clinical and VA methods (i.e., [true positives + true negatives]/total). 
 
AIDS: acquired immune deficiency syndrome; ART: antiretroviral therapy; CCC: chance-corrected concordance; CI: confidence interval; DNK: do not know; TB: tuberculosis; VA: 
verbal autopsy 
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6.2.4.4 Performance of three VA interpretation methods 
6.2.4.4.1 Estimating HIV-associated mortality among HIV-positive adults  
Of the 356 HIV-positive adults in our study, 283 (79.5%) were assigned an HIV-associated CoD by PCVA, 166 (46.6%; 
CSMF 44.7% when all assigned CoD and associated likelihoods included) by InterVA-4, and 80 (22.5%) by SmartVA-
Analyze (Table 6:3).  These proportions were slightly higher among the 300 confirmed HIV-positive individuals who 
were also reported HIV-positive at VA (PCVA 255 [85%], InterVA-4 150 [50.0%; CSMF 47.6%], and SmartVA-Analyze 69 
[23%]).  Agreement between the three VA methods was uniformly poor, measured at both individual (CCC<0 for PCVA 
vs. InterVA-4 and PCVA vs. SmartVA-Analyze) and population levels (CSMF accuracy 56% for PCVA vs. InterVA-4 and 
28% for PCVA vs. SmartVA-Analyze; Table 6:3; Figure 6:2). 
6.2.4.4.2 Specificity in assigning HIV-associated CoD 
Among all 459 individuals, PCVA assigned 287 (62.5%) an HIV-associated CoD, compared to 177 (38.6%; CSMF 37.1% 
when all assigned CoD and associated likelihoods included) by InterVA-4 and 85 (18.5%) by SmartVA-Analyze (Table 
6:4).  Compared to confirmed HIV status, PCVA had a specificity of 96.1% (95% CI 90.4–98.9); the specificities of 
InterVA-4 and SmartVA-Analyze were 89.3% (95% CI 81.7–94.5) and 95.1% (95% CI 89.0–98.4), respectively.  All three 
methods had lower specificities when compared to VA-reported HIV status, at 81.0%, 83.0%, and 90.2% for PCVA, 
InterVA-4, and SmartVA-Analyze, respectively (Table 6:4). 
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Table 6:3. Number of confirmed HIV-positive individuals (N=356) assigned an HIV-associated CoD by three VA methods, stratified by VA-reported HIV status; and agreement 
between PCVA and CCVA methods 
VA interpretation 
method 
Number assigned an HIV-associated CoD Agreement with PCVA† 
Confirmed HIV-
positive, n 
(CSMF; %/356) 
VA-reported HIV status Individual level Population level 
Positive, n 
(CSMF; 
%/300) 
Negative, n 
(CSMF; %/23) 
Do not know, n 
(CSMF; %/33) 
K (95% CI) CCC ρC CSMF accuracy 
(%) 
CCCSMF 
accuracy (%) 
PCVA 283 (79.5) 255 (85.0) 6 (26.1) 22 (66.7) - - - - - 
InterVA-4* (44.7) (47.6)‡ (28.0)‡ (29.7)‡ 0.05 (0–0.13)§ −0.03§ −0.348 56.2 −18.9 
SmartVA-Analyze 80 (22.5) 69 (23.0) 3 (13.0) 8 (24.2) 0.04 (0–0.09) −0.52 −0.998 28.3 −94.8 
*InterVA-4 CSMFs calculated from all assigned CoD with associated likelihoods 
†Answers of ’Do not know’ listed as ‘Negative’ for purposes of comparison 
‡CSMF calculated separately per stratum  
§Measures of individual agreement for InterVA-4 calculated using individuals assigned HIV/AIDS as ‘most likely’ CoD (n=166) 
 
CCC: chance-corrected concordance; CCCSMF: chance-corrected cause-specific mortality fraction; CCVA: computer-coded verbal autopsy; CI: confidence interval; CoD: cause of 
death; CSMF: cause-specific mortality fraction; K: Cohen’s kappa; PCVA: physician-certified verbal autopsy; ρC: Lin’s concordance correlation coefficient; VA: verbal autopsy 
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Figure 6:2. Venn diagram illustrating the number of confirmed HIV-positive individuals assigned HIV-associated CoD 
by the three VA methods and overlap between methods (n, [%/356]) 
 
CoD: cause of death; PCVA: physician-certified verbal autopsy; VA: verbal autopsy 
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Table 6:4. Number assigned (n=459) and specificity of three VA methods in assigning HIV-associated causes of death, 
compared to confirmed (n=103) and VA-reported (n=153) HIV status 
VA method Number assigned an HIV-
associated CoD, n (CSMF; 
%/459) 
Specificity of VA method 
Based on confirmed 
serostatus (95% CI)† 
Based on VA-reported HIV 
status (95% CI)‡ 
PCVA 287 (62.5) 96.1 (90.4–98.9) 81.0 (73.9–86.9) 
InterVA-4* (37.1) 89.3 (81.7–94.5)§ 83.0 (76.1–88.6) 
SmartVA-Analyze 85 (18.5) 95.1 (89.0–98.4) 90.2 (84.3–94.4) 
* InterVA-4 CSMFs calculated from all assigned CoD with associated likelihoods 
† n=103 individuals confirmed HIV-negative 
‡ n=153 individuals reported HIV-negative or with HIV status unknown 
§ Individuals considered ‘test positive’ if HIV/AIDS assigned as most likely CoD (n=177)  
AIDS: acquired immune deficiency syndrome; CI: confidence interval; CoD: cause of death; PCVA: physician-certified 
verbal autopsy; VA: verbal autopsy 
6.2.5. Discussion 
The VA question regarding HIV diagnosis showed moderate to high sensitivity and specificity in correctly identifying HIV 
status.  Questions added by the research team regarding ART initiation were also sensitive and a high number of ART 
initiation dates obtained from VA were within three months of the confirmed date from clinical records.  VA 
interpretation methods differed widely in their estimation of the HIV-associated mortality fraction among individuals 
confirmed HIV-positive; in particular, estimates by both CCVA methods were likely considerably lower than the true 
fraction. All VA interpretation methods showed high specificity in assigning HIV-associated CoD. 
6.2.5.1 Detecting HIV prevalence and ART initiation 
The moderate-to-high sensitivity and specificity of the HIV question in detecting HIV status seen here and in a study 
conducted in Malawi (sensitivity 83%, specificity 98%; n=842) [42] suggests that VA may be useful in generating 
estimates of HIV prevalence among deceased individuals.  However, sensitivity was lower when tested in a larger, more 
diverse population: a study conducted across six sites in Uganda, Tanzania, Malawi, Zimbabwe, and South Africa 
between 1990 and 2011 focused primarily on estimating the specificity of InterVA-4 in diagnosing HIV-associated CoD 
[29]; crude estimates of sensitivity and specificity of the VA instrument in detecting HIV status can, however, be derived 
from the data presented (sensitivity 33.7% [95% CI 32.1–35.5], specificity 93.6% [95% CI 92.5–94.6]; n=4899).  
Differences in sensitivity estimates may be attributable to increases in awareness, increases in availability of testing, 
and reductions in stigma over time, particularly as the multi-country study analysed deaths that occurred over a 20-
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year period [29].  In the Malawian study, the proportion of respondents reporting knowledge of HIV status increased 
from 48% in 2003/04 (n=300) to 99% in 2013/14 (n=303) [42].  The consistent estimates of high specificity suggest that 
VA is unlikely to overestimate HIV prevalence; further evaluations of the VA question are needed, including re-analysis 
of existing raw VA data from HDSS sites, to better assess its sensitivity and suitability for assessing HIV prevalence in 
different contexts. 
The only other study reported  to have evaluated the sensitivity and specificity of VA questions in detecting ART use 
estimated them at 92% and 46%, respectively (Malawi, 2009–2014, n=154) [42].  The low specificity seen also in our 
study suggests a need to further refine questions around ART; HIV-positive individuals are often prescribed several 
different drugs and confusion among VA respondents is understandable.  Inclusion of variants of these questions in 
future VA validation studies is recommended.   
6.2.5.2 Estimating HIV-associated mortality 
The high specificity of VA interpretation methods in assigning HIV-associated CoD seen in our study is consistent with 
previous evaluations.  Several studies have described the specificity of PCVA in Uganda (92%, n=155) [43]; Tanzania 
(89%, n=168) [44]; and Malawi (99%, n=498) [30].  In the multi-country study referred to above [29], InterVA-4 assigned 
an ‘HIV/AIDS’ CoD with a specificity of 90.1% (95% CI 89–91; n=4629); a smaller evaluation of InterVA-4 in Malawi 
produced similar results (90.3% [n=498], derived from data presented) [30]; and specificities of 77% and 78% from two 
studies in Ethiopia were reported in a systematic review of VA accuracy among hospitalised patients [45].  No studies 
were found in the literature that assessed SmartVA-Analyze in this way. 
The consistently high specificity of VA interpretation methods suggest that they are unlikely to overestimate HIV-
associated mortality.  Estimating the sensitivity of a VA method, however, is challenging even when high-quality data 
are available, given the inherent uncertainty involved in assigning CoD.  Only one study, in South Africa, has compared 
VA to CoD derived from pathological autopsy in HIV-positive individuals, and found that VA methods likely 
underestimated HIV-associated CoD [46].  In part due to challenges with ICD coding, there are few direct (autopsy or 
clinical) estimates of the HIV-associated mortality fraction among HIV-positive adults.  A recent systematic review, 
which included only studies of HIV-positive individuals entirely or mostly on ART (n=19 studies), estimated that 18.5% 
(95% CI 13–24) of deaths in HIV-positive individuals on ART in sub-Saharan countries were due to ‘non-AIDS’ causes 
(therefore 76–83% due to AIDS causes) [25].  This review, however, treated deaths due to ART toxicity as ‘non-AIDS’, 
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which may have led to an underestimation of overall HIV-associated mortality.  In populations containing fewer 
individuals on ART, the HIV-associated mortality fraction is likely to be even higher, as seen in several pathological 
autopsy studies [47].  In our study, only PCVA estimated an HIV-associated mortality fraction close to the figure above 
(79.5%); estimates by both CCVA methods were much lower (44.7% and 22.5%).  A high number of individuals in our 
study had not initiated ART; CCVA-generated estimates are therefore likely much lower than the true HIV-associated 
mortality fraction in this population.   
6.2.5.3 CRVS integration 
Plans are underway to integrate VA into CRVS systems [48–50], a proposal in part made feasible by the increased 
efficiency of CCVA methods.  Data from this and other studies, however, suggest that the two most prominent CCVA 
methods are not, as yet, sensitive or consistent enough in assigning HIV-associated CoD in areas of high HIV prevalence 
[46,51].  Both methods likely allocate insufficient weight to the question regarding HIV diagnosis, which has now been 
shown to be sensitive and specific in Malawian and South African contexts.  InterVA-4 assigns CoD based on a 
probabilistic algorithm, which weights particular questions per the recommendations of a panel of expert physicians, 
convened in 2006 [52].  In our study, physicians directly reviewing VA data gave the answer to the HIV question high 
importance, assigning an HIV-associated CoD to 85% of those reported HIV-positive and to 67% of cases where the 
respondent answered ‘Do not know’ (compared to 47% and 30% by InterVA-4 and 23% and 24% by SmartVA-Analyze 
[Table 6:4]).  In part, this is likely because all ‘Do not know’ answers are converted to ‘No’ by both CCVA methods.  
Along with adjustments to weighting, an ability to differentiate between the two answers may be needed in the 
interpretation of key questions such as this.   
SmartVA-Analyze is calibrated using CoD from the PHMRC gold standard dataset, which includes over 12,000 deaths 
from India, the Philippines, Mexico, and Tanzania [53,54].  Of 7,841 adult deaths, 443 (5.5%) were reported as HIV-
positive during VA (227 [51%] in Tanzania) and 501 (6.4%) were assigned an ‘AIDS’ CoD by clinical methods.  Even in Dar 
es Salaam, the site with the highest background HIV prevalence [55], the number of deaths among adults aged 15–49 
years considered due to AIDS was 158/983 (16.1%); cause-specific estimates from the Global Burden of Disease study 
for the same period (2007–2010) suggest that HIV/AIDS accounted for 52–58% and 67–71% of deaths among 
individuals aged 15–49 years in Tanzania and South Africa, respectively [56].  Despite the random resampling of 
datasets conducted as part of the model’s training [53], it is unlikely that CSMFs will have been generated with HIV-
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associated mortality fractions as high as seen in populations such as these, suggesting that recalibration may be needed 
for SmartVA-Analyze to be used more widely in areas of high HIV prevalence.   
6.2.5.4 Next steps 
The challenges involved in producing accurate estimates of HIV incidence, prevalence, and mortality are well 
documented [6,57].  Though changes in CSMFs may be estimated through measurement of mortality at a population 
level, the UNAIDS goal of less than 0.5 million HIV-related deaths by 2020 calls not for a reduction in the mortality 
fraction, but for an absolute reduction in events [2], which will require more accurate methods to identify individual 
HIV-associated deaths.  Additionally, with patterns of HIV-associated mortality likely to undergo major change in the 
coming years, current definitions may not allow for all HIV-associated deaths to be counted [31].  The only reliable way 
to track progress towards this goal is if all-cause mortality among HIV-positive individuals is regularly estimated.  
Current classification systems require alterations that will allow for the identification of all deaths in HIV-positive 
individuals and better predict possible changes in mortality patterns through increased availability of ART.  ICD-10 was 
adapted by WHO in 1994 and ICD-11 is not due for release until 2018 [58].  A system with greater flexibility, through 
shorter or partial revision cycles, would allow for more adaptability in the face of an evolving epidemic.  In the short 
term, other methods may provide useful data in monitoring changes in mortality patterns: a recent study from 
Mozambique found good agreement between CoD assigned by minimally-invasive autopsy and complete autopsy [59].  
These findings, and previous evaluations of this technique [60–62], suggest it may be useful in providing more accurate 
CoD data in LMIC as an adjunct to surveillance at sentinel sites. 
6.2.5.5 Limitations and strengths 
This study had limitations.  The relatively low number of HIV-negative individuals reduced the accuracy of specificity 
estimates and, despite best efforts, the HIV-positive and HIV-negative groups were not age-matched.  HIV is generally 
less likely to be considered as CoD in older individuals [63], though recent data from South Africa suggest this may no 
longer be appropriate [64], and the higher median age of those HIV-negative may have led to overestimation of the 
specificities of both the HIV diagnosis question in detecting HIV status and VA methods in assigning HIV-associated CoD.  
Estimates of the question’s sensitivity, however, should not have been affected.   
There were limitations also in the evaluation of VA interpretation methods.  Physicians assigning CoD were aware that 
some decedents were likely to have been enrolled in studies of HIV/TB and this may have led to their assigning higher 
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numbers of HIV-associated CoD.  The PHMRC VA instrument was not used for data collection and SmartVA-Analyze was 
not provided with narrative or health care experience data, which may have led to sub-optimal performance of the 
software, although the omission of these data will likely have had minimal effect, as the phrases ‘HIV’ or ‘AIDS’ are not 
classed by the software as words of interest [65]. Clinical reference CoD were not available for all decedents, meaning 
the sensitivity of VA methods in assigning HIV-associated CoD could not be assessed.   
This study’s strengths include having laboratory- or rapid test-confirmed HIV status for all those included in the analysis; 
the median time from HIV-negative test to death being two weeks, with 75% of HIV-negative individuals with a test 
result less than two months before death; and using the three leading VA interpretation methods to estimate the HIV-
associated mortality fraction among HIV-positive individuals, something not previously done in VA studies.  
6.2.6. Conclusions 
VA interpretation methods gave very different estimates of HIV-associated mortality and CCVA methods 
underestimated the HIV-associated mortality fraction.  However, VA questions were sensitive and specific in detecting 
HIV status and sensitive in detecting ART initiation.  The addition of an HIV/TB module to the VA instrument, including 
questions on treatment dates and adherence, is suggested; future VA validation studies should be used to trial new or 
modified questions prior to inclusion in the standardised VA instrument.  Modifications to classification systems are 
needed that allow for the inclusion of presumed non-HIV-associated deaths within estimates of mortality among HIV-
positive individuals; closely aligned is a need for more accurate direct estimates of HIV-associated mortality to better 
track progress towards goals set by UNAIDS. 
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6.4. Supplementary information 
Supplementary table 6:1. Questions regarding antiretroviral therapy and treatment for TB added to the WHO 2012 
VA instrument by the study team and the parent questions to which they were attached 
From WHO 2012 VA 
instrument 
Added by study team 
Parent question 
Sub-question(s) 
(if parent question = ‘Yes’) 
Sub-sub-question(s) 
(if sub-question = ’Yes’) 
Was there any diagnosis of 
Tuberculosis? 
Did s/he ever take treatment for 
TB from a clinic/hospital? 
When did s/he start TB treatment?  (If treated 
more than once, record the most recent episode) 
Which clinic/health facility did s/he attend most 
recently (name)? 
Location of clinic/health facility (nearest town) 
Were they still taking TB treatment at the time of 
death? 
If TB treatment was stopped early why was that? 
Was s/he taking medication every day in the way 
they s/he was supposed to? 
Was there any diagnosis of 
HIV/AIDS? 
Did the deceased ever take 
Antiretroviral Therapy (ART)? 
When did s/he start ART? 
Which clinic/health facility did s/he attend most 
recently (name)? 
Location of clinic/health facility (nearest town) 
Were they still taking ART at the time of death? 
If ART was stopped, why was that? 
Was s/he taking the medication every day? 
AIDS: acquired immune deficiency syndrome; ART: antiretroviral therapy; HIV: human immunodeficiency virus; TB: 
tuberculosis; VA: verbal autopsy; WHO: World Health Organization 
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7.1. Introduction 
This thesis aimed to describe the spectrum of disease and causes of death in HIV-positive adults dying in South Africa.  I 
endeavoured to do this through analysing novel data, collected from a population of mostly HIV-positive adults in South 
Africa, using MIA, VA, and abstraction from a variety of clinical sources, and through reviewing published reports of 
studies from LMIC describing tissue autopsy findings in HIV-positive adults, validation of VA for HIV- and TB-associated 
deaths, and directly estimated causes of death in HIV-positive adults.  This chapter will provide a summary of the data 
presented in the thesis and relate the main findings to the existing literature; discuss some of the implications and 
potential applications of the work presented; examine the limitations of the methods used and some of the challenges 
faced in data collection and analysis; and present a summary set of recommendations and conclusions drawn from the 
findings described. 
7.2. Discussion of findings and comparisons with literature 
7.2.1. Prevalence of TB at autopsy is high among HIV-positive adults in LMIC 
As detailed in Chapter 4, MIA was conducted in 34 HIV-positive adults who died after enrolment to the TB Fast Track 
study; evidence of active TB disease was found in 16 (47%) decedents, 14/16 (88%) individuals had extrapulmonary 
disease, and six (38%) had not been started on TB treatment between enrolment and death.  Although the autopsy 
prevalence of TB in the Lesedi Kamoso study was similar to pooled estimates of prevalence from the 2015 systematic 
review by Gupta et al. [71] (discussed in more detail below and in Chapter 2.2.4.1.1) and more recent studies from 
Uganda [94] and Zambia [180], it is important to note that the individuals included in our study were enrolled in 
primary care clinics and followed-up prospectively, something not done before in studies in LMIC, and that around 25% 
died out of hospital.  The majority of individuals included in previous autopsy studies were recruited and died in 
hospitals (see Chapter 2.2.3.2).  Together with findings from a community-based autopsy study by Omar et al. [97] 
(which found high TB prevalence but did not report on the HIV status of decedents), and despite the relatively small 
sample size and potential lack of representativeness of the general HIV-positive population (see Chapters 4.2.5.3 and 
7.4.1, below), our data suggest that TB is as important a cause of morbidity for individuals who receive most of their 
care in the community as it is for those treated mostly in secondary care. 
The results from our field research are broadly supportive of the findings of my review of autopsy studies, presented in 
Chapter 2.2, which included data from over 5,000 autopsies in HIV-positive adults conducted between 1984 and 2013.  
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Evidence of active TB was found in around 37% (crude summary estimate) of the 2,999 autopsies that included the 
lungs, in around 18% of 971 autopsies that sampled only extra-pulmonary tissue, and in over 30% of 58 autopsies in 
studies that excluded individuals with an ante mortem diagnosis of TB.  The heterogeneity of laboratory testing 
methods used, the differences in autopsy methods (complete vs. minimally-invasive approaches), and the estimation 
only of crude prevalence, without attempt at meta-analysis, all reduce the external validity of the summary results 
presented in this review.  However, the inclusion of a range of studies with varying inclusion criteria also allowed for 
review of data that may not have been included by an attempt at more rigorous meta-analysis, as conducted by Gupta 
et al. in their systematic review of 2015 [71]. 
My review included 53 autopsy studies, 25 of which were also included the systematic review by Gupta et al., where 
they found similar (or higher) pooled prevalence of TB overall (40% [95% CI 32–47]) and in sub-Saharan Africa only (43% 
[95% CI 38–48]), as well as, among those with evidence of TB at autopsy, similar prevalence of extrapulmonary disease 
(88% [95% CI 82–97]) and proportions of individuals who were not diagnosed before death (46% [95% CI 33–59]).  The 
criteria for inclusion in the Gupta review were much narrower than those I used in this thesis.  As a result, the pooled 
summary estimates presented by the authors are likely more representative of the autopsy prevalence of TB among 
HIV-positive people in LMIC overall, particularly as the authors specifically excluded studies that focused on “sub-
populations with potentially limited generalizability”, such as mine-workers or pregnant women, and those with a 
specific diagnosis, such as TB.  The use of these narrow criteria, however, also means that estimates of autopsy 
prevalence of disease in these sub-populations were not included; comparing these data with more general estimates 
of prevalence would be useful, as strategies for prevention, diagnosis, and treatment are sometimes very specific to 
certain groups (e.g., mine-workers) and knowledge of differences in disease patterns may help to refine these 
approaches.  In addition, the exclusion from the Gupta review of studies that included only individuals with a prior 
diagnosis of TB is a missed opportunity to examine the specificity of current TB diagnostic practices.  A recurring theme 
in the debate around strategies to reduce mortality in individuals with advanced HIV is the value (or perceived lack 
thereof) of empiric TB treatment in this group [335,336] (for example, the hypothetical benefit of this approach was 
central to the design of the TB Fast Track study [148,155]).  As is the case for HIV-related deaths, we do not, at present, 
have a reliable way to differentiate between people dying from TB and those dying with TB [337]; evaluation of the 
prevalence of TB disease among individuals who die after starting treatment for TB may be one way to help make this 
distinction. 
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My review of the literature does fill some of the gaps left by the Gupta review; the inclusion of a much wider range of 
studies means that data are available for some of the key groups discussed above.  For example, the seminal work of Jill 
Murray and colleagues among mine-workers in South Africa is described [227] (TB was found in the cardiorespiratory 
organs of 21% of HIV-positive individuals), as is the study by Neil Martinson et al. [87], where autopsy evidence of TB 
was found in 79% of 47 individuals diagnosed with TB in a Johannesburg hospital.  Importantly, my review included 
several studies which described findings only from extrapulmonary sites, something explicitly excluded by the Gupta 
review.  As discussed in Chapter 2.2.4.1.1, the exclusion of these data from the systematic review may have led to the 
underestimation of overall TB prevalence at autopsy; these data can also be used to guide future efforts to diagnose TB 
disease in living patients. 
7.2.2. TB is a leading cause of death in HIV-positive adults in LMIC 
Data presented in this thesis, both from direct estimation of cause-specific mortality in HIV-positive people in South 
Africa using clinical, research, and autopsy data (Chapter 5), and from the systematic review of studies estimating 
cause-specific mortality in HIV-positive people dying in LMIC (Chapter 3), suggest that TB remains a leading cause of 
death in those who have access to ART and who initiate ART before death.  As discussed in more detail below, this is 
likely to be largely because individuals start ART when their HIV disease is already at an advanced stage and the risk of 
death is extremely high.   
Of the 259 HIV-positive adults assigned a ‘Level 2’ reference cause of death by clinical reviewers in the Lesedi Kamoso 
study (i.e., using clinical and research data, but not pathological data; Chapter 5.2.3.3.2), at least 69 (27%) were thought 
to have died from HIV-associated TB; 51/69 (74%) had initiated ART between enrolment and death (median 63 [IQR 30–
125] days before death; n = 46).  Among the 34 individuals with autopsy data available (also included in the 259 above), 
14 (41%) were thought to have died from HIV-associated TB; 10/14 (72%) initiated ART after enrolment, a median 53 
(IQR 30–108) days before death (Tables 5:3 and 5:4).  Similarly, in the systematic review of studies that directly 
estimated causes of death in HIV-positive adults in LMIC, presented in Chapter 3, a pooled 29% (95% CI 24–34; random-
effects meta-analysis; n = 47 studies; n = 7,990 deaths) of decedents were assigned a TB cause of death.  This 
proportion did not change with the proportions of individuals initiated on ART per study (pooled 28% in 17 studies 
where <33% of participants initiated ART vs. 26% in 17 studies where >66% initiated ART; p = 0.52), though time 
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between ART initiation and death was reported by very few studies (Chapter 3.2.4.4.1).  TB was considered the cause of 
death in a pooled 39% (95% CI 33–46) of individuals assigned an HIV-associated cause of death (n = 5,688). 
There is evidence from large, population-based studies to support the assertion that ART is driving a reduction in 
overall mortality among HIV-positive people [264,272,338], and that it is starting to create a shift in cause-specific 
mortality patterns away from causes associated with immunosuppression, towards causes seen more often in the HIV-
negative population [339,340].  This is also one of the main findings of Chapter 3, a systematic review of studies 
assigning causes of death at an individual level, where the proportion of deaths attributable to HIV-associated causes 
was seen to have an inverse relationship with the proportion of decedents in each study who had initiated ART (85% if 
<33% initiated ART, 75% if 33–65% initiated ART, and 71% if ≥66% initiated ART; p = 0.02).  However, despite good 
evidence to support the use of ART to reduce TB incidence among HIV-positive people overall [341] and reduce 
mortality among HIV-positive people receiving treatment for TB [342], changes such as those described above for all 
HIV-associated causes of death do not, as yet, appear to be taking place for overall mortality due to HIV-associated TB; 
estimated absolute numbers of deaths due to HIV-associated TB published by WHO have remained relatively static over 
the last 10 years (from ~480,000 in 2005 to ~390,000 in 2015; see Chapter 3.2.5.1). 
Individuals with severe immunosuppression are at higher risk of death overall and particularly from death associated 
with HIV-associated TB [343–345]; the relatively small reduction in global HIV-associated TB-related mortality since the 
introduction of ART suggests that there remains a substantial proportion of the HIV-positive population who either do 
not have access to ART, or whose access to care is delayed to the point where ART alone is not enough to reduce 
sufficiently their risk of premature death.  In the systematic review in Chapter 3, in the few included studies in that 
reported it, the median time from ART initiation to death was often less than 90 days, as was the median time on ART 
among individuals in the Lesedi Kamoso study who were assigned TB causes of death.  Systematic reviews have 
consistently shown that overall mortality among HIV-positive individuals in LMIC, particularly those with low CD4 
counts, is high in the first 3–6 months after initiating ART [23,25].  Encouraging all HIV-positive people to start ART, 
regardless of CD4 count or disease stage [346,347], will hopefully prevent individuals from ever becoming so severely 
immunosuppressed.  Broader interventions to strengthen health systems, minimise barriers to care, and improve 
adherence to treatment [348,31,349,350] will also be critical in shaping a sustainable strategy to reduce HIV and TB 
mortality in the next decades. 
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7.2.3. Methods used to estimate causes of death in HIV-positive individuals are sub-optimal 
Though several studies include estimation of cause-specific mortality and discussion around the potential implications 
of excessive mortality due to specific causes, particularly TB, in HIV-positive people, the process of estimating cause-
specific mortality is less well discussed; methodological discussions appear to be reserved mostly for editorials or the 
appendices of statistical reports [351,72,84,85,11].  An issue that emerged several times in the development of this 
thesis is the high uncertainty around estimates of cause-specific mortality in HIV-positive individuals, most importantly 
around estimates of mortality due to HIV-associated TB (Chapters 1.2.2, 2.3.1, 3.2.2, 3.2.5.3, and 5.2.5.1).  Some of this 
is due to the inherent difficulty in assigning causes of death in these individuals, particularly those with advanced 
immunosuppression, who may have several disease processes underway at one time.  For example, among the 34 
individuals in whom we conducted MIA as part of the Lesedi Kamoso study, 20 (59%) had culture and/or histological 
evidence of two or more infections at the same or different sites (Chapter 4.2.4.6 and Figure 4:2).  In the autopsy 
studies reviewed in Chapter 2.2, high proportions of decedents had other infections: 19% had evidence of bacterial 
pneumonia, a further 10% evidence of other bacterial infections; 17% CMV disease; 16% toxoplasmosis; 10% 
Pneumocystis pneumonia; and 9% cryptococcal disease (crude summary estimates; Chapter 2.2.3.4 and Figure 2:2); any 
one of these conditions may lead to death in an individual with advanced HIV disease.  Few studies conducted non-TB 
cultures or reported systematically on co-prevalent infections, but when this was done, evidence of more than one 
infection was often found (>25% of decedents in two studies that did not use non-TB cultures [94,195]; >40% in one 
study that did conduct aerobic and anaerobic cultures [184]; Chapter 2.2.4.1.2).  When using study-defined codes to 
assign causes of death from data in the Lesedi Kamoso study, despite all decedents having been enrolled in large 
epidemiological studies and the extensive additional efforts undertaken to collect clinical and laboratory data, 69/259 
(27%) individuals were still assigned an ‘indeterminate’ cause of death by clinical reviewers (Chapter 5.2.4.4).  This was 
often because data were insufficient to make an assignment, or, more specifically, insufficient to distinguish between 
HIV-associated TB and other HIV-associated causes.  As discussed further below, even when sufficient data are available 
to make this distinction, however, ICD-10 conventions make this process more complicated. 
7.2.3.1 ICD-10 conventions are an obstacle to better estimates of mortality due to HIV-associated TB 
The ICD-10 system includes HIV-associated TB in one of five, broad ‘HIV’ categories; ‘TB’ definitions explicitly exclude 
HIV-associated disease (see Chapters 1.2.3.1, 2.3.1, and 5.2.2).  At a national level, most countries report only the 
three-character ICD-10 code, instead of the full, five-character code, of the single ‘underlying’ cause of death assigned 
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by automated systems such as MMDS and Iris (i.e., B20, “HIV disease resulting in infectious or parasitic diseases”, 
rather than B20.0, “HIV disease resulting in mycobacterial infection”).  This does not allow governing bodies and groups 
producing estimates of national and global burdens of disease to differentiate between mortality due to HIV-associated 
TB and other HIV-associated infectious diseases and means that national and global estimates of mortality due to HIV-
associated TB, even in many countries with functional civil registration systems, are generated through modelling of 
proxy measures, such as disease incidence and case-fatality rates, which are themselves often derived, in-part, from 
mathematical models [84]. 
I encountered these difficulties first-hand when conducting the work presented in this thesis.  For example, in the 
systematic review of studies directly estimating causes of death in HIV-positive individuals in LMIC, presented in 
Chapter 3, nine of the 56 studies included did not describe the proportion of HIV-associated deaths that were TB-
related.  The Lesedi Kamoso study set out, as much as possible, to produce data comparable with previous research and 
with international systems used to measure mortality.  Much of this involved ensuring that definitions and 
nomenclature were aligned with international norms, but we discovered that doing so would severely limit our ability 
to estimate mortality attributable to HIV-associated TB among decedents included in our study.  We were, therefore, 
required to create additional, study-specific cause of death categories to allow us to estimate this mortality fraction 
(Chapter 5.2.3.4); attempts to assess VA performance in this regard both in the literature (Chapter 2.3.3.2.1) and 
among decedents in our study (Table 5:5) were also hampered by ICD-10 coding conventions.   
7.2.3.2 VA does not differentiate well between HIV-associated TB and other HIV-associated causes of 
death 
VA is used routinely at HDSS sites in areas of high HIV and TB prevalence and VA data are increasingly being used to 
supplement to other sources of mortality data, for example, as part of large-scale exercises estimating cause-specific 
mortality (e.g., the Global Burden of Disease study, conducted by IHME [352]), or to help strengthen CRVS systems in 
specific countries [353,115].  To assess the ability of the three leading VA interpretation methods to estimate cause-
specific mortality among HIV-positive adults and, more specifically, mortality due to HIV-associated TB, I reviewed the 
literature around validation of VA for HIV- and TB-associated causes of death, and conducted a validation exercise as 
part of the Lesedi Kamoso study.    
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The review of the literature yielded 22 reference datasets that have been used to validate VA for HIV- and TB-
associated causes of death; they include over 26,000 deaths that occurred between 1990 and 2012, mostly in sub-
Saharan countries.  There was considerable heterogeneity between the reference standards used to validate VA 
interpretation methods, from the fundamental approach taken in assigning causes of death (at an individual level vs. at 
a population level), to the quality of the data, and the rigour of the process of assigning causes of death.  PCVA was the 
most accurate and precise method in assigning HIV-associated causes of death (sensitivity 65%–75%; specificity 85%–
95%).  In general, CCVA methods performed less well (sensitivity 25%–65%, specificity 80%–95%, chance-corrected 
concordance 35%–55%, and chance-corrected CSMF accuracy 70%–90%).  Only one study [290] attempted to 
differentiate between HIV-associated TB and other HIV-associated causes of death; it was therefore not possible, from 
the literature, to evaluate the overall accuracy of VA in estimating mortality due to HIV-associated TB.    
In the Lesedi Kamoso study, we compared VA-assigned causes of death with three ‘levels’ of reference standard, 
determined by the quality of data available.  VA data were interpreted by PCVA, InterVA-4.03 and SmartVA-Analyze 
v1.1.1; clinical and PCVA reviewers were asked to assign causes of death using both ICD-10 and six purpose-designed 
codes, specifically to try to estimate mortality due to HIV-associated TB.  In line with the findings of the literature 
review, PCVA performed best overall (CSMF accuracy 0.70–0.80 compared with level 2 or level 3 reference standards, 
using ICD-10 or study-defined codes; Chapter 5.2.5.4) and automated VA methods generally underestimated the 
proportion of mortality due to HIV/AIDS (sensitivity 30%–55%); this was the case whether or not autopsy data had been 
used to inform the reference standard.  Agreement between VA methods and the reference standard was uniformly 
poor at individual level, but was slightly better at population level, particularly for PCVA (Table 5:3).  
7.2.3.3 Automated VA methods underestimate overall HIV-associated mortality among HIV-positive 
people 
In addition to the 259 HIV-positive adults analysed in Chapter 5, the analysis presented in Chapter 6 included a further 
200 adult decedents (97 HIV-positive and 103 HIV-negative), all of whom had VAs completed.  Reference causes of 
death were not available for all decedents; instead, this analysis focused on evaluating the sensitivity and specificity of 
the ‘HIV diagnosis’ question in the WHO 2012 VA instrument in assigning HIV status, and the specificity of VA methods 
in assigning HIV-associated causes of death, using laboratory- or rapid test-confirmed HIV status as a reference 
standard.   
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Among 459 individuals with confirmed HIV status (n = 356 HIV-positive; n = 103 HIV-negative), the HIV diagnosis 
question was sensitive (84% [95% CI 80–88]) and specific (94% [95% CI 88–98]) in assigning HIV status.  Only one 
previous study, conducted in Malawi in 2016 [303], formally assessed the sensitivity and specificity of the VA question 
around diagnosis of HIV; results from that study were similar to ours, suggesting that algorithms used to interpret VA 
data should perhaps be recalibrated to give greater weight to the answer to this question.  Among the 306 decedents 
who were reported HIV-positive by VA, a question added to the VA instrument, “Did the decedent ever take ART?”, was 
91% sensitive and 53% specific in detecting ART use.  Again, only the study from Malawi had previously assessed this 
question, finding it 92% sensitive and 46% specific [303].  These findings suggest that, after refinement to improve 
specificity, this question should be included in the standard VA instrument (which it has been, in the 2016 instrument 
[107]), and the answers included in the algorithms used to assign causes of death in areas of high HIV prevalence.   
The process of empirically evaluating individual questions and, if needed, adjusting them before including them in the 
standardised instrument should, ideally, be adopted for future changes to VA instruments.  This will allow for questions 
to be piloted in a range of contexts, and for their relative weight to be assessed when considering the makeup of 
diagnostic algorithms.  It is not clear as to how much of this has been done for existing VA questions, but raw VA 
interviews, of which there are thousands at HDSS sites across Africa and Asia, could be used to test, retrospectively, 
particular questions of interest if a reference standard were available.  This is not, of course, always as straightforward 
as is the case for a diagnosis of HIV, where the line between positive and negative is very well defined.  However, if VA 
instruments and methods are to be refined to the point where they can reliably estimate causes of death in individual 
decedents, continuous validation, at as granular a level of detail as possible, may be needed. 
In the second part of the analysis in Chapter 6, all three VA interpretation methods showed high specificity in assigning 
HIV-associated causes of death (PCVA 96%, InterVA-4 89%, and SmartVA-Analyze 95%).  However, agreement between 
the three methods was poor at individual and population level (chance-corrected concordance <0; chance-corrected 
CSMF accuracy <0%).  CCVA methods, in particular, appeared to underestimate the HIV-associated mortality fraction: 
when the analysis was restricted to confirmed HIV-positive individuals only (n = 356), InterVA-4 and SmartVA-Analyze 
assigned 45% and 22% of decedents, respectively, an HIV-associated cause of death.  The consequences of this for 
countries with high HIV prevalence are potentially very important.  As discussed in Chapter 3 (a systematic review of 
studies directly estimating causes of death in HIV-positive adults) and in Chapter 7.2.2, above, HIV-associated causes 
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still account for a high proportion of overall mortality among HIV-positive people in LMIC.  Classification systems do 
not, at present, allow for adjustments to be made to the definition of what does and does not constitute an ‘HIV-
associated’ death, based on changes in disease and mortality patterns that may be observed as greater numbers of 
people are initiated on ART (see Chapter 7.3.3 for a more detailed discussion).  The current draft of the ICD-11, due for 
release in 2018, appears not to address this issue either, with HIV-associated deaths now classified by ‘clinical stage’, 
rather than more objective measures [354], and the continued absence of a way to record all deaths among HIV-
positive individuals.  As mentioned above, VA is being integrated into CRVS systems in several countries [115]; the 
underestimation of HIV-associated mortality in countries with high HIV prevalence may have serious negative effects on 
funding streams and overall efforts to reduce morbidity and death. 
7.3. Implications of this work 
7.3.1. For clinical practice and policy 
TB disease was not diagnosed ante mortem in 6/16 (37.5%) individuals with autopsy evidence of TB (Chapter 4), 
something also found in several previous autopsy studies [71].  This, in addition to the underestimation of HIV-
associated TB mortality by physicians reviewing clinical data that did not include findings from pathological autopsy 
(Chapter 5), suggests that clinicians likely underestimate both the prevalence of TB disease and its contribution to 
mortality in HIV-positive adults.  As discussed in Chapter 5.2.5.1, the historic focus on cough as the key to TB diagnosis 
(which may have been sufficient in the pre-HIV era) and reliance on sputum-based investigation, including Xpert 
MTB/RIF, likely lead physicians not to consider or to discount prematurely a TB diagnosis in HIV-positive individuals 
without cough or with negative results from sputum [64].   
The very high proportions of individuals with TB who had extrapulmonary and/or disseminated disease seen in our and 
previous autopsy studies suggests that alternative diagnostic strategies, including, but not limited to, non-pulmonary 
imaging and testing of extrapulmonary samples [355,356], should be employed in those at highest risk of disease.  
These are often individuals in whom routine, sputum-based diagnostic methods are less sensitive and for whom the 
consequences of a missed diagnosis very severe.  Recent studies exploring the diagnostic value of testing non-
pulmonary samples in HIV-positive individuals have shown encouraging results [357,245,358,359].  However, there 
remains a need for a cheap, sensitive, point-of-care test that allows for detection of TB disease, especially 
extrapulmonary disease, in these individuals [62]. 
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Further challenges are illustrated by the findings at MIA, of multiple, concomitant infections in individuals with 
advanced HIV and by some of the difficulties faced by reviewing physicians in assigning causes of death, even when 
provided with extensive clinical data.  These are complex patients, with many competing risks, and integrated strategies 
are needed if morbidity and mortality are to be successfully reduced.  Supporting this is evidence from studies directly 
estimating causes of death in HIV (Chapter 3), which suggests that making ART available, alone, may not be enough to 
reduce HIV-associated TB mortality at the desired rate.  Many of the individuals who die from HIV-associated TB are 
severely immunosuppressed; interventions are therefore needed that promote the early identification and treatment 
of these individuals before they reach these levels of immune compromise.  In addition to better TB diagnostics and 
streamlined diagnostic pathways [360], systemic interventions are needed that reduce delays within the health system; 
minimise loss to follow-up at various points in the treatment cascade, and promote, measure, and reinforce adherence 
to ART [361].  A cohesive ‘package of care’ is needed for these patients, particularly at hospitals, but ideally even at 
community clinics.  Encouragingly, in 2017, WHO published guidelines for the management of individuals with 
advanced HIV disease [362], which talk to the importance of “differentiated service delivery” in maximising the capacity 
of a health system to manage, optimally, patients who are most ill. 
Underlying all these issues is a need to better understand the structural, socio-economic, and behavioural factors that 
have enormous impacts on clinical outcomes, but are too often unaccounted for in the development of biomedical 
interventions [363,364].  VA narratives, collected as part of the interviews, are a potential source of rich and diverse 
data and may provide some insight into the beliefs, practices, and actions that may contribute to adverse outcomes. 
7.3.2. For HIV & TB surveillance 
Many of the difficulties involved in diagnosing TB disease in life also affect estimates of TB-associated mortality.  In the 
meta-analysis of directly estimated causes of death in HIV-positive adults, presented in Chapter 3, estimates of the TB-
specific mortality fraction among HIV-positive individuals from studies that did not use autopsy data were lower than 
estimates from those that did (pooled prevalence 24% without autopsy data [n = 29 studies] vs. 37% with autopsy data 
[n = 18 studies]).  Estimates of TB-specific mortality derived from death certificates or PCVA also rely on physician 
recognition of TB as a potential cause of death.  As discussed above, this is guided by the presence of symptoms, 
particularly cough, and/or the results of sputum-based investigations, both of which are unreliable indicators of disease 
in individuals with advanced HIV.   
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This highlights a more fundamental problem regarding TB surveillance, that the majority of surveillance activities in 
high-burden settings generally focus on individuals in whom a TB diagnosis has been confirmed or TB treatment started 
[365–367].  WHO guidance states that a “major goal of TB surveillance is to provide an accurate measure of the number 
of new TB cases and related deaths” within the population in question [368].  These are, by definition, individuals who 
have engaged, at least briefly, with health services; as the guidelines go on to concede, for notification data to provide 
accurate estimates of TB incidence, the fraction of undiagnosed cases must be negligible, requiring not only a well-
functioning health system and diagnostic infrastructure, but also good access to care for the majority of the population 
[368].  The lack of a sensitive test for HIV-associated TB, particularly extra-pulmonary TB, in individuals with advanced 
HIV disease and the documented gaps in health systems in the areas most affected by the HIV and TB epidemics 
[369,370] suggest that these criteria are often not met (see also Chapter 1).   
Including estimates of undiagnosed disease in routine surveillance may be one way to provide more comprehensive 
data around TB control in high-burden settings.  Additionally, as it requires acknowledgment of the burden of 
undiagnosed disease, this may allow for more realistic target-setting and resource allocation.  To do this in practice 
would, of course, be challenging; the validation of estimation methods would be difficult and their implementation 
logistically complex.  One approach may be to use MIA to estimate the prevalence of disease among individuals who die 
within the catchment areas of sentinel surveillance sites.  The Lesedi Kamoso study has shown that this can be done in 
community mortuaries in urban and semi-rural settings in South Africa (Chapter 4) and several studies have shown the 
sensitivity of the procedure in estimating the prevalence of infectious diseases at death, particularly TB [94,99,95] (see 
also Chapter 4.2.2).  The collection of viable samples, including for aerobic culture, in community settings, as well as 
high consent rates among families and TB Fast Track participants, add to the growing body of evidence [184,98] 
regarding the acceptability of MIA among families (and, for the first time, among a large group of adults with advanced 
HIV disease) and the feasibility of conducting community-based autopsies.  The development of a standardised, cost-
effective protocol for the autopsy procedure, laboratory testing, and interpretation of results that could be 
implemented at sentinel surveillance sites in resource-limited settings is an achievable goal, and would provide quality 
data to allow better monitoring of progress towards the global goals for reducing HIV- and TB-associated mortality. 
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7.3.3. For international disease classification systems 
The problems with ICD-10 around classifying HIV-associated TB have been discussed at length above; the addition of a 
specific three-character code for HIV-associated TB would improve the accuracy of national and global estimates of TB 
mortality, particularly in countries where CRVS networks are already established.  In the interim, studies using or 
evaluating any method(s) to assign causes of death in HIV-positive individuals, including VA, should, whenever possible, 
aim to separate HIV-associated TB from other HIV-associated causes.   
Less well discussed in the literature is a second issue with ICD-10, that a death due to the adverse effects or toxicity of 
ART may not necessarily be counted as ‘HIV-associated’.  There are already real-world examples of the confusion this 
may create: the systematic review of ‘non-AIDS’ mortality by Farahani et al. [340] (discussed in detail in Chapter 3.2.5) 
considered deaths due to ART toxicity as ‘non-AIDS’, which is technically correct, but runs contrary to guidance from 
WHO, which states that ART toxicity should be included in estimates of HIV mortality [371].  This leads to the 
underestimation of overall HIV-associated mortality, which may have severe repercussions for the structures of 
national health systems and funding streams (see also Chapter 6.2.5.2).  At present, we rely on observational studies or 
secondary analyses from trials for estimates of ART-associated mortality in LMIC and do not have reliable estimates of 
all-cause mortality among HIV-positive individuals.  A more efficient system for monitoring mortality among HIV-
positive individuals would be one that is integrated into our existing (and developing [114]) notification systems, 
allowing for consistent measurement across greater numbers of individuals in different contexts. 
This is particularly relevant because of the widespread demographic changes being seen in disease and mortality 
patterns among HIV-positive people on ART [26]; individuals who initiate and continue on ART are living longer and are 
therefore exposed to age-related co-morbidities [372,373].  In addition, there are non-communicable disease epidemics 
emerging in many LMIC, including those most heavily affected by the HIV and TB co-epidemics [374].  Individuals may 
develop multiple co-morbidities and, as is the case with the HIV and TB epidemics, the presence of one disease may 
affect the susceptibility to, clinical course of, and/or severity of another.  For example, there is already some evidence 
to suggest an interaction between TB and diabetes [375].  A final layer of complexity lies in the polypharmacy involved 
in treating individuals with multiple chronic comorbidities.  There are still few data available regarding the longer-term 
effects (i.e., more than 25–30 years) of ART, or how second or third-line antiretroviral drugs may interact with anti-
diabetic or anti-hypertensive agents, or the effects that these may have on disease and mortality patterns.   
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As discussed briefly in Chapter 3.2.5.3, a classification system that is too rigid, for example, one that requires the person 
assigning the cause of death to decide what is and is not an ‘HIV-associated’ death, limits our ability to evaluate disease 
patterns at population-level and leaves us vulnerable to unpredictable changes.  Using the same example, a system that 
permitted the enumeration of all deaths among HIV-positive individuals, regardless of cause, would allow for the 
evaluation of demographic trends and the early identification of new ‘HIV-associated’ conditions that may have been 
excluded from previous definitions.  There is also no reason such a system could not be extended to other key, chronic 
disease of interest (e.g., diabetes or hypertension).  I would suggest that the ideal surveillance system is one that allows 
us to predict events of interest, or, at the least, react to them in time to minimise potentially adverse effects.  A system 
that is too unwieldy to be adapted to changing patterns will eventually necessitate the development of workaround 
strategies (as has happened with the multiple steps currently needed to produce estimates of mortality due to HIV-
associated TB), at which point it could be argued that it becomes part of the problem, instead of the solution. 
7.4. Limitation and strengths 
In addition to the limitations and strengths described in individual chapters and those discussed above, there are other, 
overarching, factors that may have affected the internal and external validity of the data presented in this thesis. 
7.4.1. Selection bias 
7.4.1.1 In enrolment to parent studies 
The majority of decedents included in this study were enrolled to one of the three parent studies: TB Fast Track, 
XPHACTOR, or XTEND.  All three studies were conducted in South African public clinics and, though these clinics are free 
at the point of care and situated within the community, will have included only individuals both willing or able to access 
these facilities and to give written informed consent for participation.  This may have biased selection away from 
individuals who did not have the resources or support needed to get to health facilities, and those unable or unwilling 
to give consent.  These individuals may be considered at higher risk of certain illnesses, particularly those related to 
severe poverty [376], and are possibly under-represented in our data.  All three parent studies also excluded individuals 
who were on TB treatment at the point of enrolment and may therefore have selected for individuals who, if they had 
TB, presented atypically or were more difficult to diagnose for other reasons.   
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7.4.1.2 Representation among those deceased 
The proportions of participants lost to follow-up were low in all the parent trials (retention in TB Fast Track 98.6% [155], 
XTEND 99.0% [159], and XPHACTOR 93.7% [Y. Hanifa, personal communication]), suggesting that there were relatively 
few individuals who died and were not accounted for.  In TB Fast Track, in particular, extensive efforts were made to 
ascertain deaths, including the cross-checking of South African identification numbers with lists of death notifications 
held by the South African Medical Research Council and review of hospital databases for names and other identifiers of 
participants who could not be contacted.  However, despite the fairly comprehensive enumeration of deaths, only 
those decedents with relatives or friends that could be contacted and were willing to give consent for MIA and/or VA 
were included.  For MIA, this depended on the agreement of both the participant and their family.  The need for family 
involvement may, again, have led to under-representation of individuals with poor or absent support networks or may 
have selected for individuals more receptive to healthcare-related interventions, all of which may have affected our 
estimates of autopsy prevalence of disease and mortality patterns.  
7.4.2. Bias inherent in methods used 
7.4.2.1 Verbal autopsy data collection 
Our use of the WHO 2012 instrument may have led to systematic inconsistencies in the collection of VA data that made 
comparisons with other VA studies less valid.  Additionally, despite our adhering to international recommendations 
around staff training, the way in which respondents were chosen, and the way in which specific questions were asked, 
there remained several opportunities for our procedures to vary from those conducted by other groups or in other 
contexts.  A degree of variability in interpretation of questions between individual interviewers is inevitable, and this 
should not necessarily be considered a source of bias in comparing our results with other VA studies, as this is likely to 
occur in almost any context.  Nevertheless, elements that may have had a systematic effect on the data collected 
include the language in which training was conducted (English), which may have affected the interpretation or 
understanding of particular questions for all the interviewers; the languages in which the interviews themselves were 
conducted (majority Tswana, Sepedi, and isiZulu) and how particular concepts were translated into (and back-
translated from) those languages, which may differ from other studies done in South Africa and will certainly differ 
from studies done outside of South Africa; the ‘type’ of respondent interviewed (i.e., relation to the deceased), which 
may have been affected by the times at which research assistants were available to conduct interviews, and may have 
led to the exclusion of family members or carers who were bread-winners and were therefore at work during the day; 
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and the overall demographics of respondents (and research assistants), including socio-economic characteristics, 
education, health beliefs, and their own health status, which will have affected the way questions were understood or 
answered, or both, and which are likely to be different from respondents in other countries. 
To estimate the specificity of the VA HIV diagnosis question and the specificity of VA methods in assigning HIV-
associated causes of death (Chapter 6), we selected HIV-negative adults from the registers of hospital mortuaries who 
had died from causes that were not related to maternity or trauma.  By definition, these were people who died in, or 
within reach of, a hospital, and were therefore not necessarily representative of the HIV-negative population more 
generally.  Aside from the issue of generalisability of these results to other South African or sub-Saharan African 
settings, where a high proportion of deaths occur outside of hospitals, this raises a broader issue of how a hospital 
death may affect the information to which a family has access, and how this may affect the validity of data collected 
through VA.  The families of individuals who were cared for or died in hospitals may be more likely to be familiar with 
the language used in the VA interview (which is written and interpreted by physicians) than the families of those who 
were cared for at home or in a more traditional setting.  The development and validation of VA interpretation methods 
using data only from individuals who died in hospitals may therefore lead to overestimation of the overall accuracy of 
the VA method in question, particularly in the assignment of causes of death that depend heavily on the confirmation 
of a particular diagnosis, such as HIV.  By including in this study only HIV-negative individuals who died in hospitals, our 
results may have been susceptible to a form of verification bias and may have led to our overestimating the sensitivity 
of the VA instrument in detecting HIV status. 
7.4.2.2 Verbal autopsy data interpretation 
Use of the WHO 2012 instrument, rather than instruments from 2014, 2016, or the PHMRC instrument may have 
affected translation into InterVA and SmartVA-Analyze input files and, by proxy, the causes of death assigned.  As 
described in Chapters 5 and 6, PCVA reviewers were aware that decedents were likely to have been enrolled in a study 
of HIV and/or TB and that there was a high likelihood of a decedent being HIV-positive.  Confirmation bias may 
therefore have led to the increased assignment of HIV- and TB-associated causes of death.  Reviewers assigning 
reference causes of death may have been subject to the same confirmation bias, although the effect on the proportions 
of HIV- and TB-causes assigned will have varied between reviewers, because of individual differences in process and 
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differences in the data available to PCVA and clinical reviewers.  This may have been further affected by our use of 
study-specific causes of death, which focused attention on HIV-associated TB and other HIV-associated causes.   
7.4.2.3 Assigning reference-standard causes of death 
There was also variability in the information available for individual decedents, even after attempts to separate 
different ‘levels’ of information (see Chapter 5.2.4.2): better information was available to reviewers assigning reference 
causes of death for those decedents who died in hospital (and had hospital data available).  These individuals were 
therefore less likely to be assigned an ‘indeterminate’ cause of death.  Finally, despite the precautions taken in 
assigning references causes of death for levels 1 and 2 in batches of 40–50 decedents, there was still potential for 
learning among reviewing physicians.  As individual physicians became accustomed to the data that were available at 
each level, and to the classifying tendencies of their reviewing colleague(s), they may have assigned causes of death 
based on subconscious expectations of data not yet available, or adjusted their approach to align their assignments 
more closely with their colleague.  These elements were not measured or accounted for in the analysis. 
7.4.3. Strengths 
This study also had several novel elements and methodological strengths.  The recruitment of all HIV-positive 
individuals from community-based clinics, which is more representative of people receiving HIV care in South Africa, 
provides much-needed data on disease and mortality patterns in this population.  In addition to the study conducted by 
Omar et al. in the homes of patients in North West province [97], this study has shown that community-based MIA is 
feasible and acceptable in a variety of South African settings.  This strengthens the case [90] for the broader use of MIA 
in resource-limited settings, for example, as an adjunct to routine surveillance activities at sentinel sites (Chapters 5 and 
7.6.1).  As previously discussed (Chapters 5, 6, and 7.2.3), this study is the first to systematically compare VA-assigned 
causes of death with a reference standard that incorporated pathological autopsy data.  In addition, the process 
employed in this study for assigning reference causes of death was designed and implemented carefully and with 
consideration of transparency and reproducibility.  Clear criteria were established for each major cause of death, along 
with standardised guidelines for reviewers to follow; the process was regulated, through the independence of 
reviewing physicians; and simple arbitration procedures were in place to resolve disagreements between reviewers.  
Although the precautions taken to reduce physician learning may not have eliminated it completely, they marked at 
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least a recognition of, and attempts to counteract, the threats posed to the internal validity of the process, something 
that unfortunately cannot be said for many previous VA validation studies (Chapter 2.3). 
The use of study-defined causes of death (Chapter 5), in addition to ICD-10, allowed for illustration of some of the 
issues around estimating mortality due to HIV-associated TB, but also allowed for comparisons between our data, data 
from previous studies, and routine operational data.  Finally, the systematic review and meta-analysis of studies that 
directly estimated causes of death in HIV-positive adults (Chapter 3) is the first of its kind, and has limitations, but still 
provides a useful baseline for future estimations of cause-specific mortality among HIV-positive adults dying in LMIC. 
7.5. Reflective commentary 
7.5.1. Personal reflection 
I began this process in mid-2012, as an MSc student arriving in South Africa for the first time, with no prior experience 
of clinical research.  Every day of the last five years has been one of learning: I have been fortunate to have been 
involved in almost all stages of the research process, from developing a protocol, to planning and executing data 
collection, designing and coordinating data management and analysis, writing up results, and making policy 
recommendations.  I have also been extremely lucky to work with a diverse, multidisciplinary team, many of whom are 
leaders in their fields.  
As part of the data collection for this study, obtaining consent for MIA from the families of participants, I spent time in 
mortuaries and with recently bereaved families, talking about the principles of research and the ideas behind the study.  
Having to explain, on a regular basis, why I believed in the study and why research, in general, was a positive thing, 
forced me to re-examine these issues for myself.  Many individuals with whom I spoke reported having been treated 
badly at health facilities, or had been failed, repeatedly, by the structures that were put in place to support them.  All 
had very recently lost a young family member to a disease for which treatment was safe and freely available.  Having 
conversations about the value of research and, more specifically, of autopsies, in these intensely emotional situations, 
would have been impossible had I not been so sure of the importance of this work and its potential to have a positive 
impact on the lives of the people with whom I was speaking.   
As the project moved into its analysis stages, I gained an appreciation of how the data we had worked so hard to collect 
fit into national and global systems, and started to develop a better understanding of some of the challenges involved 
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in compiling the global estimates of disease and mortality that I had previously taken for granted.  Each MIA, VA, and 
set of hospital notes was a minor victory, and each was hard-fought, often involving considerable amounts of travel and 
negotiation with clinic, hospital, and mortuary staff.  I did struggle, at times, to reconcile the complex, often heart-
breaking, and deeply human stories that we were told, with the four or five characters assigned by VA software as the 
cause of death, or the crisp, clean lines of a statistical report that discussed thousands of deaths with apparent 
detachment.  I have come to recognise, however, that the choice I thought was required, between the ‘compassionate’ 
clinician and the ‘objective’ researcher, is an artificial divide.  They are, or should be, in my view, two parts of a 
synergistic whole.  As I move into the next stages of my career, I hope to strike that balance; to focus with accuracy and 
precision on the areas of life, health, and death that may, at first, cause one to want to look away. 
7.5.2. Practical lessons learnt 
Although we were successful in conducting 34 MIAs as part of the Lesedi Kamoso study, our task would have been 
made much easier by better, and earlier, engagement with the communities in which we were working.  Mostly, this 
would have involved detailed discussions, prior to starting any fieldwork, with mortuary owners and managers, local 
community and/or religious leaders, and representatives of health services, patient bodies, and law enforcement.  
Some of the difficulties we encountered were because of the size of the area we were covering: although the study was 
conducted across the three provinces mentioned, we also carried out two MIAs in the Free State, as the individual had 
travelled there before death.  However, even taking this into account, better communication between ourselves and 
mortuary owners, in particular, would have avoided some difficult and sometimes confrontational interactions.  
The process of assigning reference causes of death was enormously time-consuming and a much bigger undertaking 
than we initially thought.  The data we had access to were sometimes quite complex, often qualitative (e.g., extracts 
from hospital notes), and had to be collected from various sources and manually organised in chronological order to 
form a coherent narrative.  In addition, our decision to use at least two reviewers for each death and to assign causes of 
death based on different ‘levels’ of data meant that each decedent’s data were reviewed on at least four occasions, 
sometimes more, depending on agreement between reviewers.  Although our main analysis presented causes of death 
for only 259 individuals, this had involved well over 1,000 reviews.  This process made clear to me the impossibility of 
trying to replicate this process in any setting other than research and the need, therefore, for a simple system that 
provides a balance between accuracy and feasibility.  I hope to continue to explore this area in my future work. 
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7.6. Conclusions and recommendations 
7.6.1. Summary of recommendations 
As discussed above, the work presented in this thesis has implications across a wide range of disciplines, from everyday 
clinical practice to the way diseases are classified and counted.  Table 7:1 provides an overview of key 
recommendations and refers the reader to other parts of the thesis for more detailed discussions of specific issues. 
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Table 7:1. Summary of key recommendations made in this thesis 
Subject area Key recommendation (s) See also 
1. Clinical practice 
and policy 
a) Changes to guidelines in order to stress the high prevalence of EPTB in areas with high HIV prevalence and encourage more 
thorough investigation of high-risk individuals, particularly with, but even without, persistent symptoms; greater awareness of 
limitations of sputum-based investigation in these individuals. 
Chapters 2.2, 4.2.5.1, and 
7.3.1 
b) Encourage sampling and testing of non-pulmonary samples as part of TB diagnosis in high-risk individuals; use autopsy data 
to guide to anatomical sites that are most likely to yield a positive result.  
2. HIV & TB 
surveillance 
a) Changes to the international classification of diseases that allow for the separation of HIV-associated TB and other HIV-
associated causes 
Chapters 2.3, 3, 5, 6, and 
7.3.3 
b) Use of MIA at sentinel surveillance sites to monitor, periodically, the autopsy prevalence of TB in high-risk populations and to 
allow for direct estimation of mortality due to HIV-associated TB.  This will be helped by the development of a standardised 
protocol, for use in high prevalence settings, that specifies sampling of the anatomical sites where TB is most likely to be found. 
Chapters 2.2, 4, and 7.3.2 
c) Development of an HIV/TB module to be added to the VA instrument for use in high prevalence settings.  This should include 
questions about treatment for TB, ART initiation, and adherence to therapy. 
Chapters 5 and 6 
3. Measuring cause-
specific mortality 
a) Development of a standardised system for assigning causes of death in HIV-positive people that is compatible with ICD coding Chapters 3, 5, and 6 
b) Development of high-quality, representative, shared datasets for validation of VA methods. Chapters 2.3, and 5 
4. Future research a) The inclusion of new or experimental questions in any future VA validation studies to allow for empirical assessment of 
accuracy prior to their inclusion in the standardised instrument. 
Chapter 6 
b) An agreed format for the reporting of VA validation studies, with structured criteria and requirements for assigning reference 
causes of death and metrics for reporting agreement between VA-assigned and reference standard causes of death. 
Chapters 2.3, 5, and 6 
ART: antiretroviral therapy; HDSS: health and demographic surveillance system; MIA: minimally-invasive autopsy; TB: tuberculosis; VA: verbal autopsy
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7.6.2. Conclusions 
TB is highly prevalent among HIV-positive individuals dying in LMIC.  It remains a serious clinical and public health 
concern and a leading cause of death in these individuals.  Pathological autopsies provide the most accurate estimates 
of TB prevalence; estimates that are consistently higher than those made among living individuals, in part due to high 
prevalence of extrapulmonary disease and the absence of diagnostics that are sufficiently sensitive in individuals with 
advanced HIV.  Methods used to enumerate deaths due to HIV-associated TB are limited by ICD conventions, which 
group together all HIV-associated causes of death.  VAs, particularly when interpreted by automated methods, 
consistently underestimated HIV-associated mortality among HIV-positive individuals; because of ICD rules, VAs were 
also unable to estimate mortality due to HIV-associated TB, except when interpreted by physicians using a purpose-
designed coding system. 
The addition of MIA to other surveillance activities at sentinel sites would allow for regular direct estimation of the 
autopsy prevalence of TB and provide a real-world comparator for the modelled estimates of mortality due to HIV-
associated TB currently used to track progress and determine policy.  At a structural level, modifications to the ICD 
system to allow for the differentiation of HIV-associated TB from other HIV-associated causes would better enable 
surveillance and governing bodies to make this distinction, leading to more accurate and useful mortality data.  VA, 
though not ideal for this purpose, is currently the only feasible method for estimating cause-specific mortality among 
large groups of decedents in areas with weak or absent CRVS systems.  In regions of high HIV and TB prevalence, 
therefore, VA methods should be developed and trained using reference datasets that more accurately represent the 
mortality patterns seen in these areas, ideally with a distinction made between HIV-associated TB and other HIV-
associated causes of death.    
ART alone is not enough, at present, to reduce mortality at the rate needed to meet international targets.  Meaningful 
reductions in mortality due to HIV-associated TB will therefore require more specific, TB-focused, interventions as well 
as broader, systemic measures that aim to strengthen health services, diagnostic capabilities, and reporting 
mechanisms.  CRVS strengthening, with or without the integration of verbal autopsy, is a key part of that process and 
presents an opportunity to restructure the way that disease and cause-specific mortality are measured.  A system is 
needed that can adapt to the needs of the health and research community and that is flexible in the face of evolving 
disease and mortality patterns. 
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8.1. Appendix 1: Consent forms for minimally-invasive autopsy and 
verbal autopsy (extracted from Lesedi Kamoso study protocol, version 
5.1 [30 Jan 2015]) 
8.1.1. Participant information sheet: study participants, at enrolment to TB Fast Track/XPHACTOR 
Lesedi Kamoso: Prevalence of TB and other treatable diseases at autopsy in South Africa 
Investigators:  
London School of Hygiene & Tropical Medicine, UK:  Prof. Alison Grant, Dr Katherine Fielding, Dr Aaron Karat, Dr 
Yasmeen Hanifa 
Aurum Institute for Health Research:  Dr Salome Charalambous, Dr Kerrigan McCarthy, Dr Mpho Tlali, Prof. Gavin 
Churchyard  
Foundation for Professional Development: Ms Suzanne Johnson 
National Health Laboratory Service and University of the Witwatersrand, Johannesburg: Dr Tanvier Omar 
Johns Hopkins University, USA: Dr Neil Martinson  
University of the Witwatersrand: Prof. Kathleen Kahn 
 
[Greeting], my name is [_____]. I am a researcher with [Aurum Institute/FPD]. We are doing a research study and we 
would like to invite you to take part. Research is the process to learn the answer to a question. This information sheet 
explains the study. You are free to decide if you want to take part or not. If you decide to take part, we will ask you to 
sign or make your mark on a consent form, or give a thumbprint. Signing or marking the form means that you agree to 
take part in the study. It also means that you are aware of your right not to take part, or to stop taking part at any time. 
If you decide not to take part, this will not affect your right to health care at this clinic. 
 
Why are we doing this study? Tuberculosis (TB) is a very serious health problem in South Africa.  TB can be cured, but 
occasionally can be fatal if treatment is not started quickly.  You have already agreed to take part in the [as appropriate, 
TB Fast Track or XPHACTOR] study, which is trying to improve testing and treatment for TB.  We hope that the care you 
receive will ensure that you stay well.  However, some people in this study will be seriously ill.  Even with treatment, it 
is likely that a small number will pass away.  If we can find out why people pass away, we can design better treatments 
to keep other patients like them healthy. We will ask about 150 people in South Africa to take part in this study.  The 
study is paid for by the Bill and Melinda Gates Foundation.  
 
If you take part in this study, what will happen? If you agree to take part in this study, in the unlikely event you should 
pass away, we will take some samples from your internal organs with a needle.  The samples will come from the lungs, 
liver, spleen, veins, bladder and fluid round the spine.  The needle will make a small mark in the skin on the chest and 
abdomen.  This will not affect how the body looks.  We will also take a swab from the inside of the nose and some 
washings from the lungs by putting a small tube into the lungs from the base of the neck.  We will make sure that taking 
the samples does not delay the funeral arrangements.  If you stay well during the study, as we hope you will, this study 
will not apply to you and no samples will be taken. 
 
It will not cost you any money to take part in this study.  Equally, there is no payment to people who take part. 
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What are the risks and benefits of taking part in this study? There are no risks to taking part in this study. This study 
will not benefit you directly. It will help us to understand the causes of serious illness in people like you.  We could then 
design treatments to improve care, and reduce the risk of serious illness in people like you in the future.  
 
What happens if I do not agree to take part in this study? You do not have to take part in this study. If you do not take 
part, this will not affect the medical care that you receive at this clinic. You can decide to stop taking part in the study at 
any time, without giving a reason.  
 
How will the information collected during this study be kept confidential? We will do this in the same way as we 
explained earlier for the [TB Fast Track / XPHACTOR] study.   
 
Are there reasons why the study might be stopped early? 
We will stop the study if: 
the study is cancelled  
there could be other reasons we don’t know about yet. 
 
You can stop taking part in the study at any time. If you want to stop taking part, just tell the study team at any time.  
 
What if I have more questions I wish to ask about this study? If you have any questions about this study, please ask us 
now. If you have questions later you can ask study staff, or telephone Dr Charalambous on 010 590 1389. The 
committees giving ethical approval for this study are the Research Ethics Committees of the University of the 
Witwatersrand, South Africa and the London School of Hygiene & Tropical Medicine, UK. If you have any questions 
concerning your rights as a person taking part in a research study, you may contact Prof. Cleaton-Jones, Chairperson of 
the University of the Witwatersrand, Human Research Ethics Committee (HREC) at 011 717 2301. This is an 
independent committee established to protect the rights of research participants. 
 
We will give you a copy of this sheet which explains the study to take away with you.  
 
If you would like a copy of a report on this study, please give us an email or postal address. The final results may not be 
available until 2 years or more from now. 
 
(This information sheet will be available in the most common local languages in study clinics: e.g. Sesotho, isiXhosa, 
isiZulu, Setswana, as appropriate) 
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8.1.1.1 Consent form: study participants   
Ppt ID: AUR--- 
Lesedi Kamoso: Prevalence of TB and other treatable diseases at autopsy in South Africa 
Investigators:  
London School of Hygiene & Tropical Medicine, UK:  Prof. Alison Grant, Dr Katherine Fielding, Dr Aaron Karat, Dr 
Yasmeen Hanifa 
Aurum Institute for Health Research:  Dr Salome Charalambous, Dr Kerrigan McCarthy, Dr Mpho Tlali, Prof. Gavin 
Churchyard  
Foundation for Professional Development: Ms Suzanne Johnson 
National Health Laboratory Service and University of the Witwatersrand, Johannesburg: Dr Tanvier Omar 
Johns Hopkins University, USA: Dr Neil Martinson  
University of the Witwatersrand: Prof. Kathleen Kahn 
 
I have read the information sheet about this study (or the information sheet about this study has been read to me) and 
I understand what will be required of me and what will happen if I take part in the study. 
My questions concerning this study have been answered by: 
     
Research staff name (printed)  Signature  Date 
 
I understand that I may withdraw from this study at any time without giving a reason and without affecting my normal 
care and management. I agree to take part in the study 
     
Study participant name (printed)  Signature/mark/thumbprint  Date 
If the information sheet and consent form were translated or explained to the participant, enter the name of 
the translator here and their signature: 
     
Translator name (printed)  Signature/mark/thumbprint  Date 
If the participant gave verbal consent, enter the name of the person who witnessed the consent here and 
their signature: 
     
Witness name (printed)  Signature/mark/thumbprint  Date 
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8.1.2. Information sheet for next of kin: consent for needle autopsy 
Lesedi Kamoso: Prevalence of TB and other treatable diseases at autopsy in South Africa 
Investigators:  
London School of Hygiene & Tropical Medicine, UK:  Prof. Alison Grant, Dr Katherine Fielding, Dr Aaron Karat, Dr 
Yasmeen Hanifa 
Aurum Institute for Health Research:  Dr Salome Charalambous, Dr Kerrigan McCarthy, Dr Mpho Tlali, Prof. Gavin 
Churchyard  
Foundation for Professional Development: Ms Suzanne Johnson 
National Health Laboratory Service and University of the Witwatersrand, Johannesburg: Dr Tanvier Omar 
Johns Hopkins University, USA: Dr Neil Martinson  
University of the Witwatersrand: Prof. Kathleen Kahn 
 
[Greeting], my name is [_____]. I am a researcher with [Aurum Institute/FPD]. We are very sorry to hear about the loss 
of [name of participant]. We offer our sincere condolences to you and the family. [Pause for response: researcher to 
respond appropriately to the family member’s response.] 
We would like to invite you to give permission for your relative to contribute to a research study. Research is the 
process to learn the answer to a question. This information sheet explains the study. You are free to decide if you will 
give permission for the study or not. If you agree, we will ask you to sign or make your mark on a consent form, or give 
a thumbprint. Signing or marking the form means that you agree for your relative to contribute to the study. It also 
means that you are aware of your right to say no. If you decide not to take part, this will not affect your right to health 
care. 
 
Why are we doing this study? Tuberculosis, also called TB, is a very important health problem in South Africa. TB can 
be cured, but occasionally can be fatal. It is possible that TB played a part in the death of your relative, even if they 
were treated for it. There may be other treatable diseases that also played a part. If we can find out why people pass 
away, we may be able to design better treatments to keep other patients like them healthy. We aim to include about 
150 people in South Africa in this study. The study is paid for by the Bill and Melinda Gates Foundation.  
 
If you agree for your relative to contribute to this study, what will happen?  
If you agree, we will take some samples from [name of participant]’s body with a needle.  The samples will come from 
the lungs, liver, spleen, veins, bladder and fluid round the spine.  The needle will make a small mark in the skin on the 
chest and abdomen.  This will not affect how the body looks.  We will also take a swab from the inside of the nose and 
some washings from the lungs by putting a small tube into the lungs from the base of the neck.  We will make sure that 
taking the samples does not delay the funeral arrangements. 
 
If you would like us to let you know what we find out from the samples, and you give us contact details, we can call you 
to say what we found. Because we are taking only small samples of tissue, we will not be able to examine the body 
organs in detail. This means that we will be able to say whether we found TB or other infections, and if we found cancer 
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cells. However we will not have information on all the diseases that may have been there. It would likely take about 3 
months before we can give you these results.  
 
If we find TB, we would recommend that you and others who lived with your relative are checked for TB, if this has not 
already been done. We can give you a letter of referral to your health centre to be checked for TB, if you would like 
that.  
 
It will not cost you any money if your relative contributes to this study. Equally, there is no payment for taking part. 
 
What are the risks and benefits of taking part in this study?  
There are no risks to taking part in this study. This study will not benefit you directly. It will help us to understand the 
causes of serious illness in people like your relative.  We could then design treatments to improve care, and reduce the 
risk of death, for people like your relative in the future.  
 
What happens if I do not agree to this study? You do not have to agree for your relative to contribute to this study.  If 
you do not agree, there will be no negative consequences.  
 
How will the information collected during this study be kept confidential? All information collected during the course 
of this study will be kept securely and confidentially in a locked cupboard or filing cabinet: Prof Grant and Dr 
Charalambous are responsible for this. Your relative’s name and contact details will only be available to a restricted 
group of study staff, and when we store this information on a computer, it will be protected by a password, and kept 
separate from other information. Information from the samples will be identified on forms and on computer files only 
by a study number, not your name or contact details. When the information is analysed, nobody will know who the 
people in the study are, and the information will remain private and confidential. Information that we collect as part of 
the study may be reviewed by the Ethics Committee, and independent monitors, to check that the study procedures 
were done correctly and the information is correct. Reports about the study and results that may be published in 
scientific journals will never include any information which allows your relative to be identified. 
 
What if I have more questions I wish to ask about this study? If you have any questions about this study, please ask us 
now. If you have questions later you can ask study staff, or telephone Dr Charalambous on 010 590 1389. The 
committees giving ethical approval for this study are the Research Ethics Committees of the University of the 
Witwatersrand, South Africa and the London School of Hygiene & Tropical Medicine, UK. If you have any questions 
concerning your rights as a person taking part in a research study, you may contact Prof. Cleaton-Jones, Chairperson of 
the University of the Witwatersrand, Human Research Ethics Committee (HREC) at 011 717 2301. This is an 
independent committee established to protect the rights of research participants. 
 
We will give you a copy of this sheet which explains the study.  
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If you would like a copy of a report on this study, we can send one. We will need an email or postal address. The final 
results may not be available until 2 years from now. 
 
 
(This information sheet will be available in the most common local languages: e.g. Sesotho, isiXhosa, isiZulu, Setswana, 
as appropriate) 
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8.1.2.1 Next of kin: consent for needle autopsy  
Ppt ID:  AUR--- 
Lesedi Kamoso: Prevalence of TB and other treatable diseases at autopsy in South Africa 
Investigators:  
London School of Hygiene & Tropical Medicine, UK:  Prof. Alison Grant, Dr Katherine Fielding, Dr 
Aaron Karat, Dr Yasmeen Hanifa 
Aurum Institute for Health Research:  Dr Salome Charalambous, Dr Kerrigan McCarthy, Dr Mpho 
Tlali, Prof. Gavin Churchyard  
Foundation for Professional Development: Ms Suzanne Johnson 
National Health Laboratory Service and University of the Witwatersrand, Johannesburg: Dr Tanvier 
Omar 
Johns Hopkins University, USA: Dr Neil Martinson  
University of the Witwatersrand: Prof. Kathleen Kahn 
 
I have read the information sheet about this study (or the information sheet about this study has been read to me) and 
I understand what will happen if I agree for my relative to contribute to the study. 
My questions concerning this study have been answered by: 
     
Research staff name (printed)  Signature  Date 
I understand that I may withdraw consent for this study at any time without giving a reason 
I agree for my relative to contribute to the study 
     
Study participant name (printed)  Signature/mark/thumbprint  Date 
If the information sheet and consent form were translated or explained to the participant, enter the name of the 
translator here and their signature: 
     
Translator name (printed)  Signature/mark/thumbprint  Date 
If the participant gave verbal consent, enter the name of the person who witnessed the consent here and their 
signature: 
     
Witness name (printed)  Signature/mark/thumbprint  Date 
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8.1.3. Information sheet: next of kin consent for verbal autopsy 
Lesedi Kamoso: Prevalence of TB and other treatable diseases at autopsy in South Africa 
Investigators:  
London School of Hygiene & Tropical Medicine, UK:  Prof. Alison Grant, Dr Katherine Fielding, Dr Aaron Karat, Dr 
Yasmeen Hanifa 
Aurum Institute for Health Research:  Dr Salome Charalambous, Dr Kerrigan McCarthy, Dr Mpho Tlali, Prof. Gavin 
Churchyard  
Foundation for Professional Development: Ms Suzanne Johnson 
National Health Laboratory Service and University of the Witwatersrand, Johannesburg: Dr Tanvier Omar 
Johns Hopkins University, USA: Dr Neil Martinson  
University of the Witwatersrand: Prof. Kathleen Kahn 
 
[Greeting], my name is [_____]. I am a researcher with [Aurum Institute/FPD]. We are very sorry to hear about the loss 
of [name of participant]. We offer our sincere condolences to you and the family. [Pause for response: researcher to 
respond appropriately to the family member’s response.] 
 
We are doing a research study and we would like to invite you to take part. Research is the process to learn the answer 
to a question. This information sheet explains the study. You are free to decide if you want to take part or not. If you 
decide to take part, we will ask you to sign or make your mark on a consent form, or give a thumbprint. Signing or 
marking the form means that you agree to take part in the study. It also means that you are aware of your right not to 
take part, or to stop taking part at any time. If you decide not to take part, this will not affect your right to health care. 
 
Why are we doing this study? Tuberculosis, also called TB, is a very important health problem in South Africa. TB can 
be cured, but occasionally can be fatal. It is possible that TB played a part in the death of your relative, even if they 
were treated for it.  There may have been other treatable diseases that played a part. If we can find out why people 
pass away, we may be able to design better treatments to keep other patients like them healthy.  We will ask about 600 
people in South Africa to take part in this study.  The study is paid for by the Bill and Melinda Gates Foundation.  
 
If you take part in this study, what will happen? If you agree to take part in this study, we will ask you general 
questions about your relative. This will include where s/he was born; the sort of work s/he did; questions about illness 
s/he had during his/her life. We will ask details about what happened in his/her final illness, including what treatment 
s/he received at clinics and hospitals. We would be very grateful if you would let us record the interview.  If you give us 
permission we will record the interview on tape, so that we don’t miss any of the things you say.  We will also make 
notes on your answers during the interview and we may quote things that you say in future reports, although there will 
be no way to identify you (your name or other details will never appear).  These questions will take about 45-60 
minutes in total. 
 
If you agree to take part in this study, we will give your ZAR100 in recognition of your time. [If you have had to spend 
money on travel to talk to us, we will give you ZAR20 to reimburse your costs.] 
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What are the risks and benefits of taking part in this study? Thinking about your relative’s final illness may bring back 
the grief of losing your relative. You can stop the interview at any time, without giving a reason. There are no direct 
benefits to you of taking part in this study. This study will help us understand the causes of serious illness in people like 
your relative. We could then design treatments to improve care, and reduce the risk of death, for people like your 
relative in the future.  
 
What happens if I do not agree to take part in this study? You do not have to take part in this study. You can stop 
taking part in the study at any time, without giving a reason.  
 
How will the information collected during this study be kept confidential? All information collected during the course 
of this study will be kept securely and confidentially in a locked cupboard or filing cabinet: Prof Grant and Dr 
Charalambous are responsible for this. If you give permission, we will tape record the interview we have with you.  The 
interview may be written down and translated into English.  We may type the information into a computer database.  
The computer texts will be stored anonymously, which means that you will be identified by a study number only, not 
your name.  Tapes will also be stored only with study numbers attached.  When we have finished the study, we will 
destroy any links between the information you gave us and your name.  If we publish the results of the study, we will 
keep interview data for at least two years after the study is finished for checking or further analysis.  If we do not 
publish the results, we will keep interview data for up to 6 years for the same purposes.  At this time it will not be 
possible to link the information you give us back to you.  
 
Your relative’s name and contact details will only be available to a restricted group of study staff, and when we store 
this information on a computer, it will be protected by a password, and kept separate from other information (such as 
information about their health) that you give us. The health information you give us will be identified on forms and on 
computer files only by a study number, not your relative’s name or contact details.  When the information is analysed, 
nobody will know who the people in the study are, and your information will remain private and confidential. 
Information that we collect as part of the study may be reviewed by the Ethics Committee and independent monitors, 
to check that the study procedures were done correctly and the information is correct. Reports about the study and 
results that may be published in scientific journals will never include any information which allows your relative to be 
identified. 
 
What if I have more questions I wish to ask about this study? If you have any questions about this study, please ask us 
now. If you have questions later you can ask study staff, or telephone Dr Karat on 010 590 1360. The committees giving 
ethical approval for this study are the Research Ethics Committees of the University of the Witwatersrand, South Africa 
and the London School of Hygiene & Tropical Medicine, UK. If you have any questions concerning your rights as a 
person taking part in a research study, you may contact Prof. Cleaton-Jones, Chairperson of the University of the 
Witwatersrand, Human Research Ethics Committee (HREC) at 011 717 2301. This is an independent committee 
established to protect the rights of research participants. 
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We will give you a copy of this sheet which explains the study.  
 
If you would like a copy of a report on this study, please give us an email or postal address. The final results may not be 
available until 2 years or more from now. 
 
(This information sheet will be available in the most common local languages: e.g. Sesotho, isiXhosa, isiZulu, Setswana, 
as appropriate) 
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8.1.3.1 Consent form: next of kin consent for verbal autopsy  
Ppt ID: AUR--- 
Lesedi Kamoso: Prevalence of TB and other treatable diseases at autopsy in South Africa 
Investigators:  
London School of Hygiene & Tropical Medicine, UK:  Prof. Alison Grant, Dr Katherine Fielding, Dr Aaron Karat, Dr 
Yasmeen Hanifa 
Aurum Institute for Health Research:  Dr Salome Charalambous, Dr Kerrigan McCarthy, Dr Mpho Tlali, Prof. Gavin 
Churchyard  
Foundation for Professional Development: Ms Suzanne Johnson 
National Health Laboratory Service and University of the Witwatersrand, Johannesburg: Dr Tanvier Omar 
Johns Hopkins University, USA: Dr Neil Martinson  
University of the Witwatersrand: Prof. Kathleen Kahn 
• I have read the information sheet about this study (or the information sheet about this study has been read to 
me) and I understand what will be required of me and what will happen if I take part in the study. 
• My questions concerning this study have been answered by: 
     
Research staff name (printed)  Signature  Date 
I understand that I may withdraw from this study at any time without giving a reason.  I agree to take part in the study 
     
Study participant name (printed)  Signature/mark/thumbprint  Date 
I agree for the interview to be tape-recorded  
     
Study participant name (printed)  Signature/mark/thumbprint  Date 
If the information sheet and consent form were translated or explained to the participant, enter the name of the 
translator here and their signature: 
     
Translator name (printed)  Signature/mark/thumbprint  Date 
If the participant gave verbal consent, enter the name of the person who witnessed the consent here and their 
signature: 
     
Witness name (printed)  Signature/mark/thumbprint  Date 
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8.2. Appendix 2: Summaries of three parent studies  
(adapted from the Lesedi Kamoso study protocol) 
8.2.1. The TB Fast Track study  
Research ethics committee reference numbers  
University of the Witwatersrand:   R14/49 M111177 
London School of Hygiene & Tropical Medicine:  6099 
 
Background:  New TB diagnostics have potential to reduce mortality due to TB among people with HIV in developing 
countries.  Urine lipoarabinomannan (LAM) antigen testing has high specificity and moderate sensitivity among HIV-
positive individuals with advanced immunosuppression.  This test is now available formulated for point-of-care use, at 
low cost, and could be used in primary care settings to identify TB among those at highest risk of both TB and of death 
among people with HIV, as could haemoglobin and body mass index. 
 
Aims: To determine 6-month mortality among adults with HIV and CD4 ≤150, presenting for ART, managed using a 
point-of-care technology-based algorithm to rapidly identify individuals at high risk of TB and ensure they start TB 
treatment, then ART; and to compare this to 6-month mortality among adults managed according to standard practice 
based on South African guidelines. 
  
Methods: Open-label, pragmatic cluster-randomised trial, with primary health clinics as the unit of randomisation.  
Adults (at least 18 years) with CD4 ≤150 cells/µl who are not yet taking ART and who have not had TB treatment in the 
last 3 months will be eligible.  There are few exclusion criteria, such that study participants will be broadly 
representative of ambulatory patients with HIV and low CD4 counts.  
 
In 12 intervention clinics, consenting adults will be assessed based on symptoms, urine LAM, haemoglobin 
concentration and body mass index.  The study algorithm (Figure 1) will use the results of these assessments to classify 
individuals as high, medium or low probability of TB.  Those with high probability will start TB treatment immediately, 
followed by ART after 2 weeks.  Those with medium probability of TB will follow the South African guidelines (sputum 
smear, chest radiography and trial of antibiotics) and will be reviewed after one week, to be re-categorised as low or 
high risk of TB.  Those categorised as low probability of TB will start ART as soon as possible.  
 
In 12 control clinics, patients will be managed in the usual way, following South African national guidelines. All 
participants in both arms will be followed up to at least 6 months.  The primary outcome is all-cause mortality at 6 
months.  We will also explore the cost-effectiveness of this management strategy. 
 
Significance: If the study management strategy proves effective in reducing mortality, this algorithm could be 
implemented in resource-constrained settings and could substantially reduce early on-ART mortality. 
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Appendix figure 1. TB Fast Track study algorithm, used with the kind permission of Prof Alison Grant 
 
ART: antiretroviral therapy; asap: as soon as possible; BMI: body mass index; Hb: Haemoglobin; HIV: Human 
immunodeficiency virus; LAM: lipoarabinomannan; TB: tuberculosis  
 
8.2.2. The XPHACTOR study 
Research ethics committee reference numbers  
University of the Witwatersrand:    M120343 
London School of Hygiene & Tropical Medicine:  6165 
 
Background:  Intensified tuberculosis (TB) case finding is a key activity in HIV/TB programmes, and is recommended for 
people with HIV at every clinical encounter.  Updated guidelines from WHO recommend TB screening using a new tool 
comprising any of current cough, fever, night sweats or weight loss (hereafter the "WHO screening tool") which was 
designed to maximise sensitivity and negative predictive value.  However, the specificity, and consequently positive 
predictive value, of the WHO screening tool is low.  
 
The new polymerase chain-based TB diagnostic test Xpert MTB/RIF (Cepheid) has higher sensitivity than sputum smear, 
but lower sensitivity than mycobacterial culture, particularly for sputum smear negative specimens, and is costly.  Xpert 
MTB/RIF is recommended by WHO as the initial test for TB suspects who have HIV infection.  The combination of new 
screening guidelines generating an expanded number of HIV-infected TB suspects requiring testing, plus a new test at 
higher cost, has major implications for health services in resource-constrained settings with a high burden of TB. 
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We hypothesise that an algorithm which prioritises immediate testing for individuals at highest risk of TB mortality 
(based on CD4 count and BMI) and/or transmitting TB (based on cough), while allowing deferral of investigation for 
those assigned lower priority, will reduce health service costs with minimal risk to patients.  We propose to test such an 
algorithm among adults attending clinics in South Africa for HIV care.  
 
The optimal management of symptomatic individuals whose first Xpert MTB/RIF test has a negative result is not yet 
clear. Current guidelines recommend that the “smear negative” algorithm is followed (sputum for mycobacterial 
culture, chest radiograph, a course of antibiotics then review). It has been proposed that it would be more cost-
effective to undertake an immediate second Xpert MTB/RIF test, but there are no empiric data on which to base this 
decision. 
 
Aims: 
To evaluate an algorithm which identifies, among HIV-infected clinic attendees, those who are "high priority" for 
immediate investigation with Xpert MTB/RIF, and allows watchful waiting for those assessed as lower priority, 
comparing  
(i) outcomes and costs using the study algorithm vs.  
(ii) modelled outcomes and costs assuming testing according to the WHO-recommended strategy. 
 
To compare two strategies for further investigation of adults with HIV who are suspected of having TB, but whose first 
Xpert MTB/RIF test is negative, comparing  
(i) outcomes and costs following the South African national guidelines for further investigation vs.  
(ii) modelled outcomes and costs assuming a second Xpert MTB/RIF test was performed immediately. 
 
To determine diagnoses among HIV-infected clinic attendees who have symptoms suggesting TB, but who do not have 
a diagnosis of TB based on investigations performed before or at the 3-month visit. 
 
To determine the "natural history" of TB symptoms among individuals without a final diagnosis of TB, in order to 
estimate the likely demand for repeat Xpert MTB/RIF testing among patients attending regularly for HIV care. 
 
Methods:  
Aim 1: interventional cohort study, in which we implement the study algorithm among a representative sample of 
adults attending three HIV clinics in South Africa. All participants will be assessed and the study algorithm used to 
assign each to either "high priority" for immediate testing with Xpert MTB/RIF, or "medium/low priority" for watchful 
waiting. Those assigned medium/low priority will be asked to give a sputum specimen to be stored for study purposes. 
All participants will be reviewed monthly for TB symptoms, with Xpert MTB/RIF testing initiated if, at the follow-up visit, 
they now fulfil criteria for "high priority" or have persistent “medium priority” features. All participants will be followed 
to three months, then tested for TB based on sputum and blood samples for mycobacterial culture. At the end of the 
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study we will compare outcomes and costs observed based on the study algorithm with modelled outcomes and costs 
assuming immediate testing with Xpert MTB/RIF based on the WHO recommended algorithm. 
 
Aim 2: cohort study, using data from participants in study aim 1 who undergo Xpert MTB/RIF testing with a negative 
result, and have a CD4 count below 200 cells/µl. Study staff will facilitate further management according to South 
African guidelines; patients will be followed to determine outcomes, and costs estimated. In addition, at the point 
where the first Xpert MTB/RIF is negative, an additional sputum specimen will be collected for storage, and tested with 
Xpert MTB/RIF at the end of the study. Outcomes and costs observed following the South African guidelines will be 
compared to modelled outcomes and costs that would have been incurred if a second Xpert MTB/RIF test had been 
carried out immediately. 
 
An additional group of participants will be recruited to strengthen aim 2: these are individuals not taking ART who have 
a CD4 count below 200 cells/µl, who may be identified following a recent HIV test, or as part of follow-up in pre-ART 
care. These individuals will not be recruited to follow the main XPHACTOR study algorithm since the risk of active TB is 
very high; thus, all will have sputum sent immediately for MTB/RIF, and none will have testing deferred. However, if 
their initial Xpert MTB/RIF test result is negative, they could contribute to aim 2. Subsequent follow up will be as for the 
main study. 
 
Aim 3: at each of two of the study clinics, a subgroup of the first 100 individuals who remain symptomatic by the month 
3 visit but whose investigations for TB are negative will be assessed by a research clinician, further investigations 
arranged, and final diagnosis assigned by month 6. 
 
Aim 4: data from monthly visits of participants contributing to study aims 1 and 3 will be used to estimate the 
frequency of TB symptoms at repeated visits and thus estimate the demand for repeat testing in routine HIV care. 
  
Significance 
This study will identify an evidence-based algorithm, which is feasible to implement within HIV clinics, to guide the use 
of TB diagnostic investigations. It will address how the effectiveness and cost-effectiveness of a Xpert MTB/RIF based 
diagnostic algorithm are influenced by how many, and which, patients are selected to undergo testing. The results will 
complement our larger study of the effectiveness, cost-effectiveness and impact on TB control of Xpert MTB/RIF, and 
provide evidence to guide the rational use of Xpert MTB/RIF in national roll-out in South Africa and other settings 
where HIV and TB are both prevalent.  
 
8.2.3. The XTEND study 
Research ethics committee reference numbers 
University of the Witwatersrand:   R14/49 M110827 
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London School of Hygiene & Tropical Medicine:  6041 
 
Background 
South Africa is rolling out Xpert MTB/RIF, a new diagnostic test with improved sensitivity for detection of active 
tuberculosis combined with simultaneous detection of rifampicin resistance. The test has a greatly reduced turn-around 
time compared with mycobacterial culture, but cost per test substantially greater than the smear microscopy it is 
intended to replace. It is not yet clear whether this will improve patient-relevant outcomes, and how it will contribute 
to tuberculosis control (both drug susceptible and drug resistant) in South Africa and elsewhere.  
 
Aim 
To evaluate the effectiveness and cost effectiveness of Xpert MTB/RIF in the investigation of TB and TB drug resistance, 
and its impact on patient and programme outcomes and transmission at a population level. 
 
Specific objectives 
• To measure the effectiveness of Xpert MTB/RIF in improving patient and programme outcomes. 
• To determine the likely population level impact on TB transmission of using Xpert MTB/RIF in the investigation of 
TB and TB drug resistance, using mathematical modelling 
• To estimate the cost-effectiveness of Xpert MTB/RIF from a patient and health system perspective  
 
Methods  
Study design 
A cluster randomised pragmatic trial (CRT) will be conducted, where 20 laboratories in South Africa, in high burden TB 
districts will be randomised to receive Xpert MTB/Rif technology early, and 20 to receive this technology later.  
• Intervention laboratories will receive Xpert MTB/RIF early 
o TB suspects who attend facilities that use these laboratories will have one Xpert MTB/RIF instead of 
two smears at diagnosis 
o Patients that are sputum Xpert MTB/RIF positive will have a second sputum specimen collected for 
smear microscopy (with additional culture and DST for those detected with rifampicin resistant TB), in 
line with South African national guidelines 
• Control laboratories will use standard of care diagnostic tests for TB, as per South African national guidelines, 
during the study, and then implement Xpert MTB/RIF:  
o two smears using fluorescent staining (Auramine O) will be done for all TB suspects,  
o Culture will be done if any of the following criteria are met:  
▪ Suspects are smear negative, and symptomatic, including those who are HIV positive;  
▪ high MDR-TB risk;  
▪ or a prior history of TB. 
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The NHLS is currently rolling out Xpert MTB/Rif in a phased way. The laboratories in high burden TB districts have all 
already received Xpert. The 20 laboratories in medium to high districts are all due to receive Xpert MTB/Rif as part of 
this study. In other words, this study is ‘nested’ within the national roll out of Xpert. The laboratories that are 
participating in this study were identified in early 2011 by the NDoH and role-players. For planning needs, the random 
allocation of laboratories in this study to receive Xpert diagnostic tests early (Dec/Jan 2011) or late (June 2012) was 
done earlier in the year.  
 
Selection of PHCs for participation 
Prior to initiation of the study, two community or primary health care facilities will be chosen for each participating 
laboratory. The sub-district and district health managers will select the clinics, based on the volume of TB suspects seen 
per quarter, the availability of space within the facility to accommodate two researchers, and other factors (including 
presence of other research projects at that facility, or other active NGO support for facilities that may interfere with the 
study.  
 
Enrolment and follow-up of participants 
At each PHC, TB suspects will be offered an opportunity to participate, until 120 suspects have been enrolled at each 
site. Informed consent will be taken according to approved protocols. Participants will be followed up for 6 months. 
Amongst the participants, some will develop TB disease and be started on TB treatment. These participants will be 
followed up for 6 months after the start of initiation of TB treatment. During the course of the study, research nurses 
will collect information on demographic characteristics, TB and HIV history, clinic usage, economic indicators, diagnostic 
tests done, and results, and outcome.  
 
Evaluation and analysis 
On completion of the study patient outcomes will be measured on TB suspects and TB patients attending clinics being 
serviced by these laboratories, and will include six month mortality amongst TB suspects as the primary outcome. We 
will determine whether the advent of Xpert MTB/RIF alters provider behaviour with respect to investigating TB 
suspects, and to estimate costs from the patients' perspective. Comprehensive economic costs (including costs to the 
health system) will also be measured, together with the parameters required for the modelling of population impact. 
 
Significance of this study 
These data will enable us to estimate effectiveness, cost and cost-effectiveness of implementation of Xpert MTB/RIF in 
the context of national roll-out. The data generated will populate mathematical and economic models which will 
explore the impact of roll-out of Xpert MTB/RIF on TB control, in South Africa and elsewhere. In addition, the data will 
allow us to model the effect of varying test algorithms on cost-effectiveness and future resource requirements; and will 
guide the development of further work to test how Xpert MTB/RIF can best be used within the health system to 
improve patient outcomes and TB control.  
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8.3. Appendix 3: Regulatory documents 
8.3.1. Ethical approvals 
8.3.1.1 London School of Hygiene & Tropical Medicine 
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8.3.1.2 University of the Witwatersrand 
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8.3.2. Cause of death notification letter to families (MIA only) 
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8.3.3. Referral to clinical letter for families (MIA or VA) 
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8.4. Appendix 4: Data collection and processing 
8.4.1. Verbal autopsy instrument (adapted from WHO 2012) 
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Hospitalisation CRF 
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8.4.2. Sample timeline for clinical reviewers: 1 
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8.4.3. Sample timeline for clinical reviewers: 2 
 
 
An autopsy study exploring the spectrum of disease in individuals with advanced HIV 
 in primary care clinics in South Africa 
 Page 333 of 383 Chapter 8: Appendices 
8.5. Appendix 5: Standard operating procedures and detailed methods 
8.5.1. Minimally-invasive autopsy procedure (simplified procedure for non-clinical operator) 
8.5.1.1 Before starting the autopsy 
8.5.1.1.1 Documentation and permissions 
1. Ensure you have all the appropriate documentation as described in the checklist 
2. Ensure that formal informed consent has been obtained either from the participant or the appropriate family 
member 
3. Ensure that the procedure has been discussed with the family at large and that at least verbal (if possible 
written) permission has been granted 
4. Ensure that the mortuary/hospital have been informed of the procedure in as much time as possible, and that 
they have been in communication with the responsible member of the family 
8.5.1.1.2 Safety principles 
1. N95 mask 
2. Goggles 
3. Hat 
4. Gown 
5. Overshoes 
6. Gloves at all times 
1. Remove potential slip/falling hazards 
2. Extraction fan switched on if available 
3. Establish a clear path between procedural site and sharps bin 
1. Only one person using needles at any time 
2. Vocal notification of sharps use 
3. General sharps awareness 
4. Use of sharps bin 
8.5.1.2 Setting up 
1. Ideally try to establish well lit, well ventilated and spacious working area (though frequently not possible; use 
head-torch if lighting insufficient) 
2. Inform mortuary staff that they must be wearing an N95 mask if they are to observe or be in the same room 
3. Set up large white bin bag using sello-tape in an easily accessible location that does not compromise the 
sterile field 
4. Use 1 folding table to unpack and set up autopsy kit  
5. Set up sterile working area on other folding table and pour povidone iodine (without touching field) 
6. Label all CLS sample containers with the participant ID (*don’t forget the blood culture bottle!*) 
7. All NICD containers should also be labelled with participant ID, date of autopsy and sample type (e.g. blood, 
CSF, etc) 
8. Pour sterile saline (using sterile method) into TB (blue-top) universal containers for lung tissue, liver tissue and 
spleen tissue 
9. Pour formalin into the two histology universal containers (red-top) 
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8.5.1.3 Systemic examination 
8.5.1.3.1 Observation 
1. Put on a pair of large, non-sterile gloves 
2. Make a formal observation of the body (head, arms, chest, abdomen, back, legs) paying particular attention to:  
3. General appearance 
4. Muscle mass (degree of wasting) 
5. Hands & nails 
6. Skin changes (evidence of rash, jaundice, trauma, coagulopathy, etc) 
8.5.1.3.2 Examination for lymphadenopathy 
1. Submandibular (under the jaw) 
2. Cervical (neck) 
3. Supraclavicular (above the clavicles) 
4. Axillary (armpits) 
5. Inguinal (groin) 
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Appendix figure 2. Guide to putting on sterile gloves 
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8.5.1.4 Liver biopsy 
8.5.1.4.1 Equipment needed 
1. Disposable scalpel x 1 
2. Biopsy needle x 1 
3. 18G hypodermic (pink) needle x 1 
4. Pack of sterile gauze x 1 
5. Alcohol swabs x 4 
6. Pair of sterile gloves x 1 
7. Histology (red-top) universal container (Label: ‘R lung and liver’) *pre-filled with formalin* 
8. TB (blue-top) universal container (Label ‘Tissue (liver)’) *pre-filled with sterile saline* 
9. Microbiology (white-top) universal container (Label: ‘Tissue (liver)’) *dry * 
10. ‘Liver’ placemat 
8.5.1.4.2 Procedure details 
1. Put on a pair of large, non-sterile gloves 
2. Open the sterile equipment onto the field (using sterile technique) 
3. Biopsy needle 
4. Scalpel 
5. Hypodermic needle 
6. Sterile gauze 
7. Identify the appropriate point for needle insertion (RIGHT mid-clavicular line, just inferior to the costal margin 
[see Figure 1]) and mark the point with a felt pen 
Appendix figure 3. Anatomical site for liver biopsy 
 
 
8. Using the ‘dirty hand/clean hand’ method, clean the point and the surrounding are with at least four alcohol 
swabs, using the prescribed technique (start at the middle, move outwards in a clockwise motion) 
9. Place a spare piece of absorbent material under the torso, where you are likely to have dripping iodine 
10. Using the ‘dirty hand/clean hand’ method, clean the point and surrounding area with a cotton ball soaked in 
povidone iodine (removed carefully from the sterile area with the clean hand) 
11. BEFORE PUTTING ON STERILE GLOVES: 
• Make sure that the relevant pots (with lids removed) are on the appropriate placemats in an 
accessible location 
• Ensure that sharps bin is open and easily accessible 
• Double check that all necessary sterile equipment has been opened onto the field 
12. Put on a pair of sterile gloves using appropriate technique (see Section 2) 
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   STERILE   
13. Open one of the drapes contained in the sterile procedure pack and tear it in half, taking care to keep the folds 
away from the body and upper arms 
14. Place one of the drape pieces back into the sterile field and fold the remaining piece in half longitudinally and 
then in half again 
15. Tear a small hole in the sterile drape and dispose carefully of the waste, taking care not to contaminate 
yourself 
16. Place the drape over the abdomen of the deceased, with the hole over the previously marked area 
17. TAKE CARE NOT TO TOUCH THE BODY WHILE PLACING THE DRAPE 
18. Use sterile gauze to carefully clean away the residual iodine from the sterilised area 
19. Using the scalpel, make a small nick in the skin in the area previously marked 
20. Place a piece of sterile gauze in your new sterile field (on the abdomen of the deceased) and rest your 
hypodermic needle on it 
21. Using your right hand, insert the biopsy needle (with the cutting blade withdrawn) into the nick made by your 
scalpel and direct it supero-infero-laterally until you feel the tip entering the liver 
22. After you feel the tip of the needle enter the organ, push it in a further 1-2cm without changing the direction 
23. Holding the body of the needle steady with your right hand, push the cutting blade forward, slowly, with your 
left hand until you feel it click closed 
24. Holding the entire needle (body and cutting blade) closed, withdraw it from the abdomen, being particularly 
aware of people/items around you 
25. Pull back the cutting blade to examine the sample 
26. If you have obtained a satisfactory sample, transfer the biopsy needle to your left hand, pick up the 
hypodermic needle with your right hand and, taking care to maintain sharps safety and sterility, transfer the 
tissue sample into the appropriate container 
27. Be careful not to touch any of the sample pots with either the biopsy needle or the hypodermic needle 
28. Remember: for histology, the important thing is sample quality; for TB & micro, the important thing is sample 
quantity 
29. Try to obtain at least 5 samples of high quality for histology and at least 8-10 samples (each) for microbiology 
and TB 
30. When all samples have been obtained to your satisfaction, place the biopsy needle and the hypodermic needle 
into the sharps bin immediately 
   STERILE    
31. Clean excess iodine from the area and dispose of the drape 
32. Remove sterile gloves 
33. Close the universal containers tightly and place the microbiology and TB containers immediately into an 
environment where they will be maintained at 2-8C  
34. Prepare for lung biopsies 
8.5.1.5 Lung biopsies 
8.5.1.5.1 Equipment needed 
1. Disposable scalpel x 1 (re-use) 
2. Biopsy needle x 1 
3. 18G hypodermic (pink) needle x 2 
4. Pack of sterile gauze x 1 (if needed) 
5. Alcohol swabs x 8 
6. Pair of sterile gloves x 1 
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7. Histology (red-top) universal container x 2 (Labels: ‘R lung and liver’ and ‘L lung and spleen’) *pre-filled with 
formalin* 
8. TB (blue-top) universal container (Label ‘Tissue (lung)’) *pre-filled with sterile saline* 
9. Microbiology (white-top) universal container (Label: ‘Tissue (lung)’) *dry * 
10. ’Lungs’ placemat 
8.5.1.5.2 Procedure details 
1. Put on a pair of large, non-sterile gloves 
2. Open the sterile equipment onto the field (using sterile technique) 
3. Biopsy needle x 1 
4. Hypodermic needle x 2 
5. Sterile gauze (if necessary) 
6. Identify the appropriate points for needle insertion (LEFT and RIGHT mid-clavicular lines, 2nd intercostal space 
[see Figure 2]) and mark the points with a felt pen 
Appendix figure 4. Anatomical sites for lung biopsies 
 
 
7. Using the ‘dirty hand/clean hand’ method, clean the intended insertion points and the surrounding are with at 
least four alcohol swabs each, using the prescribed technique (start at the middle, move outwards in a 
clockwise motion) 
8. Place a spare piece of absorbent material in the armpits and under the neck, where you are likely to have 
dripping iodine 
9. Using the ‘dirty hand/clean hand’ method, clean the intended insertion points and surrounding areas with a 
cotton ball soaked in povidone iodine (removed carefully from the sterile area with the clean hand, *separate 
cotton ball for each site*) 
10. BEFORE PUTTING ON STERILE GLOVES: 
• Make sure that the relevant pots (with lids removed) are on the appropriate placemats in an 
accessible location 
• Ensure that sharps bin is open and easily accessible 
• Double check that all necessary sterile equipment has been opened onto the field 
11. Put on a pair of sterile gloves using appropriate technique (see Section 2) 
   STERILE    
12. Open one of the drapes contained in the sterile procedure pack and tear it in half (or use a remaining half 
drape), taking care to keep the folds away from the body and upper arms 
13. Place one of the drape pieces back into the sterile field and fold the remaining piece in half, longitudinally, and 
then into thirds 
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14. Tear two small holes in the sterile drape, location depending on the size of the deceased’s chest, and dispose 
carefully of the removed piece, taking care not to contaminate yourself 
15. Place the drape over the chest of the deceased, with the holes over the area intended for needle insertion - 
*TAKE CARE NOT TO TOUCH THE BODY WHILE PLACING THE DRAPE* 
16. Use sterile gauze to carefully clean away the residual iodine from the sterilised areas (using a circular motion, 
as previously) 
17. Using the scalpel, make a small nick in the skin in the insertion point for the RIGHT lung 
18. Place a piece of sterile gauze in your new sterile field (on the chest of the deceased) and rest your hypodermic 
needle on it 
19. Using your right hand, insert the biopsy needle (with the cutting blade withdrawn) into the nick made by your 
scalpel and direct it postero-medially until you feel a bit more resistance.  Lung tissue tends to collapse post-
mortem, and it can feel little like you are pushing a needle into a small pillow filled with straw…   
20. After you feel the tip of the needle enter the lung, push it in a further 1-2cm without changing the direction 
21. Holding the body of the needle steady with your right hand, push the cutting blade forward, slowly (this is 
particularly important with the lung biopsies), with your left hand until you feel it click closed 
22. Holding the entire needle (body and cutting blade) closed, withdraw it from the abdomen, being particularly 
aware of people/items around you 
23. Pull back the cutting blade to examine the sample 
24. Use the hypodermic needle to try and stretch out your sample along the shaft of the needle.  Lung tissue is 
very delicate and can get crushed in the biopsy process, so very often what looks like a very small sample can 
actually be very large! 
25. If you have obtained a satisfactory sample, transfer the biopsy needle to your left hand, pick up the 
hypodermic needle with your right hand and, taking care to maintain sharps safety and sterility, transfer the 
tissue sample into the appropriate container (ensure that right and left lung samples go into the appropriate 
histology pots) 
26. Be careful not to touch any of the sample pots with either the biopsy needle or the hypodermic needle 
27. Remember: for histology, the important thing is sample quality; for TB & micro, the important thing is sample 
quantity 
28. Try to obtain at least 5 samples of high quality for histology and at least 8-10 samples (each) for microbiology 
and TB from the right lung 
29. When all right lung samples have been obtained to your satisfaction, use the scalpel to make a nick in the pre-
marked position on the left chest wall and repeat the procedure (you may need a fresh piece of gauze at this 
stage) 
30. It is suggested that you move to the left of the deceased to complete the left lung biopsies 
31. Try to obtain at least 5 samples of high quality for histology and at least 8-10 samples (each) for microbiology 
and TB from the left lung 
32. When all left lung samples have been obtained to your satisfaction, place the biopsy needle and the 
hypodermic needle into the sharps bin immediately 
   STERILE    
33. Clean excess iodine from the area and dispose of the drape 
34. Remove sterile gloves 
35. Close the universal containers tightly and place the microbiology and TB containers immediately into an 
environment where they will be maintained at 2-8C.  The ‘R lung and liver’ histology container can also be 
placed into the insulated box at this stage  
36. Prepare for spleen biopsy 
8.5.1.6 Spleen biopsy 
8.5.1.6.1 Equipment needed 
1. Disposable scalpel x 1 (re-use) 
2. Biopsy needle x 1 
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3. 18G hypodermic (pink) needle x 1 
4. Pack of sterile gauze x 1 (if needed) 
5. Alcohol swabs x 4 
6. Pair of sterile gloves x 1 
7. Histology (red-top) universal container (Label: ‘L lung and spleen’) *pre-filled with formalin* 
8. TB (blue-top) universal container (Label ‘Tissue (spleen)’) *pre-filled with sterile saline* 
9. Microbiology (white-top) universal container (Label: ‘Tissue (spleen)’) *dry * 
10. ‘Spleen’ placemat 
8.5.1.6.2 Procedure details 
1. Put on a pair of large, non-sterile gloves 
2. Open the sterile equipment onto the field (using sterile technique) 
3. Biopsy needle 
4. Hypodermic needle 
5. Sterile gauze (if necessary) 
6. Identify the appropriate point for needle insertion (LEFT mid-clavicular line, below the costal margin [see 
Figure 3]) and mark the point with a felt pen 
7. Using the ‘dirty hand/clean hand’ method, clean the intended insertion point and the surrounding area with at 
least four alcohol swabs, using the prescribed technique (start at the middle, move outwards in a clockwise 
motion) 
8. Place a spare piece of absorbent material under the torso, where you are likely to have dripping iodine 
9. Using the ‘dirty hand/clean hand’ method, clean the point and surrounding area with a cotton ball soaked in 
povidone iodine (removed carefully from the sterile area with the clean hand) 
Appendix figure 5. Anatomical site for splenic biopsy 
 
 
10. BEFORE PUTTING ON STERILE GLOVES: 
• Make sure that the relevant pots (with lids removed) are on the appropriate placemats in an 
accessible location 
• Ensure that sharps bin is open and easily accessible 
• Double check that all necessary sterile equipment has been opened onto the field 
11. Put on a pair of sterile gloves using appropriate technique (see Section 2) 
   STERILE    
12. Open one of the drapes contained in the sterile procedure pack and tear it in half (or use a remaining half 
drape), taking care to keep the folds away from the body and upper arms 
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13. Place one of the drape pieces back into the sterile field and fold the remaining piece in half longitudinally and 
then in half again 
14. Tear a small hole in the sterile drape and dispose carefully of the removed piece, taking care not to 
contaminate yourself 
15. Place the drape over the abdomen of the deceased, with the hole over the area intended for needle insertion - 
*TAKE CARE NOT TO TOUCH THE BODY WHILE PLACING THE DRAPE* 
16. Use sterile gauze to carefully clean away the residual iodine from the sterilised area (using a circular motion, as 
previously) 
17. Using the scalpel, make a small nick in the skin in the area previously marked 
18. Place a piece of sterile gauze in your new sterile field (on the abdomen of the deceased) and rest your 
hypodermic needle on it 
19. Using your right hand, insert the biopsy needle (with the cutting blade withdrawn) into the nick made by your 
scalpel and direct it supero-postero-laterally until you feel the tip entering the spleen  
20. After you feel the tip of the needle enter the organ, push it in a further 1-2cm without changing the direction 
21. Holding the body of the needle steady with your right hand, push the cutting blade forward, slowly, with your 
left hand until you feel it click closed 
22. Holding the entire needle (body and cutting blade) closed, withdraw it from the abdomen, being particularly 
aware of people/items around you 
23. Pull back the cutting blade to examine the sample 
24. If you have obtained a satisfactory sample, transfer the biopsy needle to your left hand, pick up the 
hypodermic needle with your right hand and, taking care to maintain sharps safety and sterility, transfer the 
tissue sample into the appropriate container 
25. Be careful not to touch any of the sample pots with either the biopsy needle or the hypodermic needle 
26. Remember: for histology, the important thing is sample quality; for TB & micro, the important thing is sample 
quantity 
27. Try to obtain at least 5 samples of high quality for histology and at least 8-10 samples (each) for microbiology 
and TB 
28. When all samples have been obtained to your satisfaction, place the biopsy needle and the hypodermic needle 
into the sharps bin immediately 
   STERILE    
29. Clean excess iodine from the area and dispose of the drape 
30. Remove sterile gloves 
31. Close the universal containers tightly and place the microbiology and TB containers immediately into an 
environment where they will be maintained at 2-8C  
32. Prepare to extract CSF 
8.5.1.7 CSF sampling 
8.5.1.7.1 Equipment needed 
1. Spinal needle x 1 
2. Syringe x 1 
3. Hypodermic (pink) needle x 1 
4. Alcohol pads x 4 
5. Pack of sterile gauze x 1 
6. Pair of sterile gloves x 1 
7. Beige-top vacutainers x 4 (2 for Micro, 2 for TB) 
8. Red-top vacutainer x 1 (if CSF clear) 
9. Purple-top (EDTA) vacutainer x 1 (if CSF bloodstained) 
10. ‘CSF’ placemat 
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8.5.1.7.2 Procedure details 
1. Put on a pair of large, non-sterile gloves 
2. If possible, always approach from the right of the body, so that the top of the head is towards your left (non-
dominant) hand 
3. Turn the head towards the patient’s left shoulder 
4. You may need to apply some pressure to the left arm to move the left shoulder inferiorly 
5. Palpate the spinous processes of the cervical spine, moving superiorly, until you find the gap between the 
superior-most vertebral body and the base of the skull (in the midline [see Figure 4]) 
6. Using the ‘dirty hand/clean hand’ method, clean the intended insertion point and the surrounding area with at 
least four alcohol swabs, using the prescribed technique (start at the middle, move outwards in a clockwise 
motion) 
7. Place a spare piece of absorbent material under the head, where you are likely to have dripping iodine 
8. Using the ‘dirty hand/clean hand’ method, clean the point and surrounding area with a cotton ball soaked in 
povidone iodine (removed carefully from the sterile area with the clean hand) 
9. BEFORE PUTTING ON STERILE GLOVES: 
• Make sure that the necessary vacutainers are on the appropriate placemats in an accessible 
location 
• Ensure that sharps bin is open and easily accessible 
• Double check that all necessary sterile equipment has been opened onto the field 
 
10. Put on a pair of sterile gloves using appropriate technique (see Section 2) 
Appendix figure 6. Sagittal section of brain, showing entry point for CSF extraction 
 
   STERILE    
11. Place a sterile sheet over the head and use your left hand to stabilise 
12. Get onto your haunches to ensure better estimation of the needle’s plane 
13. Ensure that the needle’s bevel is always facing upwards (see Figure 5) 
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Appendix figure 7. Diagram of needle tip showing ideal bevel position 
 
 
14. Insert the spinal needle into the pre-identified spot, directing it gently towards the middle of the eyes 
15. Once the needle is inserted to roughly 4/5 of its length, remove the cutting needle from the core and carefully 
attach the syringe, taking care not to twist the needle 
16. Gently draw on the syringe to extract 20ml of CSF 
17. Attach a hypodermic needle to the syringe and transfer the CSF into the 5 waiting vacutainers (red-top if clear, 
purple-top if bloodstained) 
   STERILE    
18. Transfer the two parts of the spinal needle and the hypodermic needle into the sharps bin immediately 
19. Use a swab to clean the remaining iodine and dispose of the sterile sheet 
20. Remove sterile gloves 
21. Transfer the 5 vacutainers to an environment of 2-8C 
22. Prepare to tidy up and complete autopsy 
8.5.1.8 Finishing the autopsy (checklist) 
8.5.1.8.1 Cadaver 
1. Cleaned up  ..........................................................................................................................................................  
2. Sutures  ................................................................................................................................................................  
3. Plasters  ...............................................................................................................................................................  
8.5.1.8.2 Samples 
1. TB labelled  ..........................................................................................................................................................  
2. TB packed  ...........................................................................................................................................................  
3. Micro labelled  .....................................................................................................................................................  
4. Micro packed  ......................................................................................................................................................  
5. Histology labelled  ...............................................................................................................................................  
6. Histology packed  ................................................................................................................................................  
7. NICD labelled  ......................................................................................................................................................  
8. NICD packed  .......................................................................................................................................................  
8.5.1.8.3 Equipment 
1. Wiped down with cleaning fluid  .........................................................................................................................   
2. Packed  ................................................................................................................................................................  
3. White waste bag sealed and transferred to red waste bag (while still wearing protective clothing)  ................  
4. Red waste bag sealed and disposed (ideally at health facility)  ..........................................................................   
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8.5.2. Summary of laboratory procedures (adapted from upgrading report) 
Summary of samples obtained and laboratory tests done as part of minimally-invasive autopsy procedure 
Sample 
type 
Test type Basic tests Reflex tests 
Looking for AFB Fungi Bacte
ria 
Maligna
ncy 
Pneumocyst
is jirovecii 
Aerobic 
bacteria 
Cryptococcus  
neoformans 
Mycobacterium 
tuberculosis 
Bacterial 
species 
Confirmatio
n of AFB 
ID TB complex 
+/- INH/RIF 
resistance 
Non-
tuberculous 
mycobacteria 
Test ZN 
stain 
Grocot
t stain 
B&H 
stain 
IP stain Immuno-
fluorescenc
e 
Aerobic 
culture 
Crypto-
coccal 
antigen 
Crypto-
coccal  
culture 
MGIT 
culture 
Xpert 
MTB/ 
RIF 
Bacterial 
ID (if +ve 
bacterial 
stain) 
ZN stain (if 
+ve MGIT) 
Hain 
GenoType 
MTBDRplus (if 
+ve MGIT) 
Hain GenoType 
MTB CM/AS (if 
+ve MGIT & -ve 
MTB ID) 
TB/ 
Micro-
biology  
Lung biopsies (R&L) 
N/A 
X ✓ X ✓ ✓ X 
N/A 
✓ ✓ ✓ 
BAL ✓ ✓ X X ✓ ✓ ✓ ✓ ✓ 
Liver X X X X ✓ X ✓ ✓ ✓ 
Spleen (+/-LN) X ✓ X X ✓ X ✓ ✓ ✓ 
CSF X X ✓ X ✓ X ✓ ✓ ✓ 
Histo-
logy 
Block 1 (RL + liver) ✓ ✓ 10% 5% 
N/A 
✓ 
N/A Block 2 (LL + spleen) ✓ ✓ 10% 5% ✓ 
(+/- Block 3) ✓ ✓ 10% 5% ✓ 
+ve: positive; -ve: negative; AFB: Acid-fast bacilli; BAL: Bronchoalveolar lavage; CSF: Cerebrospinal fluid; G+ve: Gram positive; G-ve: Gram negative; ID: identification; INH=Isoniazid; 
IP: immunoperoxidase; L: Left; LL: Left lung; LN: Lymph node(s); MGIT: Mycobacteria growth indicator tube; MTB: Mycobacterium tuberculosis; R: Right; RIF: Rifampicin; RL: Right 
lung; TB: tuberculosis; ZN: Ziehl-Neelsen; 
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8.5.3. Assigning clinical causes of death: overview (adapted from upgrading appendix) 
 
CoD: cause of death; ICD: International classification of diseases; L1: Level 1; L2: Level 2; L3: Level 3; LK: Lesedi Kamoso  
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8.5.4. Stata code for generation of MMDS input file from PCVA or clinical CoD 
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8.5.5. Stata code for conversion of WHO 2012 data into appropriate format for SmartVA-Analyze 
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8.6. Appendix 6: Miscellaneous 
8.6.1. Response to peer reviewer for research paper 2 (Chapter 4) 
Dr Pere-Joan Cardona 
Academic Editor 
PLOS ONE 
02 September 2016 
 
Dear Dr Cardona, 
 
Re: PONE-D-16-18440 
 
Autopsy Prevalence of Tuberculosis and Other Potentially Treatable Infections among Adults with Advanced HIV 
Enrolled in Out-Patient Care in South Africa 
 
Thank you for the opportunity to respond to the reviewer’s comments.  Her/his comments are shown in bold and our 
responses in normal font.  All page and line numbers referenced below correspond to the document named 
RevisedManuscriptWithTrackedChanges.docx. Text from the original manuscript is shown in grey, dashed boxes, and 
text from the revised manuscript in solid, black boxes. 
 
1. The study background identifies causes of high early mortality among HIV-positive adults starting ART as a key 
issue the study wanted to address. However, in the decedents, only 74% were actually on ART at some point after 
enrolment. What happened to the other 26% and was there any correlation with autopsy findings? 
Thank you for your comment.  Existing literature documents that early mortality is high both among HIV-positive 
people who start ART and among those with advanced disease who have not yet started ART.  In our study, causes of 
death in both groups were of interest.  In the parent clinical trial, TB Fast Track, we recruited people with advanced 
disease at the point their CD4 count was known, reflecting the reality of clinical practice, because we were interested in 
the potential for empirical TB treatment to influence clinical outcomes if implemented at the earliest opportunity.  The 
evidence cited in the background includes reference to mortality among people who have not started ART. 
 
To explain this better, we have added a reference (Ref 3: Bassett et al. JAIDS 2016 Apr) and made a minor amendment 
to the text (page 4, lines 64-66).   
 
 
Original text 
Mortality in the first year of antiretroviral therapy (ART) remains high, particularly among those with 
advanced HIV disease in resource-constrained settings [1]. 
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TB Fast Track was a pragmatic study. In the intervention arm, study staff were guided by the study algorithm 
concerning when participants started TB treatment or ART, but final decisions were at the discretion of the clinic 
doctor; in the control arm, participants were managed according to routine practice.  Six (66%) of the nine decedents 
who underwent MIA and did not receive ART prior to death were started on TB treatment prior to death and died a 
median 11.5 days after enrolment, so were unlikely to have had time to start ART (according to South African practice, 
usually started two weeks after the start of TB treatment).  The remaining three individuals died one, 14, and 48 days 
after enrolment (decedents 30, 17, and 08, respectively; S2 Table).  According to verbal autopsy narratives from 
relatives of the deceased, decedent 17 was thought to have TB by clinic staff, but did not return to the clinic to start 
treatment; and decedent 08 was being investigated for TB by the clinic and referral hospital, but encountered delay 
waiting for tests. 
 
With a total sample of 34 decedents, we have very low power to compare between groups, so we have not made 
comparisons for example between ART status and autopsy findings (of the 25 decedents who started ART, 14 [56%] had 
autopsy evidence of TB and 11 [44%] did not).  Summary data, including length of time on ART prior to death, are 
included in the supplementary material (S2 table).  
 
We have not changed the manuscript with regards to the second part of the reviewer’s comment. 
 
2. What is the correlation between full autopsy and MIA in terms of sensitivity and specificity for TB (or other 
infections)? I don’t think this is adequately discussed?  
 
At present there is only one study which has compared MIA to full autopsy (Ref 18: Cox et al. JAIDS 2014;67(2):169-76).  
Results from a large study comparing full autopsy to MIA are awaited (Bassat et al. Lancet Glob Health 2013; 1:e125-
e126). 
 
We have added more detail to the methods concerning the performance of MIA compared to full autopsy (page 4, lines 
82-90). 
 
Revised text (page 4, lines 64-66) 
Mortality among HIV-positive adults prior to starting and in the first year of antiretroviral therapy 
(ART) remains high, particularly among those with advanced disease in resource-constrained settings 
[1-3][22–24].   
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3. For those selected to have an MIA, there does seem to be some selection bias in that the decedents who did not 
have an MIA (the overwhelming majority) were much less likely to be on TB treatment, and therefore may well have 
significantly different of TB detectable at autopsy if they had received autopsy. The study could well underestimate 
the true rate of TB in this population and maybe this needs to be discussed further? 
 
Thank you for raising this.  As stated in the methods, we conducted MIA on everyone possible, but a potential 
explanation for this difference in TB treatment may be that those taking TB treatment were more likely to have regular 
contact with clinics, increasing the likelihood of our ascertaining their death in time for MIA.  We agree that because 
individuals who underwent MIA were more likely to have been treated for TB compared to those who did not undergo 
MIA, we could have underestimated TB prevalence at death in the overall study population.   
 
We have now addressed this in the text (page 13, lines 320-326).  
 
 
 
Original text 
Full pathological autopsy with sampling of all organs remains the gold standard for assigning cause of 
death [15,16], but it is expensive, time consuming, and not well accepted by families, who are often 
required to provide consent [17].  There is growing evidence that minimally invasive autopsy (MIA) 
can provide useful information relevant to cause of death, particularly with regards to infectious 
diseases [16,18].   
Revised text (page 4, lines 82-90) 
Full pathological autopsy with visualisation and sampling of all organs remains the gold standard for 
assigning cause of death [17,18], but it is expensive, time consuming, and not well accepted by 
families, who are often required to provide consent [19].  There is growing evidence that minimally 
invasive autopsy (MIA) can provide useful information relevant to cause of death, particularly with 
regards to TB and other infectious diseases [20,21]; one study, involving 96 HIV-positive adults in 
Uganda, compared histology from MIA to that from full autopsy and found that MIA was 71% 
sensitive and 100% specific in detecting TB [18].  Adding culture and/or other bacteriological 
modalities to MIA would likely improve its sensitivity in this regard.   
Original text 
Those who had MIA and those who did not were largely similar with regard to characteristics at 
enrolment and during follow up.  In this group, we found the autopsy prevalence of active TB to be 
almost 50%.   
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4. Does the overall study population selected into TB Fast Track exhibit some selection bias compared to the “at-risk” 
population? Were certain people more likely to have participated or not? 
 
TB Fast Track criteria were very inclusive: adults, with CD4 150 cells/L, not on TB treatment or ART at the time of 
enrolment, and well enough to not require referral to hospital (respiratory rate <30/minute, pulse <120/minute and 
systolic blood pressure >90mmHg).  As such, only 38/3091 (1.2%) individuals were screened and not enrolled, 26/38 
(68.4%) because they declined to take part.  Of the 3053 individuals enrolled, a further 31 (1.0%) were subsequently 
excluded, leaving 3022 for final analysis (NB: this was previously stated as 3032 and has been corrected [page 7, line 
176]).  We are therefore reasonably confident that the overall study population is representative of adults with 
advanced HIV, not on ART or TB treatment, attending public primary health clinics in these parts of South Africa.  
 
We have not changed the manuscript. 
 
5. Line 94 – maybe identify public service PHCs versus private? This is important in that public health services cater 
for uninsured people of lower socio-economic status. This is the “at-risk” population from which the study 
population is derived. 
 
Thank you, we have amended the text so that PHCs are now referred to as ‘public sector’ (page 4, line 93; page 5, line 
100). 
 
6. Could silicosis play a confounding role if the study population contains many former miners? Ex-miners in 
Southern Africa are known to have high prevalence of silica dust exposure and silicosis. Thus the high prevalence of 
TB at MIA could really be only applicable to this type of population. It’s not clear in reference 21. There is no 
reference to occupation for those employed. With this in mind, how generalizable are these findings? 
 
Information on occupation was unfortunately not collected at enrolment to TB Fast Track.  However, the majority of 
study sites (16/24) were in areas (Ekurhuleni and Tshwane) not known as labour-sending areas for mines and over half 
of those enrolled to the study were women, who rarely work underground.   Questions around mining history were 
included in verbal autopsies, which were administered to the families of 212 TB Fast Track decedents (including the 34 
Revised text (page 13, lines 320-326) 
Those who had MIA and those who did not were largely similar with regard to characteristics at 
enrolment and during follow up, although those with MIA were more likely to have been treated for 
TB between enrolment and death.  This, together with the likelihood that MIA will miss some cases 
that may be identified by full autopsy [18], suggests that the prevalence of TB at death among the 
entire population of decedents in TB Fast Track may have been even higher than the almost 50% 
found in this sample. 
An autopsy study exploring the spectrum of disease in individuals with advanced HIV 
 in primary care clinics in South Africa 
 Page 374 of 383 Chapter 8: Appendices 
who underwent MIA); nine (4.2%) reported that their relative had worked underground and only one of these 
decedents underwent MIA, where no evidence of TB was found (decedent 25, S2 table).  None of the lung samples 
obtained as part of MIA showed any evidence of silicosis on histological examination.  We therefore believe that our 
findings are generalisable to other adults with advanced HIV receiving the majority of their care from community 
facilities in low- and middle-income countries with a high TB burden.  
 
We have not changed the manuscript. 
 
7. Line 44 – it seems from the methods section some were followed up for more than 6 months. 
 
Thank you, this was an error.  We have amended the text to reflect that participants had ‘at least’ six months’ follow-up 
(page 3, line 44; page 5, line 106). 
 
8. Line 51 and 160 and 335 – are the bacterial results clinically relevant still 5 days after death on average? Could 
these be artefacts or bacteria that have thrived since death rather than represent a clinical infection that contributed 
to death? Although this is mentioned, I don’t think this has been adequately discussed. Is there any other literature 
to reference around this? 
 
This is still a contested issue, but there is some evidence to suggest that a delay between death and autopsy should not 
have a major impact on the validity of results, as long as the body is kept refrigerated.   
 
We have now discussed this in more detail (page 15, lines 372-384) and added additional references, including a review 
of over 5000 autopsies (Ref 43: Morris et al. J Clin Path 2006;59(1):1-9). 
 
 
 
Original text 
The interpretation of culture results from autopsy specimens is not straightforward and is 
complicated further when the procedure is conducted many days after death, providing greater 
opportunity for tissue autolysis and translocation of organisms to compartments they did not occupy 
in life [36,37].  Pathologists have suggested that the translocation of organisms to CSF and blood is 
inevitable and may even be facilitated by post-mortem examination [38].  In our study, samples from 
all sites, except CSF, grew some organisms that were likely artefact (S1 Table). 
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9. Line 59 – this paper could maybe suggest further research is needed to define the structured pathway. For 
instance, the algorithm used to assign TB treatment at enrolment seems to miss many cases of active TB found at 
autopsy; only 63% with TB at autopsy were on TB treatment between enrolment and death. 
 
Thank you for raising this.  We should have mentioned that of the six individuals with TB at autopsy who were not 
started on TB treatment, five were enrolled to the control arm of TB Fast Track and were therefore not assessed using 
the study algorithm.   
 
We appreciate that this was not clear enough in the text and have amended the manuscript appropriately (page 9, lines 
235-237).  
 
 
 
 
 
10. Line 75 – however most decedents died in hospital in this study (74%). Maybe the point is not where they died but 
where they received most of their care? 
 
Although a high proportion of individuals in this study did die in hospital, we consider the 26% that died outside of 
hospital to be a vital part of this study.  Almost all previous autopsy studies in sub-Saharan Africa have included only 
individuals who die in hospitals; data on causes of death those dying outside of this setting are sparse and it may be 
Revised text (page 15, lines 372--384) 
The interpretation of culture results from autopsy specimens is not straightforward and may be 
complicated further when the procedure is conducted many days after death, potentially providing 
greater opportunity for tissue autolysis and translocation of organisms to compartments they did not 
occupy in life [40-42].  However, there is evidence to show that the time from death to autopsy does 
not have a major effect on false-positive bacterial results if the body is kept refrigerated [43-44].  One 
study, conducted among 507 infants with sudden and unexpected deaths, even suggests that a 
longer interval may allow for fewer false-positive results [45]; and there are reports of pathogens 
recovered from bodies in states of advanced decomposition [46,47].   In our study, samples from all 
sites, except CSF, grew some organisms that were likely artefact (S1 Table); data from each decedent 
were reviewed individually by a microbiologist to decide on likely contaminants. 
Original text 
Six (38%) individuals with evidence of TB at autopsy were not started on TB treatment ante-mortem. 
Revised text (page 9, lines 235-237) 
Six (38%) individuals with autopsy evidence of TB were not started on TB treatment ante mortem, 
five of whom were enrolled to the control arm of TB Fast Track. 
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that there are important differences in causes of death depending on the location of death.  Although our sample size is 
too small to draw any conclusions in this regard, our sample was drawn from a trial population broadly inclusive of 
adults with advanced HIV disease in primary care and is not biased by place of death. We have made minor 
amendments to the background to add clarity (page 4, lines 73-77). 
 
 
 
 
 
11. Line 170 – were any of the 2401 lost to follow up and is there any source of selection bias here? 
 
Overall loss to follow up was very low in TB Fast Track, with vital status at six months ascertained using various sources, 
including patient interview, case note abstraction, and use of the South African ID number.  Vital status at 150 days 
post-enrolment was known for 2972/3022 (98.3%) individuals. 
 
NB: The number of individuals enrolled to TB Fast Track after the autopsy sub-study started was 2396, rather than the 
previously stated 2401.  This error has now been corrected (page 7; lines 176-179). 
 
Among the 2396 who were asked for permission for autopsy at enrolment, 226 individuals died; vital status at 150 days 
was known for 2346/2396 (97.9%) individuals.   
 
We would suggest that the relatively low loss to follow-up among those recruited after August 2013 was unlikely to 
have biased selection for autopsy.  We have not made changes to the manuscript. 
 
12. Line 216 – is it unexpected that only 5 / 16 tested Xpert MTB/RIF positive? I would have thought his unusual or 
worth commenting on? 
 
Xpert MTB/RIF was conducted only on BAL samples, compared to culture and histology on almost all other samples.  
This was due to budget limitations, but also because we were primarily interested in recovering viable MTB, whereas 
Xpert MTB/RIF also identifies dead bacilli.  In addition, two individuals with autopsy evidence of TB did not have BAL 
Original text 
Pathological autopsy studies provide the most accurate estimates, but the vast majority have 
included only hospitalised adults and do not necessarily represent the broader population of people 
who receive out-patient care from primary care clinics and may die outside of hospitals [13]. 
Revised text (page 4, lines 73-77) 
Pathological autopsy studies provide the most accurate estimates, but almost all have only included 
individuals recruited after admission to hospital and do not necessarily represent the broader 
population who receive the majority of their care from primary health clinics and may die outside of 
hospitals [15].   
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samples obtained, so the proportion with positive Xpert MTB/RIF is actually 35.7% (5/14).  Regardless, we do agree 
that this issue requires more attention and have discussed further the potential use of Xpert MTB/RIF in autopsy 
studies, including a reference to recently published work from Mozambique (Ref 21: García-Basteiro, Scientific Reports 
2016;6:20703; page 16, lines 393-404). 
 
 
 
 
13. Line 318 to 322 – is it worth expanding a little more on the formidable challenges? 
We agree and have expanded our description (page 14, lines 345-352). 
 
 
Original text 
Combining BAL Xpert MTB/RIF with BAL mycobacterial culture would have detected nine of our TB 
cases; adding mycobacterial culture of lung tissue would add a further two; and histological 
examination of lung tissue a further three; accounting for 88% of the TB seen in our decedents. 
Revised text (page 16, lines 393-404) 
Combining BAL Xpert MTB/RIF with BAL mycobacterial culture would have detected nine of our TB 
cases; adding mycobacterial culture of lung tissue would add a further two; and histological 
examination of lung tissue a further three; accounting for 88% of the TB seen in our decedents.  The 
role of Xpert MTB/RIF as part of the autopsy process is not established: a recent study testing post 
mortem liver, lung, and brain tissue found that it detected TB in 7/8 (87.5%) cases, although the gold 
standard used was another PCR technique, rather than liquid culture [21].  In our study, only 5/14 
(35.7%) decedents with BAL specimens and evidence of TB had a positive Xpert MTB/RIF, though 
this test was done only on BAL specimens, whereas culture and histology were conducted on 
specimens from many other anatomical sites, many of them extrapulmonary.  There were three 
decedents whose BAL specimens were Xpert MTB/RIF negative, but culture positive for MTB 
(decedents 2, 4, and 33; S2 table).  More work is needed to establish the optimum use of this and 
other molecular techniques in post mortem specimens. 
Original text 
WHO now recommends Xpert MTB/RIF for use on extrapulmonary samples [32] and, though there 
are formidable challenges in establishing alternative diagnostic algorithms and care pathways for 
those at highest risk of extrapulmonary disease, particularly in primary care in resource-limited 
settings, these data suggest that they are obstacles that must be overcome in order to achieve any 
meaningful reduction in TB mortality. 
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14. Line 333 and 334 – is it worth mentioning the latest guidelines to start ART on initial HIV diagnosis? 
These are now referred to (page 15, lines 366-368). 
 
15. Line 497 – close bracket 
Many thanks.  This has been amended accordingly (page 19, line 564). 
 
Other alterations made to the manuscript 
1. We can confirm that separate ethical approvals were received for the parent study and the autopsy sub-study.  
Line 153 of the manuscript and the submission ethics statement have been amended accordingly 
2. Minor changes to overall numbers of TB Fast Track participants enrolled (page 7, lines 176-179) 
3. Minor rewording to the description of reference 34 (Lawn 2015; page 14, lines 340-345) 
4. Addition of a more detailed description of reference 4 (Bates 2015; page 15, lines 358-361) 
5. Addition of an extra figure (new Figure 1) which provides examples of some of the histological changes 
observed at autopsy 
6. Added references:  
a. Ref 3: Bassett et al. JAIDS 2016 Apr 
b. Ref 21: Garcia-Basteiro et al. Nature 2016 
c. Ref 37: WHO 2016 ART guidelines 
d. Ref 43: Morris et al. J Clin Path. 2006;59(1):1-9 
e. Ref 44: Christoffersen et al. Forensic Sci Int. 2015;250:27-32 
f. Ref 45: Weber et al. Forensic Sci Int. 2010; 198(1-3):121-5 
g. Ref 46: Maujean et al. J Forensic Sci. 2013; 58(4): 1069-70 
h. Ref 47: Palmiere et al. J Forensic Leg Med. 2015;30:21-4 
 
Thank you again for your review of this article.  We trust that these revisions are satisfactory and look forward to 
hearing from you. 
 
Kind regards, 
 
Aaron Karat 
Corresponding author 
 
  
Revised text (page 14, lines 345-352) 
WHO recommends Xpert MTB/RIF for use on extrapulmonary samples [35].  However, there are 
formidable practical and financial challenges in establishing alternative diagnostic algorithms and 
care pathways in primary care in resource-limited settings, in particular, the lack of a sensitive, cost-
effective, point-of-care diagnostic test, and the difficulties in obtaining suitable specimens samples 
in individuals who cannot produce sputum.  Regardless, the data suggest that these are obstacles 
that must be overcome in order to achieve any meaningful reduction in TB mortality. 
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8.6.2. Response to peer reviewers for research paper 3 (Chapter 5) 
Dr Petros Isaakidis 
Academic Editor 
PLoS One 
 
03 March 2017 
Dear Dr Isaakidis, 
 
Re: PONE-D-16-43976 
 
Measuring mortality due to HIV-associated tuberculosis among adults in South Africa: comparing verbal autopsy, 
minimally-invasive autopsy, and research data; Karat AS, et al. 
 
Thank you for the opportunity to respond to the reviewers’ comments.  Their comments are shown in bold and our 
responses in normal font.  All page and line numbers referenced below correspond to the document named 
RevisedManuscriptWithTrackedChanges.docx. Text from the original manuscript is shown in grey, dashed boxes, and 
text from the revised manuscript in solid, black boxes. 
 
 
1. Population versus Individual level accuracy. The findings suggest better VA performance at population level. It can 
be argued that improved performance at the population level is still valuable information for policy decisions. Given 
the pertinence of the finding in this regards, readers will likely anticipated a discussion on; particularly given the poor 
performance at the individual level. 
 
Thank you for this comment.  We agree that this issue required further discussion and, as a combined response to this 
and the point raised by Reviewer #2, we have added to the text the sub-section below.   
 
 
 Amendment #1 (Discussion) 
Added text (page 19, lines 486–514) 
Moving forward 
In the absence of robust, validated CRVS data, there are few alternatives to VA that are both feasible and cost-effective 
to generate estimates of cause-specific mortality in countries with high HIV and TB prevalence [65,66].  Although, in this 
study, VA methods performed poorly in assigning individual CoD, it should be noted that VA is primarily intended to 
generate population-level estimates [18], and that performance in this regard was better.  However, when using study-
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defined codes, which were designed to allow for the differentiation of HIV-associated TB from other HIV-associated 
causes, the population-level accuracy of PCVA was still sub-optimal (ρC 0.70 and CSMF accuracy 0.71 compared to L2 
standard [n=259]; Table 3), confirming the difficulty of making this distinction. 
 
The challenges of diagnosing HIV-associated TB disease are well documented [67,68] and, as found in a recent 
systematic review of autopsy studies [4], in the absence of new diagnostics it is likely that clinicians will continue to 
underdiagnose TB, which will have important implications for measuring progress towards the WHO targets described 
above [16].  Improvements are needed to TB surveillance methods, which, at present, consist mostly of enumerating 
individuals already diagnosed and started on treatment [69–71].  Minimally-invasive autopsy is a useful technique for 
estimating the prevalence of infectious diseases [72,73], is acceptable to a high proportion of families [26,74], and 
could be used periodically for surveillance at sentinel sites [75], allowing for more accurate evaluation of the impact of 
disease-focused interventions. 
 
Population-level estimates of cause-specific mortality are extremely valuable and improving the accuracy of VA-
generated estimates would be of benefit, regardless of whether or not VA is used to assign individual CoD.  The 
continued development and sharing of gold standard datasets that include pathological autopsy data, better reflecting 
the high proportions of HIV-associated mortality seen in high-burden countries and including both hospital and 
community deaths in different populations, would allow for greater standardisation in future validation studies.  The 
parallel development of a structured, standardised process for CoD assignment, similar to that described in the Coding 
Causes of Death in HIV (CoDe) project [76], but assigning CoD matched to ICD codes [77], would increase the value of 
this exercise. 
 
2. VA methods will ultimately be as good as the information gathered during the interviews. What role could recall 
bias have played in the quality of information given that the median time to VA after death was quite (....but 
typically so) long i.e 146 (IQR 82-290) days 
 
Thank you for the comment.  Although the median time from death to VA was just outside the ‘ideal’ window described 
by previous authors, it was well within the maximum 12 months recommended by WHO.  In addition, recent work by 
colleagues at Agincourt HDSS, South Africa, using VA data in WHO 2012 format, showed only minor differences in 
cause-specific mortality fractions (CSMFs) generated by InterVA-4 for adults with VA conducted 0–5 months after death 
compared with those with VA conducted 6–12 months after death (Hussain-Alkhateeb L, et al. Emerg Themes 
Epidemiol. 2016;13: 1–6).  Specifically, the CSMF ratios between the two groups for the 3759 deaths attributed to 
‘HIV/AIDS’ or ‘pulmonary TB’ were 1.03 (99% confidence interval [CI] 0.93–1.13) and 1.07 (99% CI 0.97–1.19), 
respectively. 
 
The small impact of recall period on causes of death assigned by VA is corroborated by work from colleagues at the 
Institute of Health Metrics and Evaluation (Serina P, et al. Popul Health Metr. 2016;14: 40).  This evaluation of 1394 
adult deaths in India and the Philippines, using the Tariff 2.0 method (the method employed by SmartVA-Analyze), 
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found that the probability of obtaining a ‘correct’ VA-assigned cause of death (compared with the gold standard used in 
the study) decreased by around 0.6% per month; the probability of accuracy of VAs conducted 4–11 months after death 
was 95.9% of those conducted within three months after death.  As such, we do not feel that the time from death to 
VA, and therefore recall bias, will have had a substantial influence on our outcomes. 
 
We have amended the ‘limitations and strengths’ sub-section of the manuscript as detailed below and have cited the 
two studies described above.  
 
 
 Amendment #1 (Discussion) 
Original text 
This study had limitations: physicians who reviewed clinical and VA data were aware… 
 
Amended text (page 19, lines 517–520) 
This study had limitations: the median time from death to VA was slightly longer than the ideal three months that some 
recommend, but was well within the maximum 12 months recommended by WHO and was therefore considered 
unlikely to have had a substantial effect on VA-generated estimates [78,79]; physicians who reviewed clinical and VA 
data were aware… 
 
3. On page 4 of 23, it is indicated that the WHO 2012 VA instrument was used, with additional questions around 
treatment for TB and HIV.......... What informed the choice of these questions and how could they have impacted on 
the overall findings, relative to studies that will strictly apply the WHO instrument? 
 
Our apologies that this was not described clearly enough in the methods.  Although these questions were added to the 
instrument and used in interviews, the answers were not provided to the physicians or software assigning CoD, all of 
which were provided only with data consistent with the WHO 2012 instrument.  It is possible that the use of these 
questions affected the way that respondents relayed or interviewers recorded information in the free narrative section 
of the instrument.   
 
These two points have now been included in the manuscript, as described below. 
 
 
 Amendment #1 (Methods) 
Original text 
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VA data were interpreted using both physician-certified verbal autopsy (PCVA) and computer-coded verbal autopsy 
(CCVA) methods.   
 
Revised text (page 6, lines 142–143) 
VA data included in the WHO 2012 VA instrument (i.e., excluding data from study-specific added questions around ART 
use, treatment for TB, health beliefs, or health service use) were interpreted using both physician-certified verbal 
autopsy (PCVA) and computer-coded verbal autopsy (CCVA) methods. 
 
 
 Amendment #2 (Discussion) 
Original text 
…the reference CoD assigned represent our best estimates using the data available, the true CoD may still differ.  
InterVA-4 and SmartVA-Analyze are designed for use with the WHO 2014 and PHMRC VA instruments, respectively, 
therefore… 
 
Revised text (page 20, lines 525–528) 
…the reference CoD assigned represent our best estimates using the data available, the true CoD may still differ.  
Questions on ART and TB treatment, added to the VA instrument by the study team, may have led to changes in how 
events were reported in the free narrative section; the answers to the questions themselves, however, were not 
provided to reviewing physicians or to either software.  InterVA-4 and SmartVA-Analyze are designed for use with the 
WHO 2014 and PHMRC VA instruments, respectively, therefore… 
 
1. The authors conclude safely that more accurate methods are needed to directly estimate HIV associated TB. 
Agreed. But what about the subject of the paper? Is there any hope for VA to fill this data gap with modified 
questions? Or should we admit the limitations of VA and invest in other methods of measurement? If so, what 
should these be to measure at least population level mortality accurately? 
 
Thank you for your comment.  We agree that this issue required more discussion and, as a combined response to this 
and the first point raised by Reviewer #1, we have added the sub-section ‘Moving Forward’ to the discussion (page 19, 
lines 486–514 of the manuscript; provided on pages 1–2 of this letter). 
 
1. Minor amendments to author affiliations (page 1) 
2. Minor changes to punctuation and grammar throughout the manuscript 
3. Hyphens replaced with en dashes throughout manuscript, as appropriate 
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4. Minor changes to formatting of all tables (pages 9, 11, 12, 14, and 15) 
5. Addition of Prof Lucas and Dr Morris-Jones to the acknowledgments (page 21, lines 593_594) 
6. Minor updates to specific references: 
a. Ref. 14: Appendix to 2015 WHO Global TB report replaced with appendix to 2016 WHO Global TB 
report (Glaziou P, et al.) 
b. Ref. 26: Article described as ‘in press’ has now been published; reference updated accordingly (Karat 
AS, et al.) 
7. Updates of all references to include DOI and/or PMID, where available (pages 21–26) 
8. New references added: 
a. Ref. 65: Garenne M, et al. Bull WHO 2006 
b. Ref. 66: de Savigny D, et al. Glob Health Action 2017 
c. Ref. 67: Dheda K, et al. Respirology 2013 
d. Ref. 68: Lawn SD, et al. Lancet Infect Dis 2013 
e. Ref. 69: Maher D, et al. Int J Tuberc Lung Dis 2005 
f. Ref. 70: Auld SC, et al. Int J Tuberc Lung Dis 2013 
g. Ref. 71: Podewils LJ, et al. BMC Public Health 2015 
h. Ref. 72: Castillo P, et al. PLoS Med 2016 
i. Ref. 73: Martinez MJ, et al. Diagn Microbiol Infect Dis 2016 
j. Ref. 74: Wong EB, et al. PLoS One 2012 
k. Ref. 75: Byass P. PLoS Med 2016 
l. Ref. 76: CoDe Working Group 2013 
m. Ref. 77: Korenromp EL, et al. Int J Tuberc Lung Dis 2009 
n. Ref. 78: Serina P, et al. Pop Health Metrics 2016 
o. Ref. 79: Hussain-Alkhateeb L, et al. Emerg Themes Epidemiol 2016 
 
Thank you again for your review of this article.  We trust that these revisions are satisfactory and look forward to 
hearing from you. 
 
Yours sincerely, 
 
Aaron Karat 
Corresponding author 
